UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 1 of 263PROTOCOL PS0015 AMENDMENT 5.4
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND,
SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY 
TO EVALUATE THE EFFICACY AND SAFETY OF 
BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO 
SEVERE CHRONIC PLAQUE PSORIASIS
PHASE 3b
EudraCT Number: 2017-003784-35
IND Number: 128707
Sponsor:
UCB Biopharma SRL
Allée de la Recherche 60
1070 Brussels
BELGIUM
Protocol/Amendment number Date Type of amendment
Final Protocol 26 Mar 2018 Not applicable
Protocol Amendment 1 17 Oct 2018 Substantial
Protocol Amendment 1.1 (US, Australia, Belgium, Poland, and 
Germany)11 Jan 2019 Non-substantial
Protocol Amendment 2 06 May 2019 Substantial
Protocol Amendment 3 23 May 2019 Substantial
Protocol Amendment 3.1 (US, Australia, Poland, and Germany) 23 May 2019 Non-substantial
Protocol Amendment 4 06 Feb 2020 Non-substantial
Protocol Amendment 4.1 (US, Poland, and Germany) 12 Feb 2020 Non-substantial
Protocol Amendment 5 09 Jun 2020 Substantial
Protocol Amendment 5.1 (US) 09 Jun 2020 Not applicable
Protocol Amendment 5.2 (Poland and Germany) 18 Jun 2020 Substantial
Protocol Amendment 5.3 (Canada) 01 Oct 2021 Not applicable
Protocol Amendment 5.4 (US) 01 Oct 2021 Not applicable
Confidential Material
Confidential
This document is the property of UCB and may not –in full or in part –be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.PUBLIC numbenumbeIC
BLU
llPCOPYarma Srma
RechercRecherc
70 Bruss0 Brus
BELGBELG
This docuProtocoProtoccumentmendmeendmet
ol AmendAmenen
otocol Amocol AmmcudProPrddodcannot 1 (US, A(US, Aot
nt 44no
ment 4.ent 4.ancbe beused a, BelgiuBelgiud
usto tosupport elss
UMM
ppsuany  6060marketing 55authorization DY Y 
ATE TATE T
appAmendmemendmepplication (US, PolUS, Po
5ion
ment 5.1 (Ument 5.1 at
endment 5ndmentlicpp
enaandstralia, ralia, dndaany ny
olaextensions sonsi
m, PolandPolanden
eor ovariations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 2of 263STUDY CONTACT INFORMATION
Sponsor
UCB Biopharma SRL
Allée de la Recherche 60
1070 Brussels, BELGIUM
Sponsor Study Physician
Name:
Address: UCB Biopharma SRL
Chemin du Foriest
B-1420 Braine- l’Alleud
Belgium
Phone:
Fax:
Clinical Project Manager
Name:
Address: UCB BIOSCIENCES GmbH
Alfred -Nobel-Str. 10
40789 Monheim
GERMANY
Phone:
Fax:
Clinical Trial Biostatistician
Name:
Address: UCB
208 Bath Road, Slough, SL1 3WE, UK
Phone:
Fax:PUBLIC C
ENCES ENCES
belel-Str. Str. 
onheimonhLICLICCOPY YPY
C
This document t
hone:one:m
Fax:Faxcudddcannot t
ostatiostati
ananananctbe beebeused usuto 0support po
mbHmbHupany yanmarketing maauthorization utha
applicationUCBUCB
202ion
calicccc
ppnon and sticianicianaany nyaanextensions ns
exor orvariations nstiorithereof. of.
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 3 of 263Clinical Monitoring Contract Research Organization
Name: PAREXEL International (IRL) Limited-Ireland
Address: Ireland Limited
70 Sir John Rogerson’s Quay
Dublin 2, IRELAND
Phone: +353 (1) 477 3171
Fax: +353 (1) 477 3308
PUBLIC COPY 
This document cannot be used to support any marketing authorization atizaor
uth
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 4 of 263SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: +32 2 386 24 21
USA and Canada: +1 800 880 6949
or +1 866 890 3175
Email Global: DS_ICT@ucb.com 
PUBLIC COPY 
This document cannot be used to support any marketing authorization atiriz
tho
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 5 of 263TABLE OF CONTENTS
LIST OF ABBREVIATIONS..................................................................................................12
1 SUMMARY.....................................................................................................................162 INTRODUCTION ...........................................................................................................182.1 Psoriasis ................................................................................................................... ....18
2.1.1 Global epidemiology of psoriasis ........................................................................192.1.2 Current treatments for psoriasis...........................................................................19
2.2 Bimekizumab ...............................................................................................................21
2.2.1 Clinical.................................................................................................................2 2
2.2.1.1 Completed studies .....................................................................................22
2.2.1.2 Ongoing studies.........................................................................................23
2.2.2 Nonclinical...........................................................................................................23
3 STUDY OBJECTIVES....................................................................................................243.1 Primary objective.........................................................................................................243.2 Secondary objectives ...................................................................................................243.3 Other objectives ...........................................................................................................2 4
4 STUDY VARIABLES.....................................................................................................254.1 Primary efficacy variable.............................................................................................254.2 Secondary variables .....................................................................................................25
4.2.1 Secondary efficacy variables ...............................................................................25
4.2.2 Secondary safety variables ..................................................................................25
4.3 Other variables............................................................................................................. 25
4.3.1 Other efficacy variables.......................................................................................254.3.2 Other safety variables ..........................................................................................264.3.3 Pharmacokinetic variable.....................................................................................274.3.4 Immunological variable .......................................................................................27
5 STUDY DESIGN.............................................................................................................275.1 Study description .........................................................................................................275.2 Study periods ............................................................................................................... 27
5.2.1 Screening Period..................................................................................................28
5.2.2 Treatment Period .................................................................................................28
5.2.3 OLE Period ..........................................................................................................295.2.4 OLE2 Period ........................................................................................................305.2.5 Safety Follow-Up Periods....................................................................................305.2.6 Premature End of Treatment................................................................................31
5.3 Study duration per subject ...........................................................................................31
5.4 Planned number of subjects and sites ..........................................................................31
5.5 Anticipated regions and countries................................................................................32PUBLIC ..................
..................
y variablvariabl
variabvariabCOPY ...
..................
................
............
This document y desde
Study peudy pe
.1
5.2.2.2.2
5.25.2cannotkineticnetic
nologicaologica
ESIGNSIGN
scriscrbearia
ariableariableused less....
................
ablesblesto ss.............support .........
................
...................
.................any ....
.................
....marketing ..
....................
..................
..................
.................
.....authorization 8
....1919
............191
...............
.........
application .........
ptiontion.....
iodsds......
Screeningcreenin
TreatmTreat
OLOLand ariaria
l variablvariablany ...
.................
bleble.extensions .......
................
...............
...............
..............
...or ........
.variations ...
...............
................
...............
..............thereof...........2222
................
................
.....
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 6 of 2635.6 Schedule of study assessments.....................................................................................32
5.7 Schematic diagram.......................................................................................................445.8 Rationale for study design and selection of dose.........................................................46
5.8.1 Study design.........................................................................................................465.8.2 Dose selection......................................................................................................47
6 SELECTION AND WITHDRAWAL OF SUBJECTS...................................................476.1 Inclusion criteria .......................................................................................................... 47
6.2 Exclusion criteria .........................................................................................................4 8
6.3 Eligibility for the OLE Period......................................................................................516.4 Eligibility for the OLE2 Period....................................................................................52
6.4.1 All subjects (OLE2 Groups A and B)..................................................................52
6.4.2 OLE2 Period Group A subjects ...........................................................................526.4.3 OLE2 Period Group B subjects ...........................................................................52
6.5 Withdrawal criteria ......................................................................................................54
6.5.1 Potential drug-induced liver injury IMP discontinuation criteria........................56
7 STUDY TREATMENTS.................................................................................................577.1 Description of investigat ional medicinal products ......................................................57
7.2 Treatments to be administered .....................................................................................587.3 Packaging................................................................................................................... ..63
7.4 Labeling .................................................................................................................... ...63
7.5 Handling and storage requirements .............................................................................63
7.6 Drug accountability......................................................................................................647.7 Procedures for monitoring subject compliance............................................................647.8 Concomitant medications/treatments...........................................................................65
7.8.1 Permitted concomitant treatments  (medications and therapies) ..........................65
7.8.1.1 Topical medications ..................................................................................657.8.1.2 Other medications......................................................................................65
7.8.2 Prohibited concomitant treatments (medications and therapies) .........................65
7.8.2.1 Vaccines ....................................................................................................67
7.9 Blinding.................................................................................................................... ....67
7.9.1 Procedures for maintaining and breaking the treatment blind.............................68
7.9.1.1 Maintenance of IMP blind.........................................................................687.9.1.2 Breaking the treatment blind in an emergency situation ...........................68
7.10 Randomization and numbering of subjects..................................................................688 STUDY PROCEDURES BY VISIT ...............................................................................698.1 Screening Visit (2 to 5 weeks).....................................................................................708.2 Treatment Period..........................................................................................................71
8.2.1 Baseline Visit.......................................................................................................71PUBLIC ..............
..................
................
requiremrequireCOPYMP discMP di
................
cinal proinal pr
This document Proro
2.11
BlindiBlindi
7.9.19.1
77cannot conconc
Topical mpical 
OtherOther
ohibithibitbeations/ons
omiomused menten
..............
ng subjg subto .........
tsts..support ...
ductsucts...
..................
..................
...anytinuatiotinuat
..........marketing ..............
..................
...................
................
...........authorization ..4747
...........4747
..............
..............
applicationm
d concod conco
VaccineVaccin
ngg...............
ProceduProce
.1.11.1
2andtanan
medicatiedicati
edicatdicaany atmenttmen
t treatmtreaextensions ..
................
..............
...............
...............
t compcomor ....
........variations ................
................
n criterin criteri
................
...thereof. .......51
................ 55
................
.............
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 7 of 2638.2.2 Week 1 and Week 2 Visits (±3 days relative to Baseline)...................................72
8.2.3 Week 3 Visit (±3 days relative to Baseline) ........................................................738.2.4 Week 4 Visit (±3 days relative to Baseline) ........................................................738.2.5 Week 8 and Week 12 Visits (±3 days relative to Baseline) ................................748.2.6 Week 16 Visit (±3 days relative to Baseline) ......................................................758.2.7 Week 20 (±3 days relative to Baseline) and Week 28 Visits (±7 days relative to 
Baseline) ..............................................................................................................76
8.2.8 Week 24 Visit (±3 days relative to Baseline) ......................................................768.2.9 Week 32 Visit (±7 days relative to Baseline) ......................................................778.2.10 Week 36 Visit (±7 days relative to Baseline) ......................................................78
8.2.11 Week 40 Visit (±7 days relative to Baseline) ......................................................79
8.2.12 Week 44 Visit (±7 days relative to Baseline) ......................................................798.2.13 Week 48 Visit (±7 days relative to Baseline) ......................................................80
8.3 OLE Period .................................................................................................................. 81
8.3.1 Week 48 Visit (±7 days relative to Baseline) ......................................................818.3.2 Week 52 Visit (±7 days relative to Baseline) ......................................................818.3.3 Week 56 Visit (±7 days relative to Baseline) ......................................................828.3.4 Self-injection at home (Weeks 60, 68, 76, 80, 88, 92, 100, 104, 112, 116, 124, 
128, 136, and 140) ...............................................................................................83
8.3.5 Week 64 (±7 days relative to Baseline), Week 84, Week 108, Week 132 Visits 
(±14 days relative to Baseline) ............................................................................83
8.3.6 Week 72 (±7 days relative to Baseline) and Week 120 Visits (±14 days relative 
to Baseline) ..........................................................................................................85
8.3.7 Week 96 Visit (±14 days relative to Baseline) ....................................................868.3.8 Week 144 Visit (±14 days relative to Baseline) ..................................................87
8.4 OLE2 Period ................................................................................................................8 9
8.4.1 OLE2 Screening (up to 4 weeks) –applicable for OLE2 Group B only.............89
8.4.2 OLE2 Baseline Visit ............................................................................................908.4.3 Self-injection at home (OLE 2 Weeks 4, 8, 16, 32, and 40).................................91
8.4.4 OLE2 Week 12, Week 24, and Week 36 Visits (±14 days relative to OLE2 
Baseline) ..............................................................................................................92
8.4.5 OLE2 Week 48 Visit (±14 days relative to OLE2 Baseline)...............................93
8.5 Premature End of Treatment Visit ...............................................................................948.6 Safety Follow-Up Visit (20 weeks after final dose up to Week 144, ±7 days) ...........948.7 Safety Follow-Up Visit 2 (20 weeks after final dose in the OLE2 Period, ±7 days)...958.8 Unscheduled Visit........................................................................................................959 ASSESSMENT OF EFFICACY......................................................................................959.1 Psoriasis Area Severity Index ......................................................................................95
9.2 Investigator’s Global Assessment ................................................................................96PUBLIC eks 6ks 6
............
lative toative to
to Baseto Base
s relas reCOPYselineselin
BasBaseline
e to Base to Bas
60, 660 6
This document Selfel
OLEOL
BB
8.4.5.4.5
8.58.5
8686cannot................
Screenicreeni
E2 Bas2 Bas
ffinjinjbe±14
it (±14it (±14usedive to ve to 
................
4daysdaysto Ba
ne)ne).....
Bsupport )
line)ine)...
8, 76, 80,, 76, 8
.................
aseline)selineany ..............
..............marketing ...........
................
.....................
.................
...............authorization to o
.........7676
.................
................
application linene
ection at hection a
E2 Week 2 Week
aseline)seline)
OLE2 WOLE2
rematurematuand .......
ng (up tog (up to
VisVisany elala
ays relaays rel
....extensions,
..............
), Week, Week
..............
aseline) seline) 
.............
ativetiveor88, 928, 92variations.............
..................
...............
..............
........thereof. ....7
..............77
...............
.................
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 8 of 2639.3 Dermatology Life Quality Index..................................................................................97
9.4 Scalp IGA................................................................................................................... ..97
9.5 mNAPSI...................................................................................................................... .98
9.6 pp-IGA ...................................................................................................................... ...98
9.7 European Quality-of-Life 5-Dimensions 3-Level Questionnaire ................................999.8 Patient Global Assessment of psoriasis .......................................................................999.9 Itch, pain, and scaling numerical rating scale ..............................................................999.10 PASE questionnaire .....................................................................................................999.11 PGADA for arthritis visual analog scale ...................................................................1009.12 Photographs................................................................................................................ 100
9.13 WPAI-SHP V2.0........................................................................................................100
10 ASSESSMENT OF PHARMACOKINETIC VARIABLES.........................................10110.1 Pharmacokinetic variables .........................................................................................10111 ASSESSMENT OF IMMUNOLOGICAL VARIABLES.............................................10112 ASSESSMENT OF SAFETY........................................................................................10112.1 Adverse events...........................................................................................................10 1
12.1.1 Definitions .........................................................................................................101
12.1.1.1 Adverse event ..........................................................................................10112.1.1.2 Serious adverse event ..............................................................................10212.1.1.3 Adverse events of special interest ...........................................................103
12.1.1.4 Other safety topics of interest..................................................................103
12.1.2 Procedures for reporting and recording adverse events.....................................103
12.1.2.1 Description of adverse events..................................................................10412.1.2.2 Rule for repetition of an adverse event....................................................10412.1.2.3 Additional procedures for reporting serious adverse events ...................104
12.1.3 Follow up of adverse events ..............................................................................10512.1.4 Pregnancy ..........................................................................................................10512.1.5 Suspected transmission of an infect ious agent via a medicinal product............106
12.1.6 Overdose of investigational medicinal product .................................................106
12.1.7 Safety signal detection.......................................................................................106
12.2 Laboratory measurements..........................................................................................107
12.2.1 Evaluation of PDILI ..........................................................................................108
12.2.1.1 Consultation with Medical Monitor and local hepatologist ....................11212.2.1.2 Immediate action: determination of IMP discontinuation.......................11212.2.1.3 Testing: identification/exclusion of alternative etiology.........................11312.2.1.4 Follow-up evaluation...............................................................................115
12.3 Other safety measurements........................................................................................115
12.3.1 Assessment and management of TB and TB risk factors ..................................115..............
ventvent ....
nts of spets of spe
ty topicty topic
tCOPY .............
.................
...............
This documentSusu
OverOver
.77 SS
2LabLa
12.212.2cannot itionaon
up of adp of a
gnancynancy
spectepecteber repetir repet
al pal pused s of iof 
ing and ng and 
of advef advto cial ial 
interintersupport ...
................
..................
..................
intereinteany ................
..........marketing ............
..................
...................
................
.............authorization ..9999
...........9999
..............
..............
application..
d transmd transm
dose of inose of 
afety signfety sig
boratory mratory
EvaEvandroco
verse everse e
.......anyn of ann of an
eduresedurextensions ..
................
restst........
estt...........
recordincordin
e eveneveor ....
........variations ................
................
.................
................
...thereof. ...1001
..............1010
................
.............
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 9 of 26312.3.1.1 Tuberculosis assessment by IGRA..........................................................118
12.3.1.2 Chest x-ray for tuberculosis ....................................................................11812.3.1.3 Tuberculosis questionnaire......................................................................11812.3.1.4 Tuberculosis management.......................................................................118
12.3.2 Pregnancy testing...............................................................................................11912.3.3 Vital signs ..........................................................................................................11912.3.4 12-lead electrocardiograms................................................................................12012.3.5 Physical examination .........................................................................................12012.3.6 Height and body weight.....................................................................................12012.3.7 Assessment of suicidal ideation and behavior ...................................................120
12.3.8 Patient Health Questionnaire-9..........................................................................120
12.4 Other study measurements.........................................................................................121
12.4.1 Demographic information..................................................................................12112.4.2 Medical history ..................................................................................................12112.4.3 Psoriasis history.................................................................................................12112.4.4 Data Monitoring and Adjudication Committees................................................121
13 STUDY MANAGEMENT AND ADMINISTRATION ...............................................12113.1 Adherence to protocol................................................................................................12113.2 Monitoring ................................................................................................................. 121
13.2.1 Definition of source data ...................................................................................122
13.2.2 Source data verification .....................................................................................122
13.3 Data handling.............................................................................................................1 23
13.3.1 Case Report Form completion ...........................................................................12313.3.2 Database entry and reconciliation......................................................................12313.3.3 Subject Screening and Enrollment log/ Subject Identification Code list............123
13.4 Termination of the study............................................................................................12313.5 Archiving and data retention......................................................................................12413.6 Audit and inspection ..................................................................................................12413.7 Good Clinical Practice ...............................................................................................12414 STATISTICS .................................................................................................................12 4
14.1 Definition of analysis sets..........................................................................................124
14.2 General statistical considerations...............................................................................12514.3 Planned efficacy analyses ..........................................................................................126
14.3.1 Analysis of the primary efficacy variable..........................................................126
14.3.1.1 Sensitivity analyses .................................................................................127
14.3.2 Other efficacy analyses......................................................................................128
14.3.2.1 Analysis of the secondary efficacy variables ..........................................128
14.3.2.2 Analysis of the other efficacy variables ..................................................128PUBLIC ..............
..............
datadata ..
icationicationCOPY .............
n Commn Com
MINISTMINIST
This documentanan
ood Clind Clin
TATISTATIS
1DeDe
14.214.2
14.14cannot reenien
of the sf the 
g and daand da
nd insd insbey and rey and r
ngngused .......
..............
compleomplto .........
...supportttette
RATIONATION
..................
..................
...any ................
eses......marketing ..............
..................
...................
................
.............authorization 119119
......120120
.............. 1
..............
application ta r
pectionpection .
cal Practal Pra
ICSICS......
inition ofnition 
eneral sneraland andn
udydy.......
retentetentanynciliatincilia
EnrolEnrextensions ..
................
..............
...............
...............
onn......or ....
........variations ..............
................
................
................
...thereof. ...1201
..............1212
...............
.............
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 10 of 26314.4 Subgroup analyses .....................................................................................................130
14.5 Planned safety and other analyses..............................................................................130
14.5.1 Safety analyses...................................................................................................13014.5.2 Pharmacokinetic analyses..................................................................................13014.5.3 Immunogenicity analyses ..................................................................................130
14.6 Handling of protocol deviations.................................................................................13014.7 Handling of dropouts or missing data........................................................................13114.8 Planned interim analysis ............................................................................................13214.9 Determination of sample size.....................................................................................13215 ETHICS AND REGULATORY REQUIREMENTS....................................................132
15.1 Informed consent .......................................................................................................132
15.2 Subject identification cards........................................................................................13315.3 Institutional Review Boards and Independent Ethics Committees............................13315.4 Subject privacy...........................................................................................................1 34
15.5 Protocol amendments.................................................................................................13416 FINANCE, INSURANCE, AND PUBLICATION .......................................................13417 REFERENCES ..............................................................................................................13418 APPENDICES ...............................................................................................................13718.1 Protocol Amendment 1 ..............................................................................................13718.2 Protocol Amendment 1.1 ...........................................................................................160
18.3 Protocol Amendment 2 ..............................................................................................161
18.4 Protocol Amendment 3 ..............................................................................................20918.5 Protocol Amendment 3.1 ...........................................................................................20918.6 Protocol Amendment 4 ..............................................................................................21318.7 Protocol Amendment 5 ..............................................................................................21718.8 Protocol Amendment 5.1 ...........................................................................................21718.9 Protocol Amendment 5.4 ...........................................................................................23019 DECLARATION AND SIGNATURE OF INVESTIGATOR .....................................26220 SPONSOR DECLARATION ........................................................................................263
LIST OF TABLES
Table 5‒1: Schedule of study assessments, Scre ening and double-blind Treatment 
Periods..............................................................................................................33
Table 5‒2: Schedule of study assessments, OLE Period ...................................................37
Table 5-3: Schedule of study assessments, OLE2 Period .................................................40
Table 7‒1: Dosing scheme, double-blind Treatment Period..............................................59
Table 7‒2: Dosing scheme, OLE Period............................................................................60PUBLIC ..............
..................
................
22........COPY .............
CATIONCATIO
...............
This documentRAR
NSOR DSOR 
TablTablcannot menme
endmenndme
Amendmmendm
ATIOATIObe nt 44....
t5t5used .......
..............
1...........to .........
...support ...
................
..................
.................
...any ................
..........marketing ..............
..................
...................
mitteesttees .
.............authorization 130130
......131131
.............. 1
..............
applicationme
N AND AND
ECLARAECLARand ...
5.1.1......
nt 5.4t 5.4any ................
..........extensions ..
................
..............
...............
...............
..........or ....
........variations ................
................
................
................
...thereof. ...1321
..............1313
...............
.............
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 11 of 263Table 7‒3: Dosing scheme, OLE2 Period..........................................................................62
Table 7‒4: Prohibited psoriasis medications......................................................................66
Table 9‒1: Body areas for calculation of percent BSA for PASI ......................................96
Table 9‒2: Five-point IGA.................................................................................................97
Table 9‒3: Scalp IGA.........................................................................................................98
Table 9‒4: pp-IGA .............................................................................................................99
Table 12‒1: Anticipated serious adverse events for the population of subjects with 
moderate to severe chronic plaque psoriasis..................................................103
Table 12‒2: Laboratory measurements..............................................................................108
Table 12‒3: Required investigations and follow up for PDILI..........................................110
Table 12‒4: PDILI laboratory measurements....................................................................114
Table 12‒5: PDILI information to be collected .................................................................115
LIST OF FIGURES
Figure 5‒1: Schematic diagram, Screening and double-blind Treatment Period 
(through Week 48) ...........................................................................................44
Figure 5‒2: Schematic diagram, OLE Period (Week 48 through Week 144).....................45
Figure 12-1: Schematic diagram of TB test results and study eligibility ...........................117
Figure 14‒1:Hypothesis testing..........................................................................................126 PUBLIC nin
..................
, OLE POLE P
ram of Tram of T
ngngCOPY F FIGUF FIG
ng andg an
This document cannot be used TB
.............to test rtest support URER
doubleouble -b
...................
iod (Weod (Weany ESESmarketing ..................
..................
.................
.................authorization 988
..........9999
th h 
..............
application and any extensions .......
eek 48 teek 48 
sults anults an
................orind Tind 
.variations .........
...............
Trthereof. ...1031
..............11
...................
.
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 12 of 263LIST OF ABBREVIATIONS
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the curve
axSpA axial spondyloarthritis
BA bioavailability
BCG Bacillus Calmette-Guerin
BP blood pressure
BSA body surface area
cAMP cyclic adenosine monophosphate
CDC Centers for Disease Control
CDMS clinical data management system
CI confidence interval
CMH Cochran-Mantel-Haenszel
CPM Clinical Project Manager
CPMP Committee for Proprietary Medicinal Products
CRO contract research organization
CSR Clinical Study Report
CTCAE Common Terminology Criteria for Adverse Events
DLQI Dermatology Life Quality Index
DMC Data Monitoring Committee
ECG electrocardiogram
eCRF electronic Case Report Form
eC-SSRS electronic Columbia Suicide Severity Rating Scale
ePRO Electronic Patient-Reported Outcome
EQ-5D-3L European Quality-of-Life 5-Dimensions 3-Level
EudraCT European Union Drug Regulating  Authorities Clinical Trials
FAS Full Analysis Set
GCP Good Clinical PracticePUBLIC nagemnage
ntervalnterval
-ManteMante
cal Procal PCOPY hosphatehospha
ControlControl
menmen
This document RFRF
eCeC--SSSS
ePePcannot ClinCli
ComCobetract ract r
nicalnicausedject Mct M
tee for e for PP
esesto HaenHaen
Mansupport t systemsystem
nszeany marketing authorization 
application Dermer
Data Dat
e
SandS
mmon Temon T
matomatany rch orrch 
udy Reudy Rextensions el
agerager
roprietaoprieta
rgor variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 13 of 263GMP Good Manufacturing Practice
HCV hepatitis C virus
HCV Ab hepatitis C antibody
HIV human immunodeficiency virus
HLT High Level Term
IB Investigator’s Brochure
IBD inflammatory bowel disease
ICF Informed Consent Form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
Ig immunoglobulin
IGA Investigator’s Global Assessment
IGRA interferon-gamma release assay
IL interleukin
IMP investigational medicinal product
IND Investigational New Drug
IRB Institutional Review Board
IRT interactive response technology
iv intravenous(ly)
LOCF last observation carried forward
LTB latent tuberculosis
LTBI latent tuberculosis infection
mAb monoclonal antibody
MI multiple imputation
mNAPSI Modified Nail Psoriasis Severity Index 
MS Maintenance Set
NRI nonresponder imputation
NSAID nonsteroidal anti-inflammatory drug
NTMB nontuberculous mycobacterium
OLE open-label extension
OL2S OLE2 Period Set
OLS Open-Label SetPUBLIC medimed
nal Newal New
nal Revnal Rev
ctive rctive rCOPY e assaye assay
icinacina
This document SI
S
NRINRI
NSNcannot ateate
latenlatebe obsebse
ent tuent tused esponspon
ous(ly)us(ly)
rvatrvatto ew Bw 
sesesupport productroduc
Drugrug
BoarBoaany marketing authorization 
application mon
multipmul
Mandt tuberctuber
noclonocloany n can c
rculosisrculosis
lextensions d
echnolochnolo
arriarrior variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 14 of 263PASE Psoriatic Arthritis Screening and Evaluation
PASI Psoriasis Area Severity Index
PD pharmacodynamic(s)
PDE phosphodiesterase 
PDILI potential drug-induced liver injury
PEOT Premature End of Treatment
PFS prefilled syringe
PGADA Patient's Global Assessment of Disease Activity
PHQ-9 Patient Health Questionnaire-9
PK pharmacokinetic(s)
PK-PPS Pharmacokinetics Per-Protocol Set
pp-IGA palmoplantar Investigator’s Global Assessment
PPS Per-Protocol Set
PS Patient Safety
PsA psoriatic arthritis
PSO psoriasis
PT preferred term
Q4W every 4 weeks
Q8W every 8 weeks
QOL quality of life
RS Randomized Set
SAE serious adverse event
SAP Statistical Analysis Plan
sc subcutaneous(ly)
scalp IGA scalp- specific Investigator’s Global Assessment
SFU Safety Follow-Up
SOP Standard Operating Procedure
SS Safety Set
TB tuberculosis
TEAE treatment-emergent adverse event
TNF tumor necrosis factor
ULN upper limit of normalPUBLIC d termd term
4 wee4 weeCOPY 
This document GAGA
U
SOPSOP
SSSScannot RaRa
serioserbe ity ofy o
ndomndomused ks
weekseeks
f liff lifto support any semarketing essmenssmeauthorization 
application Stat
subcusub
scandus adves adv
tisticaisticany ed Seted Setextensions or variations nttthereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 15 of 263VAS visual analog scale
WPAI-SHP Work Productivity and Activity Impairment Questionnaire-specific 
health problem
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 16 of 2631S U M M A R Y
This is a Phase 3b, multicenter, randomize d, double-blind, active comparator-controlled, 
parallel-group study to evaluate the efficacy and safety of bimekizumab compared with 
secukinumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
The study population consists of adult subjects ( ≥18 years of age) with a diagnosis of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area Severity Index [PASI] score ≥12 and 
body surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] 
score ≥3 [on a 5 -point scale]) who are a candidate for secukinumab, or for systemic PSO therapy 
and/or phototherapy.
Approximately 935 subjects will be screened in  order to have 700 subjects randomized in the 
study. For each subject, the study will last a maximum of 165 weeks and will consist of 
5 periods: a Screening Period (2 to 5 weeks), a double-blind Treatment Period (48 weeks; final 
dose at Week 44), an Open-Label Extension (OLE) Period (96 weeks; final dose at Week 136 for subjects receiving bimekizumab 320mg Q8W and at Week 140 for subjects receiving 
bimekizumab 320mg Q4W) followed by a Safety Follow-Up (SFU) Period (20 weeks after the 
final dose of investigational medicinal product [IMP]  depending on subject’s participation in the 
second OLE Period [OLE2 Period]; see paragraph below). 
Subjects participating in the OLE2 Period (implemented as part of Protocol Amendment #5.4)
will enter the OLE2 Period after completing the OLE Period (at Week 144), including subjects in the SFU period and subjects who have completed the SFU Period. The OLE2 Period will be a 
48-week treatment period with final visit at OLE2 Week 48, followed by a SFU Period (SFU2, 
20 weeks after the final dose of IMP administered in the OLE2 Period). 
During the first 16 weeks of the double-blind Treatment Period, eligible subjects will be 
randomized 1:1 to receive one of the following blinded IMP regimens:
xBimekizumab 320mg administered subcutaneously (sc) every 4 weeks (Q4W)
xSecukinumab 300mg administered sc at Base line and Weeks 1, 2, 3, and 4 followed by 
dosing Q4W
Subjects receiving bimekizumab 320mg will rece ive placebo sc on Weeks 1, 2, and 3 in order to 
maintain the blind. 
Approximately 350 subjects will be randomized to bimekizumab 320mg and approximately 
350 subjects will be randomized to secukinuma b. Investigational medicinal product will be 
administered at Baseline, Weeks 1, 2, 3, and 4 and then Q4W thereafter, until Week 44 (double-
blind Treatment Period). All doses w ill be administered in the clinic.
At Week 16 subjects in the bimekizumab 320mg treatment arm will be re-randomized 1:2 to 
receive bimekizumab 320mg Q4W or bimekizumab 320mg every 8 weeks (Q8W). To maintain 
the blind after re-randomization, subjects in the bimekizumab 320mg Q8W treatment arm will 
receive placebo at Weeks 20, 28, 36, and 44. Subjects in the secukinumab arm will continue to receive secukinumab 300mg Q4W.
At the completion of the Week 48 visit a ssessments, subjects may receive open-label 
bimekizumab treatment for an additional 96 weeks during the OLE Period. All subjects enrolling PUBLICinging
e complcomp
l visit atl visit a
IMP admIMP adm
he douhe dou
ffCOPY P] deP] 
ph belowh belo
mplememplem
g the Othe
This documentately 3ely 3
jects wilcts wi
nisteredistered
ind Tread Trea
At WeAt W
recreccannot a
g bimekibimek
nd. d. 
500be min
dminisdminisusedblee--blibl
the follohe follo
istereistereto ministeminist
indinsupport nted as ed as
OLE PerioLE Per
ted the SFd the S
OLE2 LE2 WW
eredereany ding oding 
pamarketing ndomdom
will consiwill cons
Perioeriod (4d 
s; final do final 
or subjectsubjec
FU) PerFU) Pe
nsauthorization ate e 
nd nd 
[IGA] IGA] 
PSO thePSO th
mizemiz
application subjects ubjec
l be randobe rand
at BaselinBase
tment Perment Pe
16 sub6 suband umab 3mab 3any susu
ered sc ared sc aextensions FU PU P
Week ek 4848
d in the in the 
TreatmTreatm
wing bliing bl
ubcutbcutord (at Wd (at 
PeriPerivariationsdos
ts recei rece
ririod (20od (20
subject’subject’
t of Prof Pr
Wthereof. d in the in the
ist of of 
4848weekweek
se at We at W
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 17 of 263in the OLE Period will, after signing a new ICF, be evaluated for eligibility, be randomized, and 
receive their first dose of bimekizumab in the OLE Period. 
During the OLE Period, eligible subjects will receive the following IMP regimens as determined 
by th e subject’s treatment regimen and PASI response in the double -blind Treatment Period. 
At Week 48, subjects receiving:
xBimekizumab 320mg Q4W who achieve PASI90 at Week 48 of the double-blind Treatment 
Period will be randomized 1:1 to receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W.
xBimekizumab 320mg Q4W who do not achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q4W.
xBimekizumab 320mg Q8W who do not achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q4W.
xBimekizumab 320mg Q8W who achieve PASI90 at Week 48 of the double-blind Treatment 
Period will receive bimekizumab 320mg Q8W.
xSecukinumab who do not achieve PASI90 at We ek 48 of the double-blind Treatment Period
will receive bimekizumab 320mg Q4W.
xSecukinumab who achieve PASI90 at Week 48 of  the double-blind Treatment Period will be 
randomized 1:1 to receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W.
During the OLE Period, subjects will attend study visits at Weeks 52, 56, 64, and 72, and then 
every 12 weeks. 
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W at Week 64 or at the next  scheduled clinic visit after implementation 
of Protocol Amendment #5.1 if the subject has already completed Week 64.
All subjects not enrolling in the OLE Period will have the Week 48 study assessments and will 
enter the SFU Period.
Subjects withdrawing early from the study will  undergo the Premature End of Treatment (PEOT) 
Visit assessments and will enter the SFU Period.
After the implementation of Protocol Amend ment #5.4 (addition of a 48-week treatment period, 
ie, OLE2 Period), subjects will be invited to c ontinue or reinitiate their treatment as per the 
following OLE2 Groups:
xOLE2 Group A: Subjects in the treatment phase of the OLE Period at the time of Protocol 
Amendment #5.4 implementation will attend the Week 144 Visit and directly roll over to the OLE2 Period. These subjects will continue receiving bimekizumab 320mg Q8W for 
40 additional weeks, starting from the first treatment visit of the OLE2 Period (ie, Week 
144/OLE2 Baseline Visit; the Week 144 Visit will coincide with the Week 144/OLE2 Baseline Visit and data collected at this visit will be used as baseline data for subjects entering the OLE2 Period).
xOLE2 Group B: Eligible subjects who have  completed the Week 144 Visit and are in the 
SFU or have completed the SFU of the OLE Pe riod at the time of Protocol Amendment #5.4PUBLICW
umab 3umab 
will attenwill atten
will cwillCOPYWeek 4Week 
Week 4Week
This document mplemplem
2 Period)Period
wing OLng OL
OOLE2LE2
AmAmcannot ing earlyg early
s and wand w
menmenbe if 
n the On the Ousedhange fange 
eek 64 ok 64 
the suhe suto fsupport 8 of the dof the
0mg Q4Wmg Q4
study vtudy vany of the dof the marketing 8 of the doof the 
 of the doof the authorization atment tment 
mab 320mb 320
oubleuble
application ll e
ation of Pation of
, subjectssubjec
E2 Group2 Grou
Group Aroup 
ndmentdmenand from thfrom th
enter nterany ec
E PeriodE Perioextensions W orW o
visits at Wvisits at
om bimem bime
r at the nat the n
ctthashaoroubleubl
r bimrb ivariations oubleuble--bb
oubleuble--bb
bthereof. lind nd
doubleouble -bb
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 18 of 263implementation, will reinitiate their treatmen t in the OLE2 Period after having undergone 
Screening assessments during a 4-week OLE2 Screening Period. The first dose will be 
administered at the Week 144/OLE2 Baseline Visi t and data collected at this visit will be 
used as baseline data for the OLE2 Period. Subjects in OLE2 Group B with an IGA score ≥3 
at the Week 144/OLE2 Baseline Visit will be tr eated with bimekizumab Q4W for the first 16 
weeks, and then will switch to bimekizumab 320mg Q8W. Subjects in OLE2 Group B with an IGA score <3 at the Week 144/OLE2 Baseline  Visit will be treated with bimekizumab 
Q8W from the Week 144/OLE2 Baseline Visit.
During the OLE2 Period (Week 144/OLE2 Baseline  to OLE2 Week 48), all subjects will attend 
study visits every 12 weeks. All subjects will be treated until OLE2 Week 40 (last dose of bimekizumab 320mg Q8W).
Following completion or early withdrawal from the OLE2 Period, subjects will undergo the SFU 
of the OLE2 Period (SFU2) and will return for the SFU2 Visit 20 weeks after the last dose of IMP administration.
The primary objective of the study is to compare the efficacy of bimekizumab administered sc 
for 16 weeks versus secukinumab at achieving complete clearance (PASI100) in subjects with 
moderate to severe chronic plaque PSO. The se condary objectives of the study are listed in 
Section 3.2 .
The primary efficacy variable is the PASI100 response, defined as complete clearance from 
Baseline in the PASI score, at Week 16. The secondary efficacy variables are listed in 
Section 4.2 .
Pharmacokinetic variables are listed in Section 4.3.3 . The immunological variable is listed in 
Section 4.3.4 .
Pharmacokinetic and immunological variables will be evaluated to assess their relationship to 
treatment response.
Safety variables to be assessed are adverse events (AEs), vital signs, electrocardiograms (ECGs), 
and measurements of laboratory parameters.
2 INTRODUCTION
2.1 Psoriasis
Psoriasis is a common, chronic inflammatory diseas e characterized by a series of linked cellular 
changes in the skin: hyperplasia of epidermal kera tinocytes, vascular hyperplasia and ectasia, and 
infiltration of T-lymphocytes, neutrophils, and other types of leukocytes in affected skin. Though 
the pathophysiology of PSO is not fully understood, the importance of T-cells and inflammatory 
cytokines has been demonstrated by the clinical benefit provided by therapies directed at these 
targets (Krueger and Ellis, 2005).
There are a variety of forms of PSO including plaque, guttate, inverse, pustular, and 
erythrodermic. Plaque PSO is the most common, comprising approximately 80% to 90% of all cases. Approximately 17% of those with PSO have moderate to severe disease (Kurd et al, 2008).PUBLICI10
6..The The
sted in sted in COPYpletele
ondary oondary
00 resp0 re
This documentis a coma com
s in the in the 
tration oation o
he pathoe patho
cytokicytok
targtarcannotbooratrat
TRODURODU
PsoriPsoribe ssed aressed ar
oroused gical varal vatoectionectiosupport onse, defnse, d
condary eondar
4anyranceanc
jectives jectivemarketing ts will uns will un
ks after thks after 
bimekizbimek
e( Peauthorization 6 
ith h 
mab mab 
ts will awill a
st dose t dose 
application asisis
mon, chroon, ch
skin: hypeskin: hyp
f TT--lymplym
physiologhysiolo
has behas band y papa
UCTIOCTIOany adverse adverse
arametramextensions efficffi
.3.3.3. Th. Th
ables wiles wiorned aned 
cacycacvariations zumab azumab 
PASI100ASI100
s of the of the 
asthereof. of f 
ndergo tdergo t
he last dhe last 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 19 of 263In addition to the impact on skin, PSO has a multitude of psychosocial and emotional effects on 
patients, including increased self-consciousness, frustration, fatigue, depression, and suicidal 
ideation. As a result, patients frequently report sleeping problems, difficulties at work, problems interacting with family members, disrupted  leisure activities, and sexual difficulties 
(Dowlatshahi et al, 2014; Gottlieb, 2005; Mukhtar et al, 2004; Ortonne, 2004; 
Krueger et al, 2001).
A number of comorbidities have been associated with PSO, especially with more severe PSO. 
Psoriatic arthritis (PsA), cardiovascular dise ase, metabolic syndrome, chronic pulmonary 
disease, peptic ulcer disease, renal disease, and diabetes have all been demonstrated to have an 
increased prevalence in PSO patients  (Yeung et al, 2013; Christophers et al, 2010;
Gisondi et al, 2007; Gelfand et al, 2006).
2.1.1 Global epidemiology of psoriasis
Psoriasis affects approximately 3% of the US adult population (Rachakonda et al, 2014;
Kurd and Gelfand, 2009) and its onset can begin at any age (Augustin et al, 2010;
Icen et al, 2009). The reported worldwide incidence and prevalence of PSO varies greatly 
depending on age, gender, ethnicity, and geography primarily due to genetic and environmental factors. Estimates of incidence and prevalence incl ude all types of PSO. Plaque PSO is the most 
common form of the disease; therefore, reported estimates of the magnitude of this condition are 
likely weighted heavily by this subtype. Both the incidence and prevalence of PSO are higher among Caucasians and those living at higher lati tudes. Psoriasis affects approximately 2% to 4% 
of the population of western countries. Geographical differences are also influenced by case 
definition, study design, and the definition of prevalence (Parisi et al, 2013; Langley et al, 2005;Raychaudhuri and Gross, 2000).
2.1.2 Current treatments for psoriasis
Therapy for patients with PSO varies according  to the severity of disease. Limited or mild 
disease is often treated with topical therapies such as corticosteroids and vitamin D analogs. Patients with more severe disease are of ten treated with phototherapy, methotrexate, 
cyclosporine, the oral phosphodiesterase (PDE) 4 i nhibitor apremilast, or biologic agents, such as 
tumor necrosis factor (TNF) antagonists, interl eukin (IL) 12/23 inhibitors, IL-23p19 inhibitors, 
and IL-17A inhibitors. The effectiveness of TNF inhibitors in the treatment of PSO has been 
demonstrated in many Phase 3 clinical studies and has led to the approval of multiple TNF 
inhibitors for use in patients with moderate to severe PSO. Interleukin inhibitors approved for this indication include the IL-12/23 antag onist ustekinumab, the IL-23p19 antagonist 
guselkumab, the IL-17A inhibitors secukinum ab and ixekizumab, and the IL-17 receptor 
antagonist brodalumab. 
Standard therapies for PSO are listed below:
xTopical steroids (eg, triamcinolone, mo metasone, clobetasol, betamethasone, and 
hydrocortisone) are generally used as first-line treatment of PSO. High-strength steroids are 
typically reserved for use on the arms and legs. Areas such as the face and skin folds (axillary, inguinal regions, etc) are usually treated with a low-potency steroid. Chronic use of topical steroids can lead to corticosteroid-re lated side effects and is generally discouraged.PUBLIC igher gher
s. Geogs. Geog
efinitionefinition
).)
menmeCOPYy primpr
nclude alclude a
ted estimed esti
th the inh the in
latlt
Thisxdocumentfor user use
cation intion i
kumab, umab,
ntagonistagonis
StandStandcannotphosphhosph
or (TNF(TNF
itors. Ttors. T
n manymany
iibe topicopic
diseasedisease
hhusedts for s for 
varies acaries a
cal tcal tto osupportateste
cidence dence
tudes. Psudes. P
aphical dphical d
f prevalprevanyy duedu
types of types o
s of thofmarketing akondakonda e
ustininetetal,
nce of Pnce of 
et oetauthorization PSO. SO. 
ary ry 
d to havto hav
0;;
application he
Phase Phase 3
n patients patien
clude thelude th
he ILe IL--171
brodalumrodalu
therapherapand diestes
antagonntago
effecteffecanyerapirap
re oftenre often
teraseteraextensionsso
differenffere
alence (Plence (P
soriasioriasi
cordingording
iesior nd nd
riasis iasisvariationst
l,20102010
PSO varPSO var
geneticgenetic
f PSO. PPSO. P
he magnmagn
prevprethereof. al,al,2020
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 20 of 263xVitamin D analogs (eg, calcipotriol and tacalcitol) are commonly used to treat 
mild-to-moderate PSO, and work best within the mild patients. They are safe but lack efficacy for more severe disease.
xPhototherapy is a frequent option for moderate to severe patients, but the inconvenience of 
multiple treatment visits and varying efficacy limits its use in the market.
xMethotrexate is a systemic immunosuppressant and is used in moderate to severe PSO 
patients. Toxicity concerns, particularly  in older patients, are a major drawback.
xCyclosporine is a systemic immunosuppressant used in patients with severe, recalcitrant PSO 
who have failed at least one systemic therapy or in whom other systemic therapies are contraindicated. In recommended dosages cyclos porine can cause systemic hypertension and 
nephrotoxicity, therefore, renal function must be monitored during therapy.
xApremilast is an oral small-molecule inhibitor of  PDE4 that is also approved for treatment of 
adults with moderate to severe plaque  PSO. Phosphodiesterase 4 inhibitors work 
intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. Phosphodiesterase 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the 
dominant PDE in inflammatory cells. Phosphodi esterase 4 inhibition elevates intracellular 
cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF α, IL-23, IL-17, and other inflammatory cytokines.
xBiologics, including TNF α inhibitors (adalimumab, etanercept, and infliximab), 
IL-12/23 inhibitors (ustekinumab), the IL-23p19 an tagonist (guselkumab), IL-17A inhibitors 
(secukinumab and ixekizumab), and the IL-17 receptor antagonist brodalumab are the treatment options of choice for patients with moderate to severe plaque PSO who are 
candidates for systemic therapy or phototherapy. These products are injected sc or delivered 
via intravenous (iv) infusion. Different from the traditional systemic drugs that impact the entire immune system, biologics target specific  parts of the immune system and offer reduced 
multi-organ toxicity and adverse effects a ssociated with traditional treatments.
TNFα inhibitors, while effective, come with boxed warnin gs including the risk of serious 
infections and reports of lymphoma and malign ancy in children and adolescent patients. 
The efficacy of TNF α inhibitors in treating PSO is attributed to their inhibition of 
Th17-T cells.
Ustekinumab has been approved in the US and th e EU for the treatment of patients with 
moderate to severe plaque psoriasis who are candidates for phototherapy or systemic 
therapy. Ustekinumab is a human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) 
that binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23
cytokines, naturally occurring cytokines that are involved in inflammatory and immune 
responses, such as natural killer cell acti vation and CD4+ T-cell differentiation and 
activation.
Secukinumab and ixekizumab have been approved  in the US and the EU for the treatment 
of moderate to severe plaque PSO in adult patients who are candidates for systemic 
therapy or phototherapy. Secukinumab is a human IgG1 mAb that selectively binds to the 
IL-17A cytokine and inhibits its interaction with the IL-17 receptor. Ixekizumab is a 
humanized IgG4 mAb that selectively binds with the IL-17A cytokine and inhibits its PUBLICrs (adars (ad
b), the IL), the IL
b), and tb), and t
e for pate for pat
erapy erapCOPYphoh
odiesteodiest
s the infs the i
other infther in
alili
This documenttekinumkinum
moderamodera
therathera
ththcannot s, whiwhi
d reportrepor
acy of TNy of T
cells.cells.bed adverdve
leleusedor phopho
DifferenDifferen
ogics tagics tatohe I
nts wints w
totsupport am
ammatmmat o
mumab, eumab, 
23p19 a23p19 a
ILL--1717
hany(cAc
e 4 inhie 4 inh
mmatorymato
ormarketing ic hyc hy
rapy.rapy.
o approveo approv
4 inhibitoinhibi
nd antid anti -in
AMP)AMauthorization calcitranalcitra
rapies aapies a
yperyper
apptpplication ab has beb has b
e to severe to sev
py. Usteky. Uste
binds wbinds
ytokineokineandeffeff
s of lymof lym
Fα inhiα inhiany gg
effectseffec
ective, ctive
hextensionsetan
antagonntagon
receptoreceptor
moderaoder
therapy.herapy
t from thfrom th
et spet speor yy
nercenercevariations tors wrs w
nflammaflamma
P)--specifspeci
bition eition e
ry respoy respo
cytokcytokthereof. re e 
tension ansion 
ed for trd for tr
worwor
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 21 of 263interaction with the IL-17 receptor. Interleukin- 17A is a naturally occurring cytokine that 
is involved in normal inflammatory and immune responses. Both drugs inhibit the release 
of pro-inflammatory cytokines and chemokines.
Guselkumab has been approved in the US and EU for the treatment of adult patients with 
moderate to severe plaque PSO who are candid ates for systemic therapy or phototherapy. 
It is a human monoclonal IgG1 λ antibody that selectively binds to the p19 subunit of 
IL-23 and inhibits its interaction with the IL-23 receptor. Interleukin-23 is a naturally 
occurring cytokine that is involved in normal inflammatory and immune responses. 
Guselkumab inhibits the release of pro-inflammatory cytokines and chemokines.
Brodalumab has been approved in the US for the treatment of moderate to severe plaque 
psoriasis in adult patients who are candidates for systemic therapy or phototherapy and 
have failed to respond or have lost response to other systemic therapies. In the EU, 
brodalumab is indicated for the treatment of moderate to severe plaque PSO in adult 
patients who are candidates for systemic therapy. Brodalumab is a human monoclonal 
IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. Blocking IL-17RA 
inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory 
cytokines and chemokines. Brodalumab has a black box warning regarding suicidal ideation and behavior.
2.2 Bimekizumab
Bimekizumab (UCB4940) is an engineered, humanized, full-length mAb of IgG1 subclass of approximately 150,000 Daltons which is expressed in a genetically engineered Chinese hamster 
ovary cell line. Bimekizumab has high affini ty for human IL-17A and human IL-17F and 
selectively and potently inhibits the activity of both isoforms in vitro. Interleukin-17A and IL-17F are key pro-inflammatory cytokines believ ed to play important roles in autoimmune and 
inflammatory diseases. Bimekizumab is being developed for the treatment of patients with 
inflammatory diseases such as PsA, PSO, and axial spondyloarthritis (axSpA).
While anti-IL-17A antibodies have demonstrated efficacy in patients with PSO, PsA, and 
ankylosing spondylitis, as yet, no therapeutic approach selectively and potently inhibits the 
activity of both IL-17A and IL-17F isoforms in vitro. Bimekizumab has been designed to inhibit the activity of IL-17A and IL-17F subtypes of IL-17. This property makes bimekizumab 
distinctly different from the other IL-17-target ing agents, like secukinumab and ixekizumab 
(selective anti-IL-17-A mAb) or brodalumab (anti-IL-17 receptor mAb).
Overexpression of IL-17A, IL-17C, and IL-17F in  lesion tissue suggests that broader IL-17
blockade may be more beneficial in the treatm ent of plaque PSO. However, blocking all IL-17
isoforms (including the IL-17E isoform, also known as IL-25) may not be the optimal approach. The role of IL-25 in PSO and other IL-17 mediate d diseases has not been well established; 
however, it has been suggested that IL-25 may play a beneficial role in inflammatory conditions 
associated with type 1 T helper mediated immune  responses, such as PSO (as opposed to type 2
T helper mediated) (Valizadeh et al, 2015). Thus, it can be hypothesized that inhibition of both 
IL-17A and IL-17F is associated with additional benefits in PSO compared with selective 
IL-17A inhibition or a broader IL-17 blockade.PUBLIC ngineerengineere
s which s which 
has hihas hiCOPYF hh
includinclu
b has a bb has 
ThisTdocument of ILfI L
y differendifferen
tive antive anti
verexpreerexpre
blockablocka
isofisofcannot ch
ntibodieibodie
ylitis, asitis, as
ILIL--17A17A
LL-1717beekizumkizu
h as Psh as Psusedgh affiaff
he activie activi
ry cytoky cyto
matod, 
expreexpr
finiinisupport lac
humanhuma
ssanymeme
g the relthe re
k box k bomarketing e t
r phototphoto
rapies. Inapies. In
e plaque e plaque
mab is a huab is a 
and inhibnd inh
r, andr, anauthorization py. y. 
f 
rally lly 
nses. nses. 
kines.nes.
o seveseve
application and Ind 
A and ILA and I
nt from thfrom 
ILIL--1717--A A
ssion of Ision of
may bemay b
nclands have have 
yet, no tet, no 
ILLany is beiis b
A, PSO, a, PSO, 
demextensions nized, fuized, fu
sed in a ed in a 
ty for hufor hu
ty of botof bo
nes beles bel
ior variations humanman
bits its is its i
d ILIL--25.25
ease of ase of 
warningwarninthereof.re plaque plaq
herapy aerapy a
n the EUthe EU
PSO inPSO in
nmnm
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 22 of 2632.2.1 Clinical
2.2.1.1 Completed studies
Five clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, 
UP0031 in 12 healthy volunteers, and UP0042 in 48 healthy volunteers. 
UP0008 was a Phase 1, single ascending dose study in adults with mild-to-moderate PSO 
affecting ≤5% BSA. In this blinded study, single doses of up to 640mg (approximately 8mg/kg 
in an 80kg adult) were evaluated without any safety concerns. A total of 26 subjects with PSO with less than 5% of body surface involvement were treated with a range of single iv doses from 
8mg to 640mg. There were no clinically relevant safety findings identified at any dose and all 
doses were well tolerated. The pre-specified ex ploratory assessment of disease activity showed 
clinically relevant and statistically significant improvements at the higher doses studied.
RA0124 was a Phase 1, open-label, parallel-group, single-dose study in healthy subjects. The 
primary objective of this study was to determine the absolute bioavailability (BA) of single sc 
doses of bimekizumab (80mg and 160mg). The sec ondary objectives were to evaluate the dose 
proportionality of bimekizumab 80mg and 160mg sc, a nd to evaluate the safety and tolerability 
of these sc doses and 160mg given by iv infusion. In RA0124, the absolute BA was similar for the 2 doses tested (0.656 and 0.631 for the bimekizumab 80mg and 160mg sc doses, 
respectively). The pharmacokinetics (PK) of bime kizumab was linear in the tested dose range 
and the median half-life following sc admini stration was similar to that following iv 
administration (27.81 days and 28.25 days for bimekizumab 160mg sc and 160mg iv, respectively).
Bimekizumab has also been investigated in a Phase 1b, proof of concept, randomized, placebo 
controlled, multiple dose study (PA0007). The primary objective of PA0007 was to assess the 
safety and PK of multiple dose administration of iv bimekizumab in subjects with PsA. Four 
active doses and a placebo were tested. Drug was administered as a loading dose at Week 0, and 2 additional doses were administered at Week 3 and Week 6. In each treatment group, subjects 
received a total of 3 doses of bimekizumab, administered every 3 weeks as shown below:
x80mg loading dose followed by 40mg at Weeks 3 and 6
x160mg loading dose followed by 80mg at Weeks 3 and 6
x240mg loading dose followed by 160mg at Weeks 3 and 6
x560mg loading dose followed by 320mg at Weeks 3 and 6
The results of this study demonstrated that all doses of bimekizumab were well tolerated and 
there were no unexpected clinically relevant safety findings.
Infections (mostly nasopharyngitis) were the most commonly reported events in both the active 
treatment and the placebo group. None of the infections were considered serious or required 
treatment with antibiotics. Two subjects in the active treatment group experienced 1 local 
candida infection each (oropharyngitis and vulvovagi nitis, respectively) that were nonserious and 
resolved with topical therapy. There was a potential reduction in mean neutrophil count in the 
active treatment group, although this drop was not clinically relevant and a clear relationship PUBLIC o
dminisdmini
5days fdays
nvestignvestig
(P(PCOPYsc, ansc, a
on. In RAon. In RA
imekizuimekizu
f bimef bim
ThisIdocumentg loadinloadin
60mg lo0mg lo
The resuThe res
theretherecannotoses ofes of
dose folose fo
ding dong dobe were tre t
ministeminist
bbused ated ied 
A0007).007).
adminisdminis
testtestto in ain asupport mab 80ab 80
kizumab izuma
ation wasion w
or bimekir bimekany evaluevalu
124, the124, the
0mg0marketingany ny
ease actiease act
er doses sr dose
y in healtin hea
availabilivailab
tives wtives 
tauthorization y 8mg/kgmg/kg
with Pwith P
le iv dose iv do
y dosdos
application se follow follo
g dose foldose fo
ading dosding d
ts of thiss of thi
no unoand mekmek
owed bywed banyd. Dru. D
d at Wed at W
kizumkizuextensions s simsi
izumab umab
Phasehase 11
The primhe pri
ation otion o
ugorwas lwas 
milamilavariationsthy y
lity (BAy (BA
were to ewere to 
te the sate the sa
he absoluabsolu
and 16and 1
inthereof.es fres
e and allnd all
vity shoty sho
studied.studied
y subjsub
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 23of 263with dose or time was not evident. Some increases in liver function tests were reported, but none 
had a convincing relation ship to exposure to IMP. The exploratory analysis showed clinically 
relevant improvement in activity of PsA and in skin involvement in those subjects with 
concomitant active psoriatic lesions.
UP0031 was a Phase 1, open -label, parallel -group, randomized, s ingle -dose study to evaluate the 
BA, PK, and tolerability of 2 different formulation s of bimekizumab in healthy subjects. Subjects 
receiving Formulation A (histidine -based) were administered two 1mL injections of 80mg each 
of bimekizumab and subjects recei ving Formulation B (acetate -based) were administered a 
single injection of bimekizumab 160mg given as a 1mL injection. Six subjects were randomized 
to each bimekizumab formulation. The geometric means for area under the curve (AUC) were 
similar between bim ekizumab 2x80mg and 1x160mg groups and the relative BA for 
Formulation B vs Formulation A was 96.1% (95% confidence interval [CI]: 72.7%, 127.0%). 
Administration of the 2 formulations of bimekizumab used in this study identified no new safety 
issues. There were no treatment -emergent adverse events (TEA Es) leading to discontinuation, 
and no serious adverse events (SAEs) or fatalities were reported. The only preferred term (PT) 
experienced by more than 1 subject in either treatment group was injection site pa in (5 subjects 
[83.3%] and 3 subjects [50%] in the 2x80mg and 1x160mg groups, respectively). The most 
frequently reported TEAE considered related to the IMP was injection site pain, experienced by 
5subjects (83.3%) and 3 subjects (50.0%) in the 2x80mg and 1x160mg groups, respectively. 
There were no clinically significant laboratory values reported in the study.
UP0042 was a randomized double -blind, placebo -controlled, single -dose, parallel -group study to 
evaluate the safety, tolerability, and pharmacokinet ics of bimekizumab administered as 
subcutaneous injection to Japanese and Caucasian healthy subjects. This study demonstrated that 
the PK profiles following single administration of  80mg, 160mg, and 320mg with sc injection 
were dose proportional with a lin ear elimination in both Japanese and Caucasian subjects and 
that the PK profiles of Japanese and Caucasian subjects were consid ered to be generally similar. 
A single dose of bimekizumab (80mg, 160mg, or 320mg) administered as sc injection was 
generally and well tolerated in healthy Japanese  and Caucasian subjects and no major 
differences in safety findings were observe d between Japanese a nd Caucasian subjects.
Additional information on completed studies is available in the Investigator’s Brochure (IB).
2.2.1.2 Ongoing studies
All ongoing studies at the time of Protocol Amendment #5.4 implementation are presented and 
described in the current version of the IB .
2.2.2 Nonclinical
Parallel inhibition of IL -17A and IL -17F has been shown to be efficacious in a variety of animal 
models of inflammatory disease. Intravenously administered bimekizumab was well tolerated in 
repeat dose toxicology studies in Cynomolgus monkeys with a no adverse effect level of 
200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
enteritis (observed in the single dose study) a nd asymptomatic mild colonic ulceration in a 
proportion of animals (in the repeat dose study); this latter finding was not associated with 
hematology abnormalities. Data suggest that bim ekizumab has induced primary lesions to the 
mucosa associated lymphoid tissue via a pha rmacologically related mechanism. In a second 
repeat -dose study, none of the minor apoptosis/necrosis findings observed in gut associated PUBLICnd, placd, pla
d pharmad pharm
ese and Cese and C
gle admigle adm
inineCOPY x160x16
the IMPhe IMP
the 2x8he 2x8
ory valry val
Thisrdocumentg studistudi
d in thein the
2
ParallelParalle
modmodcannot ndingsdings
tion on on on 
OngoinOngoibeb (8(
erated ierated 
swswusednistis
ar eliminelimi
and Caund Cau
80mg80mto CaucaCauca
tratiotratiosupport mg amg a
ues report repo
boo--controcont
cokinetokinet icic
asianasiaany roupsroup
was injecwas inje
andand1marketing BA fBA 
]: 72.7%]: 72.7%
y identifiedentif
eading to ading t
The only he onl
as injects injec
srauthorization he he 
bjects jects 
mg each each 
red a ed a 
e randomrandom
e (AUC(AUC
forfor
application g stu st
 at the timat the 
current vurrent 
NoncNon
nhibitionhibition
nflafand erere
completemplete
ududany 1606
healthy ealthy
observobseextensions olledlled
s of bimof bim
n healthyhealthy
n of 80mof 80m
ation in ion in
casian sasian s
0mg0mgor ed ind 
ds ids ivariationso d
y preferprefer
tion siteion site
respectivrespectiv
ction sittion sit
1x160mx160m
nt hnt hthereof.  werew
%, 127.0%127.0%
ed no need no n
disconiscon
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 24 of 263lymph nodes were revealed. In animals given the highest dose of bimekizumab in the study 
(20mg/kg/week), a slightly higher number of protozoa ( Balantidium coli ) was observed in the 
cecum and colon as compared to the control an imals and low dose animals. Therefore, gut 
associated lymph node lesions observed in the firs t study are considered to be accidental and/or 
linked to exaggerated pharmacology and proliferation of Balantidium coli and are considered the 
consequence of a change in local mucosal immuni ty. To date, similar findings have not been 
seen in studies in humans.
Additional information on the nonclinical data for bimekizumab is available in the current 
version of the IB.
3 STUDY OBJECTIVES
3.1 Primary objective
The primary objective of this study is to compar e the efficacy of bimekizumab administered sc 
for 16 weeks versus secukinumab at achieving complete clearance (PASI100) in subjects with moderate to severe chronic plaque PSO.
3.2 Secondary objectives
The secondary objectives of the study are to:
xEvaluate the efficacy of bimekizumab compared with secukinumab after 4 weeks, 16 weeks, 
and 48 weeks of treatment.
xAssess TEAEs, SAEs, and TEAEs leading to withdrawal adjusted by duration of subject 
exposure to IMP.
3.3 Other objectives
The other objectives of the study are to demonstrate the effects of bimekizumab on the following aspects of the disease:
xAssess the efficacy of bimekizumab over time
xAssess the change of skin-related quality of life (QOL)
xAssess the change of general health-related QOL
xAssess the change in nail PSO over time in subjects with nail PSO at Baseline
xAssess the change in psoriatic scalp disease over time in subjects with scalp PSO at Baseline
xAssess the change in psoriatic palmoplantar diseas e over time in subjects with palmoplantar 
PSO at Baseline
xAssess the change in patient global assessment PSO score
xAssess the change in symptoms of PSO (itch, pa in, and scaling) as reported by subjects 
xAssess work productivity status
xAssess the safety and tolerability of bimekizumab
xAssess the PK of bimekizumabPUBLIC AEs leadAEs lead
tivestivesCOPY ompareompare
This document he che c
ess the cs the c
Assess tAssess 
PSO PSO
xxAAcannot b
e of skinof skin
hange ofnge of
hanghanbe bimekibimekiused y are to dare to to support d with sewith s
ng to withg to wiany marketing kizumab kizuma
(PASI100PASI1authorization e 
rent nt 
application ge
e in nail e in nail
hange in pange in
he changechan
at BaselinBaseli
thehandrelaterelate
eneral neralany umab ovumab ov
dqextensions thdrawadrawa
emonstrmonstor ukiukvariations 00) in ) in
inuminuthereof. adminiadmini
ns usu
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 25 of 263xAssess the immunogenicity of bimekizumab
xAssess the maintenance of efficacy of bimekizumab dosing Q4W versus Q8W
xAssess the safety and efficacy of initiating bimekizumab therapy in subjects who received 
secukinumab in the double-blind Treatment Period
4 STUDY VARIABLES
4.1 Primary efficacy variable
The primary efficacy variable is the PASI100 response, defined as complete clearance from 
Baseline in the PASI score, at Week 16.
4.2 Secondary variables
4.2.1 Secondary efficacy variables
The secondary efficacy variables are:
xPASI75 response at Week 4
xPASI90 response at Week 16
xPASI100 response at Week 48
xIGA response (0/1) (defined as Clear or Almost Clear with at least a 2-category improvement 
relative to Baseline) at Week 16
4.2.2 Secondary safety variables
The secondary safety variables are:
xTEAEs adjusted by duration of subject exposure to IMP
xSAEs adjusted by duration of subject exposure to IMP
xTEAEs leading to withdrawal adjusted by dur ation of subject exposure to study treatment
4.3 Other variables
The other variables are listed below and will be  evaluated according to the planned assessments 
(Table 5‒1,Table 5‒2, and Table 5-3 ).
4.3.1 Other efficacy variables
The other efficacy variables are listed below a nd will be evaluated according to the planned 
assessments ( Table 5‒1,Table 5‒2, and Table 5-3 ). This excludes the time points for the primary 
and secondary variables specified above in Section 4.1 and Section 4.2.1 , respectively.
The other efficacy variables are:
xPASI75, PASI90, and PASI100 response
xTime to PASI75, PASI90, and PASI100 response 
xAbsolute and percent change from Baseline in PASI 
xPercentage of subjec ts with PASI ≤1, ≤2, ≤3, and ≤5PUBLIC or 
ety varity vari
s are:s are:COPY AlmoAlm
ThisTdocument Tablab
O
e other eother e
assessmesessme
and seand scannot thdhd
er varer var
bles areles are
ee55be on ofn o
drawadrawaused of subjef subje
f subfs u bto ablesupport st Clear wClear
esesany marketing authorization nce fromce fro
application listed sted
22, and , and T
Other effOther ef
fficacy vacacy v
nts (ts (TablTab
dary vdary vand ablesbles
bbany ect eect 
adjusteddjustedextensions t exposuexposu
expexporith atith avariations tlthereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 26 of 263xIGA response (Clear)
xIGA response (Clear or Almost Clear with at least 2 category improvement relative to 
Baseline)
xShift from Baseline in IGA score
xAbsolute and percent change from Ba seline in the BSA affected by PSO
xAbsolute and percent change from Baseli ne in the product of IGA and BSA (IGAxBSA)
xChange from Baseline in Dermatology Life Quality Index (DLQI)
xPercent of subjects achieving a DLQI total score of 0 or 1
xPercent of subjects achieving a minimal clinically important difference (improvement from 
Baseline of 4 or more) in the DLQI
xChange from Baseline in the Patient's Global Assessment of Disease Activity (PGADA) for 
the arthritis visual analog scale (V AS) in subjects with PsA at Baseline
xChange from Baseline in Patient Global Assessment of PSO score
xChange from Baseline in symptoms of PSO (itch, pain, and scaling)
xChange from Baseline in Modified Nail Ps oriasis Severity Index (mNAPSI) score for 
subjects with nail PSO at Baseline
xPercent of subjects achieving mNAPSI75, mNAPSI90, and mNAPSI100 for subjects with 
nail PSO at Baseline
xScalp- specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear with at least 2-category improvement relativ e to Baseline) for subjects with scalp PSO 
at Baseline
xPalmoplantar Investigator’s Global Assessment (pp -IGA) response (Clear or Almost Clear 
with at least 2-category improvement relative to Baseline) for subjects with palmoplantar 
PSO at Baseline
xResponses to the European Quality-of-Life 5- Dimensions 3-Level (EQ-5D-3L) dimensions, 
absolute and changes from Base line in EQ-5D-3L VAS scores
xChange from Baseline in Work Productivity and Activity Impairment Questionnaire-specific 
health problem (WPAI-SHP) V2.0 adapted to PSO scores
xChange from Baseline in the Psoriatic Arthritis Screening and Evaluation (PASE) 
questionnaire scores (function score , symptom score, and total score)
xShift from Baseline in PASE sc ore suggestive of PsA (<47 versus ≥47)
4.3.2 Other safety variables
Other safety variables to be assessed are:
xSeverity and frequency of AEs
xChange from Baseline in vital signsPUBLIC NNAPSI7APSI
r’s Glor’s GloCOPY mene
O (O (itch, pitch
PsoriaPsoria
This document an
ge from e from 
alth probth pro
ChangChang
quequecannot ory iry 
 the Eurhe Eur
d chanchanbetor’s Gtor’s G
impimpused bal Aal A
improvemproveto Assesssupportis SeveriSever
5, mNAP, mNAany SO sSO 
n, and s, andmarketing e (improv(impro
sease Actease A
at BaselinBasel
corcoauthorization BSA)SA)
applicationop
ges fromes from
Baseline iaselin
lem (WPlem (W
e from Bafrom B
ionnaireonnaiand rov
ean Qan Qanybal Assal As
vement emenextensions PSI90, aSI90, a
ssment (sment (
ment relent reor y Iny Ivariations tivityvity
ne
e
scalingaling ))
ndexndethereof. vement fment f
y( Py( P
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 27 of 263xECG results
xChange from Baseline in clinical laboratory values (chemistry, hematology, and urinalysis)
xChange from Baseline in Patient Health Questionnaire-9 (PHQ-9) scores
Physical examination findings considered clinically significant changes since the physical 
examination at the Screening Visit will be recorded as AEs.
4.3.3 Pharmacokinetic variableThe PK variable is the plasma concentration of bimekizumab.
4.3.4 Immunological variable
The immunological variable is the anti-bimekizumab antibody level prior to and following IMP 
administration.
5 STUDY DESIGN
5.1 Study description
PS0015 is a randomized, double-blind, secukinumab-c ontrolled, parallel-group study to evaluate 
the efficacy and safety of bimekizumab administered sc to subjects with moderate to severe chronic plaque PSO. To be eligible to participate in  this study, subjects must be adults with a 
diagnosis of moderate to severe plaque PSO (PASI ≥12 and BSA ≥10% and IGA score ≥3 [on a 
5-point scale]) who are candidates for sec ukinumab, or for systemic PSO therapy and/or 
phototherapy.
5.2 Study periods
This study will include the following periods: 
xA Screening Period (2 to 5 weeks) 
xA double-blind Treatment Period (48 weeks; final dose at Week 44) 
xAn optional OLE Period (96 weeks; final dose at Week 136 for subjects receiving 
bimekizumab 320mg Q8W and at Week 140 for subjects receiving bimekizumab 320mg Q4W) followed by a SFU Period (20 weeks afte r the final dose of IMP administered in the 
OLE Perio d depending upon subject’s participation in the OLE2 Period ), and 
xAn optional 48-week OLE2 Period followed by a SFU Period (SFU2, 20 weeks after the final 
dose of IMP administered in the OLE2 Period).
The OLE2 Period was added as per Protocol Amend ment #5.4 at the time when subjects will still 
be treated in the OLE (prior to Week 144 Visit) or will have finished treatment in the OLE (after 
completing Week 144 Visit):
xSubjects in the treatment phase of the OLE Period at the time of Protocol Amendment #5.4
implementation will attend the Week 144 Visit and directly roll over to the OLE2 Period. These subjects will continue receiving bimekizumab 320mg Q8W for 40 additional weeks, 
starting from the first treatment visit of the OL E2 Period (ie, Week 144/OLE2 Baseline Visit; 
the Week 144 Visit will coincide with the Week 144/OLE2 Baseline Visit and data collected 
at this visit will be used as baseline data for subjects entering the OLE2 Period).PSO SO
r secukinecuki
dsds
owowCOPYmabmab-conco
istered sistered
cipate inipate in
(PA(PA
This document ood
ptional ional 
ose of IMe of IM
he OLEOLE
be treabe trea
comcomcannotPeriod riod 
20mg Q0mg Q
wed by ad by a
d depedepebeent Perent Peusedng periog perio
weeks)weeks)to supportc toto
this studhis stu
SI ≥12 an≥12 
umab, or mab, oany olled, polled, p
o subjesubj
dmarketing to and foto and foauthorization 
applicati8-ationSFU
nding upnding u
week week O
MP adminiP admin
2 Period wPeriod
d in the in the
Wand96 wewe
8W andW and
U PeU Pany d (48d (48 ww
eks;ekextensionsr for syor s
ds: s: or, s,
d BSABSA
ysvariations arallelrallel --g
ects withcts with
subjesubjethereof. ollowinglowin
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 28 of 263xEligible subjects who have completed the Week  144 Visit and are in the SFU or have 
completed the SFU of the OLE Period at the time of Protocol Amendment #5.4implementation, will reinitiate their treatmen t in the OLE2 Period after having undergone 
Screening assessments during a 4-week OLE2 Screening Period. The first dose will be 
administered at the Week 144/OLE2 Baseline Vi sit and data collected at this visit will be 
used as baseline data for the OLE2 Period. S ubjects in OLE2 Group B with an IGA score ≥3 
at the Week 144/OLE2 Baseline Visit will be treated with bimekizumab Q4W for the first 16 
weeks, and will then switch to bimekizumab 320mg Q8W. Subjects in OLE2 Group B with an IGA score <3 at the Week 144/OLE2 Baseli ne Visit will be treated with bimekizumab 
Q8W from the Week 144/OLE2 Baseline Visit.
During the OLE2 Period (Week 144/OLE2 Baseline  to OLE2 Week 48), all subjects will attend 
study visits every 12 weeks. All subjects will be treated until OLE2 Week 40 (last dose of 
bimekizumab 320mg Q8W).
Following completion or early withdrawal from the OLE2 Period, subjects will undergo the SFU 
of the OLE2 Period (SFU2) and will return for the SFU2 Visit 20 weeks after the last dose of IMP administration.
The end of the study is defined as the date of the last visit of the last subject in the study.
5.2.1 Screening Period
The Screening Period will last 2 weeks, but can be extended up to a total of 5 weeks in cases 
where a laboratory assessment needs to be repeated or to allow washout of prohibited medications. During this time, eligible subjects will be informed about the study and sign the 
Informed Consent Form (ICF), laboratory data (hematology, urine, and biochemistry tests) will 
be obtained, and the doses of medications used to treat PsA (if applicable) will be verified as 
stable. The Screening Period will also enable washout of any medications not permitted for use 
during the study. Subjects who require prophylaxis for latent tuberculosis (LTB) infection must 
be on treatment for at least 8 weeks prior to their first dose of IMP. These subjects may be rescreened once they have completed the first 8 weeks of prophylaxis treatment.
One rescreening may be allowed after consultation with the Medical Monitor.
The assessments to be performed at the Screening Visit are presented in Table 5‒1.
5.2.2 Treatment PeriodDuring the first 16 weeks of the 48-week double-blind Treatment Period, approximately 700 
subjects will be randomized 1:1 to receive the following blinded IMP regimens:
xBimekizumab 320mg administered sc Q4W (350 subjects)
xSecukinumab 300mg administered sc at Base line and Weeks 1, 2, 3, and 4 followed by 
dosing Q4W (350 subjects)
Subjects receiving bimekizumab 320mg will rece ive placebo sc on Weeks 1, 2, and 3 in order to 
maintain the blind. 
At Week 16 subjects in the bimekizumab 320mg treatment arm will be re-randomized 1:2 to 
receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W. To maintain the blind after re-PUBLIC, but c, but c
s to be rs to be r
igible sugible su
, labora, labora
medicmedCOPY he last vihe last vi
This document TT
the firsthe firs
ects willts wil
BimBim
xxcannot ve ce 
y be allobe all
s to be pto be p
reareabeo r
8weekwee
compcomusedor
ations tions 
l also enalso e
requirequirtobjec
y datay datsupport be extenbe ext
epeated orpeated 
cts wilts wany of the lof the lmarketing subjebje
40 (last d40 (last 
subjects wubjects
0 weeks aweekauthorization e ≥3 ≥3 
first 16 first 16 
p B withB with
kizumakizuma
ctscts
application erforrfo
tment Pment 
16 weeks16 wee
be randome rand
kizumabizumab
umandwed aftwed aft
rmermeanyprp
prior toprior t
ted the ed theextensionsnded
or to alloto all
ll be infl be in
(hematohemato
sed to treed to tre
able wasble was
rophyophyor d up du pvariations wiill ull u
after thfter th
last subast subthereof. will atteill atte
dose of ose o
undund
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 29 of 263randomization, subjects in the bimekizumab 320mg Q8W treatment arm will receive placebo at 
Weeks 20, 28, 36, and 44. Subjects in the secukinumab arm will continue to receive 
secukinumab 300mg Q4W.
Investigational medicinal product will be administer ed in the clinic by sc injection at the time 
points specified in the schedule of assessments ( Table 5‒1).
Subjects withdrawing early from the study will undergo the PEOT Visit assessments and will 
enter the SFU Period.
The assessments to be performed at each double- blind Treatment Period Visit are presented in 
Table 5‒1.
5.2.3 OLE Period
After completion of the Week 48 visit assessments, s ubjects will be allowed to enroll in the OLE 
Period. All subjects enrolling in the OLE Period will sign a new ICF, and then receive the 
following IMP regimens as determined by the s ubject’s treatment regimen and PASI response in 
the double-blind Treatment Period. 
At Week 48, subjects receiving:
xBimekizumab 320mg Q4W who achieve PASI90 at Week 48 of the double-blind Treatment 
Period will be randomized 1:1 to receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W.
xBimekizumab 320mg Q4W who do not achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q4W.
xBimekizumab 320mg Q8W who do not achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q4W.
xBimekizumab 320mg Q8W who achieve PASI90 at Week 48 of the double-blind Treatment 
Period will receive bimekizumab 320mg Q8W.
xSecukinumab who do not achieve PASI90 at We ek 48 of the double-blind Treatment Period
will receive bimekizumab 320mg Q4W.
xSecukinumab who achieve PASI90 at Week 48 of  the double-blind Treatment Period will be 
randomized 1:1 to receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W.
During the OLE Period, subjects will attend study visits at Weeks 52, 56, 64, and 72, and then 
every 12 weeks. At study visits, IMP will be ad ministered in the clinic by sc injection as 
applicable. In between study visits, s ubjects will self-inject IMP at home.
The subject’s dosing interval will change from bimekizumab 320mg Q4W to bimekizumab 
320mg Q8W at Week 64, or at the next scheduled clinic visit after implementation of 
Protocol Amendment #5.1 if the subject has already completed Week 64. 
The last dose bimekizumab 320mg Q8W in the OLE Period will be administered at Week 136. 
The End of Treatment Visit of the OLE Period will be the Week 144 Visit.
All subjects not enrolling in the open-label stud y will have the Week 48 study assessments and 
will enter the SFU Period.PUBLIC do not do not 
 bimekibimeki
W who W who 
veveCOPY ASI90 aASI90
e bimek bimek
ThisPdocument ed ed
he OLE  OLE
12 week2 week
plicable.icable.
The suThe su
320320cannot do non
ekizumakizum
b who awho a
d 1:1 t1:1 tbeekizumkizum
tatauseddo no n
bimekizmekiz
whowho aato um
not acnot acsupportt WW
zumab 3umab 
chieve PAhieve PA
mab 32ab 3any Week 4Week 
32marketing wed to ened to e
aand thennd the
regimen agimenauthorization will will 
resentedesented
applicationhie
o receiveo receiv
Period, sueriod, 
s. At stud. At stu
In between betw
ect’s doct’s d
Wandhihi
b 320m320m
eve Pve Pany 320m320m
eve PAve Pextensions ASI90 SI90
20mg Q40mg Q
hieve PAieve P
umab 32mab 32
ieve Peve Por 0mvariationsand Pnd P
48 of the of the
0mg Qmg Qthereof. nroll in oll in
receivereceive
AA
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 30 of 263The assessments to be performed at each OLE Period visit are presented in Table 5‒2.
5.2.4 OLE2 Period
Subjects enrolled as per Protocol Amendment #5.1 will be treated in the OLE Period until Week 
136 (last dose of bimekizumab 320mg Q8W) and will be followed in a SFU Period for 20 weeks after attending the Week 144 Visit (see Section 5.2.3) . After the implementation of Protocol 
Amendment #5.4 (addition of a 48-week treatment pe riod, ie, OLE2 Period), subjects will be 
invited to continue or reinitiate their tr eatment as per the following OLE2 Groups:
xOLE2 Group A: Subjects in the treatment phase  of the OLE Period at the time of Protocol 
Amendment #5.4 implementation will attend the Week 144 Visit and directly roll over to the 
OLE2 Period. These subjects will continue receiving bimekizumab 320mg Q8W for 
40 additional weeks, starting from the first treatment visit of the OLE2 Period (ie, Week 
144/OLE2 Baseline Visit; the Week 144 Visit will coincide with the Week 144/OLE2 
Baseline Visit and data collected at this visit will be used as baseline data for subjects 
entering the OLE2 Period).
xOLE2 Group B: Eligible subjects who have completed the Week 144 Visit and are in the 
SFU or have completed the SFU of the OLE Pe riod at the time of Protocol Amendment #5.4
implementation, will reinitiate their treatmen t in the OLE2 Period after having undergone 
Screening assessments during a 4-week OLE2 Screening Period. The first dose will be 
administered at the Week 144/OLE2 Baseline Vi sit and data collected at this visit will be 
used as baseline data for the OLE2 Period. S ubjects in OLE2 Group B with an IGA score ≥3 
at the Week 144/OLE2 Baseline Visit will be treated with bimekizumab Q4W for the first 16 
weeks, and then will switch to bimekizumab 320mg Q8W. Subjects in OLE2 Group B with 
an IGA score <3 at the Week 144/OLE2 Baseli ne Visit will be treated with bimekizumab 
Q8W from the Week 144/OLE2 Baseline Visit. 
During the OLE2 Period (Week 144/OLE2 Baseline  to OLE2 Week 48), all subjects will attend 
study visits every 12 weeks. All subjects will be treated until OLE2 Week 40 (last dose of 
bimekizumab 320mg Q8W).
Following completion or early withdrawal from the OLE2 Period, subjects will undergo the SFU 
of the OLE2 Period (SFU2) and will return for the SFU2 Visit 20 weeks after the last dose of IMP administration.
The assessments to be performed at each visit of the OLE2 Period are presented in Table 5-3 .
5.2.5 Safety Follow-Up Periods
The assessments for the SFU Visits are presented in Table 5‒1, Table 5 ‒2, and Table 5-3.
Two SFU Periods are considered since Protocol Amendment #5.4 implementation: a first SFU 
following the OLE Period and a second SFU (S FU2) following the OLE2 Period (added as per 
Protocol Amendment #5.4 implementation).
Subjects having completed Week 144 Visit and who are in the SFU or have completed the SFU 
will be invited to reinitiate th eir treatment in the OLE2 Period. 
Subjects still being treated in the OLE Period (not  having attended Week 144 yet) will have the 
opportunity to directly roll over in the OLE2 Period without participating in the first SFU.PUBLICBa
2 PeriodPerio
 Visit wVisit w
to bimekto bimek
eek 144eek 144
OLEOLCOPYpp
eriod aeriod
ent in theent in 
OLE2 SOLE2 S
aselineselin
This Pdocumentments ents 
e assessasses
Two STwo S
follfollcannotW
n or earor ear
d (SFU(SFU
tion.on.
tbe All sAll s
W).W).usedOLO
2 BaselBasel
144/144/OO
ububto izumum
LE2 BLE2 Bsupport creeningeenin
Visit andVisit an
Subjects ubject
ll be treal be tre
mab 3mabanyWW
he timehe tim
LE2 PeLE2
gPmarketingg Q8Q
Period (Period 
e Week 14Week 
line data ne dat
Week 14Week authorization be e 
of ProtocProtoc
y roll ovroll ov
8W 8W
application be perfore perf
Safety FSafety 
ments for ents fo
U PeriodPerioandy withdwith
) and wand wany cts wcts w
draextensions in On O
ated wited wit
320mg Q20mg Q
aseline Veline V
ne Visit. Visit
E2 Bas2 Bas
wililordata data
OLEOLEvariations fo
44 Visi44 Visi
of Protoof Proto
eriod afriod af
eriod. eriod. thereof. er to r 
for 
ie, Wee, Wee
44/OLE44/OLE
or subjor sub
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 31 of 263Subjects who decide not to participate in OL E2 Period will undergo the first SFU period for 
20 weeks after their last dose in the OLE Period.
All subjects who have completed treatment in the OLE2 Period (ie, have completed the OLE2 
Week 48 Visit), or have withdrawn from IM P during the OLE2 Period before OLE2 Week 48,
will have a SFU2 Visit 20 weeks after thei r final dose of IMP administered up to OLE2 
Week 48.
5.2.6 Premature End of TreatmentSubjects withdrawing early from the study will undergo PEOT Visit assessments (see 
Section 8.5) and will enter the SFU or SFU2 Period depending on when subjects withdraw.
5.3 Study duration per subject
For each subject, the study will last a maximum of up to 165 weeks, as follows:
xScreening Period: 2 to 5 weeks
xDouble-blind Treatment Period: 48 weeks (final dose at Week 44)
xOLE Period: 96 weeks (final dose at Week 136 for subjects receiving bimekizumab 320mg 
Q8W and at Week 140 for subjects receiving bimekizumab 320mg Q4W) followed by a 
Safety Follow-Up Period: a SFU Visit is planne d 20 weeks after the final dose of IMP visit in 
the OLE Period (this SFU will not apply to subjects directly rolling over from the OLE to the OLE2 Period [see Section 5.2.5 ])
Subjects eligible for the OLE2 Period (added as part of Protocol Amendment #5.4) will enter the 
OLE2 Period after completing Week 144 of the OLE Period. The OLE2 Period will include a 
48-week treatment period with a final visit at OLE2 Week 48 and a SFU Period (SFU2) of 
20 weeks after the final dose of IMP administered in the OLE2 Period. 
For the subjects in the OLE2 Period, maximum study duration will depend on the time between 
their participation in the OLE until Week 144 and the start of the OLE2 Period:
x209 weeks for subjects still being treated in the OLE Period and who will directly roll over to 
the OLE2 Period at Week 144
x225 weeks for subjects who have completed Week 144 and the SFU; these subjects will have 
a 4-week Screening Period before reinitiating tr eatment in the OLE2 Period. Note: for these 
subjects, the study duration will not be continuous.
xBetween 209 and 225 weeks for subjects who have completed Week 144 and are
participating the in the SFU. For these s ubjects, the maximum study duration will depend 
upon when they stop the 20-week SFU period to enter the 4-week OLE2 Screening Period.
5.4 Planned number of subjects and sites
Approximately 935 subjects will be screened in  order to have 700 subjects randomized in the 
study. There will be approximately 350 subjects in the bimekizumab 320mg treatment arm and 
350 subjects in the secukinumab 300mg treatment arm. The planned number of study sites is 
approximately 86. Every eligible subject who signs an ICF will be randomized.PUBLIC ply
iod (addiod (add
Week 14Week 14
h a finah a fina
IMIMCOPY6 for sufor
g bimekg bimek
plannedplanned
y to suto s
This documentScSc
ts,the sthe s
etwween 2een 2
particippartici
upoupo
5.454cannotects stcts st
at Weeat We
or subjer subje
creenireenibeLE untiE unt
tilltillused l visivis
P admiadmi
riod, miod, m
lto4 of th of th
it atit atsupport 20 we0 we
bjects direects d
d as partas part
he Oany cts reccts re
umab 32umab 32
eekskmarketing follows:llows
ekk44)44)
eiauthorization ee e 
withdrawithdra
applicationcts ws w
ng Periodng Perio
udy duratdy dur
09 and 09 and 22
ating the ting th
when thwhen thand beibei
k 144144
who whoany Week 14Week 
ng treang trextensions t of Protof Prot
OLE PerLE Pe
OLE2LE2 WW
istered tered 
ximumimumorctly rctlyvariations eiving biiving b
20mg Q0mg Q
after tafter t
rothereof. w.w.
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 32 of 2635.5 Anticipated regions and countries
The regions planned for study conduct are Nort h America, Western Europe , and Central/Eastern 
Europe, with possible extension to other regions and countries.
5.6 Schedule of study assessments
The schedule of study assessments is presented in Table 5‒1for the Screening and double-blind 
Treatment Periods, in Table 5‒2for the OLE Period, and in Table 5-3 for the OLE2 Period. At 
each visit, all study assessments should be performed prior to ad ministration of IMP.
COPY 
This document cannot be used to support any marketing authorization lind nd 
od. At d. At 
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 33 of 263Table 5‒1: Schedule of study assessments, Screening and double-blind Treatment Periods
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first dose)1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
Informed consent X
Inclusion/exclusion X Xc
Urine drug screen X
Demographic data X
Psoriasis history X
eC-SSRS X X X X X X X X X X X X X X X X X
Significant past medical history 
and concomitant diseasesX Xd
Physical examc, eX X X X X X
Height X
Body weight X X X X X
Vital signsfX X X X X X X X X X X X X X X X X X
Hematology and biochemistry X X X X X X X X X X X X X
Urinalysis X X X X X X X X
ECG X X X X
Pregnancy testinggX X X X X X X X X X X X X X X
Hepatitis B and C testinghX
HIV testingiX
Chest x-rayjX
IGRA tuberculosis test X XPUBLIC XXICICICICUB
LICUBUBUBPUBP
COPY 
YPYOPOPOPOPCOCCCCThis sis tisdocument XX
XXnmememememcu
eststdo
cannotXXtotXXnoooo
X
aaancacccc
beeXX XXeeebebbbb
used 
ddddsdssseusu
to otoooosupport 
ttttortXXpooopoppppsup
any nnnnyanaaa
marketing 2828ke
nkekekerkearrmmmmm
authorization 
a
odsdshouuutauappXXpplication 
onXXononononatiicXXlicicicicppaaaaa
andXXdddd andaaaa
any yXX Xyyynyannan
extensions Xsson
XXssionsennnxt
nexexxex
or orXoororor
variations 
nsnsnsnstinstititioatiiaavavavaava
thereof. 3232 33he
ofthhhh
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 34 of 263Table 5‒1: Schedule of study assessments, Screening and double-blind Treatment Periods
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first dose)1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
Tuberculosis questionnaire X X X X X X X
PASI X X X X X X X X X X X X X X X X
Percentage of BSA X X X X X X X X X X X X X X X X
Blood sample for 
bimekizumab/secukinumab plasma concentrations
kX X X X X X X X X X X X
Blood sample for 
anti-bimekizumab antibodiesk X X X X X X X X X X X X
IGA X X X X X X X X X X X X X X X X
DLQI X X X X X X X
Patient Symptoms (itch, pain, 
and scaling)X X X X X X X
PHQ-9 X X X X X X X X X X X X X X
scalp IGAlX XlXlXlXlXlXlXlXl
mNAPSImX XmXmXm
pp-IGAnX XnXnXn
Patient Global Assessment of 
psoriasisX X X X X X X
PASE X X
PGADA X XoXoXo
WPAI -SHP V2.0 X X X XXXCLICX
BLLLUB
LUUUPUP
COPY XXY
XX
PYYCOPCCThis 
document 
eeeemeumocd
cannot XXot XX
otototot
XXnncacacacaca
be bellbebebebe
used 
dedddus
duuuu
to XXoXXtoooosupport Xort
XX XXpooosup
o
XXssuuusu
any XXn
XXnnnyan
marketing 2828ke
n
XXkekekerke
X XXarrm
rmmmm
authorization 
a
odsdshouuutauapplication 
onXXonononc
on
Xcccaicplaaaapa
and XXdandanananan
any Xyynyanynyyany
extensions XXonXXonononson
XX XXssins
XX XXttennnext
ne
or oroororor
variations 
nsXXnsnsnsins
XX Xtititioati
XX
iaaava
a
thereof. 3232 33he
ofthhhh
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 35 of 263Table 5‒1: Schedule of study assessments, Screening and double-blind Treatment Periods
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first dose)1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
Photographs of skin and nails 
(subset of sites)X X X X X X X X X
EQ-5D-3L X X X X X
Concomitant medication X X X X X X X X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X X X X X X
Randomizati on X X
IRTpX X X X X X X X X X X X X X X X X
IMP adminis trationqX X X X X X X X X X X X X X X
BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG= electrocardiogram; eCRF=electronic Case Report Form; eC-SSRS=el ectronic 
Columbia Suicide Severity Rating Scale; EQ -5D-3L=European Quality-of-Life 5-Dimensions 3-Level; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; 
IRT=interactive response technology; mNAPSI=Modified Nail Psoriasis  Severity Index; PASE=Psoriatic Arthritis Screening and Eval uation; PASI=Psoriasis 
Area Severity Index; PEOT=Premature End of Treatment; PGADA=Patient’s Global Assessment of Disease Activity; PHQ -9=Patient Health Questionnaire-9; 
pp-IGA=palmoplantar Investigator’s Glob al Assessment; PsA=psoriatic arthritis; scalp IGA=scalp- specific Investigator’s Global Assessment; SFU=Safety 
Follow-Up; TB=tuberculosis; WPAI-SHP=Work Productivity and Ac tivity Impairment Questionn aire-specific health problemX XXCLICXXBLILILIUB
L
y Index; y Index; 
ropeanrope
UBUBUB
COPY XXYOP
Y
XXOPOPOPCOPCCCOCThis 
document 
cannot Prodro
bent; P
ent; PsAent; PsA
ductivducti
used C
Qualityality
ent; IGRnt; IGR
Nail Psoril Psor
GADGAD
toXoG=elecG=ele
oooosupport XortXortortortport
XX XXppppupXXsupupupsup
any XX XXyanXXaaa
marketing 2828ke
nkekekem
rkemmmam
authorization 
a
odsdshouuutauapplication 
and 
any=PaP
soriatic asoriatic
and Actiand Acti
extensions XXn XX
nnnssonrocardiogcardiog
Life 5fe 5-DD
A=interfernterfer
sis Seveis Seve
tientien
ssio
or oroooo
variationsXnsonnatiXXatatataat
XXaaarvav
thereof. 3232 33he
of
Xthhhh
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 36 of 263Table 5‒1: Schedule of study assessments, Screening and double-blind Treatment Periods
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first dose)1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
aVisit windows of ±3 days from the first dose from the Week 1 visit to the Week 24 visit. Visit windows of ±7 days from Week 28 t hrough Week 48/PEOT. 
The SFU Visit window is ±7 days relative to the scheduled visit date.
bThe SFU Visit will occur 20 weeks after the final dos e if subject does not enroll in the OLE Period.
cIncludes evaluation of signs and symptoms of active TB and risk for exposure to TB.
dEnsure no significant changes in medical history.
eThe physical examination will be performed as per Section 12.3.5 .
fVital signs (blood pressures, pulse rate, and temperature) are to be measured prior to  blood sampling, and prior to dosing, whe re applicable.
gPregnancy testing will consist of serum testing at the Screening.  Urine pregnancy testing will be performed at all other visits .
hSubjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B su rface antigen; 2) positive for 
anti-hepatitis B core antibody are exclud ed. A positive test for HCV is defined as : 1) positive for hepatitis C antibody, and 2 )positive via a confirmatory test 
for HCV (for example, HCV polymerase chai n reaction) are also excluded. Subjects will also be tested for anti-hepatitis B surfa ce antibody.
iThe HIV test results will not be recorded in the eCRF.
jScreening chest x-ray must occur within 3 months prior to Screening Visit.
kAll blood samples taken prior to dosing.
lThe scalp IGA will be assessed only for those subjects wi th scalp involvement (scalp IGA score >0) at Baseline.
mThe mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.
nThe pp-IGA will be assessed only in subjects with palmoplantar involvement (pp-IGA score >0) at Baseline.
oThe PGADA is assessed for all subjects at Baseline. At all subseq uent visits, the PGADA is only for subjects with PsA at Base line (defined as a past medical 
history of PsA or PASE ≥47).
pIMP administration is based on randomization.
qThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled dosing visit. From Week 8 through Week 24, t he dosing window is 
±3 days relative to the scheduled dosing visit. From Week 28 throug h Week 48, the dosing window is ±7 days relative to the sched uled dosing visit.PUBLICy of thy of t
CV is defV is de
lso exclulso exclu
to Screento Screen
thth
COPY TB.B
red prior red prior
pregnancregnanc
he fohe foThis 
document 
cannot Week 4 iWeek 4 
visit. Frosit. Fr
bemop
At all sAt all 
used scalp invoalp invo
nvolvemeolveme
plantarlantar
tog Visit.g Visit
support o bloodbloo
y testing westing w
lowing criwing c
ned as: 1) pd as: 1)
ed. Subjecd. Subjec
any d samds
marketing 2828ke
n
ws of ±7 ds of ±7 
od.od.
kekeke
authorization 
a
odsdshouuutauapplication 
and±2 days 2 days
Week Week 22any vovo
equent vequent
extensions positivsitiv
ts will alwill al
vement (ement 
t (mNAP(mNAP
lvemvem
orl beb
ria: 1) ia: 1)
effvariations daysy
mpling, apling, a
e perpe
thereof. 3232 33he
of
s fromfromthhh
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 37 of 263Table 5‒2: Schedule of study assessments, OLE Period
Visita/
Week
Protocol activity
48 (1st OLE dose)Year 2 Year 3
SFUb52
56
60
64
68
72
76
80
84
88
92
96
100
104
108
112
116
120
124
128
132
136
140
144/PEOT
C CCHCHCHHCHHCHHCHHCHHCHHCC
Informed consent X
EligibilitycX
eC-SSRS XX X X X X X X X XX
Physical examd,eX X X X X X X XX
Body weight X X
Vital signsfXX X X X X X X X XX
Hematology and biochemistry XX X X X X X X X XX
Urinalysis X X X X X X X XX
ECG X X
Pregnancy testing (urine)gXXXXXXXXXXXXXXXXXXXXXXXXX
IGRA tuberculosis test X X
Tuberculosis questionnaire X X X X X X X X XX
PASI XX X X X X X X X X
Percentage of BSA XX X X X X X X X X
Blood sample for bimekizumab 
plasma concentrationshX X X XX
Blood sample for anti ‑bimekizumab 
antibodieshX X X XX
IGA XX X X X X X X X X
DLQI X X X X
Patient Symptoms (itch, pain, and 
scaling)X X X X X X X X X
PHQ-9 XX X X X X X X X X
scalp IGAiX X X X
mNAPSIjX X X XPUBLIC XXCCCCLICXXLILILICCCLIC
XXBBLLLUB
L
XXUBUBUBPUBPPPUUUPUPPPP
COPY CCYYYYYPYYPPYPYOOPYOOOOCOOCOCOCOCOCThis 
sdocument
tntntntnt nt
, and and 
ennnnumocdod
cannot XXoootnnotnnnnnanc
beeXeeebebbbeb
used
dXXXXddd sedssseusXXusususus
to oXXoootototototosupport X
torXXorororpporpppopopouppp
Xuuuppppppsupsususususss
any CCnynynynyanyaaannnana
marketing 
1
104104
1088gmarkket
ng
Hmmmm
authorization 
ahoapplication 
onXXXXooonnntionttioioiocat
iocacacacappappppa
and dandaaannnan
any XyXXyyynyXanynynyanyaaaa
extensions 
s X
sssons
XXononononXXsssiooons
onsnsnsensXXXXtetetenxtexxxtttext
XXexexexe
orrXrrroroooo
variations 
ons
HHHCooonaioaaatriaaaaririivari
XXvavavavav
thereof. Year 3ear 3112112
11616eoeoothereo
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 38 of 263Table 5‒2: Schedule of study assessments, OLE Period
Visita/
Week
Protocol activity
48 (1st OLE dose)Year 2 Year 3
SFUb52
56
60
64
68
72
76
80
84
88
92
96
100
104
108
112
116
120
124
128
132
136
140
144/PEOT
C CCHCHCHHCHHCHHCHHCHHCHHCC
pp-IGAkX X X X
EQ-5D-3L X X X X
PASE X X
PGADAlX X
WPAI-SHP V2.0 X X
Concomitant medication XX X X X X X X X XX
Adverse events XX X X X X X X X XX
Randomization X
IRTmX XX X X X X X X X XX
IMP administration –Q4W n, o, p X XXXXXXXXXXXXXXXXXXXXXXX
IMP administration –Q8W n, oX X X X X X X X X X X X
BSA=body surface area; C=clinic; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC RF=electronic Case Report Form; eC-
SSRS=electronic Columbia Suicide Sever ity Rating Scale; EQ-5D-3L=European Quality-of-Life 5-Dimensions 3- Level; H=home; HCV=hepatitis C virus; 
HIV=human immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal
product; IRT=interactive response technology; mNAPSI=Modified Nail Psoriasis Severity Index; PASE=Psoriatic Arthritis Screening  and Evaluation; 
PASI=Psoriasis Area Severity Index; PEOT=Premature En d of Treatment; PGADA=Patient’s Global Assessment of Dise ase Activity; PHQ-9=Patient 
Health Questionnaire- 9; pp IGA=palmoplantar Investigator’s Global Ass essment; PsA=psoriatic arthritis; scalp IGA=scalp -specific Investigator’s Global 
Assessment; SFU=Safety Follow-Up; TB=tuberculosis; WPAI SHP=Work  Productivity and Activity Impairment Questionnaire-specific he alth problem
aVisit windows of ±7 days from Week 48 through Week 72. Visit windows of ±14 days from Week 76 through Week 144. The SFU Visit window is ±7 days 
relative to the scheduled visit date.
bThe SFU Visit will occur 20 weeks after the final dose.
cCriteria for OLE Period, Section 6.3.
dIncludes evaluation of signs and symptoms of active TB and risk for exposure to TB.
eThe physical examination will be performed as per Section 12.3.5 .
fVital signs (blood pressures, pulse rate, and temperature) are to be measured prior to  blood sampling, and prior to dosing, whe re applicable.
gPregnancy testing will consist of urine pregnancy testing at all visits. Home pregnancy test kits will be provided to participan ts for use between clinic visits.PUBLIC 
CCCCLICXXLILILICCCLIC
XXBBLLLUB
LUBUBUBPUBXPPPUUUPUPPPP
COPY CCYYYYYPYYPPYPYOOPYOOOOCOOCOCOCOCOCThis ting wting w
document eek 4ek 
ate..
weeks aweeks a
Sectionection 66
signs andigns an
nation wination w
pressurpressur
willwill
cannotestigsti
y; mNAPmNAP
T=Prema=Prema
plantar Inlantar I
TB=tubTB=tub
48 th8t h
beLife
Scale; EScale; 
ator’ator
usedXXdXXXXddd sedXXssseusQuaQuaususus
to ooootoXtotototosupport 
tororororpporpppopopouppp
Xuuuppppppsupsususususss
any CCnyXXnynynyanyaaannnana
marketing 
1
104104
1088gmarkket
ng
Hmmmm
authorization 
ahoapplication ve
rculosisulosi
ough Weekough We
er the finaler the fin
.
symptomsymptom
be performbe perfor
lse ratlse rat
andI=ModMod
ure End oe End o
stigatortigato
any y Indy In
5D5D--3L=3L
lobal Asobal 
ifiedifi
extensions 
s X
sssons
XXononononsssiooons
o
XnsnsnsensXXXXtetetenxteXX
xxxtttext
dexdexeee
orrXrrroroooo
variations 
ons
HHHCooonaioaaatria XXaaaririivari
XXvavavavav
thereof. Year 3ear 3112112
11616eoeoothereo
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 39 of 263Table 5‒2: Schedule of study assessments, OLE Period
Visita/
Week
Protocol activity
48 (1st OLE dose)Year 2 Year 3
SFUb52
56
60
64
68
72
76
80
84
88
92
96
100
104
108
112
116
120
124
128
132
136
140
144/PEOT
C CCHCHCHHCHHCHHCHHCHHCHHCC
hAll blood samples taken prior to dosing.
iThe scalp IGA will be assessed only for those subjects with scalp involvement (scalp IGA score >0) at Baseline.
jThe mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.
kThe pp-IGA will be assessed only in subjects with palmoplantar involvement (pp-IGA score >0) at Baseline.
lThe PGADA is assessed o nly for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47).
mIMP administration is based on randomization.
nFrom Week 48 through Week 72, the dosing window is ±7 days relati ve to the scheduled dosing visit. From Week 76 through the Wee k 140 Visit, the dosing 
window is ±14 days relative to the scheduled dosing visit. 
oIf self-injected at home, the subject/caregiver  will document the date, body location, k it number and time point of administrat ion of study medication. All 
used syringes will be disposed of by su bjects/caregivers as determined by the Inves tigator in an acceptable disposal (sharps) co ntainer directly after the 
administration. The subjects/caregivers return the documentation to gether with any used/unused containers at the next scheduled  clinic visit.
pQ4W IMP administration only applies to those subjects who have not yet changed to Q8W at Week 64, or at the next scheduled clinic visit (ie, Week 72, 
Week 84, Week 96, Week 108, Week 120, or Week 132) if the su bject has already completed the Week 64 visit after implementation o f 
Protocol Amendment #5.
PUBLIClve
efined aefined 
ays relatiays relati
ment thement the
as deas 
COPY CCYment (scalpent (sc
mNAPSI sNAPSI 
ement (ment
YYYYThis 
document 
cannot 
be 32) if2) i
useddateat
erminedrmined
tation togtion to
who haveho hav
thethe
to e, body, bod
support IGAIG
ore >0) are >0) 
p-IGA scoIGA s
past mediast me
to the scho the s
any CCnyAAscoresco
tnynyny
marketing 
1
104104
1088gmarkket
ng
Hmmmm
authorization 
ahoapplication 
and 
any ubjectbjec
extensions cal 
heduled dheduled 
location,cation
y the Invy the Inv
ther withher with
ot yet chyet c
hh
ore >0) e >0)
historhisto
variations 
ons
HHHCooonaio
e >0) at B>0) at B
aselineseline
t
aaat
thereof. Year 3ear 3112112
11616eoeoothereo
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 40 of 263Table 5-3: Schedule of study assessments, OLE2 Period
Visit a/
WeekOLE2 PeriodOLE2 Screening b
W144/OLE2 
Baseline
OLE2 W4
OLE2 W8
OLE2 W12
OLE2 W16
OLE2 W24
OLE2 W32
OLE2 W36
OLE2 W40
OLE2W48/
PEOT
SFU2 c
C H H C H C H C H C C
Protocol activity OLE2 Groups A + B
Informed consent Group B Group A
Eligibility Group B Group A+B
Urine drug screen Group B
Significant past medical history 
and concomitant diseasesdGroup B
Physical exam eGroup B Group Af+ B X X X X X
Body weight Group Af+ B X
Vital signs gGroup B Group Af+ B X X X X X
Hematology and chemistry Group B Group Af+ B X X X
Urinalysis Group B Group Af+ B X X X
Pregnancy testing (urine) hGroup B Group Af+ B X X X X X X X X X X
Hepatitis B and C testing Group B
HIV testing iGroup B
IGRA TB test Group AfX
Tuberculosis questionnaire Group B Group Af+ B X X X X
PASI Group B Group Af+ B X X X X
Percentage of BSA Group B Group Af+ B X X X X
IGA Group B Group Af+ B X X X X
DLQI Group Af+ B X X XPUBLIC 
CCCCCLICBBBBLUB
+B+BP
COPY CPYPPYPYCOCThis 
isdocument GroteGrGreeenmememememeumocdo
cannotGroup Group 
t
GrouGrouotn p BBnnnnan oup Bup Baaaac
be Af+ + 
up Aup Aff+ +beb
used 
ds+ BBssseusBBusususus
to tosupport 
orppppoppupppps
any HHany
marketing 
OLEOLE
E2 W32W32m
et
gmmmm
authorization 
ahoaaauaappGroup BGroupplication 
n
GroGrionat up Bup B Gatatatat
Group Broup B
icplaGroGroaaapaa
and + BB
p AAff+ B+ Bdana
any nyaaaana
extensions 
snssssonnsennnx
nxxteexeeee
or ro
variations 
OLOoCC
ooonio
OLOLriav
thereof. E
2 W362 W36
fffth
of
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 41 of 263Table 5-3: Schedule of study assessments, OLE2 Period
Visit a/
WeekOLE2 PeriodOLE2 Screening b
W144/OLE2 
Baseline
OLE2 W4
OLE2 W8
OLE2 W12
OLE2 W16
OLE2 W24
OLE2 W32
OLE2 W36
OLE2 W40
OLE2W48/
PEOT
SFU2 c
C H H C H C H C H C C
Protocol activity OLE2 Groups A + B
Patient Symptoms (itch, pain, 
and scaling)Group Af+ B X X X X
PHQ-9 Group B Group Af+ B X X X X
ECG Group Af
Blood sample for bimekizumab 
plasma concentrations jGroup Af
Blood sample for 
anti‑bimekizumab antibodies jGroup Af
scalp IGA Group Af
mNAPSI Group Af
pp-IGA Group Af
EQ-5D-3L Group Af
PASE Group Af
PGADA Group Af
WPAI-SHP V2.0 Group Af
eC-SSRS Group B Group Af+ B X X X X X
Concomitant medication Group B Group Af+ B X X X X X
Adverse events Group BkGroup Af+ B X X X X X
IRT X Group Af+ B X X X X XPUBLIC 
CLICBBBBLUBAAffUUUU
COPY CPYPPYPYCOThis 
isdocument 
tnmememememe
n
umocdo
cannotGrouGrout
GroGrootnnnnnananananac
be A
oup Aoup Affeb
used s f
ssseus
to tototototosupport Xorppupppps
any HHany
marketing 
OLEOLE
E2 W32W32m
et
gmmmm
authorization 
ahoaaauaapGrouGroapplicationGro
GroupGroun
GroGronatatatatiat
Group Boup Bicaaa
Group BGroupplaaaapaa
and Aff
up AAffd
oup Aup Affana
any y aaaana
extensions 
sXX
sss sonssssix
nsxxteex
or rvariations 
OLOoCC
ooonio
OLOLriav
thereof. E
2 W362 W36
fffth
of
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 42 of 263Table 5-3: Schedule of study assessments, OLE2 Period
Visit a/
WeekOLE2 PeriodOLE2 Screening b
W144/OLE2 
Baseline
OLE2 W4
OLE2 W8
OLE2 W12
OLE2 W16
OLE2 W24
OLE2 W32
OLE2 W36
OLE2 W40
OLE2W48/
PEOT
SFU2 c
C H H C H C H C H C C
Protocol activity OLE2 Groups A + B
Bimekizumab administration 
Q4W/Q8Wl, m, nGroup BlX X X X X X X
Bimekizumab administration 
Q8Wm, nGroup A+BlX X X X X
BSA=body surf ace area; C=clinic; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC-SSRS=electronic Columbia Suicid e Severity Rating Scale; 
IGA=Investigator’s Global Assessment; H=home; IMP=investigational medicinal product; IRT=interactive response technology; OLE =open label extension; PASI=Psoriasis 
Area Severity Index; PHQ-9=Patient Health Questionnaire-9; PSO=p soriasis; Q4W=every 4 weeks; Q8W= every 8 weeks; SFU2=Safety Fol low-Up #2; TB=tuberculosis; 
W=Week.
Note: Subjects may self -inject IMP at home; self-injection training will be provid ed to the subject/caregivers by qualified site personnel. 
aVisit windows of ±14 days from the first dose at all visits except SFU2. The SFU2 Visit window is ±7 days from final dose.
bAssessment for the OLE2 Screening is applicable to subjects in OLE2 Group B , ie, subjects who agreed to reinitiate thei r treatment after having completed the Week 144 
Visit. 
cThe SFU2 Visit will occur 20 weeks after the final dose.
dOnly applicable for subjects who completed the SFU period; only ne w or modified medical history since completing SFU will be ent ered in eCRF.
eThe physical examination will be performed as per Section 12.3.5.
fThese tests are performed as part of Week 144 visit (the Week 144 Visit coincides with the Week 144/OLE2 Baseline Visit for subj ects in Gro up A, ie, direct enroller from 
OLE to OLE2 Period).
gVital signs (sitting systolic and diastolic blood pressure, pulse rate, and temperature) are to be measured prior to blood samp ling, and prior to dosing, where applicable.
hUrine pregnancy testing will be performed at all visits. Pregnancy test results must be negative prior to administering IMP. Hom e pregnancy test kits will be provided to 
participants for use between clinic visits.
iThe HIV test results will not be recorded in the eCRF.
jAll blood samples taken prior to dosing.
kCollected only from subjects in the SFU.
PUBLIC XCLICUBuality Indeuality Ind
tigatiotiga
UUU
COPY CPYPPYPY
XCOThis 
documentastolic blolic bl
e performeerform
clinic vislinic vis
not be recbe re
en prior toprior to
m subjects subjects
cannot al dose.dose
he SFU pe SFU p
ed as peras per S
ek 144 vik 144 vi
bening
s except xcep
jects injects in
used;  E
al medicmedic
=psoriasispsoriasis
will bwill 
to toCG=elCG=eltototosupport Xorpp
XXupppp
any HHany
marketing 
OLEOLE
E2 W32W32m
et
gmmmm
authorization 
ahoaaauaapplication ct
t (the Whe W
d pressure, pressure
d at all visitst all vis
s.
rded in the ed in th
dosing.sing.
the SFU.e SFU
and iod; only d; only 
on 12.3n 12.3
any rovo
2. The S2. The
LE2 GroupE2 Group
extensions 
ssss s
s
ctrocardiorocardio
l product;l product;
Q4W=eve4W=ev
vided ided
sssi
or XXrvariations 
OLOoCC
ooonio
OLOLriav
thereof. E
2 W362 W36
fffth
of
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 43 of 263Table 5-3: Schedule of study assessments, OLE2 Period
Visit a/
WeekOLE2 PeriodOLE2 Screening b
W144/OLE2 
Baseline
OLE2 W4
OLE2 W8
OLE2 W12
OLE2 W16
OLE2 W24
OLE2 W32
OLE2 W36
OLE2 W40
OLE2W48/
PEOT
SFU2 c
C H H C H C H C H C C
Protocol activity OLE2 Groups A + B
lQ4W IMP administration only applies to those subjects who have entered the OLE2 Period as part of Group B, and had an IGA ≥3 upon entry of OLE2 Period. These 
subjects will receive Q4W dosing for 16 weeks, then will change from Q4W to Q8W dosing. Subjects who have entered the OLE2 Period as part of Group B with an IGA 
<3 upon entry of OLE2 Period will receive Q8W dosing from the W144/OLE2 Screening Visit onwards.
mThe dosing window is ±14 days relative to the Week 144/OLE2 Baseline Visit.
nIf self-injected at home, the subject/caregiver will document the date, body location, kit number and time point of administrat ion of study medication. All used syringes will 
be disposed of by subjects/caregivers as determined by the Investigator in an acceptable disposal (sharps) container directly a fter the administra tion. The subjects/caregivers 
return the documentation together with any used/unused containers at the next scheduled clinic visit.
PUBLIChe 
4W to QW to 
44/OLE2 /OLE2 
aseline Visseline Vi
date, boddate, bod
vestigatorvestigator
ntainers antainers a
COOLE2 POLE2
Q8COPY CPYPPYPYCOThis 
document 
cannot 
be 
used the nehe n
tolocat
an accean acc
ext sxt
supporriod as partod as pa
W dosing. Sudosing
creening Viening V
ion, kiion,
ort or
any HHany
marketing 
OLEOLE
E2 W32W32m
et
gmmmm
authorization 
ahoaaauaapplication 
and 
any 
extensionsubj
sit onwat onw
t number number 
able dispole disp
heduled ceduled c
orf Grouf Gro
cts whcts whrrvvariaOLOLriations 
OLOoCC
ooonioriav
thereof. E
2 W362 W36
fffth
of
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 44 of 2635.7 Schematic diagram
The study schematic diagram for PS0015 from Screening through Week 48 is presented in 
Figure 5‒1,from Week 48 through Week 144 is presented in Figure 5‒2,and from Week OLE2 
Screening to the OLE2 Week 48 Visit is presented in Figure 5‒3.
Figure 5 ‒1: Schematic diagram, Screening and double-blind Treatment Period 
(through Week 48)
Screening Treatment period (double-blind) 
Safety follow -up 
visit 20 weeks 
after last dose
Baseline 16
WeekSFU visit 20 
weeks after 
last dose
48Dosing
12 20 24 28 32 36 40 44 48
Primary endpoint
PASI100 response2–5 weeksDosing Dosing Dosing Dosing Dosing Dosing Dosing Dosing Dosing Dosing Dosing
Dosing
(SEC or 
PBO)Open- label 
extension 
periodBimekizumab 320mg Q4WN=700
Secukinumab 300mg Q4Wn=350
n=350Bimekizumab 320mg Q8WBimekizumab 320mg Q4W
1:2 re-
randomization
Open-label
extension
periodor
IGA=Investigator’s Global Assessment; IMP=investigational medicinal product; PASI100=Psoriasis Area Severity 
Index complete response; PBO=placebo; Q4W=every 4 weeks; Q8W=every 8 weeks; SEC=secukinumab; 
SFU=safety follow-up 
Note: At Week 28 and all following visits, subjects on conti nuous treatment for at least 12 weeks with a persistent 
IGA score ≥3 over at least a 4 -week period are defined as nonresponders and should discontinue IMP.PU
P
PU
P
PUB
BL
BLI
L
LIC
C 
CC
20C
BL
mary
ye
P
PASI10C
C
CO
C
COPY
PY
PY
PY 
C
C
sing
COP
This document cannot 44-bewing visiwing vis
week weekused 
d
d
d
 IMP=invMP=inv
ebo;bo;Q4Q4
t
to
to
o 
poin
spon
 s
sup
p
upp
pp
p
por
ort
t 
pp
24pp
tport
a
any
y
ny
y 
Dosinga
m
m
ark
rke
ng
ng 
ggg
marmarketingketingngngnhorization 
a
aut
tho
hori
oriz
authauthSa
application and any ubjects ubjects
iod are dod arexten
ens
ns
nsi
nsions
s
ns
s
k
3
stigationgation
=every 4every 4
or 
r
oooo
v
v
varia
a
iat
atio
 
s
s
ing
 Do
vaionsions
th
h
the
e
her
e
ereof.herefollow -u
20 wee
ter last 
hethth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 45 of 263Figure 5 ‒2: Schematic diagram, OLE Period (Week 48 through Week 144)
PASI=Psoriasis Area Severity Index; PASI90=90% improvement in the PASI score; Q4W=every 4 weeks; 
Q8W=every 8 weeks
Note: The subject’s dosing interval will change from bimekizumab 320mg Q4W to bimekizumab 320mg Q8W at 
Week 64, or at the next scheduled clinic visit (ie, Week 72, Week 84, Week 96, Week  108, Week 120, or Week 
132) if the subject has already completed the Week 64 vis it prior to implementation of Protocol Amendment #5.1.
=90% im90% im
change frchange fr
linic visitnic visit
mpleted tmpleted tC
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 
This document cannot be used e WWtom 
ie, Weee, We
eekeek66suppoovement invemen
bimekizimek
k7
poooooooooooorrrrrrrrrrrrtttttttttttt 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnyyyyyyyyyyyyyyyy 
mmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaarrrrrrrrrrrrrrrrrrrrkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeetttttttttttttttttttttttttttttttttttttttinngg tion 
aaaaaaaaaaaaaaauuuuuuuuuuuuuuuuutttttttttttttttttttttttthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhoooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrriiiiiiiiiiiiizzzzaaaaaaati
application and any extensions ntheth
zumabumab 3232
72, Week, Week
4 visit priisit prior e PAPA
orrrrrrrrrrr
vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaariatttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnssssssssssssssssssssssssssssssssssss 
thereofffff. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 46 of 263Figure 5 ‒3: Schematic diagram, OLE2 period  (from OLE2 Screening through 
OLE2 Week 48)
IGA=Investigator’s Global Assessment; IMP=investigational medicinal product; OLE=Open Label Extension; 
Q4W=every 4 weeks; Q8W=every 8 weeks; SFU2=Safety follow-up; W=week
Note: Q4W/Q8W IMP administration only applies to those subj ects who have entered the OLE2 Period as part of 
Group B, and ha d an IGA ≥3 upon entry of OLE2 Period. These subjects will receive Q4W dosing for 16 weeks, 
then will change from Q4W to Q8W dosing.
5.8 Rationale for study design and selection of dose
5.8.1 Study design
A randomized, double-blind, active comparator-cont rolled study design has been selected to 
demonstrate efficacy and safety of bimekizu mab relative to secukinumab. The study population 
will include adults with moderate to severe chronic plaque PSO and allow subjects who have 
received previous biologic treatment as well as those who are biologic treatment naïve. The 
primary efficacy outcome measure (based on PASI) and other efficacy assessments included in 
this study are consistent with those used for other PSO studies and are considered appropriate for establishing efficacy of bimekizumab. A trea tment period of 48 weeks (final dose at Week 44)
will be used to demonstrate the superiority of bimekizumab versus secukinumab based on 
PASI100 at Week 16, along with the maintenance of efficacy of bimekizumab at Week 48.
The addition of the OLE Period will allow collection of long-term efficacy and safety data from 
eligible subjects on open-label bimekizumab for an additional 96 weeks.
PUment; ment; IMM
w
UUUUUUUUUUUUUBBBBBBBBBBBBLLLLLLLLLLLLIIIIIIIIIIIICCCCCCCCCCCCC 
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 
Thisedocumentzed, dod, do
rate effite eff
nclude aclude a
ceived pived p
primaryprimar
this this cannot ionale nale
Study dtudy d
ouben en
Q8W dQ8W dused P=inve=inv
eeks; SFUks; SFU
only appnly app
ntry ofntry otoestiti
ttooooooooooooo 
ssssssssssssssssssssssssssssssssssssssssssssssssssssssuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuupppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppoooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrttttttttttttttttttttttttttttttttttttttttttttttttttt  
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy 
mmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaarrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrkkeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeettttttttttttttinnnnnnnnnggggggggggggggggggggggggggggggggggggggggggggggggggggggggggg ation 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaauuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuttttttttttttttthhhhhhhhhhhhhhhooooorizati
application esigsig
blele--blind,blind
cacy and acy and
dults withults w
evious bivious b
efficacy fficacy 
are candfor stuor stu
gngnany LELE
g.g.extensiational mtional m
2=Safety=Safety
es to thosto thos
E2 Pe2P
sssssssssssssiiiiiiiiiiiiooooooooooooonnnnnnnnnnnnsssssssssssss 
ooooooooooooorrrrrrrrrrrr  
vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaarrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrriiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaattttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnsss 
thhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhheeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeerrrrrrrreeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff.........................  
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 47 of 263The OLE2 Period will 1) collect additional long -term safety data; 2) explore safety data in
subjects who have temporarily stopped bimekizumab and could have been exposed to other 
treatments; and 3) provide an additional 48-week treatment period for subjects continuing their 
current treatment or reinitiating trea tment at the Week 144/OLE2 Baseline Visit.
5.8.2 Dose selection
Bimekizumab doses ranging from 64mg to 480mg were evaluated in the Phase 2b multicenter, 
randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study PS0010. 
Bimekizumab 320mg was found to have an acceptab le safety profile, only required 2 injections 
per treatment administration, and achieved significant PASI responses at Week 12 (summarized 
in the IB). Furthermore, data from the Ph ase 2a multicenter, randomized, subject-blind, 
investigator-blind study PS0016 and PK/PD modeli ng in this PSO population indicates improved 
responses through Week 16. Therefore, a bimekizumab dose of 320mg Q4W through Week 16
was selected for this study.
Based on pooled data from the Phase 3 studies (PS0008, PS0009, and PS0013), during the
maintenance period bimekizumab 320mg Q8W provided efficacy results similar to 
bimekizumab 320mg Q4W. Therefore, at Week 64, subjects receiving bimekizumab 320mg Q4W will switch to receive bimekizumab 320mg Q8W. Subjects who are 
receiving bimekizumab 320mg Q4W treatment who al ready completed the Week 64 visit at the 
time of implementation of Protocol Amendment #5.1 will be switched to bimekizumab 320mg Q8W at the next scheduled clinic visit. This change in dosing interval will 
reduce subject and site burden, while allowing collection of more long-term safety data on the 
bimekizumab 320mg Q8W dosing regimen.
Subjects who are participating in the OLE Period can directly roll over to the OLE2 Period and 
continue receiving bimekizumab 320mg Q8W. Eligi ble subjects who are in the SFU of the OLE 
Period or who have completed the SFU at the time of Protocol Amendment #5.4 implementation 
can reinitiate their treatment in the OLE2 Period based on their current disease activity, as 
measured by IGA: subjects with IGA score <3 will receive bimekizumab 320mg Q8W, whereas 
subject s with IGA score ≥3 will receive 16 weeks of bimekizumab 320mg Q4W, in line with the 
original initial treatment period, followed by 320mg Q8W for the remaining dosing timepoints of the OLE2 Period.
6 SELECTION AND WITHDRAWAL OF SUBJECTS
6.1 Inclusion criteria
To be eligible to participate in this study, all of the following criteria must be met at Screening 
and be reconfirmed at the Baseline Visit:
1. Subject has provided informed consent. 
2. Subject is considered reliable and capable of adhering to the protocol (eg, able to understand 
and complete diaries), visit schedule, or medic ation intake according to the judgment of the 
Investigator.
3. Male or female at least 18 years of age.
4. Subject must have had chronic plaque PSO for at least 6 months prior to the Screening visit.PUBLIC chedched
allowinallowin
g regimeg regime
g in the Og in the
ab 3ab COPYsubu
e bimeke bimek
nt who at who
ment #5ment #5
ulel
This2document InIn
e eligibleligib
d be recbe rec
1.1.SuScannot ≥3 ≥3
ment perint peri
SELESELEben t
with Iwith 
willwilusedOLL
20mg Q0mg Q
he SFU ae SFU 
the OLhe OLto n.
E PerE Persupportreadea
1will bwill b
clinic vilinic v
g collecticollectianyreceiece
umabumab 323
dy comdy cmarketing on indicn indi
Q4W throu4W throu
and PS00nd PS
cy resultsy resu
vingvauthorization nter, nter, 
10. 0. 
injectioinjectio
2 (summ(summ
t-blindblind
application CTIOCTIO
clusionusio
e to particto part
onfirmednfirme
ct hasth a sandre
od, folld, follanyE2 2
A scoreA scor
ceive 1ceive
owextensionsis
ion of mon of 
od can dd can d
W. EligW. Elig
t the timthe tim
PeriPerior swsw
t. t. ThiThvariations013), d13), 
ts similats simil
ng g
20mg0mg QQ
ompletedmplete
witchwitcthereof. ar
tes imprs impr
ugh Wegh We
d
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 48 of 2635. Subject must have PASI ≥12 and BSA affected by PSO ≥10% and IGA score ≥3 on a 5 -point 
scale.
6. Subject must be a candidate for systemic PSO therapy and/or phototherapy.
7. Subject must be considered, in the opinion of the Investigator, to be a suitable candidate for 
treatment with secukinumab per regional label ing and has no contraindications to receive 
secukinumab as per the local label.
8. Female subjects must be:
Postmenopausal: Menopause is defined as 12 consecutive months of amenorrhea, for 
which there is no other obvious pathological or physiological cause.
Or, permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy)
Or, if of childbearing potential (and engaged in sexual activity that could result in 
procreation), must be willing to use a hi ghly effective method of contraception 
throughout the duration of the study until 20 weeks after last administration of IMP, and 
have a negative pregnancy test at Visit 1 (S creening) and immediately prior to first dose. 
The following methods are considered highly effective when used consistently and correctly:
◦Combined (estrogen and progestogen) hormon al contraception associated with 
inhibition of ovulation (oral, intravaginal, or transdermal)
◦Progestogen-only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implantable)
◦Intrauterine device 
◦Intrauterine hormone-releasing system 
◦Vasectomized partner
◦Abstinence as a form of birth control is generally not allowed in the study unless 
abstinence is in accordance with a subject’s preferred and common lifestyle. Study 
personnel must confirm the continued use of abst inence is still in accordance with the 
subject’s lifestyle at regular intervals during the study.
9. Subject agrees not to change their usual sun exposure during the course of the study and to 
use ultraviolet A/ultraviolet B (UVA/UVB) sunscreens if unavoidable exposure occurs.
6.2 Exclusion criteria
Subjects are not permitted to enroll in this study if any of the following criteria are met:
1. Female subject who is breastfeeding, pregnant, or plans to become pregnant during the study 
or within 20 weeks following the final dose of IMP.
2. Subject previously participated in a bimekizumab clinical study and received at least 1 dose 
of the IMP (including placebo).
3. Subject is currently participating in another study of a medication (systemic) under 
investigation. Subject must be washed out of the medication for 12 weeks or at least 5 half-
lives prior to the Baseline Visit, whichever is greater.PUBLIC intraintra
nal contnal cont
antable)ntable)COPYhly effhly e
togen) hogen) h
avagavag
This document agreegre
ltravioleraviole
Subjectsubjects
1.1.Fcannota
is in acin ac
el must l must 
ct’s lifet’s life
es nes nbe tner
form form used releasineleasinto supportormonalrmona
inal, oral, or tr
aception ceptioany ve wheve whmarketingeral salperal salp
that couldhat cou
od of contof con
last admist adm
d immeimmauthorization orrhea, rhea, 
application styly
ot to chanot to ch
t A/ultravA/ultr
ExclusExcl
are not pere not p
suand ordanrdan
confirm onfirm 
le at re at rany f birth cobirth c
nce wnceextensionsn associaassoci
g systemsystemoronon
nsdermnsdervariationstracrac
inistratiistrati
ediately diately
n used cn used c
ntracentracthereof. ingectomgectom
ld resultd resul
cepticept
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 49 of 2634. Subject is currently participating in another study of a topical medication under investigation. 
Subject must be washed out of the medication for 4 weeks prior to the Baseline Visit.
5. Subject is currently, or was within the 4 weeks prior to the Baseline Visit, participating in 
another study of a medical device under investigation.
6. Subject has a known hypersensitivity to any excipients of bimekizumab or secukinumab.
7. Subject has a form of PSO other than chronic plaque-type (eg, pustular, erythrodermic and 
guttate PSO or drug-induced PSO).
8. Subject has an active infection or  history of infection(s) as follows:
Any active infection (except common cold) within 14 days prior to Baseline
A serious infection, defined as requiring hos pitalization or iv anti-infective(s) within 
2 months prior to the Baseline visit
A history of opportunistic, recurrent, or chronic infections that, in the opinion of the 
Investigator, might cause this study to be detrimental to the subject. Opportunisticinfections are infections caused by uncom mon pathogens (eg, pneumocystis jirovecii, 
cryptococcosis) or unusually severe infections caused by common pathogens (eg, cytomegalovirus, herpes zoster)
9. Subject has concurrent acute or chronic vira l hepatitis B or C or human immunodeficiency 
virus (HIV) infection. Subjects who have evid ence of, or tested positive for hepatitis B or 
hepatitis C are excluded. A positive test for the hepatitis B virus is defined as: (1) positive for 
hepatitis B surface antigen or (2) positive for an ti-hepatitis B core antibody. A positive test 
for the hepatitis C virus (HCV) is defined as: (1) positive for hepatitis C antibody (HCV Ab) 
and (2) positive via a confirmatory test for HCV (for example, HCV polymerase chain 
reaction).
10. Subject has received any live (includes atte nuated) vaccination within the 8 weeks prior to 
the Baseline visit (eg, inactivated influenza and pneumococcal vaccines are allowed, but 
nasal influenza vaccin ation is not permitted).
11. Subject has received Bacillus Calmette-Guerin (BCG) vaccinations within 1 year prior to the 
Baseline Visit.
12. Subject has known tuberculosis (TB) infection, is  at high risk of acquiring TB infection, or 
has current or history of nontuberculous mycobacterium (NTMB) infection. A subject with 
LTB (a positive interferon-gamma release assay [IGRA] and diagnosis confirmed by TB 
specialist) may be rescreened once and enro lled after receiving at least 8 weeks of 
appropriate LTB infection therapy and if no evid ence of therapy-related hepatotoxicity has 
occurred prior to the first injection (a lanine aminotransferase [ALT]/aspartate 
aminotransferase [AST] remain ≤3 times the upper limit of normal [ULN]).
Subject has a past history of active TB invol ving any organ system unless adequately treated 
according to World Health Organization/Cen ters for Disease Control (CDC) therapeutic 
guidance and proven to be fully recovered upon consult with a TB specialist.
Refer to Section 12.3.1 for details on determining full TB exclusion criteria.o have o have
tive test ive test 
(2)(2)posipos
HCV) is HCV) is 
irmatirmCOPYon pn
tions cations c
viral hviral 
This document has kas k
urrent orrent o
TB (a poB (a po
specialspecial
apprapp
oocannotcinatioinati
eived Bived B
it.
knoknobe liveive
nactivanactiv
ononusedde
ory testy tes
(in(intotive
fined afined 
fsupport epatitis Bpatitis
vidence ofdence
for the heor the h
e for anforany ens ens
ed by coed by cmarketing seliel
infective(nfective
that, in thhat, in
the subjehe sub
(eg, (egauthorization c and and 
inene
application wn tubercwn tube
r history ohistory
sitive inteitive in
st) may bt) may 
priate LTpriate L
ed prdand is ns n
acillus Cillus Cany udesude
d influed influ
not perot pextensions of, o,
epatitisatitis
antinti--hepahep
s: (1)(1)popo
or HCVor HCV
sa tsa toroor Cr C
or tesrt e svariationshe opie opi
ect. Oppect. Opp
 pneumpneum
ommonmmon
Cothereof. e(s) withs) with
nii
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 50 of 26313. Subject has a history of a lymphoproliferative disorder including lymphoma or current signs 
and symptoms suggestive of lymphoproliferative disease.
14. Subject has any active malignancy or history of malignancy within 5 years prior to the 
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer.
15. Subject has a diagnosis of inflammatory conditions other than PSO or PsA, including but not 
limited to rheumatoid arthritis, sarcoidosis, or sy stemic lupus erythematosus. Subjects with a 
diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they have no active 
symptomatic disease at Screening or Baseline.
16. Subject has had major surgery (including joint surgery) within the 3 months prior to the 
Baseline Visit, or has planned major surgery within 6 months after entering the study.
17. Subject has any systemic disease (ie, cardiovascular, neurological, renal, liver, metabolic, 
gastrointestinal, hematological, immunological, etc) considered by the Investigator to be 
uncontrolled, unstable, or likely to progress to a clinically significant degree during the 
course of the study.
18. Subject has had myocardial infarction or stroke within the 6 months prior to the Screening 
Visit.
19. Subject has laboratory abnormalities at Screening, including any of the following:
a.≥3.0x ULN of any of the following: ALT, AST, alkaline phosphatase (ALP); or >ULN 
total bilirubin ( ≥1.5xULN total bilirubin if known Gilbert’s syndrome).
b. White blood cell count <3.00x10
3/μL
c. Absolute neutrophil count <1.5x103/μL
d.Lymphocyte count <500 cells/ μL
e. Hemoglobin <8.5g/dLf. Any other laboratory abnormality, which, in the opinion of the Investigator, will prevent
the subject from completing the study or will interfere with the interpretation of the study results.
Individual screening tests for which the result s are in error, borderline, or indeterminate for 
inclusion in the study can be repeated once for confirmation during the Screening Period.
Upon retesting, subjects whose results remain outside this threshold should not be randomized.
20. Subject has any other condition, including medical or psychiatric, which, in the Investigator's 
judgment, would make the subject unsuitable for inclusion in the study.
21. Subject has previous exposure to secukinumab.
22. Subject has experienced primary failure (no response within 12 weeks) to one or more IL-17
biologic response modifiers (ie, brodalumab, ixekizumab), or to more than one biologic 
response modifier other than an IL-17.PUBLICwing: Awing: A
otaotal bilil bili
<3.00x1<3.00x1
unt <unCOPYke withke with
ScreenScreen
This 2documental sl s
ion in thn in th
on retestn retes
andomindomi
20.0.SubjSub
jujucannotratory atory 
rom comm com
creencreenbe dLd
ababused<1.5x10.5x10
cells/μ cells/to 33/μL/μLsupport ing, inclung, inc
LT, AST,T, AST
ubin if knbin if knany he 6 mhe 6 mmarketinghs ps p
ering theering the
renal, lenal, l ivi
by the Iny the I
gnificant dificanauthorization but not but not 
cts with s with 
e no actie no acti
prior rior
applicationing tests ng tests
e study castudy c
ing, subjeing, sub
ed.d.
ct has ant has an
ent, wntandnormnor
mpleting letingany malitymalextensions, alkalalka
nown Gown G
/μLμLording ding
linlivariationsnvesve
degree egree 
onths nths prp
anthereof. to the the 
study.tudy.
ver, metver, me
stigastiga
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 51 of 26323. Subject is taking PsA medications other than stable doses (ie, stable for at least 1 week prior 
to the Screening Visit) of nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics (see 
Section 7.8.1.2 ).
24. Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening as 
evaluated by the Investigator based on medical history, site interview, and/or results of the 
specified urine drug screen.
25a. Presence of active suicidal ideation, or pos itive suicide behavior using the "Screening" 
version of the electronic Columbia Suicide Severi ty Rating Scale (eC-SSRS) and with either 
of the following criteria:
History of a suicide attempt within the 5 years prior to the Screening Visit. Subjects with 
a history of a suicide attempt more than 5 years ago should be evaluated by a mental 
healthcare professional (eg, locally licensed psychiatrist , psychologist, or master’s level 
therapist) before enrolling into the study.
Suicidal ideation in the past month prior to th e Screening Visit as indicated by a positive 
response ("Yes") to either Question 4 or Question 5 of the "Screening" version of the eC-SSRS.
26. Subject has presence of moderately severe major depression or severe major depression, 
indicated by a score ≥15 using the screening PHQ -9. Medication used to treat depression 
should be stable for 8 weeks prior to baseline.
27. Subject is a member of Investigator site personnel directly affiliated with this study and/or 
their immediate families. Immediate family is de fined as a spouse, parent, child, or sibling, 
whether biological or legally adopted.
28. Subject is a UCB employee or employee of third-party organizations involved in the study.
29. Subject is taking or has taken prohibited psoriasis medications without meeting the 
mandatory washout period relative to the Baseline Visit ( Table 7‒2).
6.3 Eligibility for the OLE Period
Prior to entering the OLE Period, subjects on double-blind study treatment must complete all of 
the Week 48 visit assessments. Prior to initiating the OLE Period assessments, all subjects will 
be asked to read and sign a separate ICF. To be eligible to participate in the OLE Period of this 
study, the subject must have completed the double-blind Treatment Period without meeting any 
withdrawal criteria and have been compliant with the ongoing clinical study requirements. PUBLIC o basebase
ator site ator site
mediate mediate 
lly adoplly adop
oroCOPY st
e major dmajor
ning PHning PH
elinelin
This documenteadad
subjectubject
awal critwal cricannotlity fty f
e OLE POLE P
sit assest asses
d and and beke
iod reliod re
ororused tede
employmploy
n prohn prohto famimi
ddsupporteprepr
HQQ--9. Me9. M
e.
personnelersonn
ly is dly iany thh
essionessiomarketing Visitisit
uated by uated by
logist, orogist, 
g Visit as Visit a
e "Scre "Scauthorization ing" ng" 
d with eiwith ei
t. Su.S u
applicationmenmen
sign a sesign a s
must haveust hav
eria and heria andand theth
Period, sriod, s
nts. Pnts. Pany ve to thve to t
e OLe Oextensionsel directldirect
definedefined
ee of of thithi
ted psed por dicadicvariations indicatendicat
reening"eening"
n or sevor sev
ationatiothereof. bjects wects w
a mentamenta
r masterr maste
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 52 of 2636.4 Eligibility for the OLE2 Period
Prior to initiating the OLE2 Period assessments, all subjects will be asked to read and sign a 
separate ICF. 
6.4.1 All subjects (OLE2 Groups A and B)To be eligible to participate in the OLE2 Peri od, all of the following inclusion criteria must be 
confirmed for all subjects:
1. Subject provided informed consent. 
2. Subject is considered reliable and capable of adhering to the protocol (eg, able to understand 
and complete diaries), visit schedule, and medicat ion intake according to the judgment of the 
Investigator.
3. Subject completes the OLE Period to Week 144 without meeting any withdrawal criteria 
defined in Section 6.5.
6.4.2 OLE2 Period Group A subjects
To participate in the OLE2 Period, subjects stil l treated in the OLE Period and who completed 
the Week 144 Visit by the time of the implementation of Protocol Amendment #5.4 will not need 
to fulfil other eligibility criteria than those listed in Section 6.4.1 and will continue their 
treatment from the Week 144/OLE2 Baseline Visit if they do not meet any of the withdrawal 
criteria defined in Section 6.5.
6.4.3 OLE2 Period Group B subjectsInclusion criteria
To be eligible to participate in the OLE2 Peri od, all of the additional following inclusion criteria 
must be confirmed during the OL E2 Screening Period for subjects who have attended Week 144 
and are in the SFU or have completed  the SFU before Protocol Amendment #5.4
implementation:
1. Female subjects must be:
Postmenopausal: Menopause is defined as 12 consecutive months of amenorrhea, for 
which there is no other obvious pathological or physiological cause.
Permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy)
Or, if of childbearing potential (and engaged in sexual activity that could result in 
procreation), must be willing to use a hi ghly effective method of contraception 
throughout the duration of the study until 20 weeks after last administration of IMP, and have a negative pregnancy test at OLE2 Screening. The following methods are considered highly effective when used consistently and correctly
oCombined (estrogen and progestogen) hormon al contraception associated with 
inhibition of ovulation (oral, intravaginal, or transdermal)
oProgestogen-only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implantable)
oIntrauterine device PUBLIC up B up B ss
the theCOPY ated iated
ntation oation o
ted in Sed in S
neeVisiVisi
This documentmanenmanen
Or, if oOr, if 
procpro
ththcannotust be:st be:
pausal: Musal: M
here is nere is n
tlbe mpusedOLE2 PLE2 P
LE2 E2 ScrScr
pletedpletedto support ctiontio
if they dthey
bjectbject ssany e OLEe OL
ProtocolProtoco
6.46marketing he je 
ny withdry with
EPEauthorization be 
e to undto und
judgmudg
application o otheoth
y sterilizesterili
f childbeaf childb
reation), mation)
rougoughouthou
ve a nv eanand enopaunopau
er oerany he heextensions riod, alliod, al
eening Pening P
 SFUSFUor o noto nvariations Period aPeriod a
AmendAmen
.1and wand w
ot mtmthereof.erster
ment of nt of 
rawal crrawal cr
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 53 of 263oIntrauterine hormone-releasing system 
oVasectomized partner
oAbstinence as a form of birth control is generally not allowed in the study unless 
abstinence is in accordance with a subject’s preferred and common lifestyle. Study 
personnel must confirm the continued use of abstinence is still in accordance with the 
subject’s lifestyle at regular intervals during the study.
2.Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they 
have no active symptomatic disease.
Exclusion criteria
Subjects in the OLE2 Group B are not permitted to enroll in the OLE2 Period if any of the 
following exclusion criteria is met:
1. Female subjects who plan to become pregnant during the OLE2 Period or within 20 weeks 
following final dose of study medication.
2. Subject has developed any medical or psychiatric condition that, in the opinion of the 
Investigator, could jeopardize or would compromise the subject’s ability to participate in the 
OLE2 Period.
3. Any subjects with an ongoing SAE, or a history of serious infections, the Medical Monitor 
must be consulted prior to the subject’s entry in the OLE2 Period, although the decision on 
whether to enroll the subject remains with the Investigator.
4. Subject had a positive or indeterminate IGRA in the OLE study to Week 144, unless 
appropriately evaluated and treated as per Section 12.3.1 .
5. Subject may not participate in another study of a medicinal product or device under 
investigation 
6. Subject has a history of chronic alcohol or dru g abuse within 6 months prior to reentry as 
assessed by medical history, site interview, and/or results of the urine drug screen.
7. Subjects who have used systemic treatments after Week 144 must have stopped this 
treatment 1 month prior to receiving the first bimekizumab injection in the OLE2 Period (SeeSection 7.8.2 regarding prohibited medications).
8. Subject has erythrodermic, guttate, or pustular form of PSO.
9. Subject is noncompliant with the study procedures or medications in the opinion of the 
Investigator.
10. Subject has a clinical laboratory value meeting any of the following criteria:
a.≥3.0x ULN of any of the following: ALT, AST, alkaline phosphatase (ALP); or >ULN 
total bilirubin ( ≥1.5xULN total bilirubin if known Gilbert’s syndrome)
b. A laboratory value meeting any of the following criteria:
◦Absolute neutrophil count <1.0x10
3/μLPUBLIC AE, or a AE, or a 
subject’subject
ct remainct remain
ndetendeCOPY iatric coatric co
ompromomprom
This documentwhwh
ent 1 mnt 1 m
tionon7.87.8
SubjectSubject
9.9SubSubcannot tory of ory of
medical hedical 
ho havo havbe ate ine inusedrminateminate
treated aeated 
na nna ntos e
s with withsupport ise thee the
history ofstory of
entry in ntry i
hany dition thdition th
es uesmarketing Period if eriod i
LE2 PerioE2 Perauthorization the he 
ng as theas the
applicatione used sye used s
nth prior th prio
22regardinregard
has erythas eryt
ct is not is n
atandhronic ronic 
tory, sory, sany ther sther
lextensionsf seriouseriou
n the the OLOL
he InvestInvest
IGRA inGRA i
s per Seper Se
stuor variations od or wid or w
hat, in that, in th
bject’s bject’sthereof. f any of f any of 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 54 of 263◦Absolute lymphocyte count <0.2x103/μL
Subjects may enter the OLE2 Period if the result is  transient. If a retest is required, it must be 
done within 1 to 2 weeks.
11. Subject has concurrent acute or chronic viral hepatitis B or C or HIV infection. Subjects who 
have evidence of, or tested positive for hepatiti s B or hepatitis C are excluded. A positive test 
for the hepatitis B virus is defined as: (1) positive for hepatitis B surface antigen or (2) 
positive for anti-hepatitis B core antibody. A positive test for the hepatitis C virus (HCV) is 
defined as: (1) positive for hepatitis C antibody (HCV Ab) and (2) positive via a 
confirmatory test for HCV (for exam ple, HCV polymerase chain reaction).
12. There is confirmation of a pregnancy, as evidenced by a positive pregnancy test (see 
Section 12.1.4 for more information regarding pregnancies).
13. Subjects showing:
xSuicidal ideation in the past month prior to the OLE2 Screening Visit as indicated by a 
positive response ("Yes") to either Question 4 or Question 5 of the eC-SSRS.
xAny suicidal behavior since last visit.
14. Subject has presence of moderately severe or severe major depression, indicated by a score 
≥15 on the PHQ -9. Medication used to treat depression should be stable for 4 weeks prior to
Week 144/OLE2 Baseline.
15. Subject has developed any active malignancy or history of malignancy prior to the OLE2 
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell 
carcinoma, or in situ cervical cancer.
16. Subject has received any live (includes atte nuated) vaccination within the 8 weeks prior to 
the Week 144/OLE2 Baseline Visit.
6.5 Withdrawal criteria
Subjects are free to withdraw from the study at  any time, without prejudice to their continued 
care. Subjects who withdraw from the study should complete the PEOT Visit (see Section 8.5).
Subjects should be withdrawn from the study and will be encouraged to come back for the SFU
Visit 20 weeks after final dose of IMP if the subject withdraws his/her consent or the Sponsor or a regulatory agency requests withdrawal of the subject.
A subject should be withdrawn from IMP and will be asked to come back for the SFU visit 
20 weeks after final dose of IMP if any of the following events occur:
1. Subject develops an illness that in the opinion of the Investigator would interfere with his/her 
continued participation if the risk of cont inuing IMP outweighs the potential benefit.
2. Subject develops erythrodermic, guttate, or pustular form of PSO.
3. Subject is noncompliant with the study procedures or medications in the opinion of the 
Investigator.PUBLIC e malignmalign
ated and ted and
cal canccal canc
veveCOPY or seveor sev
treat depreat de
This document eks as a
ory ageny agen
bject shoect sh
weeks weeks 
1.1.SuScannotthdrawdraw
withdrawithdra
d be witbe wit
afterftebeal crial crused(includenclude
ne VisitVisitto consupporte mm
ression ession
ancy or hncy or h
nsideresiderany major dajor 
hmarketing cy tey t
ening Visning V
on 5 of thn 5 of authorization test est 
HCV) isCV) is
est (sest (
application hdrawnraw
final dosfinal do
cy requesrequ
uld be wild be w
fteer finalr fin
ct devtd e vand from tom 
w frofrom tm 
nfnfany riaia
the sheextensionshistory ostory 
ed curedd cure
attenuaattenuaor ouovariationssit as it as 
he eChe eC -SS
depressiepressi
uld buld bthereof. ee 
nd
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 55 of 2634. Subject uses prohibited concomitant medications , with the exception of topicals, as defined 
in this protocol ( Section 7.8.2 ), that may present a risk to the safety of the subject or the 
integrity of the study data, in the opinion of the Investigator and/or the Medical Monitor.
5. Subject has a clinical laboratory value meeting any of the following criteria:
a. Hepatotoxicity as described in Section 6.5.1
b. A laboratory value meeting any of the following criteria:
◦Absolute neutrophil count <1.0x103/μL
◦Absolute lymphocyte count <0.2x103/μL
Subjects may remain in the study if the result is transient. A retest is required within 1 to 
2 weeks at a scheduled or unscheduled visit. If the repeat absolute neutrophil count or 
absolute lymphocyte count is still below the allowable values, the subject must be 
withdrawn. If the repeat absolute neutrophil count or absolute lymphocyte count is above the allowable values, the subject may continue in the study.
6. The subject experiences a severe AE, an SAE, or a clinically significant change in a 
laboratory value that, in the opinion of the Investigator, merits the discontinuation of the investigational product and appropriate measures being taken.
7. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test (see Section 12.1.4 for more information regarding pregnancies).
8b. At Week 28 and all following visits, subjects  on continuous treatment for at least 12 weeks 
with a persistent IGA score ≥3 over at least a 4 -week period are defined as nonresponders 
and should discontinue IMP. 
9a. A subject considered as having either a suspected new latent tuberculosis infection (LTBI) or 
who develops active TB or pulmonary NTMB in fection during the study (including but not 
limited to, conversion demonstrated by IG RA or other diagnostic means) must be 
immediately discontinued from IMP.
The subject must be permanently withdrawn if further examinations result in a diagnosis of 
pulmonary NTMB, active TB, or if the subject is diagnosed with LTBI with no initiation of 
prophylactic treatment, prematurely discontinues prophylactic treatment, or, in the opinion of 
the Investigator or Sponsor, is noncompliant with prophylactic TB therapy.
Confirmed active TB is an SAE and must be captured on an SAE Report Form and provided 
to the Sponsor in accordance with SAE reporting requirements. As with all SAEs, periodic 
follow-up reports should be completed as per prot ocol requirements until such time as the TB 
infection resolves.
Additional information on TB policies is provided in Section 12.3.1 .
10. Subjects with newly diagnosed inflammatory bowel disease (IBD) or with IBD flares during 
the study must:
Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist
Discontinue IMP and be followed-up unt il resolution of active IBD symptomsPUBLICformatforma
isits, subisits, su
≥3 over ≥3 over 
MP. MP. COPYr a a
vestigatvestiga
asures basure
uring thring th
ioi
This document stigaiga
firmed armed a
o the Spthe Sp
followfollow
infeinfcannot nu
be permbe perm
TMB, acMB, ac
c treatmtreatm
atortorbeemonsmon
ued froued froused g either either 
pulmonulmo
strstrto t leasleasupport einein
e study, atudy, 
n regardinregard
jects on cects on 
st a 4st aanyly y
merits merit
g takeng takmarketing ired wed w
trophil cotrophil c
ubject mubject m
mphocytemphocy
signisignauthorization witwit
application ent, pnt, p
or Sponsor Spon
ctive TB ive TB
onsor in ansor in
up reportup repo
ion resoon reandanentlynentl
ve TB, ve TB
remremany ed by ed by
m IMP.IMP.
ywextensions ng 
continuontinu
4-week week 
a suspecsuspec
y NTMy NTM
IIor s eviev
pregnpregvariations te c
ificant cicant 
the dische disc
en.
videidethereof. hin 1 to n 1 to
ount or unt or
must be ust be 
count ount
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 56 of 263If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
the Medical Monitor and UCB study physician to confirm the subject’s suitability for continued participation in the study.
11a. Subjects must be referred immediately to a mental healthcare professional (eg, locally 
licensed psychiatrist, psychologist, or master’s level therapist) and may be withdrawn from the study based upon the Investigator’s judgment of benefit/risk for:
Active suicidal ideation as indicated by a positive response (“Yes”) to Question 4 of the 
“Since Last Visit” version of the eC -SSRS.
Moderately severe major depression as indicated by a PHQ-9 score of 15 to 19 if this 
represents an increase of 3 points compared to last visit.
12a. Subjects must be referred immediately to a mental healthcare professional (eg, locally 
licensed psychiatrist, psychologist, or master’s level therapist) and must be withdrawn for:
Active suicidal ideation as indicated by a positive response (“Yes”) to Question 5 of the 
“Since Last Visit” version of the eC -SSRS
Any suicidal behavior since last visit
Severe major depression as indicated by a PHQ- 9 score ≥20
The mental health consultation must be recorded in source documentation.
Investigators should attempt to obtain information on subjects in the case of withdrawal or
discontinuation. For subjects considered as lost to follow-up, the Investigator should make an 
effort (at least 1 phone call a nd 1 written message to the subject), and document his/her effort 
(date and summary of the phone call and copy of the written message in the source documents), 
to complete the final evaluation. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source documents. The electronic Case Report Form (eCRF) must document the primary reason for withdrawal or discontinuation.
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance.
6.5.1 Potential drug-induced liver injury IMP discontinuation criteria
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitan t medications and herbal supplements that are 
not medically necessary should also be discontinued.
The PDILI criteria below require immediate and permanent discontinuation of IMP for subjects 
with either of the following:
xALT or AST ≥ 8xULN
xALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN
The PDILI criterion below requires im mediate discontinuation of IMP for:PUBLICt be ret be r
ain infoain info
nsiderednsidere
d 1 wrid 1 wri
eceCOPY d by a Pd by a P
Thiswdocument PoPo
s with pwith p
t be discbe disc
ot medicmedi
The PThe P
iicannot nuatiouatio
d contaconta
dvance.vance.
oteotebe easonaso
CCase Rase R
nnused tten men 
all and cand c
. All resAll res
n(s)n(s)toas losas lo
mesmessupportHQQ--9 sc9 s
rded in sded in
mation onation o
st tottany marketing 15 5
fessional fessiona
nd must bd must
nse (“Yesse (“Yauthorization om m 
onon4 of 4 of
to 1to 1
application ential druntial d
otential drotential 
ontinued. ntinued
ally necesly nec
I critI critand t the Methe Meanyor reor r
port Forport Foextensions ou
on subjecsubjec
o followfollow
sage to tage to t
opy of thpy of th
lts of thts of t
ememor re e
rce drcevariations be we w
es”) to Qes”) to Q
≥20≥20thereof. if this f this 
(eg, loc(eg, lo
withdwithd
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 57 of 263xSubjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis sympto ms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative cause), rash, or eosinophilia (ie, >5%).
If a nondrug-related cause for the symptoms can be confirmed, these subjects may resume 
IMP administration after discussion with the responsible UCB physician, but only when therequirements for rechallenge with IMP as provided in Section 12.2.1.2.1 are followed.
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigator.
xSubjects with ALT or AST ≥5xULN and <8xULN, total bilirubin <2xULN, and no 
eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 12.2.1 with repeat tests 
performed in two weeks. Upon re-test, if AL T or AST values have reduced to <5xULN, the 
subject can continue with the study. However, if ALT or AST remains ≥5xULN and 
<8xULN after re-test, IMP should be temporarily withheld and subject should undergo a 
repeat test in two weeks. If ALT or AST values remain ≥5xULN even after the second 
re-test, then the subject should be permanently withdrawn from the study and should be followed for possible drug-induced liver injury.
If subjects are unable to comply with the applicable monitoring schedule, IMP must be 
discontinued immediately.
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are comp lete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source doc uments. The eCRF must document the primary 
reason for IMP discontinuation.
7 STUDY TREATMENTS
7.1 Description of investigational medicinal products
The IMPs used in this study are bimekizumab, secukinumab, and placebo.
xBimekizumab will be supplied in a 1mL prefilled syringe (PFS) at a concentration of 
160mg/mL (55mM sodium acetate, 220mM glycine, 0.04% polysorbate 80 at pH 5.0) for sc 
injection.
xSecukinumab is commercially available and will be supplied as a 150mg/mL single-use PFS 
for sc injection.
xPlacebo will be supplied as 0.9% sodium chl oride aqueous solution (physiological saline, 
preservative free) of pharmacopeia (US Pharma copeia/European Pharmacopeia) quality in a 
1mL PFS for sc injection.
Further details of the IMPs and their specifications are provided in the IMP Handling Manual.PUBLIC ver
with the with the
o obtaio obtai
SCOPYrily wirily w
alues remlues r
nently wnently w
r injurinju
This documents used inused in
imekizumekizu
160mg160mg
injeinjecannotinuatinuati
UUDY TDY 
DescDescbe reasoaso
ded in tded in tused n infoinf
ubjects jects 
ng are cg are c
n(sn(sto ormormsupport ithdrawhdraw
y.
applicablepplicablanySTS
eld andeld an
n ≥n ≥5xU5x
wnmarketing N, anN, a
eg,g,fatigufatigu
2.2.12.1withw
s have redhave r
T remaT remauthorization thehe
d.
f the f the 
nd nnd n
application riptionption
this studyhis stu
mab will mab wi
/mL (55mmL (55
ion.on.and TREATREATanyfor IMor I
e source e sourceextensionse monmon
ation on ion on
with PDIth PDI
mplemple tete
MPMPor tvariations th reprep
duced touced t
mains ≥5x ains ≥5
subject subject 
ULN eveLN eve
from throm ththereof. o 
ue, nausenause
peatpea
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 58 of 2637.2 Treatments to be administered
Unblinded study staff will be responsible for preparation of the clinical trial material, including 
recording the administration information on source documents, and administration of the IMP as 
sc injections. The unblinded personnel will not be involved in the study in any way other than assuring the medication is taken from the correc t kit and administering the drug to the subjects.
Suitable areas for sc injections are the lateral abdominal wall, upper outer thigh, or upper arm. 
During each dosing visit, each of the injections should be administered at a separate injection 
site. Injection sites should be rotated at each visi t and injections should not be given into a PSO 
plaque or areas where the skin is tender, bruised, erythematous, or indurated. The injection should last approximately 10 to 15 seconds.
An IMP Handling Manual will be provided to each site containing instructions regarding drug 
preparation and dosing.
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W at Week 64 or at the next scheduled clinic visit after implementation 
of Protocol Amendment #5.1 if the subject has already completed the Week 64 visit. 
The dosing scheme for Baseline through Week 44 is depicted in Table 7‒1.The dosing scheme 
from Week 48 through Week 140 is depicted in Table 7‒2.
PUBLIC COPYyy
4 is dep4 is de
in n TableTab
This document cannot be used to support 7‒‒22any tete
ted inted in TT
2marketing ions regaions reg
gQ4W toQ4W
clinic visiinic vi
d the Wd theauthorization arm. rm.
ection ction 
into a Pinto a P
injectionjectio
application and any extensions or variations o 
sit after after 
WeekWeek 66
ableble77‒‒thereof. n 
arding dding d
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 59 of 263Table 7‒1: Dosing scheme, double-blind Treatment Period
Week
Dose AssignmentBaseline 
(first dose)1 2 3 4 8 12 16a20 24 28 32 36 40 44
Bimekizumab 
320mg●● ○○○○○○●●●●●●Q4W
●●●●●●●●●●●●●●●●
Q8W
●●○○●●○○●●○○●●○○
Secukinumab 
300mg ▲▲ ▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲
Q4W=every 4 weeks; Q8W=every 8 weeks
Notes: A bimekizumab 160mg injection is depicted by a black circle ( ●). A placebo injection is depicted by a white circle ( ○). Asecukinumab 150mg injection 
is depicted by a black triangle ( ▲). 
aSubjects in the bimekizumab 320mg treatment arm will be re-rando mized 1:2 to receive bimekizumab 320mg Q4W or bimekizumab 320mg  Q8W.PUBLIC mize
COPY placebo inlacebo
ed 1:2 d 1:2
YYThis 
document 
cannot 
be 
used 
to support ectict
o receive breceive
any y
on is don isnyyymarketing ●ng
●●●●etirk
▲▲▲▲ma
authorization 
a
8 33hhhouthaapplication 
and 
any 
extensions 
ormekizumekiz
variations 
s
▲▲▲▲nsssati
s
depicted bpicted 
iatatat
thereof. ●●●●of.re
○○○○het
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 60 of 263Table 7‒2: Dosing scheme, OLE Period
Week
Dose 
Assignment
48 (1st 
OLE) Year 2 Year 352
56
60
64a,b
68
72a,b
76
80
84a,c
88
92
96a,b
100
104
108a,c
112
116
120a,b
124
128
132a,c
136
140
C C C H C H C H H C H H C H H C H H C H H C H H
Bimekizumab 
320mg Q4W●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
Bimekizumab 
320mg Q8W●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●●
C=clinic; H=home; OLE=Open-Label Extension; Q4W=every 4 weeks; Q8W=every 8 weeks
Notes: A bimekizumab 160mg injection is depicted by a black circle ( ●).
aThe subject’s dosing interval will change from bimekizumab 320mg Q4W to bimekizumab 320mg Q8W at Week 64 or at the next scheduled clinic visit (ie, 
Week 72, Week 84, Week 96, Week 108, Week 120, or Week 132) after implementation of Protocol Amendment #5.1 if the subject has already completed 
the Week 64 visit.
bSubjects whose dosing interval is  changed to bimekizumab 320mg Q8W should be dosed at this visit and will re ceive kits for home administration 8 weeks 
later.
cSubjects whose dosing interval is  changed to bimekizumab 320mg Q8W should NOT be dosed at this visit and will receive kits for home administration 4
weeks later.fte
mgmQ8WQ8W
bb320mg320mg
COPY 
Yevery 8 wevery 8 
W to bimW to bim
r impleimp
YYYThis 
document 
cannot 
be 
used 
toQ8W shQ8W s
support kizumabzuma
mentation oentation
hould be dould be d
houlh
any nksks
3nnny
marketing 
112112ting
CC Htitintingktin
●●●●●●kkkem
rk
●●●mmmam
authorization 
a
YearYearho66utututautapplication 
and 
any 
extensionsdosed atosed a
ld NOT bNOT b
orfP r o t ofP r o t
variations ●●●nonononaton
0mgmgQQ
atatat
thereof. 
1
120120a,baere
of
HHereereretherethththth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 61 of 263During the OLE Period, IMP administration on weeks with no scheduled clinic visit should 
primarily be performed by subjects at home. Se lf-injection training will be provided to the 
subject/caregiver by qualified site personnel at  Week 48 (upon signature of the ICF). Additional 
training may be provided by site staff at subs equent clinic visits as needed. At Week 48 and 
subsequent clinic visits, the subject/caregiver  will perform self-administration under the 
supervision of the site staff to ensure that study medication is being properly and safely injected. 
After the implementation of Protocol Amend ment #5.4 (addition of a 48-week treatment period, 
ie, OLE2 Period), subjects will be invited to c ontinue or reinitiate their treatment as per the 
following OLE2 Groups:
xOLE2 Group A: Subjects in the treatment phase  of the OLE Period at the time of Protocol 
Amendment #5.4 implementation will attend the Week 144 Visit and directly roll over to the 
OLE2 Period. These subjects will continue receiving bimekizumab 320mg Q8W for 
40 additional weeks, starting from the first treatment visit of the OLE2 Period (ie, Week 
144/OLE2 Baseline Visit; the Week 144 Visit will coincide with the Week 144/OLE2 Baseline Visit and data collected at this visit will be used as baseline data for subjects 
entering the OLE2 Period).
xOLE2 Group B: Eligible subjects who have completed the Week 144 Visit and are in the 
SFU or have completed the SFU of the OLE Pe riod at the time of Protocol Amendment #5.4
implementation, will reinitiate their treatmen t in the OLE2 Period after having undergone 
Screening assessments during a 4-week OLE2 Screening Period. The first dose will be 
administered at the Week 144/OLE2 Baseline Vi sit and data collected at this visit will be 
used as baseline data for the OLE2 Period. S ubjects in OLE2 Group B with an IGA score 
≥3at the Week 144/OLE2 Baseline Visit will be treated with bimekizumab Q4W for the first 
16 weeks, then will switch to bimekizumab 320mg Q8W. Subjects in OLE2 Group B with an 
IGA score <3 at the Week 144/OLE2 Baseline Visit will be treated with bimekizumab Q8W from the Week 144/OLE2 Baseline Visit. 
During the OLE2 Period (Week 144/OLE2 Baseline  to OLE2 Week 48), all subjects will attend 
study visits every 12 weeks. All subjects will  be treated until OLE2 Week 40 (last dose of 
bimekizumab 320mg Q8W).
The dosing scheme from Week 144/OLE2 Baseli ne through OLE2 Week 40 is depicted in 
Table 7‒3.PUBLICweek Oeek O
LE2 BasLE2 Bas
OLE2 PeOLE2 Pe
BaselineBaseline
h to bimh to biCOPY completomple
LE PerioE Per
tment iment i
OLOL
This document cannot eeks. ks
g Q8W)Q8W)
me frome frombeWeek 1Week 1
AlAlusedmekizukizu
4/OLE2 OLE2
aselineaselintorio
Visit wVisit 
umsupport d at tat
n the OLhe OL
E2 Screen2 Scree
line Visine Visi
d. Subjd. Sub
ilany d the Wethe W
the tithemarketing m
rectly roectly r
20mg Q80mg Q8
LE2 PeriLE2 Pe
h the Wethe W
baseline daselinauthorization ted. ed. 
period, eriod, 
er the the 
me of Pe of P
application Wand susu
Week 1eek 1any/OLE2 OLE2
bjects bjectextensionsnin
it and dand 
jects in ects in 
ll be trebe tre
ab 320mab 320m
Baselineaseline
Visit. isit. or E2 P2 
g Perg Pevariations eek 1k 1
data fordata for
eek 144 k 144 
ime of Pme of 
PerioPerithereofrotocolotocol
ll over toover t
8W for W for 
od (ie, od (ie, 
44/44/
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 62 of 263Table 7‒3: Dosing scheme, OLE2 Period
Visits/Week
Dose AssignmentOLE2 PeriodWeek 144/ OLE2
Baseline
OLE2 W4
OLE2 W8
OLE2 W12a
OLE2 W16
OLE2 W24b
OLE2 W32
OLE2 W36c
OLE2 W40
CH H CHCHC H
Bimekizumab 320mg Q4W/Q8W d●● ●● ●● ●● ●● ●● ●● ●●
Bimekizumab 320mg Q8W ●● ●● ●● ●● ●● ●●
C=Clinic; H=home; IGA=Investigator’s Global Assessment; IMP=investigational medicinal product; Q4W/Q8W=every 4 weeks for 16 weeks, followed by 
every 8 weeks; Q8W=every 8 weeks; OLE=Open Label Extension; W=week
Notes: A bimekizumab 160mg injection is depicted by a black circle ( ●).
aSubjects will receive kits for home administration 4 weeks later.
bSubjects will receive kits for home administration 8 weeks later.
cSubjects should NOT be dosed at this visit and w ill receive kits for home administration 4 weeks later.
dQ4W/Q8W IMP administration only applies to those subjects who have entered the OL E2 Period as part of Group B, and had an IGA ≥3 upon entry of 
OLE2 Period. These subjects will receive Q4 W dosing for 16 weeks until OLE2 Week 16, then will change from Q4W to Q8W and will receive their next 
dose at the scheduled clinic visit OLE2 Week 24.
PUBLIC W=wW=
le (e (●●).).
er.
later.ater.
ve kits fove kits fo
ubjects ubjects 
r1r
COPY C
●●PYOP●●OPOPOPOP igationalgational
weekweekCOOOThis 
document 
cannot 
be 
used ho hao h
weeks uweeks u
tohome ahome a
ve eve
support medicinal edicinartrtany nnnnyanaaaa
marketing 
LE2E2WW242rk
HHm
authorization 
ahouthaapplication 
and 
any 
extensions ministratioistrati
tered theed the
til OLE2l OLE2
or rodrod
vaduct; uct;variations 
OLOonat●●
iaaaa
●●●●arva
thereof. 
WW3232h
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 63 of 263Once subjects/caregivers as determined by the In vestigator (or designee) have been trained, the 
study medication may be administered at home. The subject will receive the required number of 
syringes for injections at each visit needed to  perform the Q4W or Q8W administrations at home. 
Subjects who are unable to or decide not to self-inject IMP or those without a family 
member/friend/caregiver who can help, will not be  discontinued, but may continue to visit the 
site for unscheduled visits for IMP administration only. 
If administered at home, the subject/caregive r will document the date, body location, kit number 
and time point of administration of study medication. 
All used syringes will be disposed of by subjects/caregivers as determined by the Investigator in 
an acceptable disposal (sharps) container  directly after th e administration. The 
subjects/caregivers return the documentation together with any used/unused containers at the 
next scheduled clinic visit. 
7.3 Packaging
The IMPs will be packaged and labeled according to Good Manufacturing Practice (GMP) 
guidelines and applicable laws or regulations. They w ill be suitably packaged in such a way as to 
protect the product from deteri oration during transport and storage. Further information 
regarding storage and transport conditions are provided in the IMP Handling Manual.
7.4 Labeling
The IMPs will be labeled in accordance with the current International Council for Harmonisation 
(ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include any locally required statements. If necessary, labels will  be translated into the local language.
7.5 Handling and storage requirements
Refer to the IMP Handling Manual for the storage conditions of the IMP.
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by the Invest igator is to be kept in a secured area with 
limited access according to the stora ge conditions ment ioned on the label.
Appropriate storage conditions must be ensured either by controlling the temperature (eg, room,
refrigeration unit) or by completion of a temperature log in accordance with local requirements 
on a regular basis (eg, once a week), showin g actual and minimum/maximum temperatures 
reached over the time interval.
In case an out of range temperature is noted, it mu st be immediately reported as per instructions 
contained in the IMP Handling Manual.
The IMP will be shipped to the study sites in temperature controlled containers. Out-of-range 
shipping or storage conditions must be brought to the attention of the sponsor or designee, 
immediately. Authorization to use any out-of-ra nge IMP must be documented and received prior 
to dispensing or administering the IMP at the study site.
In addition, the Investigator (or designee) will in struct the subject/caregiver on how to handle the 
IMP during transport, and how to store the IMP following the instruction guide. Cooler bags 
with freezer packs will be provided to the subjects/caregivers. Specific attention will be put on 
the transport from site to home using cold bags, and the subject/caregiver will be instructed to PUBLICe with e with
PracticePractic
, labels labels 
nd stond stoCOPYsport ansport 
providedprovid
This idocumentbasas
ver thr the e 
e an outan out
ntained tained
The IMThe IM
shipshipcannotp
ng to thg to th
e conditcondi
it) or by) or by
sis (egs (egbe e) is is
roductroduc
hehused rageage
ual for thl for t
resprespto will bill b
er eersupport e currentcurre
(GCP) anGCP) a
be trabe tanytaba
storagestorag
the IMthe IMmarketing containcontai
ufacturingfacturin
bly pacbly pauthorization number umber 
Investignvesti
application comom
, once a , once a
me intervme inte
of range of range
n the IMPthe IM
will bewill b
tand stortor
ions muons mu
mpletmpleanynsibnsi
tored bytored b
rage cageextensions Intn
nd GMPGMP
anslatednslated
equiremquirem
e storagstorag
blebleor ernaernvariations g PractiPracti
ackaged ckaged
FurtherFurther
MP HandP Handthereof. at
ers at thes at the
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 64 of 263put the IMP as quickly as possible into his/her refrigerator. In case of broken refrigerator, or 
broken or lost syringes, the subject will inform the site immediately and new IMP will be 
supplied. All efforts should be made to follow the treatment scheme as per protocol.
7.6 Drug accountability
A Drug Accountability form will be used to record IMP dispensing and return information on a by subject basis and will serve as source documentation during the course of the study. Details of any IMP lost, damaged (eg, due to breakage or wastage), not used, partially used, disposed of at 
the study site, or returned to the sponsor or desi gnee must also be recorded on the appropriate 
forms. All supplies and pharmacy documentation must be made available throughout the study 
for UCB (or designee) to review.
In order to maintain the blind, all IMP documen tation (eg, shipping receipts, drug accountability 
logs, interactive response technology [IRT] randomization materials) must be maintained and 
accessed by unblinded, trained site personnel only. Designated, unblinded site personnel must be appropriately trained and licensed (per country guidelines) to administer injections.
Unblinded study staff will be responsible for receipt, inventory, and destruction of used kits. The 
packaging identifies each kit by a unique number, but due to the commercial packaging of the 
comparator, the unblinded study staff will be responsible to maintain the blind. Unblinded study 
staff will be responsible for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial material, including recording the administration information on source document.
The OLE2 Period will be unblinded and bli nding precautions will not be applicable.
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.
The Investigator should assign some of the Investigator’s duties for drug accountability at the 
study site to an appropriate pharmacist/designee.
The Investigator must ensure that the IMP is used only in accordance with the protocol.
Periodically, and/or after completion of the clinica l phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expired IMP must be reconciled and either 
destroyed at the site according to local laws, regulations, and UCB Standard Operating 
Procedures (SOPs) or returned to UCB (or desi gnee). Investigational medicinal product intended 
for the study cannot be used for any other purpose than that described in this protocol.
7.7 Procedures for monitoring subject compliance
During the double-blind Treatment Period (up to  Week 44), investigational medicinal product 
will be administered in the clinic and complian ce will be determined at the visit by study 
personnel. Drug accountability must be recorded on the Drug Accountability Form.
After Week 48, self-injection at home will be possible at the following weeks: Weeks 60, 68, 76, 
80, 88, 92, 100, 104, 112, 116, 124, 128, 136, 140, and at the OLE2 Weeks 4, 8, 16, 32, and 40.
Dates, body locations, kit numbers and time of self-injection will be captured using a home 
administration form. All used syringes will be di sposed of by subjects/caregivers as determined 
by the Investigator in an acceptable disposal (sha rps) container directly after the administration. 
The subjects/caregivers return the documentation together with any used/unused containers at the 
next scheduled clinic visit.PUBLIC min
and blindand blin
responsespons
ed or deed or de
somsoCOPYbut dubut d
esponsibespon
aking taaking ta
nistratistra
ThisAdocumenty canncann
ring theing the
will be awill be
persopersocannoter comr com
used, used, u
ite accote acco
OPs) or Ps) or 
nobere that e that
mpmpused strtr
me of theof th
rmacist/macist/
hto ble fe
oyed.oyed.support mper prper p
on informn infor
ing precang prec
for reforany, , 
o the coo the c
to maino ma
roomarketing ts, drug as, drug 
ust be mast be m
inded sitended si
minister inister i
and deand dauthorization n a 
tails of tails of 
sed of aed of a
propriatpropria
hout the ut the
application returnedurne
be used fbe used
ProceduProced
doubleouble -bl
dministerministe
DruDrandetioeti
nused, dused, d
ing to ng to 
ddany IMP iIMP
on of ton ofextensionsautionution
etaining aining
Investignvestig
esigneesigneeormationationvariationse p
njectioectio n
estructiostructio
mmercimmerci
ntain theain the
f stickestickethereof. stu
accountacounta
maintaineaintain
personperson
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 65 of 263Completed home administration forms should be review ed by the Investigator with the subject. If 
a subject is noncompliant with the study procedures or medications that may present a risk to the 
safety of the subject in the opinion of the Investigator, then the subject should be withdrawn as described in Section 6.5.
7.8 Concomitant medications/treatments
Any treatment administered from the time of informed consent to the final study visit will be 
considered concomitant medication. This includes me dications that were started before the study 
and are ongoing during the study.
7.8.1 Permitted concomitant treatments (medications and therapies)
The following concomitant medications are permitted during the study.
7.8.1.1 Topical medications
Subjects may continue to use topical moisturize rs or emollients, bath oils, or oatmeal bath 
preparations for skin conditions during the stud y, as needed. Over-the-counter shampoos for the 
treatment of PSO of the scalp are also permitted.
In the double-blind Treatment Period, mild and low potency topical steroids will be permitted for 
use limited to the face, axilla, and/or genitalia,  as needed. These topical medications should not 
be used within approximately 24 hours prior to study visits requiring IGA and PASI measures.
In the OLE and OLE2 Periods, the medications  listed as permitted for the double-blind 
Treatment Period will be allowed. In addition, any topical steroids and vitamin D analog 
ointment will be permitted for use, as neede d. These topical medications should not be used 
within approximately 24 hours prior to study visits requiring IGA and PASI measures.
7.8.1.2 Other medications
Subjects may take pain relievers (acetaminophen/ paracetamol, NSAIDs, opiates) as needed for 
pain but preferably not within 24 hours of the Baseline and Week 48 Visits. Intraarticular injections (eg, steroids or hyaluronic acid) are permitted and must be carefully recorded in the 
eCRF.
Subjects who are receiving an established regimen for depression should remain on stable dosing 
prior to Baseline and throughout the study. 
7.8.2 Prohibited concomitant treatmen ts (medications and therapies)
Table 7‒4presents the list of prohibited PSO medications.PUBLICdicationdicatio
n additioadditio
e, as nee, as nee
s prior to prior to
tiotioCOPYow ow potepot
as needas ne
r to studr to stu
ns
This documentPrPr
7‒44presprecannot r h
receivinceivin
ne and th and tbein 24 24
yaluroyaluroused s
s (aceta(acet
hohtoded
tudy vtudy supported. d.
y visits visits
listed as psted as
n, any topany top
d. Thes Theany y topicay topic
TheseThesmarketing h oils, or oils, o
r-thethe--coucoauthorization be be 
the studhe stud
erapiesrapies
application roughough
hibited cibited
ents the lients the and an estaan esta
houhouany rs of trs of
ic acid) ic acid)extensionspe
pical stecal st
se topicae topic
sits requts req
inophenophe
thor quq
rmittmittvariationsoa
unter shnter sh
al steroidsteroi
e topicaltopical
uiringuiringthereof. )
atmeatme
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 66 of 263Table 7‒4: Prohibited psoriasis medications
Drug Washout period relative to Baseline Visit
Topicals except for those permitted ( Section 7.8.1.1 ) 2 weeks
Systemic retinoids 1 month 
Systemic treatment (non-biological), eg:
systemic immunosuppressant agents (eg, methotrexate, 
cyclosporine, azathioprine, thioguanine)
fumaric acid esters specifically  used for the treatment of 
PSO 
systemic corticosteroids
phototherapy 1 month
Anti-TNFs, eg:
etanercept (including biosimilar)
infliximab (including biosimilar), golimumab, certolizumab 
pegol, adalimumab (including biosimilar)1 month for etanercept3 months for everything  other than etanercept
Other biologics and other systemic therapies, eg:
ustekinumab 6 months for ustekinumab
apremilast, tofacitinib 2 weeks for apremilast and tofacitinib
alefacept, efalizumab, guselkumab 3 months for alefacept, efalizumab, and 
guselkumab
tildrakizumab, risankizumab 5 months for tildrakizumab, risankizumab
briakinumab 6 months for briakinumab
rituximab 12 months for rituximab
Anti-IL-17 therapies, eg:
brodalumab
ixekizumab3months
(any prior exposure to secukinumab or 
bimekizumab is excluded [see Section 6.2 ])
Any other antipsoriatic agent (systemic) under investigation (or 
approved after the protocol is approved)3 months or 5 half -lives, whichever is greater
Any other antipsoriatic agent (topical) under investigation 1 month
IL-17=interleukin 17; PSO=psorias is; TNF=tumor necrosis factor
Up to Week 144
Subjects who take prohibited medications may be withdrawn from IMP but followed until the 
SFU Visit. The decision to withdraw a subject for  taking prohibited medications should be made 
in consultation with the Medical Monitor.
Post Week 144 (OLE2 Period)
Subjects who have used systemic treatments after Week 144 must have stopped this treatment 
1 month prior to receiving the first bimekizumab injection in the OLE2 Period. Subjects 
receiving systemic immunomodulatory medications for  an indication other than PSO must have
their eligibility confirmed by the Medical Monitor prior to enrollment in the OLE2 Period.PUBLIC COPY YY 
This documentrleukin 1ukin 1tpsopt
Week 1Week 1
ubjects wjects w
SFU VSFU V
in cin ccannot c agent (sagent (s
protocol iotocol ot
oriatic riatic acbe used usto support 66rt2 ortoany y
monmomarketing r etanercepetanerc
s for everyfor eveetiauthorization ootioatitit
applicatio; PSO=psoPSO=pstiongent (topigent (topntio
444
whootake ptake
t. The d The
ioand ystemic) uemic) u
pproveprovedaany extensions 3 m3 m
gusgusonon
exorweeks weeks
onvariations pt
ything othhing ot
ati
ths for usfor u
fthereof. he
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 67 of 2637.8.2.1 Vaccines
Administration of live (including attenuated) vaccines is not allowed during the conduct of the 
study and for 20 weeks after the final dose of IMP (see Exclusion Criterion # 10,Section 6.2 ).
Administration of inactivated vaccines is allowed during the study at the discretion of the Investigator.
7.9 Blinding
Due to differences in presentation between the bimekizumab and secukinumab, special precautions will be taken to ensure study bli nding during the double-blind Treatment Period and 
study sites will have bli nded and unblinded personnel.
For subjects receiving bimekizumab, bimekizumab will  be administered at Baseline; placebo will 
be administered at Week 1, Week 2, and Week 3; their second dose of bimekizumab will be at 
Week 4; and bimekizumab doses Q4W throug h Week 16. At Week 16 subjects in the 
bimekizumab 320mg treatment arm will be re-randomized 1:2 to receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W. To maintain the blind, subjects in the bimekizumab 320mg 
Q8W treatment arm will receive placebo at We eks 20, 28, 36, and 44. Secukinumab subjects will 
receive secukinumab at Baseline, Week 1, Week 2, Week 3, Week 4, and Q4W thereafter.
All Sponsor and Investigator site personnel involved in the study will be blinded to the 
randomized IMP assignment with the following exceptions:
xUnblinded study staff will be responsible for preparation (breaking tamper proof sticker on 
kit, etc) of the clinical trial material, including recording the administration information on source documents, and administration of the IMP as sc injections. The unblinded personnel 
will not be involved in the study in any way other than assuring the medication is taken from 
the correct kit and administering the drug to the subjects.
xBioanalytical staff analyzing blood samples for bimekizumab and anti-bimekizumab 
antibody determination.
During the double-blind Treatment Period of the study, the Sponsor will provide blinded and 
unblinded site monitors for the purposes of verify ing safety, efficacy, and drug administration 
and documentation records. Unblinded study site personnel need to be available in order to 
resolve queries. Study monitors and study site personnel, blinded to treatment assignment, will 
not discuss or have access to any drug related inform ation. This will continue at least until all 
subjects have completed the double-bl ind Treatment Period of the study.
Study sites will be required to have a written blinding plan in place, signed by the Principal 
Investigator, which will detail the site’s steps for ensuring that the double -blind nature of the 
study is maintained. Sites will be instructed to keep study subjects blind to the IMP as detailed in the site blinding plan.
After all subjects have completed the double-blind Treatment Period of the study and the interim 
analysis has occurred, unblinded study site pe rsonnel can perform assessments in the OLE and 
OLE2 Period(s) of the study.
Further details are provided in the study manual and site blinding plan.PUBLIConsible nsible
rial, incrial, in
nistrationistratio
study instudy in
terinterCOPY,
2, Wee2, We
volved ivolved
wing exwing ex
f
This document or havr ha
have coave co
dy sites wy sites w
nvestigavestiga
study study
thethecannotd TreaTrea
tors for rs for
on recorn recor
 StudyStudy
vebe atmatmusedana
g the drthe dr
g blood bloodto of tof t
ny wany wasupportn theth
ceptions:ptions
r preparaprepa
uding recding re
the IMtheanyan
WeekWee
e ste studumarketing Baselinselin
memekizumakizum
subjects subject
ceive bimeive b
ects in thets in t
nd 44. d 44
4authorization l 
nt PerioPerio
application ds
monitomonit
access tccess t o
mpleted tpleted
will be reqll be re
or, whichr, whic
maintaiainta
dandmenten
he purpe purp
. UnblUnbany t PerioPerextensionsationio
cording rding
MP as sMP as s
y other tother t
g to the to the 
amplesmplesor n (brn( bvariations mekieki
he bimbimekek
SecukinSecukin
4, and Q4, and Q
dy will bwill thereof. placebolacebo
ab will b will 
 in the in the 
izumizum
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 68 of 2637.9.1 Procedures for maintaining and breaking the treatment blind
7.9.1.1 Maintenance of IMP blind
All subject treatment details (bimekizumab or se cukinumab) will be allocated and maintained by 
the IRT system.
7.9.1.2 Breaking the treatment blind in an emergency situation
The integrity of this clinical study must be main tained by observing the treatment blind. In the 
event of an emergency for which the appropriate tr eatment for a subject cannot be made without 
knowing the treatment assignment, it will be po ssible to determine to which treatment arm and 
dose the subject has been allocated by contacting the IRT. All sites will be provided with details of how to contact the system for code breaking at  the start of the study. The Medical Monitor or 
equivalent should be consulted prior to unblinding, whenever possible.
The Clinical Project Manager (CPM) will be in formed immediately via the IRT when a code is 
broken, but will remain blinded to specific treatment information. Any unblinding of the IMP 
performed by the Investigator must be recorded in the source documents and on the Study 
Termination eCRF page.
7.10 Randomization and numbering of subjects
An IRT will be used for assigning eligible  subjects to a treatment regimen based on a 
predetermined production randomization and/ or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be st ratified by region and prior biologic exposure 
(yes/no). The IRT will generate individual assignmen ts for subject kits of IMP, as appropriate, 
according to the visit schedule. 
At Screening, each subject will be assigned a 5-digit number that serves as the subject identifier 
throughout the study. The subject number will be required in all communication between the Investigator or designee and the IR T regarding a particular subject.
At the Baseline Visit, a subject will be randomized into the study. The Investigator or designee 
will use the IRT for randomization. The IRT will automatically inform the Investigator or 
designee of the subject’s identification number. The IRT will allocate kit numbers to the subject 
based on the subject number during the course of the study. The kits are blinded.
At Week 16 subjects in the bimekizumab 320mg treatment arm will be re-randomized 1:2 to 
receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W. To maintain the blind after 
re-randomization, subjects in the bimekizumab 320mg Q8W treatment arm will receive placebo 
at Weeks 20, 28, 36, and 44. Subjects in the secukinumab arm will continue to receive secukinumab 300mg Q4W.
In the OLE Period, subjects:
xWho received bimekizumab 320mg Q4W and achieved PASI90 at Week 48 of the double-
blind Treatment Period will be randomized  1:1 to receive bimekizumab 320mg Q4W or 
bimekizumab 320mg Q8W.PUBLICn andn an
le will bwill b
r subjecr subjec
gnment gnment
te indivte indivCOPY bering obering 
ubjects ubjects
d/or d/or
This document e subjsubj
ek 16 sub16 su
ive bimee bim
randomandom
at Weeat Wee
secuseccannot andan
t, a subja sub
for randor rand
subjecubjec
jecjecbeubjectbject
d the d theused iduadua
be assibe asstowill bewill b
al asal assupporto a treata trea
packagingckagi
e produceproduc
kits of IMits of IM
es t rany f subjesubjemarketing Medicedic
ia the IRTa the IR
Any unblny un
cuments cumentauthorization In the n the 
ade withade with
mennt armt arm
ded wied wi
call
application ’s ideniden
number numbe
jects in thjects in
kizumab zumab
mization, sation
20, 2820, 28
bandect will t will
mizatioizatio
ntitiany mber wmber 
RT regarT regar
bextensionsed by tby 
MP, as aMP, as a
tratified atified
ignmengnmen
ned a 5d a orme
schedsche
ththvariationslindinndin
s and onand on
ectscts
ent regnt regthereof.h detadeta
MonitorMonito
T when when
ng
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 69 of 263xWho received bimekizumab 320mg Q4W and who did not achieve PASI90 at Week 48 of 
the double-blind Treatment Period will receive bimekizumab 320mg Q4W.
xWho received bimekizumab 320mg Q8W and who did not achieve PASI90 at Week 48 of 
the double-blind Treatment Period will receive bimekizumab 320mg Q4W.
xWho received bimekizumab 320mg Q8W and who achieved PASI90 at Week 48 of the 
double-blind Treatment Period will receive bimekizumab 320mg Q8W.
xWho received secukinumab and who did not achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q4W.
xWho received secukinumab and who achieved  PASI90 at Week 48 of the double-blind 
Treatment Period will be randomized 1:1 to receive bimekizumab 320mg Q4W or 
bimekizumab 320mg Q8W.
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W at Week 64, or at the next scheduled clinic visit after implementation
of Protocol Amendment #5.1 if the subject has already completed Week 64. 
Subjects who roll over directly from the OLE Period into the OLE2 Period will continue 
receiving bimekizumab 320mg Q8W and will keep their unique 5-digit identification number. 
Subjects who reinitiate bimekizumab after having  completed treatment (subjects in the SFU of 
the OLE Period or who have completed the SF U of the OLE Period) will receive either 
bimekizumab 320mg Q4W/Q8W or bimekizumab 320mg Q8W depending on their disease 
activity at time of reentry (bimekizumab 320mg Q4W/Q8W for subjects with IGA score ≥3 or 
bimekizumab 320mg Q8W for subjects with IGA score <3). For these subjects, the same unique 
5-digit identification number used in the study will be reused.
Subject numbers and kit numbers will be tracked via the IRT during the double-blind Treatment 
Period, the OLE Period, and the OLE2 Period.
8 STUDY PROCEDURES BY VISIT
Table 5‒1, Table 5 ‒2, and Table 5-3 provide a general overview of study assessments during the 
double-blind Treatment Period, the OLE Period, a nd the OLE2 Period, respectively. A list of 
procedures to be completed at each visit is described below.
xVisit windows of ±3 days on either side of the scheduled dosing are permitted up to and 
including Week 24; however, the Investigator should try to keep the subjects on the original 
dosing schedule. From the Week 28 Visit through the Week 72 Visit, visit windows of 
±7 days on either side of the scheduled dosing are permitted; however, the Investigator 
should try to keep the subjects on the original dosing schedule. From the Week 76 Visit 
through the Week 144/PEOT Visit, visit windows of ±14 days on either side of the scheduled dosing are permitted; however, the Investigator should try to keep the subjects on the original 
dosing schedule. The visit window is relative to Baseline and applicable for all subsequent 
visits up to Week 144/OLE2 Baseline Visit. From the Week 144/OLE2 Baseline Visit 
through the OLE2 Week 48/PEOT Visit, visit windows of ±14 days relative to the Week 
144/OLE2 Baseline Visit on either side of th e scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. Changes to the 
dosing schedule outside the visit window must be discussed with the Medical Monitor.he 
imekizumekiz
umab 32umab 3
ubjects wubjects 
used in used inCOPYod intood in
keep thekeep t
aving coaving co
SFU SFU
This document ndowdow
ding Weng We
sing schng sch
±77daysday
shoushou
ththcannotand nd TaT
ment Perent Per
compleomple
ws ows obePROCPROC
bbused he he 
will be will be 
OLE2OLE2to with Ith I
studystudysupport mpleteplete
of the OLf the O
mab 320mab 320
0mg Q4Wmg Q4W
IGA IGAanye OLEe OLE
unique 5niqu
dtdmarketing o
mg Q4WQ4W
Q4W to Q4W t
clinic visinic vis
ed Weekd Wee
2authorization oubleble--blbl
ubleble--bb
application ted
f ±3 days f ±3 day
ek 24; how24; h
edule. Frodule. F
on eithern eith
d try to ktry to k
h theht h eand le55
iod, the od, the 
d at eaat eaanyDUREDUR
33propextensions mg Qg Q
W/Q8WW/Q8W
score <score <
will be will be 
racked vcked 
eriod.riod.orE PeriE Per
Q8WQ8Wvariationsit after after
k 64. k 64. 
2 PeriodPeriod
5-digit digit 
reatmeeatmethereof. ind nd 
or 
i
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 70 of 263xThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled 
dosing visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the scheduled dosing visit. From Week 28 through the Week 72 Visit, the dosing window is 
±7 days relative to the scheduled dosing visit. From the Week 76 Visit through the OLE2 
Week 40 Visit, the dosing window is ±14 days relative to the scheduled dosing visit.
xFor the SFU and SFU2 Visits (20 weeks after the final dose), the visit window is ±7 days 
relative to the scheduled visit date.
8.1 Screening Visit (2 to 5 weeks)
Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has been approved by the Sponsor and an Instituti onal Review Board (IRB)/Independent Ethics 
Committee (IEC), and that complies with regulatory requirements. Subjects will be given 
adequate time to consider any information concerning the study given to them by the Investigator 
or designee. As part of the informed consent procedure, subjects will be given the opportunity to 
ask the Investigator any questions regarding potenti al risks and benefits of participation in the 
study.
The following procedures/assessments will be performed at the Screening Visit:
xInformed consent
xInclusion/exclusion
xUrine drug screen
xDemographic data (age, gender, race and et hnicity [according to local regulations])
xPsoriasis history including the date of onset and past treatments
xSignificant past medical history including clinically relevant past or coexisting medical 
conditions and surgeries
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xVital signs (sitting systolic and diastolic blood pressure [BP], pulse rate, and body 
temperature) should be obtained prior to blood sampling
xCollection of blood and urine samples for the following clinical laboratory tests:
Hematology and biochemistry
Urinalysis
Serum pregnancy test
Hepatitis B and Hepatitis C
HIV
IGRA tuberculosis test
xRecord 12-lead ECGPUBLIC der, raceder, race
g the dg the dCOPYrformedforme
This documenttion of on of
HematHema
UrUr
cannot tting sysng sys
e) shouldshoul
bbe g evalg evalused te of oof 
ory inclury inclto and end 
ononsupport ethniethanythe Scthe Smarketing pendeend
ts will bes will b
o thethem bym 
l be givenbe giv
enefits of nefits oauthorization ys 
e an ICan IC
entent
application d be obbe o
ood and uod and
ology andlogy an
nalysisalysis
rum prum pand olic andlic an
btabtaany ation of ation ofextensions icity [city [ acac
set and pt and p
ding cliing clior variationsn t
f particpartic
reening eening thereof. F thatth
Ethics thics 
e given given
by the Iny the In
the ophe op
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 71 of 263xChest x-ray (not necessary if performed within 3 months prior to Screening Visit and report 
is available)
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT 
8.2 Treatment Period
8.2.1 Baseline Visit
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xInclusion/exclusion (includes evaluation of signs and symptoms of active TB and risk for 
exposure to TB)
xSignificant past medical history and concomitan t diseases to ensure no significant changes 
since Screening
xHeight
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
Bimekizumab/secukinumab plasma concentrations
Anti-bimekizumab antibodies
xTuberculosis questionnaire
xPASI
xPercentage of BSAluation oluation 
istory anistory anCOPY be perforbe perfo
This document Hematolmatol
UrinUrin
cannotsystolystol
o blood sblood 
of bloodf bloodbe icicused d toconcoconcosupport med/reed/re
f signs ansigns aany ecomarketing authorization 
application and und 
ogy and bgy and 
alysisysis
rine pregine pregandand nd
amplingmpling
urinurinany diastodiasextensionsnd symd sym
mitant diitant dor variations rded prded prthereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 72 of 263xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS
xscalp IGA
xmNAPSI
xpp-IGA
xPatient Global Assessment of psoriasis
xPASE
xPGADA (only for subjects with PsA)
xWPAI-SHP V2.0
xPhotographs of skin and nails (subjects consenting to sub-study in participating centers only)
xEQ-5D-3L
xConcomitant medication
xAEs 
xUpon confirmation of subject’s eligibility, randomization will occur
xContact IRT 
After completion of the above-mentioned pr ocedures, IMP administration will occur.
8.2.2 Week 1 and Week 2 Visits ( ±3 days relative to Baseline)
The following procedures/assessments will be performed/recorded:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood samples for the followin g tests should be obtained prior to dosing:
Hematology and biochemistry
Bimekizumab/secukinumab plasma concentrations
Anti-bimekizumab antibodies
xPASI
xPercentage of BSA
xIGA
xscalp IGA for subjects with scalp involvement at BaselinePUBLIC ject’s eliect’s elCOPY senting sentin
This document prip
ction oftion of
HemHem
BBcannot ana
dures/asures/as
sitting sting s
ior to or to be ve-mm
ddWeWeused gibgi
entientito bility, bilitysupport any subub-stustumarketing authorization 
applicationysto
blood samblood sa
blood ood sams
atology anology a
imekizummekizu
bandsessmenssme
olic anlic anany ned pned
kk2 Vis2 Vis
textensions randomiandom
proproor variations udy in pady in pathereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 73 of 263xPhotographs of skin and nails (subjects consenting to sub-study in participating centers only)
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above-mentioned pr ocedures, IMP administration will occur.
8.2.3 Week 3 Visit ( ±3 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xConcomitant medication
xAEs
xContact IRT
After completion of the above -mentioned procedures, administration of IMP will occur.
8.2.4 Week 4 Visit ( ±3 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urine pregnancy test
Bimekizumab/secukinumab plasma concentrations
Anti-bimekizumab antibodies
xPASI
xPercentage of BSA
xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xPhotographs of skin and nails (subjects consenting to sub-study in participating centers only)PUBLIC d prd p
ays relaays rela
ments wments wCOPY ocedoced
This xdocumentmekizuekizu
AntiAnti--bb
PASIPASI
xxPePcannot y and bioand bio
regnancegnancbed urine d urineused d diastodiasto
plinglingto ill bel besupport ures, admes, ad
tive to Bve to B
e perep eany marketing dminimini
temperatuemperaauthorization strt
application y testestt
ab/secukib/secu
mekizummekizum
ntage tageand chemisthemistanymples fmples extensionsBaselasel
rformedformed
ic BP, p BP, pornistranistrvariations thereof. ation of tion of
ure) shore) sho
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 74 of 263xeC-SSRS
xscalp IGA for subjects with scalp involvement at Baseline
xPatient Global Assessment of psoriasis
xEQ-5D-3L
xConcomitant medication
xAEs
xContact IRT
After completion of the above -mentioned procedures, administration of IMP will occur.
8.2.5 Week 8 and Week 12 Visits ( ±3 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB (Week 12 only)
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urine pregnancy test
Bimekizumab/secukinumab plasma concentrations
Anti-bimekizumab antibodies
xTuberculosis questionnaire (Week 12 only)
xPASI
xPercentage of BSA
xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPatient Global Assessment of psoriasis
xPHQ-9
xeC-SSRS
xscalp IGA for subjects with scalp involvement at Baseline
xPhotographs of skin and nails (subjects consenting to sub-study in participating centers only)
xConcomitant medicationPUBLICles forles fo
mistrymistryCOPY P, pulseP, pul
t
This document LQIQI
PatienPatien
xxPPcannotonnainnai
of BSAf BSAbeantibodibo
rereused mab plaab pla
dito support rateat
he followifolloany e, and , andmarketing will will
aseline)seline)
rior to admor to a
of activf actauthorization occocc
application t symptomsympt
GloGand (WeWany eekeek12extensions wing g
ma conca concor testtesvariations ve TB anve TB a
body tebody tethereof. ur.
ministraministra
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 75 of 263xAEs
xContact IRT
After completion of the above -mentioned procedures, admini stration of IMP will occur.
8.2.6 Week 16 Visit ( ±3 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
Bimekizumab/secukinumab plasma concentrations
Anti-bimekizumab antibodies
xRecord 12-lead ECG
xPASI
xPercentage of BSA
xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS
xscalp IGA for subjects with scalp involvement at Baseline
xmNAPSI for subjects with nail involvement at Baseline
xpp-IGA for subjects with palmoplantar involvement at Baseline
xPatient Global Assessment of psoriasis
xPGADA (only for subjects with PsA)
xWPAI-SHP V2.0
xPhotographs of skin and nails (subjects consenting to sub-study in participating centers only)
xEQ-5D-3LCOPY concenconce
This xdocument S
p IGA fIGA 
mNAPmNAP
xxpppcannot s ((itch, itch,be used to support trationsationany marketing ture
d be obtabe obauthorization n of of 
e) sho) sh
application or subjector subje
SI for subjfor su
GA for sA for andpain, anain, anany extensions or variations thereof. uld be d be 
ained prained pr
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 76 of 263xConcomitant medication
xAEs
xContact IRT
At Week 16 subjects in the bimekizumab 320mg treatment arm will be re-randomized 1:2 to 
receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W. After completion of the above-mentioned procedures, administration of IMP will occur.
8.2.7 Week 20 ( ±3 days relative to Baseline) and Week 28 Visits ( ±7d a y s  
relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Urine pregnancy test
Bimekizumab/secukinumab plasma concentrations (Week 20 only)
Anti-bimekizumab antibodies (Week 20 only)
xPASI
xPercentage of BSA
xIGA
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above -mentioned procedures, administration of IMP will occur.
8.2.8 Week 24 Visit (±3 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood samplingPUBLIC ma 
(WeekWeekCOPY conceconc
This document IRTRT
completomplet
2.88
The The fof
IMIMcannot dicationcatiobe used to support ntrations (ration
0 only)only)any marketing dminismini
temperatemper
s shouldshouauthorization (±±77dada
strt
application on of the on of th
WeeWe
wing pwing pand any extensions orWeekWeevariations d be obtd be ob
k22thereof. ation of tion of
ure) shore) sh
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 77 of 263xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry 
Urinalysis 
Urine pregnancy test
Bimekizumab/secukinumab plasma concentrations
Anti-bimekizumab antibodies
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above -mentioned procedures, administration of IMP will occur.
8.2.9 Week 32 Visit ( ±7 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
xRecord 12-lead ECG
xPASI
xPercentage of BSA
xIGA
xDLQIPUBLIC mentiomentio
((±±COPY 
This document Hematolomatol
UrinUrin
UU
xxcannot systolystol
blood sblood 
f blood blood be icicusedne
days days 
smentsmenttod procd prosupport any marketing authorization 
application and 
gy and biy and 
alysisysis
rine pregine preg
12andandnd
amplingmpling
urinurinany diastodiasextensions edures, aures, 
relativelative
will be ll beor variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 78 of 263xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS
xscalp IGA for subjects with scalp involvement at Baseline
xmNAPSI for subjects with nail involvement at Baseline
xpp-IGA for subjects with palmoplantar involvement at Baseline
xPatient Global Assessment of psoriasis
xPGADA (only for subjects with PsA)
xWPAI-SHP V2.0
xPhotographs of skin and nails (subjects consenting to sub-study in participating centers only)
xEQ-5D-3L
xConcomitant medication
xAEs
xContact IRT
After completion of the above -mentioned procedures, administration of IMP will occur.
8.2.10 Week 36 Visit ( ±7 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Urine pregnancy test
Bimekizumab/secukinumab plasma concentrations
Anti-bimekizumab antibodies
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xPHQ-9ned proed pro
days days 
essmentsssmentsCOPY 
This document n on o
g:
Urine Urine 
BBcannot ng systog systo
r to blooto blo
of blof blobe used aluationuationtowill beill besupport edures, adures, 
elative tative tany marketing n participparticauthorization 
applicationod and urod and u
pregnancyregnan
mekizummekizu
tii-bibandic and dc and d
samplamplany extensions dminm
to Basto Bas
performerform
of signs fs i g n sor nistrnistvariations pathereof. ating cting c
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 79 of 263xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above -mentioned procedures, administration of IMP will occur.
8.2.11 Week 40 Visit ( ±7 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
xPASI
xPercentage of BSA
xIGA
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above -mentioned procedures, administration of IMP will occur.
8.2.12 Week 44 Visit ( ±7 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine samp les for the following tests should be obtained at this visit:
Urine pregnancy test
IGRA tuberculosis testPUBLIC COPY 
This documentpletionetion
he followfollow
IMP:IMP:
xcannot ioibe nnused to support any marketing perature) perature)
hould be ould bauthorization nistratiostratio
application f the the abovab
WeekWeek 444
wing proceng procand any extensions or variationsobtainobtaithereof. n of n 
) should should
ne
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 80 of 263xPASI
xPercentage of BSA
xIGA
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above -mentioned procedures, administration of IMP will occur.
8.2.13 Week 48 Visit ( ±7 days relative to Baseline)
The following procedures/assessments will be performed/recorded:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine samp les for the following tests should be obtained at this visit:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
Bimekizumab/secukinumab plasma concentrations
Anti-bimekizumab antibodies
xRecord 12-lead ECG
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xscalp IGA for subjects with scalp involvement at Baseline
xmNAPSI for subjects with nail involvement at BaselinePUBLICtolic Btolic 
g
ne sample samp
hemisthemCOPYd symd sy
BP
This documentculosis losis 
ASISI
PercenPerce
xxIGIGcannot ecukicuki
zumab umab 
lead ECad ECbe t
nunuused rytoes for ts for support  pulse ratpulse r
thethany ms of ms omarketing IMP willMP w
ded:ed:
acauthorization 
application G
uestionnaestionn
ntage of Bage ofand mabma
antibodiibodiany b plasm plasextensions ate, ,
followifollowor and and variations ctive TBctive TBthereof. l occur.l occur
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 81 of 263xpp-IGA for subjects with palmoplantar involvement at Baseline
xPatient Global Assessment of psoriasis
xPASE
xPGADA (only for subjects with PsA)
xWPAI-SHP V2.0
xPhotographs of skin and nails (subjects consenting to sub-study in participating centers only)
xEQ-5D-3L
xeC-SSRS
xConcomitant medication
xAEs
8.3 OLE Period
8.3.1 Week 48 Visit ( ±7 days relative to Baseline)
The following procedures/assessments will be performed/recorded after completion of 
assessments listed for Week 48 (Section 8.2.13 ) and prior to administration of IMP:
xSign a separate ICF for the OLE Period
xInclusion/exclusion: Confirm that subject completed the double-blind Treatment Period 
without meeting any withdrawal criteria and has been compliant with the ongoing clinical 
study requirements
xUpon confirmation of subject’s eligibility, randomization will occur
xContact IRT
Self-injection training will be provided to the subject/caregiver by qualified site personnel to 
allow self-injection to be performed at home af ter Week 48. Additional training may be provided 
by site staff at subsequent clinic  visits as needed (see Section 7.2).
After completion of the above-men tioned procedures, IMP administ ration will occur, preferably 
by self-injection under supervision of the site personnel.
8.3.2 Week 52 Visit ( ±7 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urine pregnancy testPUBLIC iodod
at subjecat subje
wal critewal crite
ctctCOPY to o
performeperforme
1313) and ) and
This document tionon
WW
followinllowin
MP:P:
xxVVcannotbe pere per
quent cuent c
n of theof the
nundundbe be probe pro
fofoused s eligibiligibito ria asupport prior tior t
t completcompl
and handanyine)ine
recorderecorde
oa dmarketing ))authorization nters onters on
applicationabovbo
er supervr super
eekek52 V52
g proceduproced
igns ignsandrmeme
inic visinic vis
veve--many ded to thded to 
d at hod at extensionsted the d the
as been s been
ity, randy, randor variations ed after d after 
dministministthereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 82 of 263xPASI
xPercentage of BSA
xIGA
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above- mentioned procedures, administration of IMP will occur for 
subjects on bimekizumab 320mg Q4W dosing only, preferably by self-injection under supervision of the site personnel.
8.3.3 Week 56 Visit ( ±7 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urine pregnancy test
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above -mentioned procedures, administration of IMP will occur, 
preferably by self-injection under supervision of the site personnel.
Distribution of IMP and accountability activities f or home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7.PUBLIC mples fomples fo
hemistrhemistrCOPYformedform
c BP, puBP, pu
Thisxdocumentsymptympt
Q-99
eCC-SSRSS
xxCoCocannot SAA
tomtbe reeused yto supportse rate, e rate,
r the follothe folany cordedcordemarketing MP will oMP will o
injectionnjectio
e)e)authorization 
application ms (s (itch, pitch,
S
omitanmitanand any extensionsowing twing or nd ndvariations prior to prior to
d bodybodythereof. occur foccur fo
nnunder under
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 83 of 2638.3.4 Self-injection at home (Weeks 60 , 68, 76, 80, 88, 92, 100, 104, 112, 
116, 124, 128, 136, and 140)
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W at Week 64 or at the next scheduled clinic visit (ie, Week 72, Week 
84, Week 96, Week 108, Week 120, or Week 132) after implementation of Protocol Amendment #5.1 if the subject has already completed the Week 64 visit. 
Subjects receiving bimekizumab 320mg Q4W will be given the opportunity for self-injection of 
bimekizumab at home on the following weeks: Weeks 60, 68, 76, 80, 88, 92, 100, 104, 112, 116, 124, 128, 136, and 140. This only applies to those subjects who have not yet changed to bimekizumab 320mg Q8W.
Subjects receiving bimekizumab 320mg Q8W will be given the opportunity for self-injection of
bimekizumab at home on the following weeks: Weeks 80, 88, 104, 112, 128, and 136.
Subjects of childbearing potential should conduct a home pregnancy test every 4 weeks. In case 
of a scheduled home self-injection the pregnancy tes t needs to be performed immediately prior to
self-injecting bimekizumab at home. If the pregnancy test result is positive, IMP should not be administered and the site should be contacted.
xAdverse events will be captured spontaneously if the subject decides to visit the site to 
receive the bimekizumab administration. 
xAll used syringes will be disposed of by subjects/caregivers as determined by the Investigator 
in an acceptable disposal (sharps) container directly after the administration. The subjects/caregivers return the documentation togeth er with any used/unused containers at the 
next scheduled clinic visit.
8.3.5 Week 64 ( ±7 days relative to Baseline), Week 84, Week 108, Week 132 
Visits (±14 days relative to Baseline)
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W as follows:
xAt Week 64 if the subject has not completed the Week 64 visit prior to implementation of 
Protocol Amendment #5.1.
xAt Week 84 if the subject has already completed the Week 72 visit prior to implementation 
of Protocol Amendment #5.1.
xAt Week 108 if the subject has already completed  the Week 96 visit prior to implementation 
of Protocol Amendment #5.1.
xAt Week 132 if the subject has already completed  the Week 120 visit prior to implementation 
of Protocol Amendment #5.1.
Subjects whose dosing interval is being change d to bimekizumab 320mg Q8W will receive kits 
for home administration as follows:
xSubjects whose dosing interval is being changed to bimekizumab 320mg Q8W at Week 64 
should be dosed at this visit, and will re ceive kits for home administration 8 weeks later 
(Table 7‒2).PUBLICof by sof by 
s) contais) conta
documedocum
ayaCOPY yy
ously if tusly i
n. . 
This document8484
ocolcolAA
WeekWeek
of Protf Pro
xxAtAtcannot WW
he subjecsubje
ndmentdmen
4 if thif thbeal willwill
as foas fused s relatirelat
ys relatrelatto ntattatsupport he se 
bjects/carects/c
ner directer direc
tion toionany subjecubjemarketingy for y for selse
128, and128, an
y test everest ev
e performperform
is posiis poauthorization ection ofction o
4, 112, 4, 112, 
ged to ed to 
application subject subjec
mendmndmene
08 if the 08 if th
cololAmeAm
eekek13213andt has nohas no
5.1.1..any ange frnge f
ows:ws:extensionsregivg
tly aftery afte
ogether gether
ve to Be to B
ve to Be to Bor vers versvariationsery 4y
med immd imm
itive, IMtive, IM
ct decidedecidethereof. f-injectiinjecti
d 136d 136 ..
4 we4w
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 84 of 263xSubjects whose dosing interval is being changed to bimekizumab 320mg Q8W at Week 84,
Week 108, or Week 132 should NOT be dosed at that visit, and will receive kits for home administration 4 weeks later ( Table 7‒2).
The following procedures/assessments will be performed/recorded. If IMP is administered on 
site during this visit, they need to be performed/recorded prior to administration of IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above -mentioned procedures, administration of IMP will occur:
xAt each of these visits for subjects on bimekizumab 320mg Q4W dosing, preferably by 
self-injection under supervision of the site pers onnel. This only applies to those subjects who 
have not yet changed to Q8W after implementation of Protocol Amendment #5.1.
xAt Week 64 only for those subjects on bimekizumab 320mg Q8W dosing, preferably by self-
injection under supervision of the site personnel.
Distribution of IMP and accountability activities for home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7. Home pregnancy tests will be provided for 
testing every 4 weeks as appropriate ( Table 5‒2).PUBLIC ain, and ain, andCOPY 
This document etiotio
ach of th of t hh
lff--finjectinject
have nhave n
xxAtAcannot n of no fbe nnused scacato alingling))support any marketing obtainebtaineauthorization should bhould b
d
application he abovehe abov
ese visitsse visit
ion underon und
ot yet chayet ch
eek 64ek 64and any extensions or variations thereof. prior torior to
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 85 of 2638.3.6 Week 72 ( ±7 days relative to Baseline) and Week 120 Visits ( ±14 days 
relative to Baseline)
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W as follows:
xAt Week 72 if the subject has already completed  the Week 64 visit prior to implementation 
of Protocol Amendment #5.1.
xAt Week 120 if the subject has already completed  the Week 108 visit prior to implementation 
of Protocol Amendment #5.1.
As depicted in Table 7‒2, subjects whose dosing interval is being changed to 
bimekizumab 320mg Q8W at one of these visits should be dosed at this visit and will receive kits 
for home administration 8 weeks later.
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
Bimekizumab plasma concentrations
Anti-bimekizumab antibodies
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xscalp IGA for subjects with scalp involvement at Baseline
xmNAPSI for subjects with nail involvement at Baseline
xpp-IGA for subjects with palmoplantar involvement at Baseline
xEQ-5D-3LPUBLICples forles fo
mistrymistryCOPY y
P, pulseP, pul
This documentntage ofge of
GAA
DLQDLQ
xxPPcannot mab anab an
uestionnestionbema conma con
ntintiused to support rateat
he followfolloany e, and , andmarketing t and wnd w
rior to admor to a
of activf actauthorization on 
lementatmentat
ii
application BSASA
symsyand odod
aireireany trationtratio
iesesextensions wing gor testtesvariations ve TB anve TB a
d body teody tethereof. l receivereceiv
ministraministr
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 86 of 263xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
xAfter completion of the above -mentioned procedures, administration of IMP will occur, 
preferably by self-injection under supervision of the site personnel.
Distribution of IMP and accountability activities for home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7. Home pregnancy tests will be provided for 
testing every 4 weeks as appropriate ( Table 5‒2).
8.3.7 Week 96 Visit (±14 days relative to Baseline)
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W at Week 96 if the subject has already completed the Week 84 visit 
prior to implementation of Protoc ol Amendment #5.1. As depicted in Table 7‒2, subjects whose 
dosing interval is being changed to bimekizumab 320mg Q8W at Week 96 should be dosed at this visit, and will receive kits for home administration 8 weeks later.
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
IGRA tuberculosis test
Bimekizumab plasma concentrations
Anti-bimekizumab antibodies
xRecord 12-lead ECG
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGAPUBLIC on of sigon of si
ananCOPY20m0m
ration 8ration 
be perforbe perfo
Thisxdocument ne pree pre
IGRA tGRA t
BimBi
cannot and biond bio
sis
gnbed urine d urineused d diastoliastol
plinglingto support med/reed/re
ns and syand syany W at W a
eeks lateeks la
ecormarketing Q4W to Q4W t
completedmplet
ted in ed in TaT
WeWauthorization r, r,
formed armed a
l be probe pro
application ancy testncy tes
berculosberculo
mekizumaekizum
ntiti--bimbimandchemistrhemistanymples fmples extensionsymptommpto
c BP, puBP, puor variationsd the Wthe W
ablele77‒2
eekek96 s96 s
ter.r.
rded prded prthereof. videdid
W
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 87 of 263xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xscalp IGA for subjects with scalp involvement at Baseline
xmNAPSI for subjects with nail involvement at Baseline
xpp-IGA for subjects with palmoplantar involvement at Baseline
xPASE
xPGADA (only for subjects with PsA)
xWPAI-SHP V2.0
xEQ-5D-3L
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
At Week 96, after completion of the above-menti oned procedures, administration of IMP will 
occur, preferably by self-injection under supervision of the site personnel
Distribution of IMP and accountability activities  for home administration to be performed as
described in Section 7.2, Section 7.5, and Section 7.7. Home pregnancy tests will be provided for 
testing every 4 weeks as appropriate ( Table 5‒2).
8.3.8 Week 144 Visit ( ±14 days relative to Baseline)
The following procedures/assessments will be  performed/recorded prior to administration of
IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine samples for the fo llowing tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
IGRA tuberculosis test
Bimekizumab plasma concentrationsPUBLICboveove-mm
nder supnder su
tability tability 
ionion7.575
ririCOPY 
This document eightight
al signs signs
obtainedtained
CollColl
ddcannot includinncludin
TBBbes
assessmassessmused and nd
te ((TablTabl
t ((±±1414toctivitictivit
SecSecsupport ntioned prioned
ervision orvision
esany marketing authorization 
application sitting sysitting s
prior to brior to 
ction oftion ofand g evaluaevaluaany nts will nts wilextensionsroceoc
of the sf the s
for homor hom
tionon7.77.7
55‒‒22))..
ays reys ror edureduvariations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 88 of 263Anti-bimekizumab antibodies
xRecord 12-lead ECG
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xscalp IGA for subjects with scalp involvement at Baseline
xmNAPSI for subjects with nail involvement at Baseline
xpp-IGA for subjects with palmoplantar involvement at Baseline
xPASE
xPGADA (only for subjects with PsA)
xWPAI-SHP V2.0
xEQ-5D-3L
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
Return of IMP and accountability activities f or home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7.
If Protocol Amendment #5.4 is im plemented at the time subjects are treated in the OLE Period 
(ie, up to Week 144; OLE2 Group A subjects), these subjects will be invited to participate in the OLE2 Period and may directly roll over and cont inue their treatment from the Week 144/OLE2 
Baseline Visit as long as they do not meet  any of the withdrawal criteria and have provided 
informed consent.
If Protocol Amendment #5.4 is implemented at the time subjects have completed the Week 144 
Visit and are in the SFU Period of the OLE Peri od or have completed the SFU of the OLE Period 
(Group B subjects), these subjects will be invited to enter the OLE2 Period to reinitiate their treatment in the OLE2 Period. However, before receiving the first dose at the Week 144/OLE2 
Baseline Visit, they will first undergo scr eening during the 4-week OLE2 Screening Period 
(Section 8.4.1 ).PUBLIC COPY menten
This (documentWeek 1eek 1
eriod anod an
ne e VisiVisi
ormed crmed 
If ProtIf Prot
VisViscannotcountabountab
n7.27.2, S
endmenndmen
4444be used to support anyaselinselimarketing neneauthorization 
application t #5.4#5.4
; OLE2 GOLE2 
d may diremay di
as long aas long
onsent.nsent.
ollAmeAmandility acy ac
ectionction 77
iiany ctivtiextensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 89 of 2638.4 OLE2 Period
8.4.1 OLE2 Screening (up to 4 weeks) –applicable for OLE2 Group B only
Prior to any study specific activities of the OLE2 Period, subjects who completed the Week 144 
Visit and are in the SFU or have complete d the SFU of the OLE Period (OLE2 Group B 
subjects) will undergo screening. Subjects w ho have used systemic treatments after Week 144 
must have stopped this treatment 1 month prior to receiving the first bimekizumab injection in 
the OLE2 Period. Screening procedures may be performed during this time. Subjects receiving systemic immunomodulatory medications for an indication other than PSO must have their eligibility confirmed by the Medical Monitor prior to enrollment in the OLE2 Period.
At the Screening Visit of the OLE2 Period (OLE2 Screening Visit), subjects will be asked to 
read, sign, and date an ICF that has been approved by the Sponsor and an IRB/IEC and that 
complies with regulatory requirements. Subjects will be given adequate time to consider any 
information concerning the study given to them by the Investigator or designee. As part of the informed consent procedure, subjects will be given the opportunity to ask the Investigator any questions regarding potential risks and benef its of continued participation in the study.
The following procedures/assessments will be performed at the OLE2 Screening Visit for 
subjects in the OLE2 Group B:
xInformed consent
xInclusion/exclusion
xUrine drug screen
xSignificant past medical history including clinically relevant past or coexisting medical 
conditions and surgeries (only applicable for subjects who completed the SFU, only new or modified medical history since completing the SFU should be entered in eCRF)
xAEs (only for subjects in the SFU)
xPhysical exam
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine samples for the following clinical laboratory tests:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
Hepatitis B and Hepatitis C
HIV
xTuberculosis questionnaire
xPASI
xPercentage of BSAPUBLIC istory inistory in
only aonlyCOPYformedform
This document on on o
Hematolmatol
UrinUri
cannot ng systog systo
r to blooto blo
f blofb lbe n the She usedlulu
pplicabplicab
ce compe comp
SFUSFUto uding uding
lsupport any the the OLOmarketing will ill 
IRB/IECRB/IEC
time to cime to
r designedesign
y to ask tto ask
ticipatioicipat
Eauthorization 4 
n in n in 
ceiving eiving 
ve their e their 
od.d.
be abe a
application d 
od and urod and u
ogy and bgy and
alysisysis
rine preine preandlic and dc and d
samplampany )extensions clinicallyinically
e for subfor sub
leting thting thor variationsee
the Invhe Inv
on in theon in th
E2 E2 ScreScrethereof. sked to ed to 
and thand tha
considerconside
. As p As p
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 90 of 263xIGA
xPHQ-9
xeC-SSRS
xPrior and concomitant medication (including new or modified medications initiated after 
SFU)
xContact IRT
8.4.2 OLE2 Baseline Visit
Subjects who will still be treated in the OL E Period at the time of implementing Protocol 
Amendment #5.4 (OLE2 Group A subjects) will atte nd Week 144 Visit and directly roll over to 
the OLE2 Period to continue their treatmen t (bimekizumab 320mg Q8W). They will undergo all 
study assessments of the Week 144 Visit and will receive bimekizumab 320mg Q8W at this visit, which will also coincide with the first visit of the OLE2 Period, ie, the Week 144/OLE2 Baseline Visit.
Subjects who have completed Week 144 Visit and ar e in the SFU of the OLE or have completed 
the SFU Period at the time of Protocol Amendment #5.4 implementation (OLE2 Group B 
subjects) will reinitiate their treatment at the Week 144/OLE2 Baseline Visit, and will be 
assigned a treatment regimen based on their dise ase severity at the Week 144/OLE2 Baseline 
Visit (bimekizumab 320mg Q4W/Q8W for subjects with IGA score ≥3 or bimekizumab 320mg 
Q8W for subjects with IGA score <3).
Applicable for OLE2 Groups A and B:
xPhysical exam
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine samples for the following clinical laboratory tests:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
xeC-SSRS
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xPHQ-9
xDLQIPUBLIC for sufor s
).)
and Bnd B :COPYreei
nt #5.4nt #5.
Week 14Week 1
r diseasdiseas
ubjubj
This document alysys
Urine preine pr
eC--SSRSSR
xTubTub
xxcannotod and ud and u
gy and gy and 
sisisbe ic anc an
samplsamplused nd dnd dto support//OO
severityeverit
ects with cts withanySFU SFU
mplemenmpleme
LE2 BLE2marketing g
directlyirect
). TheyThey ww
ab 320mg ab 320m
theeWeekWe
of toauthorization ProtocProtoc
application bio
gnancy tenancy 
rculosis culosis andrine sae sa
ochemchemanystolistol
gg
mpextensions I
ic Bic Borat tat 
GA scGA scvariations k 1414
the OLEhe OLE
ntationtation
Baselineaselin
the theWthereof. ol 
roll oveoll ove
will undell unde
g Q8W aQ8W 
4/4/OO
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 91 of 263xPatient symptoms (itch, pain, and scaling)
xConcomitant medication
xAEs
xContact IRT
Additional Procedures/assessments applicable for OLE2 Group A 
xInformed Consent 
xECG
xBlood sample for bimekizumab plasma concentrations
xBlood sample for anti ‑bimekizumab antibodies
xIGRA TB test
xscalp IGA
xmNAPSI
xpp-IGA
xEQ-5D-3L
xPASE
xPGADA
xWPAI-SHP V2.0
At the Week 144/OLE2 Baseline Visit, after completion of the above-mentioned procedures, 
administration of IMP will occur, preferably by self-injection under supervision of the site 
personnel.
Distribution of IMP and accountability activities for home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7.
8.4.3 Self-injection at home (OLE2 Weeks 4, 8, 16, 32, and 40)
Subjects receiving bimekizumab 320mg Q8W will be given the opportunity for self-injection of 
bimekizumab at home on the following weeks: OLE2 Weeks 8, 16, 32, and 40.
Subjects receiving bimekizumab 320mg Q4W/Q8W will be given the opportunity for self-
injection of bimekizumab at home on the follow ing weeks: OLE2 Weeks 4, 8, and 16. At OLE2 
Week 16, subjects receiving bimekizumab 320mg Q4W/Q8W will switch to bimekizumab 
320mg Q8W regimen and will be given the opportunity for self-injection of bimekizumab at 
home dosed at OLE2 Weeks 32 and 40.
Subjects of childbearing potential should conduct a home pregnancy test every 4 weeks. In case 
of a scheduled home self-injection the pregnancy test  needs to be performed immediately prior to 
self-injecting bimekizumab at home. If the pregnancy test result is positive, IMP should not be 
administered and the site should be contacted.COPY 
This3document receivineceivin
izumab zumab
ubjects rjects r
injectioinjectio
WeeWecannot and accnd ac
onn7.27.2
Selfelf-iibeoccur,ccurused e Visite Visito support any marketing authorization 
applicationnjectionnjectio
g bimekizbimek
at home ot home
eceiving beiving
of bimef bim
ubjandountabiluntabi
ectionctionany ferablferab
textensions fter coter cor variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 92 of 263Adverse events will be captured spontaneously if the subject decides to visit the site to receive 
the bimekizumab administration. 
All used syringes will be disposed of by subjects/caregivers as determined by the Investigator in 
an acceptable disposal (sharps) container  directly after th e administration. The
subjects/caregivers return the documentation together with any used/unused containers at the 
next scheduled clinic visit.
8.4.4 OLE2 Week 12, Week 24, and Week 36 Visits (±14 days relative to 
OLE2 Baseline)
As depicted in Table 7‒3,subjects receiving bimekizumab 320mg Q4W/Q8W should receive 
IMP at the OLE2 Week 12 Visit, and all subj ects will receive kits for home administration 
4 weeks later at OLE2 Week 16. All subjects will  receive IMP administration at the OLE2 Week 
24 Visit, and will receive kits for home administration 8 weeks later. At the OLE2 Week 36 
Visit, subjects will not be dosed and will receive kits for home administration 4 weeks later at 
OLE2 Week 40.
The following procedures/assessments will be performed/recorded at every clinic visit prior to 
administration of IMP:
xPhysical exam
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xUrine pregnancy test, for applicable subjects
xTuberculosis questionnaire 
xPASI
xPercentage of BSA 
xIGA
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS 
xConcomitant medication 
xAEs 
xContact IRT 
The following will be additional assessments wi ll be performed / recorded every 24 weeks (ie, 
OLE2Weeks 24 and 48) prior to administration of IMP
xCollection of blood and urine sa mples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistryPUBLIC lic
cable sucable suCOPY c BP, pBP,
This document omitantmitan
AEs Es 
ConCocannot(itch, pitch, pbe used to jsupport ulse rate, lse rat
ectsctsany marketingdminmi
on at then at th
the OLEhe OL
nistration stratio
ded at eved at authorization e to to 
hould reould re
nistrnistr
application medicatioedicat
act IRT ct IRTandain, an, anany ds cdextensions orand band variations every clivery cl
bothereof. ceivce
ation on 
OLE2 OLE2 
E2 WeekWee
4weekweek
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 93 of 263Urinalysis
xDLQI 
At the OLE2 Week 12 and Week 24 Visit, after completion of the above-mentioned procedures, 
administration of IMP will occur, preferably by self-injection under supervision of the site 
personnel.
Distribution of IMP and accountability activities for home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7. Home pregnancy tests will be provided for 
testing every 4 weeks as appropriate ( Table 5‒2and Table 5-3) .
8.4.5 OLE2 Week 48 Visit ( ±14 days relative to OLE2 Baseline)
The following procedures/assessments will be performed/recorded:
xPhysical exam
xBody weight
xVital signs (sitting systolic BP and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine sa mples for the following clinical laboratory tests should be 
obtained prior to dosing:
Hematology and chemistry
Urinalysis
Urine pregnancy test
IGRA TB test
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
Return of IMP and accountability activities f or home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7.PUBLIC COPYBP, pulsBP, pul
or the or the 
This document I
Patient stient s
PHQPHQ
xxcannot BSABSAbe aireaireused to support following llowinany ate, andate, anmarketing seline)seline)authorization s, , 
rmed asrmed as
be prove prov
application ymptoms mptom
9
Sand any extensions orcliniclinvariations d body tbody t
icathereof. de
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 94 of 2638.5 Premature End of Treatment Visit
If a subject is withdrawn from the study during the OLE Period (up to Week 144):
xIf the subject will be withdrawn from IMP prior to the Week 48 visit of the double-blind 
Treatment Period, the subject will undergo the same assessments as the Week 48 visit (seeSection 8.2.13 ), and will enter the SFU Period.
xIf the subject will be withdrawn from IMP prior to the Week 144 visit of the OLE Period, the 
subject will undergo the same assessments as the Week 144 visit (see Section 8.3.8 ), and will 
enter the SFU Period.
xThe subject will be encouraged to return for th e SFU Visit (20 weeks after the last received 
dose; see Section 8.6 ).
If a subject is withdrawn from the study during the OLE2 Period:
xThe subject will be withdrawn from IMP, will undergo the same assessments as the OLE2 
Week 48 Visit (see Section 8.4.5 ) and will enter the SFU2 Period.
xThe subject will be encouraged to return for the SFU2 Visit (20 weeks after the last received 
dose; see Section 8.7).
8.6 Safety Follow-Up Visit (20 weeks after final dose up to Week 
144, ±7d a y s )
The following procedures/assessments will be performed/recorded:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine samp les for the following tests should be obtained at this visit:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
Bimekizumab (secukinumab for subjects not entering the OLE Period) plasma 
concentrations 
Anti-bimekizumab antibodies
xTuberculosis questionnaire
xeC-SSRS
xConcomitant medication
xAEs
xContact IRTPUBLIC ts will bts will b
luation ouation oCOPY SFUSF
(20(20wewe
Thisxdocumentpp
imekizumekizu
concenoncen
AnAn
xxTuTcannotnd biocbioc
regnanegnanbed urine d urine
hhused d diastoldiasto
plinglingto f signsigsupport eks aks a
e performperform
ns annsanysit (2it (
fteftmarketing th
e assessmassess
eriod.riod.
20 w20authorization riod, theod, the
8), and w), and w
he last e last 
application cy testy test
mab (secuab (se
rations rations 
i-bimekibimek
culosiculosiand emistmisanymples fmples 
trytryextensionsmed/reced/re
nd sympd symp
ic BP, pBP, por variations mentsent
weeks afeeks af
r finar finathereofreceiveceive
sa ssa s
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 95 of 2638.7 Safety Follow-Up Visit 2 (20 weeks after final dose in the OLE2 
Period, ±7days)
The following procedures/assessments will be performed/recorded:
xPhysical exam 
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling
xCollection of blood and urine samp les for the following tests should be obtained at this visit:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
8.8 Unscheduled Visit
At the Investigator’s discretion, an Unscheduled Vi sit may be completed at any time during the 
study but prior to the SFU Visit or SFU2 Visit (depending on which period, OLE or OLE2, the 
participant is in), if deemed necessary for the subject’s safety and well-being.
If an Unscheduled Visit is conducted due to safety or efficacy reasons, an eC-SSRS assessment 
will be performed with the subject during the visit. If an Unscheduled Visit is conducted for 
reasons other than safety or efficacy concerns (e g, repeated collection of a laboratory specimen 
due to collection or analysis issues, injecti on for subjects not making use of home self-
injections), an eC-SSRS will not  be required at these visits.
At this visit, any assessment may be performed, as needed, depending on the reason for the visit.
9 ASSESSMENT OF EFFICACY
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp-IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training on how to perform these assessments correctly. The same assessor should evaluate the subject at each assessment.
9.1 Psoriasis Area Severity Index
The PASI is the most commonly used and valida ted assessment for grading the severity of PSO 
in clinical studies (Feldman, 2004). The PASI quant ifies the severity and extent of the disease 
and weighs these with the percentage of BSA involvement.PUBLIC sitit
an Unsan Uns
sitsitor Sor S
esesCOPY 
This 9documentAA
PASI, BSASI, BS
vestigatoestigat
(based o(based 
assesassescannoty or or
nalysis alysis 
SSRS wSRS w
y assesassesbend
subjecsubjec
efficeffused FU2 VU2 
sary for y for 
ucted ducted tohedulehedul
VisVissupport ed Vdany marketing authorization e 
at this vat this 
application sment mment 
SESSMSESS
A, IGA, A, IGA
r, anotheranoth
n local relocal re
sc oandssues, ues, 
ll not bl not bany uring thuring 
y concey conce
injeiextensions Visit mVisit m
t (depen(depen
he subjee subje
e to sato saor variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 96 of 263The percent area of involvement (BSA%) is  estimated across 4 body areas; head, upper 
extremities, trunk, and lower extremities. Assessors  will enter the degree of involvement for a 
given region on a scale of 0 to 6 (0=none; 1=1% to <10% affected, 2=10% to <30% affected, 
3=30% to <50% affected, 4=50%  to <70% affected, 5=70% to  <90% affected, 6=90% to 100% 
affected) ( Table 9‒1).
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body 
area (each on a 5-point scale); 0=none, 1=slig ht, 2=moderate, 3=marked, and 4=very marked.
The PASI score ranges from 0 to 72 with a high er score indicating increased disease severity.
Table 9‒1: Body areas for calculation of percent BSA for PASI
Body area Details of area BSA Degree of 
involvement of 
body areaa
Head Face, back of head 10% 0 to 6
Upper extremities Left, right, upper lower, flexor surface, 
extensor surface20% 0 to 6
Trunk Front, back, groin 30% 0 to 6
Lower extremities Left, right, upper lower, flexor surface, 
extensor surface, including buttocks40% 0 to 6
Total 100%
BSA=body surface area; PASI=Psoriasis Area and Severity Index
aWhere 0=none; 1=1% to <10% affec ted; 2=10% to <30% affected; 3=30% to <50% affected; 4=50% to <70% 
affected; 5=70% to <90% affe cted; 6=90% to 100% affected
The PASI75, PASI90, and PASI100 responses are based on at least 75%, 90%, and 100% 
improvement in the PASI score, respectively.
The total BSA affected by PSO will be entered as a percentage from 0 to 100.
The PASI will be completed at the visits specified in Table 5‒1, Table 5 ‒2, and Table 5-3 .
9.2 Investigator’s Global Assessment
A static IGA for PSO will be used to assess dise ase severity in all subjects during the study. The 
IGA will be completed at the visits specified in Table 5‒1,Table 5 ‒2, and Table 5-3 .
The Investigator will assess the overall severity of PSO using the following 5-point scale 
presented in Table 9‒2.PUBLIC ngg
C
s Area ans Area anLI
ected; 2=cted; 2=
ed; 6=90%ed; 6=90COPY PY
xor surfaxor surfa
buttocbuttoOP
This documentforfo
be compcomp
nvestigavestiga
sented iented icannoty
mpleted pleted 
vestigvestig
r PSOPSObe re,
PSO wPSO wused  toto
100 resp0 res
resperespeto0% to <0% to 
100%100%supporte, 
kstrt rt
pp
Severity Ieverityup
<30%<3any nyamarketing gggng
10%0%rke
20%20%maauthorization dy y
rked.ked
severityseverity
a
applicationwill be will be
eted at thted at t
or will asor will a
Tableable 9andt the vhe v
tor’s Gor’s any tiviv
l be entel be ent
visitiextensions ns IndexIndexnsnsns
% affecteaffect
affectedfected
onses arnses ar
vely.ely.or ovariations snss
30%30%ia
4040athereof. DegreeDegree
involvenvolv
boboof
tth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 97 of 263Table 9‒2: Five-point IGA
Score Short Descriptor Detailed Descriptor
0 Clear No signs of PSO; post -inflammatory hyperpigmentation may be present
1 Almost clear No thickening; normal to pink colo ration; no to minimal focal scaling
2 Mild Just detectable to mild thickening ; pink to light red coloration; 
predominately fine scaling
3 Moderate Clearly distinguishable to moderate thic kening; dull to bright red; moderate 
scaling
4 Severe Severe thickening with hard edges; bright to deep dark red coloration; 
severe/coarse scaling covering almost all or all lesions
IGA=Investigator’s Global Assessment; PSO=psoriasis
9.3 Dermatology Life Quality Index
The DLQI is a questionnaire designed for use in adult subjects with PSO. The DLQI is a skin 
disease-specific questionnaire aimed at the ev aluation of how symptoms and treatment affect 
subjects’ health related QOL. This instrument asks subjects about symptoms and feeling s, daily 
activities, leisure, work and school, personal relati onships, and treatment. It has been shown to 
be valid and reproducible in subjects with PSO. The DLQI score ranges from 0 to 30 with higher scores indicating lower health-related QOL. A 4-point change in the DLQI score (DLQI 
response) has been reported to be meaningful for the subject (within-subject minimal important 
difference); while a DLQI absolute score of 0 or 1 indicates no or small impact of the disease on 
health related QOL. Subjects will be asked to complete the DLQI as outlined in the Schedule of 
Study Assessments ( Table 5‒1, Table 5 ‒2, and Table 5-3 ).
9.4 Scalp IGA
A static IGA for scalp PSO will be used to assess disease severity on the scalp.
All subjects will complete the scalp IGA at Base line. Only subjects with scalp involvement at 
Baseline will complete the scalp IGA at the other visits specified in Table 5‒1and Table 5‒2.
Subjects with scalp involvement at Baseline are defined as those with a scalp IGA score >0 at 
Baseline.
Scalp lesions will be assessed in terms of clinica l signs of redness, thickness, and scaliness using 
a 5-point scale ( Table 9‒3).PUBLIC OL. AOL. 
aningfuaningfu
e score oe score 
wilill be asl be as
11,,TabTabCOPYon on 
ks subjeks subj
elationselation
PSO. ThSO. Th
A4A4
This documentns wils wil
t scale (cale (cannotte the t
te the sce the sc
p involvinvolv
lblbbe will bill b
he sche sused e55‒‒22
be ube utof 
ed to ed to 
aasupporthips,ps
e DLQI sDLQI 
point point chac
for the suor the s
0 or 1 inor 1
comanysymsym
s about s about
, and andmarketing red
nsng
with PSOith PS
mptompauthorization tioatititi
red;ed;modemodor
d colorcoloau
application e assessedassess
Tableble99‒3andalp IGAp IG
ment atment aanyed to d to
p IGA ap IGA
AaAextensionshan
ubject bject
indicatendicate
mplete plete 
nd TableTable
aor oreor
nge inge in
(variations O. The DO. The D
oms andms and
symptoympto
treatmeeatm
re raner athereof. ation; on; f
re
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 98 of 263Table 9‒3: Scalp IGA
Score Short Descriptor Detailed Descriptor
0 Clear Scalp has no signs of PSO; post -inflammatory hyperpigmentation may be 
present
1 Almost clear Scalp has no thickening; normal to pink coloration; no to mi nimal focal scaling
2 Mild Scalp has just detectable to mild thick ening; pink to light red coloration; 
predominately fine scaling
3 Moderate Scalp has clearly distinguishable to moderate thickening; dull to bright red, 
moderate scaling
4 Severe Scalp has severe thickening with hard edges; bright to deep dark red 
coloration; severe/coarse scaling covering almost all or all lesions
PSO=psoriasis; scalp IGA=scalp- specific Investigator’s Global Assessment
9.5 mNAPSI
Nail PSO will be evaluated using the mNAPSI. All affected nails will be scored (0 to 3) for 
onycholysis/oil drop dyschromia, nail plate crumblin g, and pitting and will  be scored (0 for “no” 
or 1 for “yes”) for leukonychia, nail bed hyperkeratosis, s plinter hemorrhages and red spots in 
the lunula. The score for an individual nail ranges  from 0 to 13 with higher scores indicative of 
more severe nail PSO. The total mNAPSI score is the sum of the scores for each individual nail. 
If a nail is unaffected, it will  be recorded as such and will not contribute to the total mNAPSI 
score. Subjects with nail PSO at Baseline are defined as those with a mNAPSI score >0 at 
Baseline.
Only subjects with nail involvement at Baseli ne will complete the mNAPSI at the other visits 
specified in Table 5‒1and Table 5‒2.
9.6 pp-IGA
A static IGA for palmoplantar PSO will be used to assess palmoplantar disease severity.
All subjects will complete the pp-IGA at Baseli ne. Only subjects with palmoplantar involvement 
at Baseline will complete the pp-IGA  at the other visits specified in Table 5‒1and Table 5‒2.
Subjects with palmoplantar involvement at Baseline  are defined as those with a pp-IGA score >0 
at Baseline.
Palmoplantar disease will be assessed in term s of clinical signs of redness, thickness, and 
scaliness using a 5-point scale ( Table 9‒4).PUBLIC I scI s
ded as sed as s
aseline aaseline 
emenemCOPYaffeff
bling, abling, 
rkeratoskerato
ranges fanges f
oreore
This document plantar dantar d
ness usiess uscannot lanan
mplete thplete t
ompletemplet
almopllmoplbe tar Ptar Pusedt at Baat Ba
5‒‒22.to supports, s, sp
rom 0 tom 0 to
s the sumthe su
ch and wh and w
e definedefineany ails ails
pitting pitting
plinterplintmarketing deep darkeep dar
l or all lesior all lesi
eti
willwiauthorization tio alingingtitiotio
on; za
to bright  brightthoa
application antar inntar i
sease wilsease w
ng a 5g a 5 --poande pppp--IGIG
he ppe pp-IIany O will bewill be
Aextensionswill nol no
ed as thoed as th
line willine wilor3 w3 
of theof the
tvariations l be scobe sco
and wiland wi
er hemorhemor
withwiththereof. ed
red d 
onsnsof
he
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 99 of 263Table 9‒4: pp-IGA
Score Short Descriptor Detailed Descriptor
0 Clear Palmoplantar areas have no signs of PSO; post -inflammatory 
hyperpigmentation may be present
1 Almost clear Palmoplantar areas have no thickening;  normal to pink coloration; no to 
minimal focal scaling
2 Mild Palmoplantar areas have just detectable to  mild thickening; pink to light red 
coloration; predominately fine scaling
3 Moderate Palmoplantar areas have clearly distingu ishable to moderate thickening; dull to 
bright red and clearly distinguishable colorati on; moderate scaling
4 Severe Palmoplantar areas have severe thickening with hard edges; bright to deep dark 
red coloration; severe/coarse scaling covering almost all or all lesions; 
numerous fissures
pp-IGA=palmoplantar Investigator’s Global Assessment; PSO=psoriasis
9.7 European Quality-of-Life 5-Dimensions 3-Level Questionnaire
The EQ-5D-3L health questionnaire provides a de scriptive profile and a single index value for 
health status. The instrument is comprised of a 5-item health status measure and a VAS. The 
EQ-5D- 3L VAS records the respondent’s self -rated health status on a vertical 20cm scale, 
graduated from 0 to 100 (0=worst imaginable heal th status, 100=best imaginable health status).
The EQ-5D-3L will be assessed at the visits specified in Table 5‒1and Table 5‒2.
9.8 Patient Global Asse ssment of psoriasis
The Patient Global Assessment of PSO is a PSO-speci fic item in which the patient responds to 
the multiple- choice question, “How severe are your psoriasis -related symptoms right now?” 
Possible responses to the question are “no symptoms,” “mild symptoms,” “moderate symptoms,” 
“severe symptoms,” or “very severe symptoms.”
The Patient Global Assessment of psoriasis will be performed at the visits specified in Table 5‒1.
9.9 Itch, pain, and scaling numerical rating scale
UCB developed and validated a new Patient Reported  Outcome measure, in the form of a patient 
symptom diary, which is used to assess key symptoms relevant to subjects with moderate to 
severe chronic plaque PSO. In this study itch, pain , and scaling items from the diary will be used 
to assess the patient-reported level of these sympto ms over time. The items will be administered 
on an electronic site tablet, during visits, as specified in Table 5‒1, Table 5 ‒2, and Table 5-3 ).
9.10 PASE questionnaire
The Psoriatic Arthritis Screening and Evaluati on (PASE) questionnaire is a self-administered 
tool to screen for active PsA in patients with  PSO (Husni et al, 2014). The questionnaire consists 
of 15 items that are divided into a 7-item symp toms subscale and an 8-item functions subscale. 
Standardized responses are based on 5 categories relating to agreement (strongly agree [5], agree [4], no idea [3], disagree [2], and strongly disagree [1]). The total maximum score is PUBLICs se
ginableginabl
t the visithe vis
bal Assbal Ass
ooCOPY imem
descripdesc
f a 5f a 5-iteite
elflf-fratra
This documentpeded
diary, wiary, w
chronic hronic
ssess thesess the
n an elean ele
9.109.10cannotssessmesessme
ch, paih, pa
d and and be estiontion
ry sevry sevused ee
PSO is SO is 
How sevow sev
na rna rtos 
ssmessmsupport m healthealt
ed health d health
health statealth st
specifiepecifany ons ns
e profile pro
hshmarketing ate scae sc
d edges; bredges; br
most all or st all ong
ark
33-Lauthorization tiotitiotio
light redlight redriz
thickenhicken
alinlinut
application n
validatedvalidate
hich is usich is u
plaque PSplaque P
patientatient -r
ctronic sitronic sandnt of pof p
, andandany“no s“no
e symptoe symp
sorextensions atus, us, 
ed in ed in TaT
nt of t of 
PSOPSO--ss
re are ye are y
syortatustatu
100100variations s
Level Qevel Q
le and ae and a
atus matus mthereof.ng; dull; dul
right to dght to d
all lesionall lesioeo
t
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 100 of 26375 points (symptom score: 35 points and function score: 40 points). Psoriatic Arthritis Screening 
and Evaluation questionnaire scores ≥47points are indicative of active PsA.
If a subject wit h a PASE score ≥47 points is referred to a rheuma tologist, the referral will be 
recorded in the eCRF. Subjects with PsA, de fined as a past medical history of PsA or PASE ≥47, 
are required to receive the additional PsA assessments (PGADA) as noted in Section 9.11 .
The PASE questionnaire will be comp leted at the visits specified in Table 5‒1and Table 5‒2.
9.11 PGADA for arthritis visual analog scale
The PGADA for the arthritis VAS will be used to provide an overall evaluation of arthritis 
disease symptoms. Subjects will respond to the question, “Considering all the ways your arthritis affects you, please mark a vertical line on the scale below to show how you are feeling today,” 
using a VAS where 0 is “very good, no symptoms” and 100 is “very poor, severe symptoms.
All subjects will complete the PGADA at Baseline. Subjects with PsA at Baseline (defined as a 
past medical history of PsA or PASE ≥47)will complete the PGADA at the visits specified in 
Table 5‒1and Table 5‒2.
9.12 Photographs
At certain clinical sites, representative photograph s of the changes in skin and nail appearance 
will be captured. Subjects who consent to th e procedure will have full body (anterior and 
posterior views) photographs taken. Only those subj ects with nail disease at Baseline will have 
nail photographs taken. Only those subjects with  palmoplantar disease at  Baseline will have 
photographs of their palms or soles of their feet taken. Only those subjects with scalp disease at Baseline will have scalp photogra phs taken. Photographs will be anonymized and will be used 
for publication purposes.
Study sites selected for photography will be trained and receive standardized photographic 
equipment by a centralized photographic vendor. Photographs will be electronically transferred from the site to the vendor.
At the end of the study, the site will receive an electronic file of all subject photographs for 
archiving.
The central photography vendor will tabulate and tran sfer all subject photos to the Sponsor at the 
end of the study.
9.13 WPAI-SHP V2.0
The WPAI-SHP V2.0 is a patient- reported questionnaire that assesses subject’s employment 
status, work absenteeism, work impairment while working (presenteeism), overall work, and 
daily activity impairment attributable to a specific health problem (WPAI-SHP) 
(Reilly et al, 1993). It has been used in several clinical studies of biologic therapy in subjects 
with plaque PSO (Kimball et al, 2012; Vender et al, 2012).
Five out of 6 items of the WPAI-SHP are regrouped into the 4 dimensions, with scores expressed 
as percentage, where higher numbers indicate grea ter impairment and less productivity, ie, worse 
outcomes, as described in the WPAI-SHP scoring rules.
The WPAI-SHP V2.0 will be assessed at the visits specified in Table 5‒1and Table 5‒2.y thoy tho
ubjects wubjects w
s of theis of thei
graphs taraphs taCOPY raphs ofaphs o
he procee proce
oseose
This document udydy
WW
WPAIWPAI S
tatus, wous, w
daily adaily a
(Re(Recannot, the sthe s
tographygraph
ybe ot
iteiteused phy willhy wil
ograpograptoken. Phen. Psupportthe he
dure wilure wi
ubjects wbjects 
ith palmoh palm
feet takeet take
hothany changchanmarketing are feere fee
r, severe ssevere s
A at BaseA at Ba
DA at theA at tauthorization ‒22..
f arthritiarthriti
ays youys you
lili
application y ven
PAIAI--SHS
HP V2.0 HP V2.
rk absentabsen
vity imity imand wilwi
ndorndorany ll recel recextensionsoplantplan
en. Onlyen. Only
tographgraph
be traine train
vendvendorhavha
th naih navariationse visitvisit
ges in skes in sk
ave fuve futhereof.ur arthrarthr
ng todayg today
symptomympto
ine (deine (d
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 101 of 26310 ASSESSMENT OF PHARMACOKINETIC VARIABLES
10.1 Pharmacokinetic variables
Blood samples for measurement of PK assessments ( Section 4.3.3 ) will be collected at the time 
points specified in the schedule of study assessments ( Table 5‒1 and Table 5 ‒2). Blood samples 
for the measurement of PK assessments will not be collected in the OLE2 Period.
At dosing visits, blood samples will be drawn prio r to dosing, and will be drawn at the same time
of the sampling for clinical laboratory tests. The ti me and date of collection will be recorded in 
the eCRF.
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. Detailed information on sample analysis will be 
provided in a bioanalytical report.
Pharmacokinetic samples from subjects receiving secukinumab will not be analyzed, but stored 
for potential future PK analysis and anti-drug antibody determination.
11 ASSESSMENT OF IMMUNOLOGICAL VARIABLES
Blood samples for measurement of antibodies to bi mekizumab will be collected at the visits 
specified in Table 5‒1andTable 5‒2. The threshold for antibody positivity will be defined prior 
to analysis. Blood samples for the measurement of antibodies to bimekizumab will not be 
collected in the OLE2 Period.
At dosing visits, blood samples will be drawn prio r to dosing, and will be drawn at the same time 
of the sampling for clinical laboratory tests. The ti me and date of collection will be recorded in 
the eCRF.
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. The presence of antibodies to bimekizumab will 
be determined using a validated  bioanalytical method. Detailed information on sample analysis 
will be provided in a bioanalytical report.
12 ASSESSMENT OF SAFETY
12.1 Adverse events
12.1.1 Definitions
12.1.1.1 Adverse event
An AE is any untoward medical occurrence in  a patient or clinical investigation subject 
administered a pharmaceutical product that does no t necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.
In order to ensure complete safety data collection, all AEs occurring during the study (ie, after 
the signing of the ICF), including any pretreatment and posttreatment periods required by the 
protocol, must be reported in the eCRF even if  no IMP was taken but specific study procedures PUBLIC l be drawl be dra
ratory teratory teCOPY LL
bimekibimek
reshold fshold
ment ofment of
This document DD
AA
AE is anAE is a
administminist
this trthis t
abnabncannotan
ESSMESSM
dversvers
DefiDefibe ated bed b
alyticaalyticaused collectioollectio
ual for tal for 
ioaioto ts. Ts. Tsupport or anr an
antibodientibod
n prior ton prior t
The tiheany AA
umab wimab w
ntibodntibmarketing sh
ample anmple a
not be anot be a
tion.n.
L VAL VAauthorization ame timeme tim
corded icorded 
hippingpping
application e e
itionstions
dverse verse
y untowauntow
ered a phaed a ph
ment. Ament. AandENT NT 
evenvenany alyticalyt
report.report.
OFextensions o dosingdosin
ime andme and
n, proceproce
s studystudy
caor s to tovariations na
ARIABRIAB
ill be cobe co
dy posity posi
ob i mbithereof. are are 
alysis wysis w
lyzed,yzed
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 102 of 263were conducted. This includes all AEs not present prior to the initial visit and all AEs that 
recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the IMP is being studied should be
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile known to the 
Investigator from the subject’s history or the Baseline Period.
12.1.1.2 Serious adverse eventOnce it is determined that a subject experi enced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:
xDeath
xLife-threatening
(Life-threatening does not include a reaction th at might have caused death had it occurred in 
a more severe form)
xSignificant or persistent disability/incapacity
xCongenital anomaly/birth defect (including that occurring in a fetus)
xImportant medical event that, based upon approp riate medical judgment, may jeopardize the
patient or subject and may require medical or su rgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section 12.1.1.3 ], allergic bronchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias that do not re sult in inpatient hospitalization, or the 
development of drug dependency or drug abuse)
xInitial inpatient hospitalization or prolongation of hospitalization
(A patient admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalizati on. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization criteria. 
However, emergency room visits that do not result in admission to the hospital would not 
qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg, life-threatening a dverse experience, important medical event].
Hospitalizations for reasons not associated with the occurrence of an AE [eg, preplanned 
surgery or elective surgery for a pre-existing condition that has not worsened or manifested 
in an unusual or uncharacteristi c manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifes ted in an unusual or un characteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to be determined)
Confirmed active TB must be reported as an SAE.  The Investigator is to complete and submit the 
TB Follow-Up Form provided.PUBLIC edicedic
f seriouseriou
ay includy includ
bronchobroncho
as thaas tCOPY that occthat occ
on appron appro
al oal o
This documentor tr t
tion of sn of 
ospitalizspitaliz
surgerysurgery
in anin a
suscannoto ao a
ial inpal inpa
e hospithospit
mergencrgenc
this crhis crbe zatioatio
a hospa hospusedpp
t do nodo no
ency or dcy or
on oron otoe, b
asm rasm r
tsupportpriate mriate m
surgical urgica
but areut arany ring in aing in a
dmarketing used deathed deaauthorization must be ust be 
applicationy roo
iteria anditeria an
erious [egious [e
ations fortions fo
or elor electivect
unusual nusual 
hashaandient hnt h
al wouldwould
om vomany proloprol
al, even l, even
osposextensions e not limnot lim
quiring uiring
result inesult in
rug abuug abu
ongongordicic
nterventervvariations h h
a fetus)fetus)
cal jucal juthereof. had ithad i
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 103 of 26312.1.1.2.1 Anticipated serious adverse events
The following Anticipated SAEs are anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure.
This list does not change the Investigator’s obligation to re port all SAEs (including Anticipated 
SAEs) as detailed in Section 12.1.2.3 .
Table 12‒1:Anticipated serious adverse events for the population of subjects 
with moderate to severe chronic plaque psoriasis
MedDRA®system order class MedDRA preferred term
Skin and subcutaneous tissue disorders Any psoriatic condition HLT
Musculoskeletal and connective tissue disorders Psoriatic arthropathy
HLT=High Level Term; MedDRA=Medical Dictionary for Regulatory Activities; SAE=serious adverse event
Note: Exception: Listed events will not be regarded as antic ipated SAEs if they are life threatening or if they 
result in the death of the study subject.
12.1.1.3 Adverse events of special interest
An AE of special interest (AESI) is any AE that a regulatory authority has mandated be reported 
on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a UCB product/compound.
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin in 
the absence of ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, 
must ALWAYS be reported to UCB as an AESI (ie, without waiting for any additional etiologic 
investigations to have been concluded). Follow-up information should then be reported if an 
alternative etiology is identified during investigation and monitoring of the subject.
12.1.1.4 Other safety topics of interestPre-specified safety topics of interest for the stud y are: infections (serious, opportunistic, fungal, 
and TB), neutropenia, hypersensitivity, su icidal ideation and behavior, depression, major 
cardiovascular events, liver function test chan ges/enzyme elevations, malignancies, and 
inflammatory bowel diseases (with gastroenterol ogy referral, as appropriate). This is based on 
findings from the IMP clinical program to date, potential risks generally associated with biologic 
immunomodulators, or findings from other medici nes with a related mechanism of action. There 
are no specific AE reporting requirements for these topics, however special monitoring, 
additional data collection activitie s, and/or enhanced signal detection activities (within UCB) are 
in place.
12.1.2 Procedures for reporting and recording adverse eventsThe subject will be given the opportunity to report AEs spontaneously. A general prompt will 
also be given at each study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review an y self-assessment procedures (eg, diary cards) 
employed in the study.PUBLIC erioe
pound.ound.
xULN AxULN A
with no awith no 
o UCBo UCB
llCOPY nterestterest
that a rethat a r
ousneousn
This documentom them the
omodulamodula
o specifspecif
ditionaltional
in placein plac
1212cannotpics ofcs of
ia, hypehype
vents, livents, li
owel dwel d
Ibeety topety top
fifiused as an s an
uded). Fded). F
duringdurintoAL
ternatterna
nAAsupport gulatoryulator
ss, expect, expe
T or AST or A
veany yamarketing dition Hion 
arthropathyrthropathyng
SAE=serioSAE=ser
are life thrre life tetiauthorization jects cts 
termermth
HLHLau
application er
iseases eases
MP clinicP clin
ors, or finrs, or f
c AE repoAE re
data colata col leandntereere
sensitivensitiv
r functfunc
(anys of ins of i
est forst fextensions ST withST with
eexplanexplan
ESI (ie, wSI (ie, w
ollowlow--upup
nvestigvestigorednesednevariations reatenate
uthoritthoritthereof. f
yeo
ous adverus adver
ningninghe
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 104 of 26312.1.2.1 Description of adverse events
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies bet ween the subject’s own words 
on his/her own records (eg, diary card) and the corresponding medical terminology should be clarified in the source documentation.
When recording the severity of an AE in th e eCRF (ie, mild, moderate, or severe), the 
Investigator may refer to the Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4 (http://ctep.cancer.gov/protocolDeve lopment/electronic_applications/ctc.htm) for 
additional guidance as needed. Details for co mpletion of the Adverse Event eCRF (including
judgment of relationship to IMP) are described in the eCRF Completion Guidelines.
12.1.2.2 Rule for repetition of an adverse event
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:
xThe outcome date of the first AE that is not re lated to the natural course of the disease being 
the same as the start date of the repea ted AE, and the outcome of “worsening”
xThe AE verbatim term being the same for the fi rst and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one
12.1.2.3 Additional procedures for reporting serious adverse events
If an SAE is reported, UCB must be informed wi thin 24 hours of receipt of this information by 
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The Investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE report form) 
provided by UCB, even if the data are incomplete, or if it is obvious that more data will be needed in order to draw any conclusions. Information recorded on this form will be entered into the global safety database.
An Investigator SAE report form will be provided to the Investigator. The Investigator SAE 
Report form must be completed in English.
It is important for the Investigator, when completing the SAE report form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited manner.
Additional information (eg, autopsy or laboratory reports) received by the Investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be summarized in the Investigator SAE report form.
The Investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subject, and to also inform participating subjects of PUBLIC ning ning
ures foures fo
st be infot be inf
on for Son for S
colcoCOPYated toated
E, and thE, and th
or the fior the f
of tof t
Thispdocument ant fot fo
nt as to t as to 
he Invee Inve
d in detein dete
expediteexpedite
AddAdcannot ase.e.
AE reporE repor
st be cobe co
or thor thbee da
y concly concusedAE AE
. The InThe In
SAE ReAE Re
ta arta arto rmed rmed
 reporeposupportst and rt and r
he first onfirst o
r reportireporti
witwany e nature natu
outcomeutcomemarketing idelinesdeline
on of the n of the
alauthorization CAE) CAE) 
c.htm) fhtm) 
RF (incF (inc
application mplep
e Investige Inves
a causal rausal
tigator is igator i
mining wmining 
d mannermanner
infand form wform w
eted eted any incoinc
sions. Inions. Iextensionsing seng se
thin 24 hhin 24
rting listng lis
vestigatoestigato
ort Formrt Form
ompomor eaevariations AE beiAE bei
l coursel course
e of “woof “w
ated Aated Athereof. or
udingding
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 105 of 263the need to inform the Investigator of any SAE within this period. Serious AEs that the 
Investigator thinks may be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the study.
Upon receipt of the SAE report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the IB.
12.1.3 Follow up of adverse events
An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow-up requirement applies to AEs, SAEs, and AESIs; further details regarding follow up of 
PDILI events is provided in Section 12.2.1.4 .
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the Investigator must provide a justification. The fol low up will usually be continued for 20 weeks 
after the subject has discontinued his/her IMP.
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety (PS) database without limitation of time.
12.1.4 Pregnancy
If an Investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the Investigator must immediately notify UCB’ s PS department by providing the completed 
Pregnancy Report and Outcome form (for contac t details see Serious Adverse Event reporting 
information at the beginning of this protocol). The subject should be withdrawn from the study 
as soon as pregnancy is known (by positive pregnancy test), and the following should be completed:
xThe subject should return for an early discontinuation visit.
xThe subject should immediately stop the intake of the IMP.
xA SFU Visit should be scheduled 20 weeks after the subject has discontinued her IMP.
The Investigator must inform the subject of i nformation currently known about potential risks 
and about available treatment alternatives.
The pregnancy will be documented on the Pregna ncy Report and Outcome form provided to the 
Investigator. The progression of the pregnancy an d the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outc ome form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to follow the health of the child for 30 days after birt h for any significant medical issues. In certain 
circumstances, UCB may request that follow up is continued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of attempts to contact the subject need to be p rovided by the Investigator and filed at the site. 
UCB’ s PS department is the primar y contact for any questions rela ted to the data collection for 
the pregnancy, eventual birth, and follow up.PUBLICbject hasect ha
notify Unotify U
form (fform (
of this pof this p
(by(bCOPYbase locbase lo
e.e.
Thisfdocumentato
availabvailab
regnancygnanc
estigatotigato
followedllowed
reporrepor
folflcannotimmemme
ould beuld be
r musmus
lbern for n for 
ediediusedrotooto
y positivositivtoor conr con
ocol)col)support become pecome
CB’s PS B’s PS 
tacttacany will be cwill bemarketing d be provibe provi
no longeno long
ollow up low up
ally be coy be cauthorization up. This . This 
ng followg follow
applicationinform nform
treatmenreatm
will be dwill be
. The proThe pr
up usingup using
he hehe heand ateltel
schedulechedulany arly darly 
y stop y stoextensionspregnegn
departmdepartm
t detailsdetails
The subhe sub
 pregnapregnaor anvariationsis ps 
ontinuedtinued
capturedapturedthereof. w up u
ided untded un
er deemer deem
provprov
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 106 of 263In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contact the subject to request consent of the partner via the 
Partner Pregnancy Consent form that has been approved by the responsible IRB/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the 
Investigator may contact the UCB/contract resear ch organization (CRO) contract monitor for the 
study. The Investigator will complete the Preg nancy Report and Outcome form and send it to 
UCB’s PS department (for contact details see Serious Adverse Event reporting information at the 
beginning of this protocol) only after the partne r has agreed that additional information can be 
captured and has provided the signed Partner Pre gnancy Consent form. UCB’s PS department is 
also the primary contact for any questions related to the data collection for the partner pregnancy, 
eventual birth, and follow up.
A pregnancy becomes a SAE in the following ci rcumstances: miscarriage, elective abortion 
when medically indicated (eg, when pregnancy is  endangering life or health of woman or when 
fetus will be born with severe abnormal ities), unintended pregnancy after hormonal 
contraceptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal demise, or any congenital anomaly/birth defect of the baby. Those SAEs must be additionally 
reported using the Investigator SAE Report form.
Should a subject become pregnant while participating in the study, the subject may be offered the 
option to enroll in a separate observational pregnancy follow-up study sponsored by UCB and 
conducted independently from study PS0015. If the st udy is available locally, the PS0015 PI will 
be provided with the locally approved informa tion about the observational pregnancy follow-up
study to inform the subject at the time the pregnancy is reported. Participation in this separate 
study will be voluntary and will not impact th erapeutic management of the subject nor interfere 
with termination and follow-up procedure s as described in study protocol PS0015.
12.1.5 Suspected transmission of an infectious agent via a medicinal 
product
For the purposes of reporting, any suspected transm ission of an infectious  agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any organism, virus, or infectious particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent.
12.1.6 Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in th e protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt).
12.1.7 Safety signal detection
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory authorities, and IRBs/IECs will be informe d appropriately and as early as possible.PUBLIC0101
informnform
memethe pthe 
not impnot imp
up procep proceCOPY ipating iipatin
pregnancregnan
5. If t5. If 
This documentOO
ive dosive dosi
orded in ded in
ollowedllowed
there there
is ais acannot dereere
e eCRF,eCRF,
protein rotein
is conss cons
vebeng, anyng, any
da sdaused dureur
smissimissi oto act theact th
res ases assupport n 
y followfollo
he study ie study
tion abouon abo
egnancy gnancy
eraperaany he studhe stu
wmarketing elective elective
ealth of wlth of 
after hormfter ho
used), ecused), e
se SAEse SAauthorization e 
n at the n at the 
can be an be 
epartmeepartme
rtner prener pr
application deredered
rdose odose
ng (beyonng (beyo
the eCRFe eCR
as any oths any o
associssociandan
and folnd fo
ransmitansmi
da nananyuspectespect
n SAE; SAE
lowextensions ut thethe
y is repois repo
peutic meutic m
describeescrib
n of an of anors avaiava
eo beo bvariationsrm
ctopic topic 
Es must s must 
dy, the sy, the 
p sp studtud
lthereof. gng
abortiobortio
woman owoman 
monal onal 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 107 of 263In addition, an independent Data Monitoring Co mmittee (DMC) will periodically review and 
monitor safety data from this study and advise UCB. Details are provided in the DMC Charter. 
Cardiovascular and Neuropsychiatric Adjudication Committees will also periodically review and 
monitor safety data from this study and advise UCB. Details are provided in the Adjudication Committee Charters.
The Study Physician or medically qualified desi gnee/equivalent will cond uct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development a nd accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital signs, laboratory or ECG results) for which data will be periodically reviewed during the course of the study.
12.2 Laboratory measurements
Clinical laboratory assessments consist of serum  chemistry, hematology, and urinalysis. A 
centralized laboratory will be used to supply all laboratory test supplies and analyze all blood 
and urine samples for hematology, biochemistry, and urinalysis measurements. Any unscheduled 
laboratory testing should also be collected using th e central laboratory. If tests are done locally, a 
concurrent sample should also be sent to the ce ntral laboratory whenever possible. Testing to 
rule out hepatitis B, hepatitis C, and HIV (see Exclusion Criterion # 9, Section 6.2 ) and a urine 
drug screen will be performed at Screening in addition to those measurements listed in Table 12‒
2.
Specific details regarding the handling and proc essing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals.PUBLIC ing inng i
ndling andling an
ed in theed in theCOPYnd urdu
the centthe cen
entralentral la
ee Exclee Excl
na dna d
This document cannot be used stusttod prp
udy laudy lasupportboraor
usion Crion Cr
dition to ition to
rocessoceany sis mis m
l laboratl labor
atory watorymarketing d durdu
tology, anlogy, 
upplies aupplies
measmeauthorization eview eview 
ntative.tative.
MP, MP, 
eg,g,AEs,AEs,
ring ring
application and any extensions t
sing of sing of 
boratoryoratoryorerioeri
hose mose mvariationsnd urind uri
and anaand an
suremenuremen
atory. If ory. If
whenevhene
ion #onthereof.vitavi
the coure cour
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 108 of 263The following laboratory parameters will be measured:
Table 12‒2: Laboratory measurements
Hematology Chemistry Urinalysis dipsticka
Basophils Calcium pH
Eosinophils Chloride Albumin (protein)
Lymphocytes Magnesium Glucose
Monocytes Potassium Blood
Neutrophils Sodium Leukocyte esterase
Hematocrit Glucose Nitrite
Hemoglobin BUN Urine dipstick for pregnancy testingc
MCH Creatinine Urine drug screen
MCHC ALP
MCV AST
Platelet count ALT
RBC count GGT
WBC count Total bilirubin
LDH
CRPb
Lipid panelb
NT-proBNPb
Serum pregnancy testingc
ALP=alkaline phosphatase; ALT=alanine aminotransfera se; AST=aspartate aminotra nsferase; BUN=blood urea 
nitrogen; CRP=C-reactive protein; GGT=gamma gl utamyltransferase; LDH=lactate dehydrogenase; 
MCH=mean corpuscular hemoglobin; MCHC=mean corp uscular hemoglobin concentration; MCV=mean 
corpuscular volume; NT-proBNP=N-terminal pro B- type natriuretic peptide; RBC=red blood cell; WBC=white 
blood cell
aA urine microscopic examination will be performed if th e result for albumin (protein), leukocyte esterase, blood 
or nitrite is abnormal. A urine microscopic examinatio n will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hyaline casts, WBC casts , RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals, triphosp hate crystals, yeast, bacteria, amorph ous urates, and amorphous phosphates.
bAssessments of NT-proBNP and CRP will not be performed during any OLE Period; in addition, lipid panel 
will not be performed during OLE2 Period.
cPregnancy testing will consist of serum testing at the initial Screening. Urine pregnancy testing will be 
performed at all other visits.
12.2.1 Evaluation of PDILI
The PDILI IMP discontinuation criteria for this study are provided in Section 6.5.1 , with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be PUBLIC ilirubinirubi
DHHLIC
CRPCRPbbBL
PULiPUPUPUPUPPCOPY PYOPC
This documents abnorabnor
onal and ral and 
als, uric as, uric 
ssessmenssme
will not will not
cPregnPregn
pepecannot e protprot
lar hemor hemo
e; NTNT--propr
copic eopic e
mbe e LT=alanLT=alan
eineinbeeeusedid panepane
NTNT-proBproed
SerSerusto ellbbtosupport t
poppsany nyaaaaamarketing g
ck for pregfor prting
rug screenug screekearmauthorization ootioattt
rizhouta
application aminationminatio
. A urine mA urine
nal tubularl tubul
cid crystalscid crysta
of NTf NT --pr
be performeperform
cy testingy testi
at atandGGGG
lobin; Mbin; M
BNP=NNP=N --tany aminotra aminot
T=gamT=ga
CHny m prem pr
nyextensions sson
ns
NPPbte
gnagnaexor orovariations nstioia
vathereof. of
gnancy tegnancy tereth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 109 of 263reported as an AESI (see Section 12.1.1.3 ), and, if applicable, also reported as an SAE (see 
Section 12.1.1.2 ).
Evaluation of PDILI consists of the diagnostic te sting and continued monitoring included in 
Table 12‒3(specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 12.2.1.1 ). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This wo uld usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in Section 12.2.1.4 ).
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be de layed waiting for the repeat result.
If tests are done locally for more rapid results,  a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laboratory are to be recorded on the applicable eCRF pages.
When IMP is discontinued, all concomitant medic ations and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the Investigator should also consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medicati on known to be hepatotoxic to a suitable 
alternative.
When IMP is stopped due to PDILI (as described in Section 6.5.1 ), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explains the hepatic findings, and the requirements provided in Section 12.2.1.2.1 are met, rechallenge with IMP may be appropriate.
Table 12‒3summarizes the approach to investigate PDILI.PUBLIC mitantitant mm
e discone discon
dically nically n
mitant mitant COPYe decise dec
e approe appro
Data froData fro
This document cannotiagnag
2.2.1.2.2.1.2
marizes tarizes bePD
equent equent
nosisnosiused medicedi
DILI (aILI (atoecessarcessa
caticatsupport m the lthe 
edicationdicatio
nued. Inued. In
ry cany p
s are tos are 
h must bmust b
loclmarketing should hould
to be repeo be re
peat resulat resu
ple shople shauthorization be a e a 
ted baseed base
s in in 
b
application eandare mare m
e approappranyde
ernativernativ
ully explly exp
metextensionsns ands and
n these cn these 
concomoncom
on known know
escribscribor hhvariations ea
lt.
ould alsould als
be madbe mad
be takene taken
al and cl and cthereof. be made made
ated, bted, b
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 110 of 263Table 12‒3: Required investigations and follow up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal 
bilirubinSymptomsaof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNbNA Hepatology consultc
Medical Monitor must 
be notified within 
24hours (eg, by 
laboratory alert) and 
subject discussed with 
Medical Monitor ASAP.Immediate, permanent 
IMP discontinuation.eEssential: Must have 
repeat liver chemistry 
values and additional 
testing completed ASAP
(see 
Section 12.2.1.3 ); 
recommended to occur 
at the site with HCP.Monitoring of liver 
chemistry values at least 
twice per week until values 
normal ize, stabilize, or 
return to within baseline 
values. d≥3xULN NA Yes
≥8xULN NA NA Hepatology consult.
Medical Monitor must 
be notified within 
24hours (eg, by 
laboratory alert) and 
subject discussed with 
Medical Monitor ASAP.Immediate, permanent 
IMP discontinuation.
≥5xULN 
and 
<8xULN<2xULN No Discussion with Medical 
Monitor required.
Consider need for 
hepatology consult if there is no evidence of 
resolution (see Follow 
up requirements). 
cFurther investigation –
immediate IMP 
discontinuation not 
required (see 
Section 12.2.1.2 ).
IMP discontinuation 
required if any of the 
following occur:
Subject cannot comply 
with monitoring 
schedule.
Liver chemistry values 
continue to increase
Liver chemistry values 
remain ≥5xULN after Essential: Every 
attempt must be made 
to have repeat liver 
chemistry values and 
additional testing 
completed within 
48hours at the site 
with HCP (see 
Section 12.2.1.3 ).Monitoring of liver 
chemistry values at least 
twice per week for 2 weeks.d
xImmediate IMP 
discontinuation required 
if liver chemistry values continue to increase.
After 2 weeks of monitoring 
liver chemistry values:
xALT or AST remains 
≥5xULN <8xULN, IMP 
should be temporarily 
withheld and subject 
should undergo repeat 
test in 2 weeks.PUBLIC ust ust
n n
by y 
alert) andalert) and
discussediscussed
al Monial MoniP
COPY ImmImm
IMOPCOThis his
document oc
cannot therhe
resolresol
upun
be ider nder 
patologypatology
isis
usedwith Mewith Me
requiredequire
eeee
dr ASAd to with ith 
SAP.AP
support diate, peiate, p
Pdiscontidiscon
ts
any a
marketing Essential: Msential
repeat lirepeat
valueval
tes
tina
authorization 
a
FFhoutapplication 
tio
ando o
tion (seon (se
requiremequirem
any or r 
onsult if onsult if
videnceviden
F
extensions 
e ical l FuFutetetenxte
oruationuatio
variationsive
s and aand a
sting coming co
ASAPASAP (
SectiSecti
rereria
anent nent 
arr
thereof.EvEof
Must havMust hav
r chemr chem
er
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 111 of 263Table 12‒3: Required investigations and follow up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal 
bilirubinSymptomsaof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
4 weeks of monitoring 
without evidence of 
resolutionContinue IMP if ALT 
or AST values 
<5xULN; continue to 
monitor at least twice 
per week until values 
normalize, stabilize, or 
return to within 
Baseline values.
If ALT or AST remains 
≥5xULN after second 
re-test, immediate, 
permanent IMP 
discontinuation 
required .
Continue to monitor until 
values normalize, stabilize, or return to within baseline values.
d
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcar e practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal
aHepatitis symptoms include fatigue, nausea, vomiting, and right u pper quadrant pain or tenderness; hypersensitivity symptoms in clude eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
bIf the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi cal Monitor.
cDetails provided in Section 12.2.1.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
dUnless an alternative monitoring schedule is agreed by the Inve stigator and UCB responsible phys ician. Determination of stabi lization is at the discretion of the 
Investigator in consultation with the hepatologist (a s applicable) and UCB respon sible physician, as needed.
eDetails provided in Section 12.2.1.2.1 .
PUBLIC 
COPY COThis 
documentd usuus
schedulhedul
ith the heh the he
12.22.2.1.2.1.
cannotapplpp
miting, ting, 
se).).
possibilitossibili
he local e local 
uallyually
beerase; ASerase; A
icablicabeeused 
to support s
any 
marketing 
tina
authorization 
a
FFhoutapplication y
epatoloatolo
be a hepate a hep
is agreed bagreed 
atologistatologis (
.
and d rightrigh
of an infa n  i n
gii
anyP=as soo=as so
DILI=poDILI=
t uppup
yyextensions xte
or 
variations ria
thereof.EvEofer
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 112 of 26312.2.1.1 Consultation with Medical Monitor and local hepatologist
Potential drug-induced liver injury events require  notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The local hepatologist is the expert usually consul ted by the treating physician for assessment and 
management of potential hepatic disease. This wo uld usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section 12.2.1.3 ) and SAE report (if applicable).
12.2.1.2 Immediate action: det ermination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring.
The immediate action is dependent on the labora tory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 6.5.1 and Table 12‒3for details).
When IMP is discontinued, all concomitant medic ations and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider dose 
reduction for medically necessary concomitant me dication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.
12.2.1.2.1 IMP restart/rechallengeSubjects who are immediately discontinued from IMP due to having met certain criteria for 
PDILI (as described in Section 6.5.1 and Table 12‒3), but for whom an alternative diagnosis is 
confirmed, ie, drug-induced liver injury  is excluded, can rarely restart IMP.
Rechallenge with IMP can occur only if ALL of the following requirements are met at the time 
of the rechallenge.
xThe results of additional testing and monitoring described in Section 12.2.1.3 and 
Section 12.2.1.4 confirm a nondrug-related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie,  a subsequent alternative diagnosis fully 
explains the hepatic findings).
xThe subject has shown clear therapeutic benefit from the IMP.
xSubject’s ALT or AST elevations do not exceed ≥5xULN.
xSubject’s total bilirubin is <2xULN.
xSubject has no signs or symptoms of hypersensitivity or hepatitis.
xDuring the double-blind Treatment Period, th e rechallenge is approved by the UCB 
responsible physician, DMC, and a hepatologist. 
xDuring the OLE and OLE2 Periods, the rechallenge is approved by the UCB responsible 
physician. 
xSubject agrees to the Investigator-recommended monitoring plan.PUBLICtinued frnued f
11and and TT
er injuryr injury
cur oncur onCOPYhe Ie 
medicatiomedicat
hepatothepat
This document s ALAL
ject’s toect’s to
SubjectSubject
xxDuDucannot assocassoc
atic findic fin
has shows sho
LT oLTbetesti
m a nonm a no
ciaciausedy if Aif A
ing aing atois exs excc
ALLLsupport oxicxi
om IMP dm IMP
blele1212‒33
ludeludany gatogato
and conand co
c to a sto amarketing ms of hes of he papa
mediate imediate
blele1212‒3
rbal suppbal sup
r shors hauthorization a 
application wn c
r AST eler AST e
tal bilirubtal biliru
has no sias no s
ng the dg the 
band ed ed
ngs).gs).
clear lear any d mm
rugug--relare
symptsympextensionsdue toue to
), but fo, but fo
ded, can d, can
L of the L of the
monimonior ohhvariations forfo
plementement
ould alsuld als
nsider chsider ch
suitableuitablethereof. atitis or titis or
investiginvestig
r detrd e
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 113 of 26312.2.1.3 Testing: identification/exclusion of alternative etiology
The measurements and additional information requi red for the assessment of PDILI events when 
there is a reasonable possibility that they may ha ve been caused by the IMP are detailed in 
Table 12‒4(laboratory measurements) and Table 12‒5(additional information). Results of the 
laboratory measurements and information collected are to be submitted to the sponsor on the 
corresponding eCRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessments should be completed and submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed: 
PUBLIC COPY 
This document cannot be used to support any marketing authorization rapid respid re
application and any extensions or variations thereof. ul
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 114 of 263Table 12‒4: PDILI laboratory measurements
Virology-related Hepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb -IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophile 
antibody or monospot testing)
Immunology Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)
Hematology Eosinophil count
Urinalysis Urine drug screen a
Chemistry Amylase
Sodium, potassium, chloride, glucose, BUN, creatinine
Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin
If total bilirubin ≥1.5xULN, obtain fractionated bilirub in to obtain % direct bilirubin
Serum CPK and LDH to ev aluate possible muscle inju ry causing transaminase
elevation
Additional Prothrombin time/INR b
Serum pregnancy test c
PK
ALP=alkaline phosphatase; ALT=alanine aminotransfera se; AST=aspartate aminotra nsferase; BUN=blood urea 
nitrogen; CPK=creatine phosphokinase; GGT=gamma glutamyltransferase; HBcAb-IgM=hepatitis B core 
antibody- IgM; HBsAg=hepatitis B surface antigen; IgM= immunoglobulin M; INR=international normalized 
ratio; LDH=lactate dehydrogenase; PDILI=potential dr ug-induced liver injury; PK=pharmacokinetic; 
RNA=ribonucleic acid; ULN=upper limit of normal
aTests in addition to the specified analytes may be pe rformed based on the Investigator’s medical judgment and 
subject history.
bMeasured only for subjects with ALT >8xULN, elevati ons in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosin ophilia (>5%), rash, and fever (without clear alternative 
cause).
cFor women of childbearing potential.
The following additional information is to be collected:PUBLIC , ch,
 ALP, AALP, AC
rubin rubin ≥≥11LI
m CPK anm CPK a
tiontionUBCOPY Y
OPYhloridehloridCO
This document nucleicle
addition ddition 
ct historyhistory
easured osured o
hypeypersenrsen
tendertende
caucau
cccannotPP
ose; ALTe; ALT
tine phosne phos
BsAg=hesAg=he
tate dehate deh
ca cca coootbe um prm pr
KKbeused d Ld L
mbin timebin timeed
egnegnusto 5xU
LDH toDH toosupport glucose, Blucose,ort
T, ALT, GALT, Gp
ULN, obLN, oupsany yanmarketing ng
itative)ative)et
(qualitativqualitark
maauthorization otioatititi
iz
ho
tain hetain heut
application pat
drogenarogen
d; ULN=ud; ULN=
o the specifhe spe
nly for subjy for sub
itivity. Hepivity. H
ess; hypers; hyperandalaninenine
phokinaseokinase
itis B sis B sddaamany cy tescy tenyaextensionsGGT, toT, to
btain fractain fracns
valuate paluate psio
INR NR bbte
tceorUN, crUN, c
taovariationsve and quand qsonatiarivthereof. rophile phile
eo
het
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 115 of 263Table 12‒5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, vitamins); 
dosages and dates should be included.
Pertinent medical history, including the following:
xHistory of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or othe r “fatty liver disease”)
xAdverse reactions to drugs
xAllergies
xRelevant family history or inheritable di sorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin deficiency)
xRecent travel
Progression of malignancy involving the liver (Note: Metast atic disease to the liver, by itself, should not be used 
as an explanation for significant AST and/or ALT elevations)
The appearance or worsening of clinical symptoms of hepati tis or hypersensitivity (eg, fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotra nsferase; PDILI=potential drug-induced liver injury
12.2.1.4 Follow-up evaluation
Potential drug-induced liver injury events requi re follow-up monitoring as described in 
Table 12‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to baseline. Determination of stabilizati on is at the discretion of the Investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
12.3 Other safety measurements
12.3.1 Assessment and management of TB and TB risk factors
All subjects will be assessed for TB at Screenin g and at the time points specified in the Schedule 
of Assessments ( Table 5‒1, Table 5 ‒2, and Table 5-3) through physical examination for signs 
and symptoms of TB, chest x-ray ( Section 12.3.1.2 ), laboratory testing ( Section 12.3.1.1 ), and 
subject questionnaire ( Section 12.3.1.3 ).
For the purposes of this study, TB definitions are as follows:
c. Known TB infection:
Active TB infection or clinical signs and symptoms suspicious for TB (pulmonary or 
extra-pulmonary).PUBLICult, if dont, if doCLIC
T=asparta=aspartaUB
alualuCOPYth compth comYPY
COC
This document cts will ts will 
essmentssmen
d symptoympto
subject qubject q
For Forcannotminmin
hepatolpatol
ther saher sa
AsseAssebej
ould cod c
nationnationused ationon
ury every evtoe aminoaminoosupport rtpoup
transanyised carised cayanymarketing ypsinpsin
by itself, sy itself
itivity (eg, vity (eg
, jaundicjaundarkmauthorization tio
disease”)ease”)
defdeftitiotio
applicas ((ication smentmen
be assesseasses
TableTable 5
ms of TBms of T
uestionnaestionn
poandgist (ast (a
ety mty many nue unnue u
f stabilif stabili
as apasextensions ns
nsferase;ferase;io
s requrequor orvariations fatigue, atigue, 
ce, fever,ce, fevers
diopulmoopulmotioriavathereof. ciency)ncy)
should nohould nt
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 116 of 263History of active TB infection involving an y organ system or findings in other organ 
systems consistent with TB infection, unless adequately treated and proven to be fully recovered upon consult with a TB specialist.
Any evidence by radiography or other imaging modalities consistent with previously 
active TB infection that is not reported in the sub ject’s medical history.
d. High risk of acquiring TB infection:
Known close exposure to another person with active TB infection within the 3 months 
prior to Screening.
Time spent in a healthcare delivery setting or institution where individuals infected with 
TB are housed and where the risk of transmission of infection is high.
e. Latent TB infection (unless appropriate prophylax is is initiated at least 8 weeks prior to IMP 
dosing and continued to completion of prophylaxis):
The absence of signs, symptoms, or physical findings suggestive of TB infection with a 
positive IGRA test (or 2 indeterminate IGRA test results) and a chest x-ray (or other 
imaging) without evidence of TB infecti on. If the result of the IGRA test is 
indeterminate, the particular IGRA test previously performed may be repeated once; if positive or indeterminate on retest, the subject may not be randomized to IMP without 
further evaluation by a TB specialist and discussion with the Study Physician, if LTBI is 
identified. The retest must be done during the protocol-defined Screening window.
Note: If available, respiratory or other specim ens must also be smear and culture negative 
for TB (CDC diagnosis of LTBI) http://www.cdc.gov/TB/topic /testing/default.htm).
f. NTMB infection is defined as a clinical infect ion caused by mycobacterial species other than 
those belonging to the Mycobacterium tuberculosis complex.
g. Tuberculosis test conversion:
A positive IGRA result for the current test when previous IGRA test results were 
negative. All subjects with TB test conversion must immediately stop IMP administration and be referred to a TB specialist for further evaluation. Confirmed TB test conversions should be classified as due to LTBI, active TB infection, or NTMB, and reported to the UCB PS function.
Subject eligibility, retesting requirements, and treatment requirements are depicted in 
Figure 12-1 .PUBLIClist
one duone du
ory or otry or o
of LTBof LTB
d as ad asCOPYn. If the. If th
prevpreviouiou
he subjehe subje
t and dand
This document PSPS
eligibilitgibili
e1212-11cannotresre
subjectsubjects
rred to ared to a
e classiclassi
S funcfuncbe ionon
sult fsult usedclinicanica
bacteriumcteriutohttp:/http:
lsupport y
t may nmay 
iscussionscussio
ng the prog the p
er specimspecim
/wanys)s
sult of sult of
performperform
notmarketing ua
h.
ast 8st 8weew
ggestive oestive
) and aand 
hauthorization monthsonths
ls infes infe
application ied aed 
ion.ion.
y, retestinretestiandwith Tth T
TB speTB spe
as duas dany the currthe curr
TB tTBextensions rotoctoc
mens mmens m
www.cdcww.cdc
infectionnfection
m tuberctubercorwith with
cololdvariations of TB inTB in
a chest xchest x
he IGRAhe IGRA
rmed mamed ma
be ranbe ran
ththereofcted wied wi
eks prioeks prio
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 117 of 263Figure 12-1: Schematic diagram of TB test results and study eligibility
IGRA TB test
IGRA TB test 
negativeIGRA TB test 
indeterminate IGRA TB test 
positive
Repeat IGRA TB 
testa
IGRA TB test 
negativeIGRA TB test 
indeterminate IGRA TB test 
positiveSubject eligible for 
study
Subject eligible for 
studyEvaluation by TB 
specialist
Latent or active 
TB negativeLatent TB 
positiveActive TB 
positive
Subject eligible for 
study
TB treatment 
initiatedNo TB treatment 
initiated
Subject eligible for 
studybSubject NOT 
eligible for studySubject NOT 
eligible for study
IGRA=interferon-gamma release assay; TB=tuberculosis
a IGRA retest must be done during the protocol-defined Screening window
b Subjects with LTBI may enter the study only after they have completed at least 8 weeks of appropriate 
prophylactic therapy and thereafter, will continue and complete the entire regimen.UBLIC PUBLPUBLLatent orPUTBLICBCOPYCOPCOPEvaluPYPY PY
This document cannot bebbebebeSubjeused sedsedsedsediv
dve
uuususto ttosuppppppport pby TB 
alist
ppuppppany yyyyaaaanymarketing mamamamarkauthorization 
application and dany aanyany any ible for
udyextensions tententensiontensionLatennspoos or oooorvariations variatithereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 118 of 26312.3.1.1 Tuberculosis assessment by IGRA
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB test is 
recommended) will be performed as described in Table 5‒1, Table 5 ‒2, and Table 5-3 for all 
subjects. The test results will be reported as positive, negative, or indeterminate. Positive and 
indeterminate TB test results must be reported as  an AE and appropriately updated once the final 
diagnosis is known (eg, active TB, latent TB, or false positive TB test). UCB also recommends
that a TB specialist be consulted where TB (latent or active) is suspected or if there are doubts regarding test results. If active TB is identifi ed, subject must undergo appropriate study-specified 
withdrawal procedures. The retest during Screening must be done during the protocol-defined 
Screening window.
12.3.1.2 Chest x-ray for tuberculosis
A plain posteroanterior chest x-ray must be pe rformed in the Screening Period unless one has 
been performed within 3 months prior to the Screening Visit. The chest x-ray (or, if done, 
computed axial tomography of the chest) must be clear of signs of TB infection (previous or current) before first IMP administration. All ch est imaging (particularly x-rays) should be 
available for review by the Investigator befor e randomization of the subject. The chest x-ray 
reading should be repeated if the TB test was confirmed positive. If the second read of the pretreatment chest x-ray is confirmed to be clear, the patient may be included in the study 
8 weeks after the start of the TB prophylactic tr eatment. If the pretreatment chest x-ray is not 
available for a re-read, it should be repeated after not ification to the radiologist that this patient is 
IGRA positive, and confirmed to be clear for signs of TB.
The chest imaging must be negative for any old or recent TB infection as determined by a 
qualified radiologist and/or pulmonary physician. Any new clinically significant findings post 
Baseline on chest x-ray must be documented in the source documents and the eCRF as an AE.
12.3.1.3 Tuberculosis questionnaire
The questionnaire “Evaluation of signs and sympto ms of tuberculosis” should be used as a 
source document. The questionnaire will be completed as described in Table 5‒1, Table 5 ‒2, and 
Table 5-3 . The questionnaire will assist with the id entification of subjects who may require 
therapy for TB. A subject who answers “Yes” to the question “Has the subject been in close 
contact with an individual with active TB, or an individual who has recently been treated for TB?” at Screening is excluded. A “Yes” response to any of the other questions within the 
questionnaire at Screening should trigger further careful assessment to determine if subject has 
LTB or active TB (see Exclusion Criterion # 12, Section 6.2 ). A “Yes” response to any of the 
questions during the study should trigger further assessments to determine if the subject has 
either LTB or active TB infection.
12.3.1.4 Tuberculosis management
LTBI and active TB identified during study
During the study, subjects who develop evidence of LTBI or active TB must immediately stop 
further administration of IMP and will be referred to an appropriate TB specialist (pulmonologist 
or infectious disease specialist) for further evaluation. Evidence of LTBI is defined as subject’s 
IGRA test converts to positive or indetermina te (and confirmed indeterminate on repeat), or the 
subject’s questionnaire or history and physical indicates that TB infection or exposure may have PUBLIC ated aated 
clear forclear for
ive for ave for a
ulmonaryulmona
be dobe dCOPYomizm
nfirmed nfirmed
ear, the ar, the
ic treatmc treatm
afteft
This Ldocumenteenien
aire at Sire at S
r active active 
tions duions d
ither LTer LT
12.312.3cannotuestes
onnairennaire
subject ubject
individundividu
ing isng isbeion of ion of
tionntionusedy pp
cumentument
questiouestioto ny oy o
hysicihysicsupportpatieatie
ment. If tnt. If 
r notificanotific
signs of Tigns of 
old orldanyof thof 
ositive. Iositive.
ent mant mmarketing Period uneriod 
est xst x--ray ra
f TB infecTB inf
icularly cularly
he sheauthorization nal al 
ndss
oubts ubts 
y-specifspecif
colol--defindefin
application al wl w
excludedexclude
creening eening
TB (see ETB (see 
uring the sng th
B or activor actandwill asll as
who answho answ
withithany ns andns an
re will be will b
sistiextensions ati
TB.B.
r recent recent 
an. Any n. Any
d in the in the 
nnairenaireor e pre p
on to on tovariations(
ction (tion 
yx--rays)rays
subject. ubject.
If the sef the se
ay be iny be in
pretrepretrthereof. nless onnless o
or, if dor, if 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 119 of 263occurred. Evidence of active TB includes, in addition to the aforementioned tests, signs and 
symptoms of organ involvement. In either situation, the subject should be carefully assessed by a 
TB specialist for active TB. Subjects diagnosed with active TB must be withdrawn from the 
study and receive appropriate TB therapy.
If a TB specialist excludes an active TB infection the subject can proceed with the IMP no earlier 
than 4 weeks after the start of an  appropriate prophylactic therapy.
Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
TB must be reported as an SAE. The Investigator is to complete and submit the TB Follow-Up
Form provided.
The subject should be transferred to the care of his/her physician and managed according to the 
best available standard of care. Subjects identifi ed as having converted to active TB during the 
study must be withdrawn and scheduled to ret urn for the PEOT Visit as soon as possible but no 
later than the next scheduled study visit and complete all PEOT Visit assessments.
The subject should be encouraged to comple te a SFU Visit (20 weeks after the final dose of 
IMP).
If infection with NTMB is identified during th e study, the same procedure as for active TB 
acquired during the study must be followed.
12.3.2 Pregnancy testing
Pregnancy testing will consist of serum testing at the initial Screening. The pregnancy test will 
be urine at other visits, including at the OLE2 Screening Visit.
The Screening Visit serum pregnancy testing result s must be negative and received and reviewed 
prior to randomization.
A negative urine pregnancy test result should be obtained immediately prior to each 
administration of IMP at the visits specified in Table 5‒1, Table 5 ‒2,and Table 5-3 . Pregnancy 
tests should be administered to all female subjec ts of childbearing potential, regardless of their 
use of birth control.
Subjects of childbearing potential should conduct a home pregnancy test every 4 weeks. Home
pregnancy tests will be provided to participants for use at Weeks 60, 68, 76, 80, 88, 92, 100, 104,112, 116, 124, 128, 136, 140, and at the OLE2 Weeks 4, 8, 16, 32, and 40. At weeks on which 
IMP dosing is scheduled (specified in Table 5‒1, Table 5 ‒2,andTable 5-3) , a negative urine 
pregnancy test result should be obtained immedia tely prior to the administration of IMP. In the 
case of a positive pregnancy test result, IMP shoul d not be administered and the site should be 
contacted.
12.3.3 Vital signs
Vital signs will be collected at every visit and will include systolic and diastolic BP, pulse rate, 
and body temperature (oral, axillary, or otic). S ubjects should be sitting for 5 minutes before and 
during vital signs assessments.
Vital signs are to be measured prior to blood sa mpling, and prior to dosing, where applicable.PUBLICm testintestin
t the t the OLOL
gnancy gnancy COPYtudy, thtudy, t
ThisVdocument, ,
g is schis sch
ncy test ry test 
of a posf a po
ntactedtacted
12.3.12.3cannot aring poring po
will be pill be p
128, 128, 1bevisi
d to alld to alused result shesult s
its spts sptosting rting support g at the inat the i
2 2 ScreenScreenany same prsame pmarketingd acac
active TBactive T
soon as poon a
t assessmassess
weeks afteeks afauthorization ier er 
med actived activ
FollowFollow --UU
ccordcord
application rov
36, 1406, 140 ,
duled (spuled (s
esult shouesult sh
itive ive pregpre
VVand tential ntial shs
videdidedany ifiefi
emale sumale extensionsitial Sial 
ning Viing Vi
sults muults mu
ould beuld be
ed ined ior ScrSvariationsme
er the fithe fi
rocedurecedurthereof.ing to thg to th
B duringduring
possiblepossibl
nts.nts.
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 120 of 26312.3.4 12-lead electrocardiograms
Twelve-lead standard ECGs will be recorded at the visits specified in Table 5‒1and Table 5‒2,
and read by a central ECG reader.
Full details of ECG recording will be provided in the ECG Manual.
12.3.5 Physical examination
A physical examination will be performed at the visits specified in Table 5‒1,Table 5‒2, and 
Table 5-3 . The physical examination will include gene ral appearance; ear, nose, and throat; eyes, 
hair, and skin; respiratory; cardiovascular; ga strointestinal; musculoskeletal; and hepatic. 
Findings considered clinically significant changes since the physical examination at the 
Screening Visit will be recorded as AEs.
12.3.6 Height and body weightHeight will be measured at Baseline only.
Body weight will be measured at the visits specified in Table 5‒1, Table 5 ‒2, and Table 5-3 .
12.3.7 Assessment of suicidal ideation and behavior
Suicidal ideation and behavior will be assessed by  using the eC-SSRS; the questionnaire will be 
self-administered by the subject and assessed by trained study personnel. This scale will be used 
to assess suicidal ideation and behavior that may o ccur during the study. The visits at which the 
eC-SSRS assessments will be performed are sp ecified in the schedule of study assessments 
(Table 5‒1, Table 5 ‒2, and Table 5-3 ).
The eC-SSRS is a standardized and validated in strument developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
Subjects respond to standardized clinical questions  that are presented in a uniform fashion. The 
eC-SSRS defines 5 subtypes of suicidal ideati on and behavior in addition to self-injurious 
behavior with no suicidal intent. The eC-SSRS tak es approximately 3 to 10 minutes to complete.
Refer to Section 6.5for eC-SSRS-related withdrawal criteria.
12.3.8 Patient Health Questionnaire-9
The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring 
the severity of depression (Kroenke et al, 2001). The PHQ-9 scores for depression range from 0 to 27, with higher scores indicating worse state. A score of 5 to 9 is considered to be minimal 
symptoms of depression. A score of 10 to 14 is considered minor depression, dysthymia, or mild 
major depression. A score of 15 to 19 is considered to indicate moderately severe major depression, and a score ≥20 is considered to be severe major depres sion.
The PHQ-9 will be assessed at the visits specified in Table 5‒1, Table 5 ‒2, and Table 5-3 .
Refer Section 6.5for PHQ-9-related withdrawal criteria.PUBLIC esssedsed
or that mor that m
formed aformed a
lee55--33))
d andd aCOPY d in d in
ation aation
sed by sed by 
db ydb y
This Tdocumentis a ms a m
rity of dy of d
7, with , with 
mptoms ptoms
major dmajor d
deprdeprcannot l inin
for eCor eC
Patienttient
mubezed
es of sues of su
tenttenusedvalidavalida
al ideatioideati
d clinid clinito resupportusing theing th
trained srained 
may occuray occu
specifispecifany 55‒‒1,
d behabehmarketingnd 
nation aation a
TaTauthorization 55‒‒22, an, an
and thrond thro
hepahepa
application Heaea
tipipurposeurpo
pression ression
higher scogher sc
of depresf depre
pressionression
,a naandT
SSRSSRS--rere
alth althanyal l 
dal idedal id
he eChe eC -Sextensionsstu
r durindurin
ied in thied in th
d instrumd instrum
n and beand b
quesquesoreCC
dy pedy pvariations ableble55‒‒22
viorior
SSRSSthereof. at; eat
ic. . 
t the he 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 121 of 26312.4 Other study measurements
12.4.1 Demographic information
Demographic information will be collected in al l subjects and include age, gender, race and 
ethnicity. Information on demographics will be co llected according to local rules and regulations. 
Demographic information will be recorded in the eCRF.
12.4.2 Medical history
A complete medical history will be collected as  part of the initial Screening assessment and 
include all clinically relevant past or coexisting medical conditions and surgeries. Findings will be recorded in the eCRF. 
For OLE2 Group B, only new or modified medical  history since completing the SFU will be 
collected at OLE2 Screening and entered in eCRF.
12.4.3 Psoriasis historyA detailed history of each subject’s PSO history will be collected and include the date of onset 
and past treatments for PSO.
12.4.4 Data Monitoring and Adjudication Committees
The DMC membership includes experienced clinic ians and a statistician, all of whom have 
expertise in clinical trials. Cardiovascular a nd Neuropsychiatric Adjudication Committees will 
also periodically review data from this trial. Both Data Monitoring and Adjudication Committee 
members may not participate in the study as principal or co-Investigators, or as study subject care physicians. The DMC will monitor the study through the last subject completing the Week 
48 and SFU visit (for subjects not participating in the OLE period). 
The Cardiovascular and Neuropsychiatric Adjud ication Committees will monitor the study 
through the last subject completing the OLE, SFU, OLE2, and SFU2 Periods for PS0015. 
Detailed role, scope, responsibilities, and complete procedures, as well as the identity of 
members, are described in the separate committee charters.
13 STUDY MANAGEMENT AND ADMINISTRATION
13.1 Adherence to protocol
The Investigator should not deviate from the prot ocol. However, the Investigator should take any 
measure necessary in deviation from or not define d by the protocol in order to protect clinical 
study subjects from any immediate hazard to their health and safety. In this case, this action 
should be taken immediately, without prior notification of the regulatory authority, IRB/IEC, or 
sponsor.
After implementation of such measure, the Investigator must notify the CPM of the sponsor 
within 24 hours and follow any local regulatory requirements.
13.2 Monitoring
UCB (or designee) will monitor the study to meet the sponsor’s monitoring SOPs, ICH -GCP 
guideline, and applicable regulatory requirements,  and to ensure that study initiation, conduct, 
and closure are adequate. Monitoring of the st udy may be delegated by UCB to a CRO or a 
contract monitor.PUBLICr anr a
s trial. Btrial. 
study astudy a
monitor monito
not parnot paCOPY cation Cation 
d clinicid clinic
nd Nend N
Thiswdocument gator ator 
necessaecessa
subjectsubjects
ould be tuld be t
sponsorsponso
AfteAftcannot n 
DY MADY MA
Adheredhere
shoshbesibilitbili
the sethe seused ticipci
ychiatrichiatric
ing theng th
iesito the stuthe st
patinpatinsupport ans and ns and
uropsychropsyc
oth Data Mh Data
prprincipaincipa
udy udany ommittommitt
amarketingg the SFg the SF
d and incand inauthorization s. 
ent and nt and
Findinginding
application nce
uld not duld not
y in deviain dev
from anyfrom an
aken immken imm
mandANAGNAG
e to e toany and coand 
ararate comte com
Eextensions MoniMon
al or coor co
y throughthrough
g in the On the 
AdjuAdju dicdic
OLE, SLE, Soratric Aatric 
itoritovariations clude thlude th
teesees
tatisticatistic
Athereof. U will will bb
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 122 of 263The Investigator and his/her staff are expected to  cooperate with UCB (or designee) and to be 
available during the monitoring visits to an swer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source data/documents for study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg, hospital and laboratory records for each subject). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol requirements, applicable authorities regulations, and Investigator’s obligations are being fulfilled, and resolve any inconsistencies in the study records.
13.2.1 Definition of source data
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some perman ent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self-stick notes). Photocopies  and/or printouts of eCRFs are not considered 
acceptable source documents.
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or ot her printouts, completed scales, or QOL 
questionnaires, for example. Source documents shoul d be kept in a secure, limited access area.
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once pr inted, these copies should be signed and dated 
by the Investigator and become a permanent part of the subject’s source documents. The 
Investigator will facilitate the process for enab ling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.
Electronic data records, such as Holter monitor records or electroence phalogram records, must 
be saved and stored as instructed by UCB (or designee).
Electronic Patient-Reported Outc ome (ePRO) measures (eg, DLQI, EQ-5D-3L, Patient Global 
Assessment of PSO, and PGADA) will be completed by each subject and will be collected 
electronically.
The data collection and database management system  will be supplied by a vendor and will be 
compliant with the relevant regulations. The data collected on the ePROs will be uploaded to a
central server database and will be sent electronically to UCB (or a designated CRO).
13.2.2 Source data verificationSource data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to  being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], x-ray films, laboratory notes). All data reported on the eCRF should be supported by source documents, unless otherwise specified in Section 13.2.1 .PUBLICs, ,
or otherr othe
 documdocum
puter geputer ge
CG repoCG repo
aaCOPY nd/od/
hich rawhich raw
chartschart
ThisSdocument lly.y.
ta colleccollec
pliant wiant w
entral sentral se
13.213.2cannotsucuc
s instruinstru
-ReporRepor
PSO, aSO, abe in thethe
h as h asused rts). s). 
permanermane
rocess focess f
ec oec otoneratederate
OnOnsupport data arata ar
diaries, xdiaries
printouts,intout
ntstsshoulshou
da ndanytoutsout
re fmarketing ent, and cnt, and
ording (inding (i
r have tehave t
ofoauthorization progresprogres
ol 
re beinge being
application nd PGAd PGA
tion and dtion and
ith the relh the re
rver databver datandted byd by
d OutcOutc
ADAanymputeput
olter molter mo
UCUextensions , comcom
ld be kebe ke
nd stored store
ce printe printe
nt part opart o
r enablienabl
er ttorraysray
mplemplvariationsca
nk, typk, typ
emporaremporar
f eCRFs eCRFs 
rst st recorec
sthereof. apablepable
i
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 123 of 26313.3 Data handling
13.3.1 Case Report Form completion
The Investigator is responsible for prompt reporting of accurate, complete, and legible data in the 
electronic eCRFs and in all required reports.
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.
Corrections made after the Investigator’ s review and approval (by means of a 
password/electronic signature) will be reapproved by the Investigator.
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF.
Detailed instructions will be provided in the eCRF Completion Guidelines.
13.3.2 Database entry and reconciliation
Case Report Forms/external electronic data will be  entered/loaded into a validated electronic 
database using a clinical data management syst em (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to ch eck for discrepancies and to ensure consistency of 
the data. This study is performed using Electronic Data Capture: the data are entered into the 
eCRFs once and are subsequently verified. An electronic audit trail system will be maintained within the CDMS to track all data changes in the da tabase once the data have been saved initially 
into the system or electronically loaded. Regular backups of the electronic data will be 
performed.
13.3.3 Subject Screening and Enrollment log/Subject Identification Code list
Thesubject’s screening and enrollment will be rec orded in the Subject Screening and Enrollment 
Log.
The Investigator will keep a Subject Identifica tion Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the stud y must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s participation.
13.4 Termination of the study
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at a 
single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by the sponsor or by th e Investigator/institution, as specified by the PUBLICges in ges in
ded. Reged. Reg
eening eeningCOPY (CDM(CD
ck for dck for d
ronic Daronic D
An eleAn ele
th
This documentTeTe
reserveeserve
ngle sitegle site
safety osafety 
unsaunsacannot for uor 
nt and et and e
ta shoula shoulbea Subjea Subj
unaunaused andnd
lment wment wto d End Ensupport ta CapCap
tronic auonic 
e databasdataba
ular backuar backuany CompCom
crepancicrepanc
pturptumarketing nto to 
ines.nes.
ed into ad into
putauthorization the ehe e
application d id
erminatiminat
s the rightthe rig
multiple multipl
ethical ithica
oryand mbmb
nrollmenollmen
dentifentifanyIdentifIdenti
iguousguouextensionsse o
kups of ups of
rollmenllme
ill be recl be recor dit trdit 
once nce variations a validaa valida
terized terized 
cies and es and
e: the d: the d
railaithereof.ectronicctroni
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 124 of 263applicable regulatory requirement(s). In addition, ar rangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.
13.5 Archiving and data retention
The Investigator will maintain adequate records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug  dispensing and disposition records, safety 
reports, information regarding subjects who discontinued, and other pertinent data.
All essential documents are to be retained by the Investigator until at least 2 years after the last 
approval of a marketing application in an IC H region and until there are no pending or 
contemplated marketing applications in an ICH re gion, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB (Committee for Proprietary Medicinal Products [CPMP]/ICH/135/95, 2002 
[Section 4.9.5]). The Investigator will contact UCB for authorization prior to the destruction of 
any study records or in the event of accidental loss or destruction of any study records. The 
Investigator will also notify UCB should he/she relocate or move the study-related files to a location other than that specified in the sponsor’s trial master file.
13.6 Audit and inspection
The Investigator will permit study-related audits  mandated by UCB, after reasonable notice, and 
inspections by domestic or foreign regulatory authorities.
The main purposes of an audit or inspection are to confirm that the rights and well-being of the 
subjects enrolled have been protected, that enroll ed subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority  is announced, the Invest igator will immediately 
inform UCB (or designee).
13.7 Good Clinical Practice
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by the 
Investigator, institution, institution staff, or de signees of the sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompl iance may result in the termination of the 
site’s involvement in the study.
14 STATISTICS
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan (SAP).
14.1 Definition of analysis sets
The Enrolled Set will consist of all subjects who have given informed consent.
The Randomized Set (RS) will consist of all randomized subjects.PUBLIC latoryatory
spectionspectio
ected, thcted, th
iate for iate for
reporepCOPY ial mial 
udits mudits m
ya u
ThisAdocumentance wnce w
ator, insor, ins
CB to seB to se
e’s invo’s invo
1414cannoty a rega reg
signee).gnee).
Good Cood C
wiibe de direde direusedhehe
rted in ced in 
d IRB/IEIRB/Ito at enren
e studystudsupportandated bdated 
thorities.horities
are to core to c
nrolledrollany file.filemarketing shouho
rement(srement(
CPMP]/ICPMP]/
n prior to tprior to
of any stuany s
e the stue the sauthorization s, ,
fety ty 
r the lashe las
g or or 
lapsapsed sed s
uld uld
application Clinin
h the prothe pr
itution, inution, 
cure comure co
lvement inement
SSand latorato
icacaany t access t access
ry autry auextensions onfirm thfirm t
ed subjecsubje
, and thaand tha
ompliancmplianc
C SOPsC SOPsor y Uy Uvariationsth
udy redy re
udyudy--relarela
UCBUCBthereof. nce nc
be retainretain
s) or by or by 
CH/135CH/135
he deste des
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 125 of 263The Safety Set (SS) will consist of all subjects that received at least 1 dose of the IMP.
The Pharmacokinetics Per-Protocol Set (PK-PPS) consists of all randomized subjects who 
received at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose without important protocol deviations  that would affect the concentration.
The Full Analysis Set (FAS) will consist of all subjects in the RS that receive at least 1 dose of 
the IMP and have a valid PA SI measurement at Baseline.
The Maintenance Set (MS) will consist of all subjec ts that receive at least 1 dose of IMP at Week 
16 or later in the double-blind Treatment Period (including the Week 16 dose).
The Open-label Set (OLS) will consist of all subjects that receive at least 1 dose of IMP at Week 
48 or later in the OLE Period (including the Week 48 dose).
The OLE2 Period Set (OL2S) will consist of all subjects that receive at least 1 dose of IMP at the
Week 144/OLE2 Baseline or later in the OLE2 Period (including the Week 144/OLE2 Baseline 
dose).
The Per-Protocol Set (PPS) will consist of all subjects in the RS who had no important protocol 
deviations affecting the primary efficacy vari able. Important protocol deviations will be 
predefined and subjects with important protocol deviations will be evaluated during ongoing data cleaning meetings prior to unblinding of the data.
14.2 General statistical considerations
Summary statistics will consist of frequency tab les for categorical variables. For continuous 
variables, summary statistics will consist of the number of available observations, arithmetic 
mean, standard deviation, median, minimum,  and maximum unless stated otherwise.
The statistical analysis of the pr imary efficacy variable and selected secondary efficacy variables 
will account for multiplicity and control the familywise Type I error rate at a 2-sided alpha level 
of 0.05 by using a fixed sequence testing procedure. 
The hypotheses (H 1, H2, H3, H4, H5, and H 6) comparing bimekizumab vs secukinumab will be 
tested at a 2-sided alpha level of 0.05.
The first 2 hypotheses (H 1and H 2) test whether bimekizumab is  non-inferior and superior, 
respectively, to secukinumab for PASI100 response at Week 16. These are the hypothesis tests 
corresponding to the primary endpoint. If these hypoth eses are rejected at a 2-sided alpha level of 
0.05, that alpha will be passed to the next test in the sequence, allowing the testing procedure to proceed.
The hypotheses associated with the subsequent tests are for selected secondary efficacy 
endpoints and are based on testing for superiority relative to secukinumab. Figure 14 ‒1presents 
the details on this procedure.PUBLIC onson
equencyquency
consist consist 
ian, minian, min
rimrimCOPYImporImp
l deviatideviati
data.data
sideside
This document ng tog to
t alpha walpha w
ed.d.
he hypothypo
endpoiendpoi
the thecannotH
ha leveleve
eses (Hes (H
secukinsecuki
ot hot hbe ence
, H, H44usedary efficy effic
d controlcontrol
e tese testoof t
mum, amum, support rationsation
tables forables for
the numhe nuany protoprot
s will bs will bmarketing least 1 doast 1 d
Week 14Week 
who hawho 
coauthorization of 
MP at Wat W
of IMPof IMP
application numab mab
primary primar
will be pasl be p
heses asseses a
s and arand a
onand of 0.0f 0.0
and Hnd H 2
fofoany ng png 
5, and H, and H
05.5extensionsr categocateg
mber ofmber o
nd maxid max
acy variacy vari
the famhe fam
procproor variations ad no imad no i
ol deviaol devia
be evalue evaluthereof.at Wet W
ose of IMe of I
4//OLE2OLE2
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 126 of 263Figure 14 ‒1:Hypothesis testing
BKZ=bimekizumab; PASI=Psoriasis Area Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks
Note: Tests for H 1, H 2, H 3, and H 4are based on all subjects initially randomized to bimekizumab compared to 
secukinumab. For H 5and H 6, testing is based on the subjects re-randomized at Week 16 to bimekizumab 320mg 
Q4W, and bimekizumab 320mg Q8W, respectively, compared to secukinumab.
14.3 Planned efficacy analyses
14.3.1 Analysis of the primary efficacy variable
The analysis of the primary efficacy variable (PASI100 at Week 16) will be based on the RS. A 
stratified Cochran-Mantel-Haenszel (CMH) test  will be performed, where region and prior 
biologic exposure (yes/no) will be used as stratification variables. Region and prior biologic exposure have been selected as stratification variables in the analysis because they are 
stratification variables in the randomization and because they may have an impact on efficacy. 
Treatment comparisons between bimekizumab an d secukinumab will be made based on the 
CMH test using the p-value for the general asso ciation. For the assessment of non-inferiority, a 
non-inferiority margin of 10% will  be used and evaluated based on the CI for the stratified 
Mantel-Haenszel risk difference between bi mekizumab and secukinum ab. A non-inferiority 
margin of 10% has been selected as this is considered to be a clinically relevant difference that 
could influence the choice of interventions used  to treat chronic plaque PSO. Therefore, a 
difference within the 10% non-inferiority margin would suggest a similar impact on efficacy between the treatments.
Nonresponder imputation (NRI) will be used to a ccount for missing data in the primary analysis. 
Specifically, any subject who withdraws from IM P prior to Week 16 or who has missing data for 
the primary efficacy variables at the Week 16 time point will be considered a nonresponder. 
Based on previous studies of biologics in subjects with moderate to severe chronic plaque PSO, 
PUBLICSeverity Severity
ased on alsed on al
g is basedg is based
Q8W, resQ8W, res
CCCCCCCCCC 
CCCCCCCCCCCCCOOOOOOOOOOOOPPPPPPPPPPPPYYYYYYYYYYYY 
Thiscdocument n varivar
nt compacompa
test usinest usin
-inferioinferio
Mantelantel
margmargcannot mary ery
antelntel--HH
(yes/noyes/no
been seeen se
iabiabbef the he 
effieffused pectivctiv
acy ancy an
prtosub
n the sn the s
vely,elysuppndex; Q4Wex; Q4W
bjects injects 
bj
pppppppppppppoooooooooooorrrrrrrrrrrrtttttttttttt 
aaaaaaaaaaaaannnnnnnnnyyyyyyyyyyyy 
mmmmmmmmmmmmaaaaaaaaaaaarrrrrrrrrrrrkkkkkkkkkkkkkeeeeeeeeeeeettttiiiiiiiinnnnnnngggggg tion 
aaaaaaaaauuthorizati
application ected ted 
es in the res in th
risons besons b
g the pg the p -v
rity margity mar
Haenszel aenszel 
10%10%andcaca
aenszelnszel
will bewill be
asasany mary mary
y variay var
(Cextensions W=every 4every 
nitially raitially r
jects rets re-r
comparedmpared
alyseslyses
o
ooooooooorrrrrrrrrrrr  
vvvvvvvvvvvvaaaaaaaaaaaarrrrrrrrrrriiaaaaaaaaaaaaatttttttttttttiiiiiiiiiiiiioooooooooooonnnnnssssss 
thhhhhhhhheeeeeeeeeeereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 127 of 263it is expected that the number of subjects who di scontinue prior to Week 16 will be low. For the 
small percentage of subjects for whom primary endpoint data are unavailable at Week 16, this 
lack of data is suggestive of an ineffective IMP, thereby supporting the imputation of nonresponse. Therefore, NRI is considered an appropriate method for handling missing data 
since achieving the clinical response and making it through 16 weeks of IMP are both critical 
components of the primary outcome.
14.3.1.1 Sensitivity analysesThe primary efficacy analysis described in Section 14.3.1 will be repeated based on the FAS and 
the PPS.
As a sensitivity analysis to the primary analysis  method, logistic regression based on the RS will 
be used. The odds ratio of the responder rates at  Week 16 will be estimated and tested between 
treatment groups using a logistic regression mod el with factors of treatment group, region, and 
prior biologic exposure (yes/no). The odds ratio, a ssociated CI, and p-value based on the Wald 
test will be presented. If the logistic regression model is unable to converge, then prior biologic 
exposure may be dropped from the model to facilita te convergence. If the model is still unable to 
converge, then region may be removed from the model as well. As with the primary analysis, missing data will be handled using NRI.
The center-by-treatment interaction will be tested by replacing region with center in the logistic 
regression model described above and adding a center-by-treatment interaction term. In the 
model, center will be based on the original cente rs prior to pooling. However, if the model is 
unable to converge due to a low number of subjects  at a given center, a pooling (to be further 
described in the SAP) will be applied in order to allow the model to converge.
In order to obtain reasonable estimates of variabil ity for a treatment arm at a given center, a 
minimum of 10 subjects will be considered accepta ble for a center to be included in the model 
without pooling. Given the 1:1 randomization alloca tion scheme at the start of the study, this 
should provide a minimum of about 5 subjects in the bimekizumab arm and 5 subjects in the 
secukinumab arm. Centers with fewer than 10 subjects will be eligible for pooling. The 
following center pooling algorithm will be used for each geographic region:
xIf a center has 10 or more subjects, then no pooling will be done for that center.
xCenters with fewer than 10 subjects will be or dered from largest to smallest with pooling 
proceeding in the following manner:
Two or more centers will be combined until the cumulative subject total is at least 10.
Once a pooled center has at least 10 subjects, the process will continue in an iterative 
fashion for the subsequent centers in the ordered list, where a new pooled center begins each time at least 10 subjects has been reached in the previous pool.
If this iterative process reaches the end of the ordered list of centers where the final 
pooled center has fewer than 10 subjects, then the subjects from the centers in that pool 
will be combined with the pooled cent er formed in the previous iteration.
This procedure is only to be pe rformed within a geographic region –there will be no pooling of 
centers across regions.PUBLICdin
ginal ceinal c
mber of mber of
plied in lied in 
estimatestimat
ccCOPY odel de
ested byested by
ng a ceg a 
This documentding inng in
Two orwo or
OnOncannotng algog algo
10 or m0 or m
h fewefewe
tbe of aboabo
with fwith fused es of of
onsidereidere
randomandom
outoutto orderder
fv a rvarsupport replaceplac
nterter-byby-tr
ers prior rs prio
ubjects abjects 
r to alrt oanyll. Al. A
ingimarketingasedsed
and tesand tes
ment grouent gro
pvalue bavalue 
convergeonver
nce. If thce. If 
swsauthorization the FAShe FAS
d on on
application r than 1than 
he followifollo
more cenmore ce
ce a poolee a poo
shion fohion fo
ht ihand thm hm
re subjee subj
0anysubjsub
wer than wer than
will wilextensions r to po p
at a givea give
allow thelow th
iability fbility f
d acceptaaccept
ation ation a
ecoreatmeatm
poolpoovariationsa
e, then, then
he modehe mod
with the pth the p
regionregion
enthereof.he RS wRS w
ed betwd betw
up, regioup, regi
sed on ed on
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 128 of 263If the center-by- treatment interaction is not found to be significant ( α=0.10), then no further
analyses will be performed. On the other hand, if the interaction is significant, further analyses 
will be conducted to determine which center or ce nters may be the source of the interaction. This 
will be done by running the logistic regression mode l (including the interaction term) where each 
center will be systematically removed from the model. The impact of a given center will be 
based on the change in the interaction p-value when that center is removed. The center or centers that appear to be driving the significant interaction effect will then be removed from the model to verify that conclusions remain the same with or without the influential center(s). 
Additional sensitivity analyses to evaluate varying assumptions related to the handling of 
missing data will also be performed a nd are described in greater detail in Section 14.7 .
14.3.2 Other efficacy analyses
14.3.2.1 Analysis of the secondary efficacy variables
The secondary efficacy variables will be analyzed for all subjects in the RS.All secondary efficacy variables are binary. Therefore, the stratified CMH test (as specified for 
the primary analysis) will be implemented to test for superiority. As in the primary analysis, NRI 
will be used to account for missing data. Sensitivity analyses for handling missing data on 
secondary endpoints are outlined in Section 14.7 .
PASI75 response at Week 4 will be analyzed for all subjects in the RS based on the randomized 
treatment group at Baseline.
Additionally, PASI100 at Week 48 will be evaluated as a secondary efficacy variable. The way 
the analysis for this variable is conducted will depend on which comparison is being made. The 
planned comparisons are as follows:
xCompare all subjects initially randomized to bimekizumab (regardless of re-randomization 
assignment at Week 16) to all subjects initiall y randomized to secukinumab based on the RS 
(H
4)
xCompare subjects who were assigned to bimekizumab 320mg Q4W at Week 16 to 
secukinumab based on the MS (H 5)
xCompare subjects who were assigned to bimekizumab 320mg Q8W at Week 16 to 
secukinumab based on the MS (H 6)
14.3.2.2 Analysis of the other efficacy variables
Other efficacy variables will be summarized by treatment and visit and will generally be 
summarized based on imputed data (NRI and mult iple imputation [MI] for binary and continuous 
variables, respectively, unless otherwise stated in the SAP). In some cases, variables may also be 
summarized based on observed case data (ie, subjects with missing data or who have 
prematurely discontinued IMP are treated as mi ssing). There may be cases where the multiple 
imputation model fails to converge. In such situations, the last observation carried forward 
(LOCF) approach will instead be used to impute the missing data. If LOCF is used instead of 
multiple imputation for this reason, this will be clearly specified in the corresponding table 
summary. Should there be no missing data for a st udy variable, then only observed case data will 
be presented. Note that for LOCF imputation, an y missing data or data collected following PUBLIC  will bewill be
conducteonduct
ollows:ollows:COPYr sus
ity anality ana
.7.7.
ed for ad for a
Thispdocument mama
AA
r efficaceffica
ummarizmmariz
variablvariabl
sumsumcannotwho who w
sed on thd on 
bjects wects w
ab basb basbe werwerused randomandom
all subjl subjtod will d willsupport ll subjectsubje
valuatedaluated
depdeany ty. Aty.
es for hes for hmarketing n the RS.he RS
fied CMHfied CM
As inAsauthorization ters ers 
model to odel to 
ling of ng of 
n14.714.7.
applicationho w
ed on theed on th
nalysis olysis
y variablevariab
ed based base
, respecrespe
dbande asas
he MS (MS (
were wereany signedsigne
Hextensions d as a seas a se
pend onend on
ized to bed to b
ts initi initorin thin variations MH test (H test (
in the prthe pr
andling ndling
hehthereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 129 of 263discontinuation of IMP will be imputed with the most recent previous value. See Section 14.7 for 
further details.
Time to PASI75/90/100 response will be estimated and presented using the Kaplan-Meier 
product-limit method based on the RS by initia lly randomized treatment groups (Bimekizumab 
vs secukinumab). This could make the interpretati on of the data challenging given that there are 
two different bimekizumab dosing regimens starting at Week 16, but it is anticipated that most responses will be observed by Week 16 when al l bimekizumab subjects are on the same regimen. 
Time to a given response will be defined as the length in days from the first dose of IMP until the 
first date when the response is achieved. Subjects who discontinue IMP prior to achieving a response will be censored at the date of IMP discontinuation. Subjects who reach the Week 48
Visit without achieving the given PASI response will be censored at the date of the Week 48
Visit. The median time to response, including the 2-sided 95% CI, will be calculated for each 
treatment. Between group differences (bimekizumab  vs secukinumab) will be analyzed with the 
log-rank statistic.
In general, data will be summarized by vi sit through Week 48 in the double-blind Treatment 
Period and then by visit in the OLE Period and OLE2 Period separately. All summaries of data 
up to Week 16 will be based on the RS for the 2 randomized treatment groups (bimekizumab and 
secukinumab). For visits after Week 16 in the dou ble-blind Treatment Period, by-visit summaries 
will be prepared for the following 3 groups of subjects:
1. Subjects in the MS summarized by the 3 maintenance treatment groups (bimekizumab 
320mg Q4W, bimekizumab 320mg Q8W, and secukinumab). Note that while the MS isprimarily defined for the evaluation of data after Week 16, these summary tables will include 
data at all visits (Baseline to Week 48) to provide a comprehensive summary of subjects by 
maintenance treatment group for the MS.
2. A subset of Group 1 above. Specifically, this will include only those subjects who are 
responders at Week 16 for the variable being summarized. This will provide an assessment of 
how efficacy is maintained among Week 16 responders.
3. Subjects in the RS summarized by the 2 randomized treatment groups (bimekizumab and 
secukinumab). Data from Baseline  to Week 48 will be included in these tables. This provides 
an intent-to-treat analysis among all randomized subjects in the study through Week 48.
All efficacy variables in the double-blind Treatm ent Period will be summarized in the manner 
described for Group 1 and 3 above . Summaries for Groups 2 will be done only for a subset of 
efficacy variables, namely, PASI75/90/100, IGA Clear or Almost Clear, Scalp IGA Clear or 
Almost Clear, pp-IGA Clear or Almost Clear, mNAPSI75/90/100, and DLQI 0/1.
In the OLE Period, efficacy variables of interest generally will be summarized descriptively by 
the combined treatment regimen in the doubl e-blind Treatment Peri od and re-randomized 
treatment in the OLE.
In general, efficacy variables will be summariz ed using descriptive statistics by treatment group 
and scheduled visit during the OLE Period based on Baseline at beginning of the study unless 
otherwise specified. 
In the OLE2 Period, selected efficacy variables of interest will be summarized descriptively by 
OLE2 Period Treatment Group during the OLE2 Period.the 3 mhe 3 
mg Q8Wmg Q8W
uation ofuation of
o Week o Week 
oup foroup forCOPY2 2 
andomandom
doubledouble -b
of subjeof subj
ma
Thistdocumentvariar
for Grofor Gro
y variabvariab
most Cleost Cle
In the OIn the O
the cthe ccannotsummumm
Data froata fro
reat anaeat ana
iableablber th
ned amned amusedthe Mhe M
Sppecificecific
he vare vartoda
8) to p8) to 
MSMSsupport lin
ts:
ntenancetenanc
 and secuand secu
ata afterta aft
roanyepep
d treatmd treat
d Treatd Tremarketing of thf th
calculatecalculat
will be anill be a
n the doubthe dou
aratelaratauthorization e e 
ost st 
regimenegimen
MP untilP until
hieving eving 
h the Wthe W
he Whe W
application ys
s in the din the d
up 1 and 3p 1 and
les, nameles, nam
ar, pppp--IGAIG
LE PerioE Perio
eddand ized zed
m BaseliBasel
is ams amanyblbl
ng Weeg We
by thbyextensionse t
ukinumkinum
er Week r Week
ovide a cide a c
lly, thisy, this
e beieb e ior reatmeatmvariations blele--blinblin
ly. All sy. All s
ment grouent gro
atment Pment Pthereof. eekek4
Weekk4848
ed for eafor ea
nalyzed nalyzed
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 130 of 263Further details on the above analyses including analysis in the OLE Period and OLE2 Period will 
be provided in the SAP.
14.4 Subgroup analyses
Subgroup analyses will be performed on the primar y and secondary efficacy variables that are 
part of the fixed sequence testing procedure described in Section 14.2 . The following variables 
for subgroup analyses will be defined: age, gender, disease duration, region, weight, body mass index, prior systemic chemotherapy or photothe rapy, prior biologic exposure, prior primary 
failure to biologics, prior systemic therapy of any kind, Baseline disease severity, and antibody 
positivity. These summaries will be based on imputed data (NRI) and will include descriptive statistics only.
14.5 Planned safety and other analyses
14.5.1 Safety analyses
Safety variables will be analyzed for all subjects in the SS. This will include all subjects who 
took at least one dose of study medication. Selected analyses will also be presented for MS, 
OLS, and OL2S. Adverse events will be coded according to the Medical Dictionary for Regulatory Activities. Adverse events will be summarized descriptively by treatment group, 
primary system organ class, High Level Term (HLT), and PT. Additional tables will summarize 
AEs by intensity and relationship to IMP, AEs leading to withdrawal from the study, SAEs, and deaths. Safety topics of interest will be summarized  and will be described in greater detail in the 
SAP. 
Laboratory values (including markedly abnormal laboratory values), urinary values, vital signs, 
and extent of exposure will be presented desc riptively by treatment group. Definitions for 
markedly abnormal laboratory values  will be provided in the SAP.
14.5.2 Pharmacokinetic analyses
Pharmacokinetic variables will be analyzed for all subjects in the PK-PPS. Bimekizumab plasma 
concentrations will be summarized  for each treatment at each scheduled visit where samples are 
collected. 
14.5.3 Immunogenicity analyses
Anti-bimekizumab antibodies will be assessed us ing a tiered approach: screening, confirmatory, 
and titer assays will be used. Anti-bimekizumab antibodies (including positivity) will be summarized by treatment at each scheduled  visit at which samples are collected.
14.6 Handling of protocol deviations
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary efficacy, key safety, or PK/PD outcomes 
for an individual subject. The criteria for identifying important protocol deviations will be defined within the appropriate protocol-specifi c document at study start. Important protocol 
deviations will be reviewed as part of the ongoing data cleaning process and all important 
deviations will be identified and documented pr ior to unblinding to confirm exclusion from 
analysis sets.PUBLIC summumm
rkedly akedly a
e presente presen
valuvaCOPYordind
mmarizemmariz
m (HLT),(HLT
AEs leadEs lead
mar
Thisfdocumentzumum
ssays ways w
rized byzed by
6
ImportImport
meamecannot ummm
mmunogmuno
mab anab abewill bewill b
marizmariuseded ed
es will s will
tic anaic anato bnormnor
descrdescsupportand nd
ing to wg to w
zed and wed and 
rmal lmaanyhe Mhe M
descripdescrip
PT. APTmarketing will includl inclu
ll also bel also 
MediMeauthorization es 
mass mass 
mary ary 
d antibod antib
e descripdescri
applicationg
ntibodiesntibodie
ll be usedbe use
treatmentreatme
HandHan
t protocproto
iand enicitynicityany alyzedalyze
for eacfor eacextensions wi
laboratoaborato
ptively tively 
e providprovid
ysessesor hdrhd
ll be dl be variationsde all se all 
be presene prese
dical Diccal Dic
ptively bvely b
Additiondditio
rawarawthereof. tiv
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 131 of 26314.7 Handling of dropouts or missing data
Study variables with multiple components may have  rules to account for partial missing data of 
1 or more components. Such rules will be defined in the SAP. The following rules are outlined for cases where variables are completely missing, including partial missing data where the data handling rules conclude that the variable should be treated as completely missing.
The analysis of the primary efficacy variable will use NRI for handling of missing data. That is, 
subjects with missing data or who have discontinue d IMP prior to Week 16 will be considered as 
nonresponders for the primary analysis.
The following sensitivity analyses for the primary efficacy variable will be performed:
1. Missing data will be addressed by using MI (Markov-Chain Monte Carlo method for 
intermittent missing data, followed by monot one regression for monotone missing data) to 
evaluate the effect of the method for handling missing data on the analysis. The actual PASI 
scores will be imputed and then dichotomized to obtain the response status. The treatment 
differences for each imputed data set will subs equently be evaluated using the stratified 
CMH test as used in the primary analysis. The re sults from each of the imputed data sets will 
be combined for overall inference using Rubin’s rules, which acc ount for the uncertainty 
associated with the imputed values (Rubin, 1987). This will be done using SAS PROC 
MIANALYZE. This procedure assumes a missing at random pattern of missingness and corresponds to an estimand of the difference in outcome improvement if all subjects tolerated 
or adhered to treatment (Mallinckrodt et al, 2012). This is an estimand of efficacy to evaluate 
the de jure hypothesis. 
2. Another sensitivity analysis will be based on observed data at Week 16. Subjects with 
missing data or who have prematurely discontinue d IMP will be treated as missing. The same 
stratified CMH test as in the primary efficacy analysis will be used.
Further details on the MI procedures will be provided in the SAP.
Missing data for the secondary efficacy variables (which are all binary) will be imputed using 
NRI. Additionally, the 2 missing data-handlin g approaches described above for the primary 
efficacy variable will be used for the secondary efficacy variables. Additional missing data handling approaches may be described in the SAP.
For other continuous efficacy variables, MI will be  used to impute missing data when possible. If 
the imputation model cannot converge, LOCF will be  used. The MI procedure will be similar to 
sensitivity analysis #1 described above with th e following differences: (1) the imputation model 
will use the change from Baseline (instead of actual) values by visit and no dichotomization will 
be necessary; (2) instead of using the stratified CMH test, the imputed data sets will be combined 
and sim ple means and standard errors will be calculated using Rubin’s rules (via SAS PROC 
MIANALYZE). For calculation of other descriptive statistics such as the median, minimum and maximum, Rubin's rules do not apply. Multiple imput ation estimates will be computed by simply 
averaging the estimates from the multip le repetitions of the imputation algorithm. fer
odtodtetta
s will bewill be
premapremaCOPYn’s rulen’s ru
1987). T1987
a missina missin
ence ience
ThisMdocumentontinuntinu
utation mtion m
ivity anvity an
ll use thuse th
be necebe nece
and sand scannotondnd
e 2 mis2 mis
will be ull be u
aches mches m
uoube oceduedu
dary edary used urely rely
rimary emary e
uresurestobased oased 
yd idisupport g at ranat ra
n outcomoutcom
2012). T2012).
onanyee
which awhich 
s will bs will
ndomarketing o methmeth
tone missone miss
analysis. analysis
ponse statunse st
valuated uluated
ach ofach oauthorization hat is, hat is, 
sidered dered 
ormed:med:
application y bebe
s efficacyefficac
odel canndel can
alysis #1 dysis #1
e change fchange
ary; (2)ary; (2)
memanding dag da
ed for thd for th
e dedeanywill bwill 
cacy vacacy va
tat-hextensions This ihis 
observebserv
continuontinu
fficacy acacy 
bebeore imprimp
is ais avariations tus. Tus. 
using thing th
f the impthe im
cccount fount f
be donee done
m pattm pattthereof. for for 
sing dating dat
The actThe ac
TheThe
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 132 of 26314.8 Planned interim analysis 
An interim analysis is planned at Week 48 a nd Week 144, details of which will be documented 
in the SAP. Additional interim analyses may be performed (details of which will be documented in the SAP). Corresponding interim Clinical St udy Reports (CSRs) may be written. A final 
analysis and updated final CSR will be prepar ed once all data through the OLE2 Period and 
SFU2 Visit have been collected. 
14.9 Determination of sample size
A total of 700 subjects will be randomly assigned in a 1:1 ratio at Baseline to one of the following treatment groups:
xBimekizumab 320mg (350 subjects)
xSecukinumab (350 subjects)
The primary efficacy analysis is based on the comparison of bimekizumab to secukinumab for 
the primary efficacy variable of PASI100 res ponse at Week 16. The assumed responder rates for 
PASI100 at Week 16 are 60% and 44% for bimeki zumab and secukinumab, respectively. The 
assumed responder rate for bimekizumab is based on the Phase 2b PS0010 data. The 
assumptions related to the responder rates for secukinumab are based on those observed in the 
CLEAR study (Thaçi et al, 2015). The power to show statistical superiority of bimekizumab relative to secukinumab under these assumptions is 98% for the primary endpoint. The power for 
the non-inferiority comparison (with 10% non-inferiority margin) under these assumptions is 
>99%.
15 ETHICS AND REGULATORY REQUIREMENTS
15.1 Informed consent
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethica l principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information s hould be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by the Investigator (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
the Investigator.
Prior to participation in the study, the ICF should be signed and personally dated by the subject 
and by the person who conducted the informed consent discussion (Investigator or designee). 
The subject must receive a copy of the signed and dated ICF. As part of the consent process, 
each subject must consent to direct access to his/her medical re cords for study-related 
monitoring, auditing, IRB/IEC review, and regulatory inspection.
All subjects enrolling in the OLE Period will sign a new ICF. Similarly, all subjects enrolling in 
the OLE2 Period will sign a new ICF.
If the ICF is amended during the study, the Investigator (or the sponsor, if applicable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF by 
the IRB/IEC and use of the amended form.PUBLIC umptiumpt
10% no10% no
ND REND RECOPYumam
d on thed on th
secukinecuki
er to sher to sh
ionion
Thisdocument gator.ator.
o participartic
by the py the 
The subjhe subj
each seach 
mocannot ationio
nformedformed
rstandabstandab
h subjesubjebeus
uiremenuireme
no fno fused GUG
entt
t be ot be otoULATULAsupportumabma
ow statisw statis
s is 98% fis 98%
inferiorinferioranysecusec
hasehase 2b2b
b are ba rmarketing kizumab zuma
The assuThe as
ukinukauthorization of the the 
application le 
ct will hwill 
pation in tpation in
erson whson w
ect must rct must 
ect muct muand He
consentonsent
to theo theanyaia
 and thand t
lsinki.lsinkextensionsfo
rity maty ma
TORORY Y
ned nedorcalca
r the pr the variationsto seco sec
umed reumed r
numab, umab, 
PS001PS001
based oased 
l supls uthereof. k
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 133 of 263All studies conducted at centers in the United Stat es must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.
The subject may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the ICF. An eCRF must not be 
started, nor may any study specific procedure be performed for a given subject, without having 
obtained his/her written consent to participate in the study.
15.2 Subject identification cards
Upon signing the Informed Consent and Assent form (as applicable), the subject will be provided with a subject identification card in the language of the subject. The Investigator will fill in the subject identifying information and medical emergency contact information. The Investigator will instruct the subject to keep the card with him/her at all times.
15.3 Institutional Review Boards and Independent Ethics 
Committees
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical princ iples that have their origin in the Declaration 
of Helsinki.
The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or  applicable country-specific regulations will 
be responsible for the initial and continuing review  and approval of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copies of the protocol, ICF, IB, 
Investigator’s curriculum vitae (if applicable), advertisement (if applicable), and all other 
subject-related documents to be used for the st udy to the IRB/IEC for its review and approval.
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate appa rent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the Investigator to  obtain an expedited review by the IRB/IEC as 
allowed.
As part of the IRB/IEC requirements for continui ng review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropri ate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by the Investigator or the sponsor, as specified 
by the applicable regulatory requirements in each concerned country. Where applicable, PUBLIC ve
nuing reuing r
tor/UCBtor/UC
if applicapplic
be used be usedCOPY iplesiple
propriatpropriat
ersionersio
This documentnges es toto
l, it mayt may
ed.d.
As part os part o
will bwill b
reqreqcannotinvonv
te hazare hazar
will notwill not
pt wherwher
abepromptprompt
olvinolviused for or
stigator igator 
tocol.ocol.to able),le)
the stthe ssupport ely cony con
or applicr appli
view and ew and
will forwwill for
, advadanyhave have
stimarketing The he 
nt Ethicnt Eth
as definas defi
thethauthorization g
ill be prol be pro
will filwill fil
InveInv
application m
e necessneces
previouslreviou
be possibe poss
f the IRB/the IRB
sponsiponsandgg
ds to sus to s
ake anke aanyeport teport
risks toisks 
ubjbextensions apprppr
ward coard co
vertisemertisem
udy to thdy to th
willl havel havorable cble c
rovarovvariations ned in loed in lo
eir origir origi
uted IRuted IRthereof. in thin
stigatorgator
cs cs 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 134 of 263Investigators are to provide the sponsor (or its representative) with evidence of such IRB/IEC 
notification.
15.4 Subject privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned at Screening.
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical rec ords that directly concern s this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during the study).
15.5 Protocol amendments
Protocol changes may affect the legal and ethical  status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary objective.
Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being implemented.
16 FINANCE, INSURANCE, AND PUBLICATION
Insurance coverage will be handled  according to local requirements.
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.
17 REFERENCES
Augustin M, Glaeske G, Radtke MA, Christophers  E, Reich K, Schäfer I. Epidemiology and 
comorbidity of psoriasis in children. Br J Dermatol. 2010;162:633-6.
Christophers E, Barker JN, Griffiths CE, Daudén E, Milligan G, Molta C, et al. The risk of 
psoriatic arthritis remains constant following initia l diagnosis of psoriasis among patients seen in 
European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548-54.
Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. National Institutes of 
Health, National Cancer Institute, Divi sion of Cancer Treatment and Diagnosis. 
http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/ctc.htm. Updated 
03 Mar 2016.
CPMP/ICH/135/95 Note for guidance on G ood Clinical Practice (EMEA) Jul 2002.
Dowlatshahi EA, Wakkee M, Arends LR, Nijsten  T. The prevalence and odds of depressive 
symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134:1542-51.PUBLIC he
SURANURAN
ndled acndled a
tiotiCOPY ood od
be madbe mad
regulregu
This documenthritirit
dermatdermat
mon Teron Ter
ealth, Nalth, N
http://cthttp://c
0303MMcannotG, Rad Rad
iasis in asis in 
Barker Barker
s remsr ebeNCESNCE
tktkused coco
n rights rights
Sto C
rding rdingsupport e as an as an
atory authory au
CE, E, ANANanystudstu
ammarketing or hoho
eports forports fo
udy andudy an
dy fudyauthorization he relevareleva
portionportion
ut not limnot lim
ospitspit
application JN, GN, G
mains conains co
ology cliogy cli n
minologyinolog
tional Canonal C
p.cancer.cancer
66and e MAM
hildrenildren
GrifGrifany A, ChACextensions ND PUND PU
to local local 
are addre addororitieoritievariations d may ald may a
fulfillingulfilling
endmeendme
sthereof. mitedit
al 
r deaths deaths 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 135 of 263Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. 
J Dermatolog Treat. 2004;15(1):27-9.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial 
infarction in patients with psoriasis. JAMA. 2006;296:1735-41.
Gisondi P, Tessari G, Conti A, Piaserico S, Sc hianchi S, Peserico A, et al. Prevalence of 
metabolic syndrome in patients with psoria sis: a hospital-based case-control study. 
Br J Dermatol. 2007;157:68-73.
Gottlieb AB. Psoriasis: Emerging therapeutic strategies. Nat Rev Drug Discov. 2005;4:19-34.
Husni ME, Qureshi AA, Keonig AS, Pedersen R, Robertson D. Utility of the PASE 
questionnaire, psoriatic arthritis (PsA) pre valenece and PsA improvement with anti-TNF 
therapy: results from the PRISTINE tr ial. J Dermatolog Treat. 2014;25(1):90-5.
Icen M, Crowson CS, McEvoy MT, Dann FJ, Ga briel SE, Maradit Kremers H. Trends in 
incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60:394-401.
Kimball AB, Yu AP, Signorovitch J, Xie, J, Tsaneva M, Gupta SR, et al. The effects of 
adalimumab treatment and psoriasis severity on self-reported work productivity and activity 
impairment for patients with moderate to  severe psoriasis. J Am Acad Dermatol. 
2012;66(2):e67-e75.
Kroenke K, Spitzer RL, Williams JB. The PHQ- 9: validity of a brief depression severity 
measure. J Gen Intern Med. 2001;16:606 –13.
Krueger G, Ellis CN. Psoriasis –recent advances in understanding its pathogenesis and treatment. 
J Am Acad Dermatol. 2005;53(1 Suppl 1):S94-100.
Krueger G, Koo J, Lebwohl M, Menter A, St ern RS, Rolstad T. The impact of psoriasis on 
quality of Life. Results of a 1998 National Psori asis Foundation patient-membership survey. 
Arch Dermatol. 2001;137:280-4.
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US 
adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60:218-24.
Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, et al. Oral curcumin 
in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. 
J Am Acad Dermatol. 2008;58:625-31.
Langley RG, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality 
of life. Ann Rheum Dis. 2005;64(Suppl II):ii18 –ii23.
Mallinckrodt CH, Lin Q, Lipkovich I, Molenb erghs G. A structured approach to choosing 
estimands and estimators in longitudina l clinical trials. Pharm Stat. 2012;11:456-61.
Mukhtar R, Choi J, Koo JY. Quality-of-life is sues in psoriasis. Dermatol Clin. 2004;22:389-95.
Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG. Feasibility and 
validation of a Computer-Automated Columbia-Sui cide Severity Rating Scale using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224-8.The PHThe PH
6:6066:606 ––
–recent recent –
3(1 Su3(1 COPYva M,va M
selfself-frep
ere psorere pso
Thisdocument ment ont 
addDermDerm
ley RG,ey RG
life. Anfe. An
MallinMall
estestcannot. The pThe p
NHANHAN
h N, VaN, Va
of mof mbe 998
280280--4.4.usedppl 1)l 1)
Menter Menter 
8 Na8 Natodvancevanc
:SSsupport asis. Jsis. J
Q-9: valid9: val
.any pta SRpta S
rted worted wor
JA mJAmarketing ith anth ant
):9090--5.5.
remers Hemers 
based stubased 
Reauthorization 5;4:19;4:19 33
ASE SE 
titi
appnplication nVoorVoor
moderate toderate
atol. 2008ol. 20
Krueger GKruege
RheumRheum
odt Codt Cand evalenale
ES 20032003
rheheany onalna
nce onceextensionsdity oty o
in unden unde
94--100.100.
A, Stern  Stern
lP slP sor fafvariations tudy. udy. 
et al. Thet al. T
rk produk produ
m Acadm Acadthereof. TNF NF 
TrendTrend
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 136 of 263Ortonne JP. Redefining clinical response in psorias is: targeting the pathological basis of disease. 
J Drugs Dermatol. 2004;3:13-20.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM , Identification and Management of Psoriasis 
and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A 
systematic review of incidence and prev alence. J Invest Dermatol. 2013;133:377-385.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from 
three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-77.
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United 
States. J Am Acad Dermatol. 2014;70:512-6.
Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset 
psoriasis. Pediatric Dermatology. 2000; 17(3):174-78.
Reilly MC, Zbrozek AS, Dukes EM. The validity  and reproducibility of a work productivity and 
activity impairment instrument. PharmacoEconomics. 1993:4(5):353-65.
Rubin D.B. Multiple imputation for nonresponse in surveys. New York, NY: John Wiley and 
Sons. 1987.
Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of 
subjects with moderate to severe plaque ps oriasis: CLEAR, a randomized controlled trial. 
J Am Acad Dermatol 2015;73:400-09.
Valizadeh A, Khosravi A, Zadeh LJ, Parizad EG . Role of IL-25 in immunity. J Clin Diagn Res. 
2015;9(4):OE01 –OE04.
Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. Work productivity and healthcare 
resource utilization outcomes for patients on etanercept for moderate to severe plaque psoriasis: 
Results from a 1-year, multicentre, open-labe l, single-arm study in a clinical setting. 
Appl Health Econ Health Policy. 2012:10(5):343-53.
Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity 
and the prevalence of major medical comorbid ity: a population-based study. JAMA Dermatol. 
2013;149:1173-9.PUBLIC psorpso
.
LJ, PariLJ, Pari
au DauCOPYn survn su
numab inumab 
riasiriasi
This document cannotMehtaMehta
of majof majo
9.beentr
Policy. Policy.used, PoulinPoulin
r patientpatien
re, opre, oto adsupport superiosuperi
: CLEARCLEA
d EG. REG. any New Newmarketing sis with ais with a
lity of a wy of a
):353353-656
Yoauthorization gs from s from
266266--77.77
ts in thes in the
application and NN, KN, K
r medicamedicaany nn--l
12:10(52:10(
KimmKimextensions Role of IRole of I
CostelloCostell
s on etanon etan
abeabeora rana ranvariationswork pork p
.
York, NYork, NY
o usteo ustethereof. UnitU
adult ondult on
pro
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 137 of 26318 APPENDICES
18.1 Protocol Amendment 1
Rationale for the amendment
The primary rationale for this amendment was to  incorporate a re-randomization at Week 16 for 
subjects in the bimekizumab 320mg treatment arm. At Week 16 subjects in the bimekizumab 
320mg treatment arm will be re-randomized 1:2 to receive bimekizumab 320mg Q4W or 
bimekizumab 320mg Q8W.
The following additional changes were also made:
xAdd the number of subjects included in the summary of the completed study UP0042
xClarify the scalp IGA and pp-IGA efficacy response criteria
xMove the PHQ-9 variable from an other safety variable to an other efficacy variable
xAdded percent of subjects achieving mNAPSI75, mNAPSI90, and mNAPSI100 for subjects 
with nail PSO at Baseline as an other efficacy variable
xClarify that all study assessments should be performed prior to administration of IMP
xClarify the study visit windows
xClarify that the PGADA should be performed on all subjects at Baseline
xDefine mental healthcare professional
xClarify the assessment and management of TB wording
xClarify the drug accountability wording
xRevise the systemic retinoid washout period
xClarify that the same assessor should evaluate the subject at each assessment
xRemove the requirement for a rheumatologist evaluation for subjects with a PASE ≥47
xClarify the IMP restart/rechalleng e requirements in case of PDILI
xAdd the definition of the Enro lled Set and Maintenance Set
xRevise the statistical analysis based on the addition of re-randomization at Week 16
Minor spelling, editorial, and formatting changes were also made, and the List of Abbreviations 
was updated.
Modifications and changes
Change #1Section 1 Summary
During the Treatment Period, eligible subjects will be randomized 1:1 to receive one of the 
following blinded IMP regimens:
xBimekizumab 320mg administered subcutaneously (sc) every 4 weeks (Q4W)PUBLIC perforerfor
sionalsional
managemmanage
ility ilitCOPY ri
performeperform
rme
ThisCdocumente the sthe staa
r spellinspellin
as updateupdat
ModifModif
Ccannotement ment 
P restartrestar
finitionnitionbessessor ssessor
ffusedwordinordin
washowashtoment ofent osupport d on all suon all 
Tany prior toprior tmarketing udy Udy U
er efficacr effica
0, and mN, and mauthorization or r 
ab 
UP0UP0
application of the Ethe 
tistical anstical a
g, editoriaedito
d.
tions aions and r a ra r
rechalleechall
Eanyould evould e
rheumheuextensions su
TB wordword
periodperiodor bjects jectsvariations cy
NAPSI1NAPSI
o adminadminthereof. 0422
y variavaria
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 138 of 263xSecukinumab 300mg administered sc at Ba seline and Weeks 1, 2, 3, and 4 followed by
dosing Q4W
Subjects receiving bimekizumab 320mg will rece ive placebo sc on Weeks 1, 2, and 3 in order to 
maintain the blind. 
Approximately 350 subjects will be randomized to bimekizumab 320mg and approximately 
350 subjects will be randomized to secukinuma b. Investigational medicinal product will be 
administered at Baseline, Weeks 1, 2, 3, a nd 4 and then Q4W thereafter, until Week 44
(Treatment Period). All doses will be administered in the clinic.
Has been changed to:
During the first 16 weeks of the Treatment Period, eligible subjects will be randomized 1:1 to 
receive one of the following blinded IMP regimens:
xBimekizumab 320mg administered subcutaneously (sc) every 4 weeks (Q4W)
xSecukinumab 300mg administered sc at Base line and Weeks 1, 2, 3, and 4 followed by 
dosing Q4W
Subjects receiving bimekizumab 320mg will receive  placebo sc on Weeks 1, 2, and 3 in order to 
maintain the blind. 
Approximately 350 subjects will be randomized to bimekizumab 320mg and approximately 
350 subjects will be randomized to secukinuma b. Investigational medicinal product will be 
administered at Baseline, Weeks 1, 2, 3, a nd 4 and then Q4W thereafter, until Week 44
(Treatment Period). All doses will be administered in the clinic.
At Week 16 subjects in the bimekizumab 320mg treatment arm will be re-randomized 1:2 
to receive bimekizumab 320mg Q4W or bimekizumab 320mg every 8 weeks (Q8W). To 
maintain the blind after re-randomization , subjects in the bimekizumab 320mg Q8W 
treatment arm will receive placebo at Weeks 20, 28, 36, and 44. Subjects in the secukinumab arm will continue to receive secukinumab 300mg Q4W.
Change #2
Section 2.2.1.1 Completed studies
Five clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, UP0031 in 12 healthy volunteers, and UP0042 in healthy volunteers. 
Has been changed to:
Five clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, UP0031 in 12 healthy volunteers, and UP0042 in 48healthy volunteers. 
Change #3 
Section 2.2.1.2 Ongoing studiesSeven additional studies of bimekizuma b in the treatment of PSO are ongoing.ukinumukinu
2, 3, and2, 3, and
ll be adml be adm
bimekizbimekiz
mgmgCOPYeive plaeive pl
mized toized t
ThisUdocumentstu
plaque aque 
1 in 12 hin 12 
s been cbeen c
Five clFive cl
modmocannot ompletmplet
udies odies obe placlac
ntinuentinueusedumam
Q4W orW or
ndomizdomiz
ceboceboto minis
ab 3ab 3support bimekizbimek
b. Investi. Inve
4 and the and th
steredsterany bo sc onbo sc omarketing randomndom
weeks (Q4eeks (Q
1, 2, 3, a, 2, 3,authorization e e 
m
applicationf bimekf bimek
SO, RA0O, RA
ealthy voealthy v
hanged tanged
cal studal stu
laqand d studistudiany at Wat W
o receivo receiextensionsigatg
en Q4Wn Q4W
d in the cin the 
20mg tr0mg tr
bimekizimekiz
tion, suion, su
WeeWeeorumabuma
tionaionavariationsand 4 fod 4 fo
n WeeksWeek
b33thereof. zed 1:1 ed 1:1 
W)W)
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 139 of 263xPS0008 is a Phase 3, multicenter, randomized, double-blind, parallel-group, active-
comparator-controlled study to evaluate the ef ficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO.
xPS0009 is a Phase 3 randomized, double-blind, pl acebo- and active comparator-controlled 
study to evaluate the efficacy and safety of bimekizumab administered sc to adult subjects 
with moderate to severe plaque PSO.
xPS0010 is a Phase 2b, double-blind, placebo-controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and pharmacodynamics ( PD) of bimekizumab in adult subjects with 
moderate to severe chronic plaque PSO.
xPS0011 is a long-term extension study for subjects who completed PS0010 to assess the 
long-term safety, tolerability, and efficacy of bimekizumab.
xPS0013 is a Phase 3, multicenter, randomized withdrawal, double-blind, placebo-controlled 
study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque PSO.
xPS0016 is a Phase 2a, subject-blind, investigator -blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO.
xPS0018 is a long-term extension study for eligib le subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab.
xPS0014 is a Phase 3, multicenter, open-label study to assess the long-term safety, tolerability, 
and efficacy of bimekizumab in adult subjects  with moderate to severe chronic plaque 
psoriasis.
Has been changed to:
Eightseven additional studies of bimekizumab in the treatment of PSO are ongoing.
xPS0008 is a Phase 3, multicenter, randomized, double-blind, parallel-group, active-
comparator-controlled study to evaluate the ef ficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO.
xPS0009 is a Phase 3 randomized, double-blind, pl acebo- and active comparator-controlled 
study to evaluate the efficacy and safety of bimekizumab administered sc to adult subjects 
with moderate to severe plaque PSO.
xPS0010 is a Phase 2b, double-blind, placebo-controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and pharmacodynamics ( PD) of bimekizumab in adult subjects with 
moderate to severe chronic plaque PSO.
xPS0011 is a long-term extension study for subjects who completed PS0010 to assess the 
long-term safety, tolerability, and efficacy of bimekizumab.
xPS0013 is a Phase 3, multicenter, randomized withdrawal, double-blind, placebo-controlled 
study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to 
severe chronic plaque PSO.PUBLICy foy f
izumabzumab
nter, openter, ope
ab in adab in adCOPY or-blinb
b in adu in adu
or elior el
This xdocumenta
o evaluevalu
h moderamoder
PS0010S0010
safetsafet
mmcannot , mumu
olled stulled stu
moderatoderat
a PhasePhasebees of bof 
ulticulticused bimbimtola
t subjt subjsupport gible subjble sub
abel stubel s
tany udy toudy 
subjectssubjectmarketing 10 to 0 to
blind, plablind, p
ult subject subje
oeauthorization uate the te the 
ects withcts wit
assass
application 3 rando rand
te the effithe ef
te to sevete to sev
is a Phasa Pha
y, efficacyefficac
ate toate toandn
udy to edy to e
to seveo seveany ekizumkizu
er, rander, ra
vaextensions udy to audy to a
cts with s with 
morects frcts fvariations cts wis w
evaluateevaluate
s with mwith mthereof. ess the ss the 
aceboacebo -
ithth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 140 of 263xPS0014 is a Phase 3, multicenter, open-label study to assess the long-term safety, 
tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis.
xPS0016 is a Phase 2a, subject-blind, investigator -blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO.
xPS0018 is a long-term extension study for elig ible subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab.
Change #4Section 4.3.1 Other efficacy variables
The following bullet has been added:
xPercent of subjects achieving mNAPSI75, mNAPSI90, and mNAPSI100 for subjects with 
nail PSO at Baseline
Change #5
Section 4.3.1 Other efficacy variables
xScalp- specific Investigator’s Global Assessment (scalp IGA) response (0/1 and 0) at 
Week 16 for subjects with scalp PSO at Baseline
xScalp IGA response (0/1 and 0) for subjects with scalp PSO at Baseline
xPalmoplantar Investigator’s Global Assessment (pp -IGA) response (0/1 and 0) for subjects 
with palmoplantar PSO at Baseline
Has been changed to:
xScalp- specific Investigator’s Global Assessment (scalp IGA) response ( 0/1 and 0 Clear or 
Almost Clear with at least 2 category improvement relative to Baseline )at Week 16 for 
subjects with scalp PSO at Baseline
xScalp IGA response (0/1 and 0) for subjects with scalp PSO at Baseline
xPalmoplantar Investigator’s Global Assessment (pp-IGA) response ( 0/1 and 0 Clear or 
Almost Clear with at least 2 category improvement relative to Baseline ) for subjects with 
palmoplantar PSO at Baseline
Change #6
Section 4.3.1 Other efficacy variables
The following bullet has been added:
xChange from Baseline in Patient Health Questionnaire-9 (PHQ-9) scores
Change #7
Section 4.3.2 Other safety variables
The following bullet has been removed:PUBLIC O at BO at B
for subjor subjf
Global Global 
BaseliBaseliCOPY sessmenessmen
BaseBas
This documentCleaClea
oplantarplanta
nge #6ge #6
Section Section 
TheThcannponse onse notPSO SO 
onse (nse (nnar Inver Inve
rwrwbeor’s s
least 2 least 2
atatused ne
GloGlotoAssessAssessupportt (scalp I(scalp 
linene
cts with sts with
meany 
Gmarketing APSIAPSI 10010authorization he safete safet
application tigatorgato
with at leath at l
PSO at BPSO at 
4.3.1 Oth3.1 Oth
ingan0/1 and1 andnd Basas
1a n dandn
r’’any al Aal A
ategoryategory
elineelineextensionsscalp Pcalp P
ent (ppt (pp I
Assesseor GAAvariations 0 forfor
A) resA) resthereof. r subrs u b
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 141 of 263xChange from Baseline in Patient Health Questionnaire-9 (PHQ-9) scores
Change #8
Section 5.2.2 Treatment Period
During the 48-week Treatment Period, approximately 700 subjects will be randomized 1:1 to 
receive the following blinded IMP regimens:
xBimekizumab 320mg administered sc Q4W (350 subjects)
xSecukinumab 300mg administered sc at Base line and Weeks 1, 2, 3, and 4 followed by 
dosing Q4W (350 subjects)
Subjects receiving bimekizumab 320mg will rece ive placebo sc on Weeks 1, 2, and 3 in order to 
maintain the blind.
Has been changed to:
During the first 16 weeks of the 48-week Treatment Period, approximately 700 subjects will be 
randomized 1:1 to receive the following blinded IMP regimens:
xBimekizumab 320mg administered sc Q4W (350 subjects)
xSecukinumab 300mg administered sc at Base line and Weeks 1, 2, 3, and 4 followed by 
dosing Q4W (350 subjects)
Subjects receiving bimekizumab 320mg will rece ive placebo sc on Weeks 1, 2, and 3 in order to 
maintain the blind. 
At Week 16 subjects in the bimekizumab 320mg treatment arm will be re-randomized 1:2 
to receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W. To maintain the blind after re-randomization, subjects in the bimekizumab 320mg Q8W treatment arm will 
receive placebo at Weeks 20, 28, 36, and 44. Subjects in the secukinumab arm will continue 
to receive secukinumab 300mg Q4W.
Change #9Section 5.6 Schedule of study assessments
The schedule of study assessments is presented in Table 5‒1.
Has been changed to:
The schedule of study assessments is presented in Table 5‒1.At each visit, all study 
assessments should be performed prior to administration of IMP.
Change #10
Table 5‒1 Schedule of study assessments
Inclusion/exclusion X X
Significant past 
medical history and concomitant 
diseasesX XcPUBLIC 0mg willmg will
bimekizbimekiz
mg QmgCOPY350 sub350 su
BaselineBaseline
This documentchangechang
chedulehedule
sessmenessmen
ChangChancannot dule of sle of s
f studystudybe0, 2
00mg Q00mg usedumm
Q4W orW or
cts in ths in th
8, 368, 36to mab 32ab 3support and Wnd W
receive peceive pany cts)cts)
WeekWemarketing , 2, and, an
roximateloximatauthorization wed by wed by 
dd
application assessmssess
d to:to:
of study af study
ts shouldshoul
#1010and udy assdy asany andn
W.W.extensionsplaceboacebo
0mg tremg tre
bimekizmekiz
 bimekbimek
d 44d4 4or variationsly 700 y 700 
ks 1, 2, s 1, 2, thereof. 3 in ordein orde
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 142 of 263Physical examd, eX X X X X X
scalp IGAlX XX XlXlXlXlXlXl
Randomization X
Has been changed to:
Inclusion/exclusion X Xc
Significant past 
medical history and concomitant diseases X Xd
Physical examc, eX X X X X X
scalp IGAlX XlXlXlXlXlXlXlXl
Randomization X X
Change #11
Table 5‒1 Schedule of study assessments, footnotes a through d, o, and q
aVisit windows of ±3 days from the first dose from the Week 1 visit to the Week 24 visit. Visit 
windows of ±7 days from Week 28 through Week 48/PEOT. The SFU Visit window is -3 and +7 
days from the last dose.
bThe SFU Visit will occur 20 weeks after the last dose.
cEnsure no significant changes in medical history.
dIncludes evaluation of signs and symptoms of active TB and risk for exposure to TB.
oThe PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical 
history of PsA or PASE ≥47).
qThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled dosing 
visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the scheduled 
dosing visit. From Week 28 through the end of the study, including the SFU visit, the dosing 
window is ±7 days relative to the scheduled dosing visit.
Have been changed to:
aVisit windows of ±3 days from the first dose from the Week 1 visit to the Week 24 visit. Visit 
windows of ±7 days from Week 28 through Week 48/PEOT. The SFU Visit window is -3 and +
±7 days from the last doserelative to the scheduled visit date .
bThe SFU Visit will occur 20 weeks after the lastfinal dose.
cEnsure no significant changes in medical history .Includes evaluation of signs and 
symptoms of active TB and risk for exposure to TB.
dIncludes evaluation of signs and symptoms of active TB and risk for exposure to 
TB.Ensure no significant changes in medical history.PUBLIC gh g
ks afterks after
es in medes in me
ndndCOPY tnotes anotes a
se from se from
WeeWee
This documentn chanchan
t windowwindow
ndows odows o
±7 days7 days
bbThThcannotrom Bom B
through rough
m Week Week
ays relys relbe y 
7).)
asasused dicic
symptommptom
for subor subto h
al histal hissupport the Weee We
k 48/PEO48/PEO
e llast dast any hrough hrough
ekmarketing ggggtingtititinnn
kkkkeetieenauthorization atatrizatrizriziz
authriz
aauauau
application ative to ive to
ed to:d to:
ws of ±3 ds of ±3 
f ±7 days ±7 day
rom theom theapViandelinlin
Week 2Week 2
8 throuthrou
tany e throue thrextensions ose.ose.
ory.ry.
ms of actof ac
cts wits wiorT. TheT. Thvariations d, o, an, o, an
1 visit visitthereof. XXfe.
XXeeeoereeeerrr
tthhehr
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 143 of 263oThe PGADA is assessed onlyfor allsubjects with PsA at Baseline (defined as a past medical 
history of PsA or PASE ≥47). At all subsequent visits, the PGADA is only for subjects with 
PsA at Baseline (defined as a past medical history of PsA or PASE ≥47).
qThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled dosing 
visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the scheduled 
dosing visit. From Week 28 through the end of the study, including the SFU visit ,the dosing 
window is ±7 days relative to the scheduled dosing visit.
Change #12
Figure 5‒1: Schematic diagram
PASI100=Psoriasis Area Severity Index comple te response; PBO=placebo; Q4W=every 4 weeks; 
SEC=secukinumab; w=Week
Note: At Week 28 and all following visits, subjects on conti nuous treatment for at least 12 weeks with a persistent 
IGA score ≥3 over at least a 4 -week period are defined as nonresponders and should discontinue IMP.
PPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUBLIICCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC 
CCCCCCCCCCCCCCCCOPYYYYYYYY 
This docume100=Psor0=Pso
EC=secuC=secu
Note: At Note: A
IGAIGA
ent 
cccaaannot 
beeeeeeeeeeeeeee 
uuuuuuuuuuuuuusssssssssssssssssssssssssseeeeeeeeeeeeeeeeeeeeeeeeedddddddddd 
ttttttttttttttttttttttttttttttttttttttttttttoooooooooooooooooooooooooooooooooooooooo 
suppppppppppppppppppppppppppppppppppppppppppppppppppppooooooooooooooooooooooooooooooorrrrt 
anyyyyy 
mmmmmmmaaaaaaarrrkkkkkkeeeeeetttttting authorization ng 
a
applicaasis Area Sis Area
inumab; wnumab; 
Week 28 anek 28 an
≥3 ov≥3
catiooonnn 
andddddddddddddddddddddddddddddddddddddddddd 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnyyyyyyyyyyyyyyyyyyyyyyyyy 
eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeexxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxteeeeeeeeeeeeeennnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnssssssssssssssssssssssssssssssionss 
orrrr 
vvvariaaaaatttttiiooooooonnnnnnnsss of. 
tttthhhhhhhhhhhheeeeeereof.
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 144 of 263Has been changed to:
IGA=Investigator’s Global Assessment; IMP=investigational medicinal product; PASI100=Psoriasis Area 
Severity Index complete response; PBO=placebo; Q4W=every 4 weeks; Q8W=every 8 weeks;
SEC=secukinumab ; w=Week
Note: At Week 28 and all following visits, subjects on conti nuous treatment for at least 12 weeks with a persistent 
IGA score ≥3 over at least a 4 -week period are defined as nonres ponders and should discontinue IMP.
Change #13
Section 5.8.2 Dose selection
Bimekizumab doses ranging from 64mg to 480mg were evaluated in the Phase 2b multicenter, 
randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study PS0010. 
Bimekizumab 320mg was found to have an acceptab le safety profile, only required 2 injections 
per treatment administration, and achieved significant PASI responses at Week 12 (summarized 
in the IB). Furthermore, data from the Ph ase 2a multicenter, randomized, subject-blind, 
investigator-blind study PS0016 and PK/PD modeli ng in this PSO population indicates improved 
responses through Week 16. Therefore, a bimekizumab dose of 320mg Q4W was selected for 
this study.
Has been changed to:
Bimekizumab doses ranging from 64mg to 480mg were evaluated in the Phase 2b multicenter, 
randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study PS0010. 
Bimekizumab 320mg was found to have an acceptab le safety profile, only required 2 injections
per treatment administration, and achieved significant PASI responses at Week 12 (summarized 
in the IB). Furthermore, data from the Ph ase 2a multicenter, randomized, subject-blind, 
investigator-blind study PS0016 and PK/PD modeling in this PSO population indicates improved 
responses through Week 16. Therefore, a bimekizumab dose of 320mg Q4W through Week 16 
and 320mg Q4W or Q8W thereafter was selected for this study.
PUBLICinv
cebo; Q4cebo; Q
s, subjects, subject
period arperiod aCOestigaestig
COPYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 
ThisBdocumentblinli
throughrough
dy.y.
s been cbeen c
BimekBimek
randrancannotd, d,
was foas fo
nistratioistratio
ermore,more
nd stud stubeg fromrom
placebplacebused 66too
definedefinesupportional mednal me
W=every 4=every 
n continuconti
da s
rt 
any 
mmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmaaarrrrrrrrrrrrrrrrrrrkkkkkkkkkkkkkkkkkkkkkkkkkeeeeeeeeeeeeeeeeeetttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiinnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnng tion 
auttttthhhhhhoooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrriiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiizzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaatttttttttttttttttttttttttttttttiii
applicationdata
dy PS00dy PS0
WeekWeek 161
hanged tanged
umamab dob daa
dand nd to d to 
n, and acand a
a froa froany mg to mg to
controlcontro
havhaextensions weeee
uous treauous trea
s nonrespnonresp
4orinal pinal p
ks; ks;QQv
variattttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnssssssssssssssssssssssssssssssssssssssssssssssssssss 
thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 145 of 263Change #14
Section 6.2 Exclusion criteria
25. Presence of active suicidal ideation, or positive suicide behavior using the "Screening" 
version of the electronic Columbia Suicide Severi ty Rating Scale (eC-SSRS) and with either 
of the following criteria:
History of a suicide attempt within the 5 years prior to the Screening Visit. Subjects with
a history of a suicide attempt more than 5 years ago should be evaluated by a mental healthcare practitioner before enrolling into the study.
Suicidal ideation in the past month prior to th e Screening Visit as indicated by a positive 
response ("Yes") to either Question 4 or Question 5 of the "Screening" version of the 
eC-SSRS.
Has been changed to:
25a. Presence of active suicidal ideation, or pos itive suicide behavior using the "Screening" 
version of the electronic Columbia Suicide Severi ty Rating Scale (eC-SSRS) and with either 
of the following criteria:
History of a suicide attempt within the 5 years prior to the Screening Visit. Subjects with 
a history of a suicide attempt more than 5 years ago should be evaluated by a mental healthcare practitioner professional (eg, locally licensed  psychiatrist, psychologist, or 
master’s level therapist) before enrolling into the study.
Suicidal ideation in the past month prior to th e Screening Visit as indicated by a positive 
response ("Yes") to either Question 4 or Question 5 of the "Screening" version of the 
eC-SSRS.
Change #15
Section 6.3 Withdrawal criteria
9. A subject considered as having either a suspected new latent tuberculosis infection (LTBI) or 
who develops active TB or NTMB infection during the study (including but not limited to, 
conversion demonstrated by IGRA or othe r diagnostic means) must be immediately 
discontinued from IMP and a PEOT Visit must be scheduled as soon as possible, but not later than the next regular visit.
The subject must be permanently withdrawn if further examinations result in a diagnosis of 
active TB, or if the subject is diagnosed with LTBI with no initiation of prophylactic 
treatment, prematurely discontinues prophylac tic treatment, or, in the opinion of the 
Investigator or Sponsor, is noncompliant with prophylactic TB therapy.
Confirmed active TB is an SAE and must be captured on an SAE Report Form and provided 
to the Sponsor in accordance with SAE reporting requirements. As with all SAEs, periodic 
follow-up reports should be completed as per protoc ol requirements until such time as the TB 
infection resolves.
Additional information on TB policies is provided in Section 12.3.1 .PUBLIC onal nal 
ore enroore enro
ast montst mont
her Queher QueCOPY 5 years 5 year
han 5 yhan 5 y
(eg(eg
This document next next 
e subjectsubjec
active TBtive T
treatmtreatm
InvInvcannot d as has h
tive TBve TB
monstramonstr
d from from 
rerebeiteriaeria
havhavused stitoh prip
on 4 oon 4 supportpriori
ars ago rs ago
locally lically
ling into ng into
ior to iorany or to thr to marketing g" vers" ver
avior usinior us
Scale cale (eauthorization cts wis withth
mental ntal 
ed by ad by a
ii
application IMP anMP a
gular visitular vis
must be pmust be
B, or if theor if th
ent, premnt, pre
tigator gatorandingng
or NTMr NTM
ed by IGd by I
nddany eithereith
Bextensionsthe stuhe st
o the Scrthe Sc
r QQuestiuestiorhouho
ensedense
ddvariationsng the " the "
eCeC--SSRSSR
he Screee Scree
uld buld bthereof.positipositi
on of theof the
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 146 of 263Has been changed to:
9a. A subject considered as having either a suspected new latent tuberculosis infection (LTBI) or 
who develops active TB or pulmonary NTMB infection during the study (including but not 
limited to, conversion demonstrated by IG RA or other diagnostic means) must be 
immediately discontinued from IMP and a PEOT Visit must be scheduled as soon as 
possible, but not later than the next regular visit .
The subject must be permanently withdrawn if further examinations result in a diagnosis of 
pulmonary NTMB , active TB, or if the subject is diagnosed with LTBI with no initiation of 
prophylactic treatment, prematurely discontinues prophylactic treatment, or, in the opinion of 
the Investigator or Sponsor, is noncompliant with prophylactic TB therapy.
Confirmed active TB is an SAE and must be captured on an SAE Report Form and provided 
to the Sponsor in accordance with SAE reporting requirements. As with all SAEs, periodic 
follow-up reports should be completed as per prot ocol requirements until such time as the TB 
infection resolves.
Additional information on TB policies is provided in Section 12.3.1 .
Change #16Section 6.3 Withdrawal criteria
11. Subjects must be referred immediately to a mental healthcare professional and may be 
withdrawn from the s tudy based upon the Investigator’s judgment of benefit/risk for:
Active suicidal ideation as indicated by a positive response (“Yes”) to Question 4 of the 
“Since Last Visit” version of the eC -SSRS.
Moderately severe major depression as indicated by a PHQ-9 score of 15 to 19 if this 
represents an increase of 3 points compared to last visit.
Has been changed to:
11a. Subjects must be referred immediately to a mental healthcare professional (eg, locally 
licensed psychiatrist, psychol ogist, or master’s level th erapist) and may be withdrawn 
from the study based upon the Investigator’s judgment of benefit/risk for:
Active suicidal ideation as indicated by a positive response (“Yes”) to Question 4 of the 
“Since Last Visit” version of the eC -SSRS.
Moderately severe major depression as indicated by a PHQ-9 score of 15 to 19 if this 
represents an increase of 3 points compared to last visit.
Change #17
Section 6.3 Withdrawal criteria
12. Subjects must be referred immediately to  a mental healthcare professional and must be 
withdrawn for:
Active suicidal ideation as indicated by a positive response (“Yes”) to Question 5 of the 
“Since Last Visit” version of the eC -SSRS
Any suicidal behavior since last visit.tely ely
pon theon the
s indicatindicat
on of thon of th
or dorCOPY to a to a
This documente s
nce Lace La
ModerModer
reprrep
ChangChang
SecSecannot eferfe
trist, psrist, ps
y based ubased u
suicidauicidbe rredrredusedepressioressio
f 3 point pointtoed b
eCeC--SSSsupport mental heental 
Investigatvestig
by a poy a p
Rany marketingort Form rt Form
with all Sith all
nts until sts unti
12.3.12.3authorization nosis of osis of 
initiatioinitiatio
n the opithe op
applicationl ideatioideati
Visit” veVisit” 
ately sevetely sev
esents an ents a
#1717andimim
ycholocholo
pon theon theany mmediamed
gisextensionsator’s jr’s 
ositive rositive r
RS.S
n as indias indi
compacompaoralthcalthca
judjdvariations su
11.thereof. ni
and provnd prov
SAEs, peSAEs, p
uch uch timtim
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 147 of 263Severe major depression as indicated by a PHQ- 9 score ≥20
Has been changed to :
12a. Subjects must be referred immediately to a mental healthcare professional (eg, locally 
licensed psychiatrist, psychologis t, or master’s level therapist) and must be withdrawn for:
Active suicidal ideation as indicated by a positive respon se (“Yes”) to Question 5 of the 
“Since Last Visit” version of the eC -SSRS
Any suicidal behavior since last visit
Severe major depression as indicated by a PHQ- 9 score ≥20
COPY 
This document cannot be used to support any marketing authorization the he 
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 148 of 263Change #18 
Table 7‒1: Dosing scheme
Week
Dose AssignmentBaseline 
(first dose)1 2 3 4 8 12 16 20 24 28 32 36 40 44
Bimekizumab 
320mg●● ○○○○○○●●●●●●●●●●●●●●●●●●●●●●
Secukinumab 
300mg ▲▲ ▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲
Notes: A bimekizumab 160mg injection is depicted by a black circle ( ●). A placebo injection is depicted by a white circle ( ○). Asecukinumab 150mg
injection is depicted by a black triangle ( ▲).
Has been changed to:
Week
Dose AssignmentBaseline 
(first dose)1 2 3 4 8 12 16a20 24 28 32 36 40 44
Bimekizumab 
320mg●● ○○○○○○●●●●●●Q4W
●●●●●●●●●●●●●●●●
Q8W
●●○○●●○○●●○○●●○○
Secukinumab 
300mg ▲▲ ▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲
Q4W=every 4 weeks; Q8W=every 8 weeks
Notes: A bimekizumab 160mg injection is depicted by a black circle ( ●). A placebo injection is depicted by a white circle ( ○). Asecukinumab 150mg
injection is depicted by a black triangle ( ▲). 
aSubjects in the bimekizumab 320mg treatmen t arm will be re-randomized 1:2 to receive bimekizumab 320mg Q4W or bimekizumab 320mg  Q8W.PUBLIC 4
CCC UB
ICUUBUBUB
COPY injeinThis 
document 0mg mg
cannos depictedepicte
le (▲). e (▲). 
treatre
not tno
be ▲▲▲bebb
used ●●●●us
to oootosupport 8 122ppppup
any  depdemarketing 
ng●●●●ngngngrk
ng
▲▲▲▲rkrkrkrk
ictedicm
authorization 
a
2828ututtutapplication by
tment armment ar
and d
y a blaca bla
dddany y▲▲▲▲nyyyayexten●●●●extensions11sssnssioene
or o
variations ▲▲i
s
d by a whby a whiiio
thereof. 3232re●●●rereret
re
▲th
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 149 of 263Change #19
Section 7.6 Drug accountability
Blinded study staff may be delegated the responsibility to receive, inventory, and destroy the 
used kits. The packaging identifies each kit by a unique number that does not correlate to the 
contents and therefore, does not unblind stud y site staff. Unblinded study staff will be 
responsible for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial material, including recording the administration information on source document.
Has been changed to:
Blinded study staff may be de legated the responsibility to receive, inventory, and destroy 
the used kits. Unblinded study staff will be responsible for receipt, inventory, and 
destruction of used kits. The packaging identifies each kit by a unique number that does not 
correlate to the contents and therefore, does not unblind study site staff , but due to the 
commercial packaging of the comparator, the unblinded study staff will be responsible to 
maintain the blind . Unblinded study staff will be responsible for preparation (breaking tamper 
proof sticker on kit, etc) of the clinical trial ma terial, including recording the administration 
information on source document.
Change #20
Section 7.6 Drug accountability
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.
Has been changed to:
The Investigator mayshould assign some of the Investigator’s duties for drug accountability at 
the study site to an appropriate pharmacist/designee.
Change #21
Table 7-2 Prohibited psoriasis medications
Systemic retinoids 3 months 
Has been changed to:
Systemic retinoids 31month s
Change #22
Section 7.9 Blinding
For subjects receiving bimekizumab, bimekizumab will  be administered at Baseline; placebo will 
be administered at Week 1, Week 2, and Week 3; their second dose of bimekizumab will be at 
Week 4; and bimekizumab doses Q4W therea fter. Secukinumab subjects will receive 
secukinumab at Baseline, Week 1, Week 2, Week 3, Week 4, and Q4W thereafter.
Has been changed to:
For subjects receiving bimekizumab, bimekizumab will  be administered at Baseline; placebo will 
be administered at Week 1, Week 2, and Week 3; their second dose of bimekizumab will be at the Invehe Inv
esignee.esignee.
ssigssiCOPY 
Thisbdocumentretinoidetinoidtennge #22ge #22
Section ection 
For For cannot soriasoriasotnnged toged tocbe sissisusedn some some 
pharmacarmacto support tigator’s gator’any marketing y
ntory, ory, 
umber umber ththg
staffstaff , bubffket staff will aff wi
r preparaprepar
ecordinecordauthorization , and dand daua
application io
ca
7.9 Blindi9 Blind
sr eand medmedanany dicatioicatiextensionsdutieutie
f the Invthe In
st/desigt/desigor sffvariationsl be be
ation (bron (b
ng the ang the athereof.destroystroyfnd 
hat doest doeere ut due tut due 
respres
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 150 of 263Week 4; and bimekizumab doses Q4W thereafterthrough Week 16. At Week 16 subjects in 
the bimekizumab 320mg treatment arm will be re-randomized 1:2 to receive bimekizumab 
320mg Q4W or bimekizumab 320mg Q8W .To maintain the blind, subjects in the 
bimekizumab 320mg Q8W treatment arm will  receive placebo at Weeks 20, 28, 36, and 44.
Secukinumab subjects will receive secukinum ab at Baseline, Week 1, Week 2, Week 3, Week 4,
and Q4W thereafter.
Change #23Section 7.10 Randomization and numbering of subjects
The following was added:
At Week 16 subjects in the bimekizumab 320mg treatment arm will be re-randomized 1:2 to 
receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W. To maintain the blind after 
re-randomization, subjects in the bimekizumab 320mg Q8W treatment arm will receive placebo at Weeks 20, 28, 36, and 44. Subjects in the secukinumab arm will continue to receive secukinumab 300mg Q4W.
Change #24
Section 8 Study procedures by visit
xThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled 
dosing visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the 
scheduled dosing visit. From Week 28 through the end of the study, including the SFU visit,
the dosing window is ±7 days relative to the scheduled dosing visit.
xFor the SFU Visit (20 weeks after the final dose), the visit should occur no more than 3 days 
prior to the scheduled visit date and with in 7 days after the scheduled visit date 
(-3 days/+7 days).
Has been changed to:
xThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled 
dosing visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the scheduled dosing visit. From Week 28 through the end of the study, including the SFU visit,
the dosing window is ±7 days relative to the scheduled dosing visit.
xFor the SFU Visit (20 weeks after the final dose), the visit should occur no more than 
3 days prior to the scheduled visit date and within 7 days after the scheduled visit date 
(-3 days/+7 days) window is ±7 days relative to the scheduled visit date .
Change #25
Section 8.2.1 Baseline Visit
xInclusion/exclusion 
Has been changed to:
xInclusion/exclusion (includes evaluation of signs and symptoms of active TB and risk for 
exposure to TB)PUBLICWeekWee
ek 28 thr28 th
relative trelative 
ks after ks after 
t datet daCOPY ugh Weegh We
k 24k2 4
This document SFU VFU V
ys priorprioren 3days/+days/+mehange #ange 
SectiSecticannotfromro
m Week Week 
ng visit.g visit.
window ndow 
ViVibe m Bam Bausedand wind wtoe finale fina
thsupportk 4 is ±24 is ±
the dosinhe dos
ough the egh the
the schehe sche
dany 
2marketing ndomdom
intain thentain the
t arm willarm wi
continue ntinueauthorization ,,
izei
application s ±77
it (20 wet (20 w
to the sco the sat7days)days) wlic255
2.1 B21andthrouhrou
From Wrom W
7 daydayany line throine thro
ughghextensionsend ond o
eduled dduled d
dose), those), t
in 7 dayin 7 dayordada
g windwin
ftftvariations to ro 
ays reays rethereof. d 1:2 to1:2 to
e blinblind ad
l receivel receiv
receirece
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 151 of 263Change #26
Section 8.2.1 Baseline Visit
After completion of the above-mentioned pr ocedures, bimekizumab or secukinumab 
administration will occur.
Has been changed to:
After completion of the a bove-mentioned procedures, bimekizumab or secukinumabIMP
administration will occur.
Change #27
Section 8.2.2 Week 1 and Week 2 Visits (±3 days relative to Baseline)
After completion of the above- mentioned procedures, placebo or  secukinumab administration 
will occur.
Has been changed to:
After completion of the a bove-mentioned procedures, IMPplacebo or secukinumab 
administration will occur.
Change #28
Section 8.2.3 Week 4 Visit (±3 days relative to Baseline)
After completion of the above-men tioned procedures, administration of placebo or secukinumab 
will occur.
Has been changed to:
After completion of the above-menti oned procedures, administration of IMPplacebo or 
secukinumab will occur.
Change #29
Sections 8.2.4 Week 4 Visit (±3 days relative to Baseline), 8.2.5 Week 8 and Week 12 Visits 
(±3 days relative to Baseline), 8.2.7 Week 20 (±3 days relative to Baseline) and Week 28Visits (±7 days relative to Baseline), 8.2.8 We ek 24 Visit (±7 days relative to Baseline), 8.2.9 
Week 32 Visit (±7 days relative to Baseline), 8.2.10 Week 36 Visit (±7 days relative to 
Baseline), 8.2.11 Week 40 Visit (±7 days relati ve to Baseline), 8.2.12 Week 44 Visit (±7 days 
relative to Baseline)
After completion of the above -mentioned procedures, administration of bimekizumab or 
secukinumab will occur.
Has been changed to:
After completion of the above-menti oned procedures, administration of IMPbimekizumab or 
secukinumab will occur.
Change #30
Section 8.2.6 Week 16 Visit (±3 days relative to Baseline)PUBLIC ati
oned prooned pro
memCOPY s, ,
ve to ve to
ThisAdocument 8.2.112.11
to Base Base
r complcompl
cukinumukinu
HaHas bscannot VisitVisit
BaselinBaseli
elative tlative t
(±7±7dada
1W1Wbe t( ±t( ±usedntioned oned to support Baseline)aseline
cedures, aedures, any cecemarketing numab adumab ad
ebo orbo mauthorization MPP
application ys relatrela
eekeek40 V40 
ine)ne)
tion of thon of t
ab will ob will
chanchanand3d
e), 8.2., 8.2.
BaseliBaseli
titiany ays reays r
Wextensionsadmindmin
proceduroceduror iivariations r secukisecukitiothereof. dministrministr
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 152 of 263After completion of the above -mentioned procedures, admini stration of bimekizumab or 
secukinumab will occur.
Has been changed to:
At Week 16 subjects in the bimekizumab 320mg treatment arm will be re-randomized 1:2 
to receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W. After completion of the 
above-mentioned procedures, administration of IMPbimekizumab or secukinumab will occur.
Change #31
Section 8.4 Safety Follow-Up Visit (20 weeks after final dose, -3 days/+7 days), section title
8.4 Safety Follow-Up Visit (20 weeks after final dose, -3 days/+7 days)
Has been changed to:
8.4 Safety Follow-Up Visit (20 weeks after final dose, -3 days/+ ±7d a y s )
Change #32
Section 9 Assessment of efficacy
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp-IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had docu mented training on how to perform these 
assessments correctly. Preferably the same assessor should evaluate the subject at each 
assessment.
Has been changed to:
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp-IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had docu mented training on how to perform these
assessments correctly. Preferably t The same assessor should evaluate the subject at each 
assessment.
Change #33Section 9.11 PASE questionnaire
The Psoriatic Arthritis Screening and Evaluati on (PASE) questionnaire is a self-administered 
tool to screen for active PsA in patients with  PSO (Husni et al, 2014). The questionnaire consists 
of 15 items that are divided into a 7-item symp toms subscale and an 8-item functions subscale. 
Standardized responses are based on 5 categories relating to agreement (strongly agree [5], 
agree [4], no idea [3], disagree [2], and strongly disagree [1]). The total maximum score is 
75 points (symptom score: 35 points and function score: 40 points). Psoriatic Arthritis Screening 
and Evaluation questionnaire scores ≥47points are indicative of active PsA. Subjects with scores 
≥47 should be referred to a rheumatologist for evaluation.
Has been changed to:
The Psoriatic Arthritis Screening and Evaluati on (PASE) questionnaire is a self-administered 
tool to screen for active PsA in patients with  PSO (Husni et al, 2014). The questionnaire consists 
of 15 items that are divided into a 7-item symp toms subscale and an 8-item functions subscale. 
Standardized responses are based on 5 categories relating to agreement (strongly agree [5], PUBLIC me asme a
GA, mGA, m
phphCOPYpppp--IGAIG
an appron appr
documedocume
sse
This documentc AA
een n forfor
ems thams tha
ndardizeardize
greeree[4][4]
7575poipo
andandcannot SE quesE que
Arthritthritbe rablyableused NAPSAP
ysician, sician, 
ho has ho has 
ytytTuto SI,SIsupport priatria
nted traied tra
sor shoulor shouany hould bhould b
tely qelymarketing ays)ys)authorization the he 
occur.ccur.
), sectiosectio
applicationt
s Screens Screen
active PsAtive Ps
are dividare div
d responserespon
no idea [no idea
(symp(sympand onnairnnaianyhe same saextensions ld
and ppnd pp --II
or an apan ap
ad docud docu
meor ingng
evaluevaluvariations be perforperfo
qualifiedalifie
g on go nthereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 153 of 263agree [4], no idea [3], disagree [2], and strongly disagree [1]). The total maximum score is 
75 points (symptom score: 35 points and function score: 40 points). Psoriatic Arthritis Screening 
and Evaluation questionnaire scores ≥47points are indicative of active PsA. Subjects with 
scores ≥47 should be referred to a rh eumatologist for evaluation.
Change #34
Section 12.2.1.2.1 IMP restart/rechallenge
xThe rechallenge is approved by the UCB responsible physician, DMC, and a hepatologist. 
The hepatologist must be external to UCB but may be a member of the DMC. It is recommended that the hepatologist be a local he patology expert or the hepatologist treating 
the subject.
Has been changed to:
The rechallenge is approved by the UCB responsible physician, DMC, and a hepatologist. The 
hepatologist must be external to UCB but may be a member of the DMC. It is 
recommended that the hepatologist be a local hep atology expert or the hepatologist treating 
the subject.
Change #35
Section 12.3.1 Assessment and management of TB and TB risk factors
b. High risk of acquiring TB infection:
Known exposure to another person with active TB infection within the 3 months prior to 
Screening.
Time spent in a healthcare delivery setting or institution where individuals infected with 
TB are housed and where the risk of transmission of infection is high.
c. Latent TB infection (unless appropriate prophylax is is initiated at least 8 weeks prior to IMP 
dosing and continued to completion of prophylaxis):
The absence of signs, symptoms, or physical findings suggestive of TB infection with a 
positive IGRA test (or 2 indeterminate IGRA test results) and a chest x-ray (or other 
imaging) without evidence of TB infecti on. If the result of the IGRA test is 
indeterminate, the particular IGRA test previously performed may be repeated once; if positive or indeterminate on retest, the subject may not be randomized to IMP without 
further evaluation by a TB specialize and discussion with the Study Physician, if LTBI is 
identified. The retest must be done during the protocol-defined Screening window.
Note: If available, respiratory or other specim ens must also be smear and culture negative 
for TB (CDC diagnosis of LTBI) http://www.cdc.gov/TB/topic /testing/default.htm).
Has been changed to:
b. High risk of acquiring TB infection:
Known close exposure to another person with active TB infection within the 3 months 
prior to Screening.PUBLIC r person person
care dcareCOPY ent of Tnt of T
This documenterm
sitive otive o
further eurther 
identiden
NNcannotf signs,igns
RA test A test 
 withouwithou
minateinatebess a
o compo compusedeliveryvery
the riskhe risk
approapprto yssupportB and Tand T
with activth activany 
Bmarketing C, and a h, and a
f the DMhe DMar pert or tert ormaauthorization tologist.ogist.
t is is 
ologist tlogist t
applicationev
the partthe par
indetermindeterm
valuationvaluatio
fied. Theed. Th
ote: If avte: If av
TB TBand ymptmpt
or 2 indr 2 ind
videncdencany riata
tion of pon of
tomsomextensions ve TB ine TB in
etting oretting o
of transmf transm
te prepor rvariationsMC. It C. Itsthe hepthe hepon
risk fisk fthereof. reatinea
epatopatololo
is
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 154 of 263Time spent in a healthcare delivery setting or institution where individuals infected with 
TB are housed and where the risk of transmission of infection is high.
c. Latent TB infection (unless appropriate prophylax is is initiated at least 8 weeks prior to IMP 
dosing and continued to completion of prophylaxis):
The absence of signs, symptoms, or physical findings suggestive of TB infection with a 
positive IGRA test (or 2 indeterminate IGRA test results) and a chest x-ray (or other 
imaging) without evidence of TB infecti on. If the result of the IGRA test is 
indeterminate, the particular IGRA test previously performed may be repeated once; if positive or indeterminate on retest, the subject may not be randomized to IMP without 
further evaluation by a TB speciali stzeand discussion with the Study Physician, if LTBI 
is identified. The retest must be done during the protocol-defined Screening window.
Note: If available, respiratory or other specim ens must also be smear and culture negative 
for TB (CDC diagnosis of LTBI) http://www.cdc.gov/TB/topic /testing/default.htm).
Change #36
Section 12.3.1.1 Tuberculosis assessment by IGRA
If latent or active TB is identified, subject mu st undergo appropriate study-specified withdrawal 
procedures. 
Has been changed to:
If latent or active TB is identified, subject must unde rgo appropriate study-specified withdrawal 
procedures. 
Change #37
Section 12.3.1.3 Tuberculosis questionnaire
The following sentence was deleted:
Subjects with a latent or active TB infe ction must be withdrawn from the study.
Change #38
Section 12.3.1.4 Tuberculosis management
During the study, subjects who develop eviden ce of LTBI or active TB must immediately stop 
further administration of IMP and will be referred to an appropriate TB specialist (pulmonologist 
or infectious disease specialist) for further evaluation. Evidence of LTBI is defined as subject’s IGRA test converts to positive or indeterminate (and confirmed indeterminate on repeat), or the 
subject’s questionnaire or history and physical indicates that TB infection or exposure may have 
occurred. Evidence of active TB includes, in addition to the aforementioned tests, signs and
symptoms of organ involvement. In either situation, the subject should be carefully assessed by a 
TB specialist for active TB. Subjects diagnosed with active TB or LTBI should be withdrawn 
from the study and receive appropriate TB or prophylaxis therapy.
Has been changed to:
During the study, subjects who develop evidence of LTBI or active TB must immediately stop 
further administration of IMP and will be referred to an appropriate TB specialist (pulmonologist PUBLIC ubject mubject mCOPY AA
undergoundergo
This documenttudyud
ministrministr
ctious diious d
RA test cA test c
ubject’sbject’s
occurroccur
symsymcannot TubercTuberc
y, suby, subbe del
tive Ttive Tused uestionnestionn
letedetedto support must underst underany ppropripproprimarketing hy
reeningeening
mear and mear an
pic /testingc /testiauthorization a 
er er
d once; d once
IMP witMP wi
ysiciansician
application ul
bjects whjects wh
tion of IMon of I
sease spesease sp
onverts tonverts t
questionnuestion
EvideEvideand osis msis many infectioinfectioextensionsergo appgo ap
aireireor variations ng/
iate studate studthereofhou
, if LTif LT
windowindow
d cultured cultur
/defaudefau
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 155 of 263or infectious disease specialist) for further evaluation. Evidence of LTBI is defined as subject’s 
IGRA test converts to positive or indetermina te (and confirmed indeterminate on repeat), or the 
subject’s questionnaire or history and physical indicates tha t TB infection or exposure may have 
occurred. Evidence of active TB includes, in addition to the aforementioned tests, signs and 
symptoms of organ involvement. In either situation, the subject should be carefully assessed by a 
TB specialist for active TB. Subjects diagnosed with active TB or LTBI should must be 
withdrawn from the study and receive appropriate TB or prophylaxis therapy.
Change #39
Section 14.1 Definition of analysis sets
The following sentence has been added:
The Enrolled Set will consist of all subjects who have given informed consent.
Change #40
Section 14.1 Definition of analysis setsThe following sentence has been added:
The Maintenance Set (MS) will consist of all subjec ts that receive at least 1 dose of IMP at Week 
16 or later in the Treatment Period (including the Week 16 dose).
Change #41
Figure 14-1 Hypotheses testing of secondary efficacy endpoints
PUBLIC of secoof seco
PPPPPPPPPPPPUCOPY bjects thjects th
g the Wehe W
This docu
ument 
cccccccaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnoooooooooooooottttt 
be 
ussssed to ndardar
tosupport ek 16k 16
ry effry eany receivereceive
6 dosdomarketing nsent.sent.authorization a 
appliiiiiiicccccccaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaatttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiioooooooooooooooooooooooonnnnnnnn 
and 
aaaaaannnnnnnnnnyyyyyyyyyyyy sions ficacy ecacy e
eeeeeeeeeeeexxxxxxxxxxxxtensor variations e at leasat leas
e).e).thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 156 of 263Has been changed to:
BKZ=bimekizumab; PASI=Psoriasis Area Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeksNote: Tests for H
1, H 2, H 3, and H 4are based on all subjects initially randomized to bimekizumab compared to 
secukinumab. For H 5and H 6, testing is based on the subjects re-randomized at Week 16 to bimekizumab 
320mg Q4W, and bimekizumaba 320mg Q8W, respectively, compared to secukinumab.
Change #42
Section 14.3.1.1 Sensitivity analysis
In order to obtain reasonable estimates of variabil ity for a treatment arm at a given center, a 
minimum of 10 subjects will be considered accepta ble for a center to be included in the model 
without pooling. Given the 1:1 randomization allo cation scheme, this should provide a minimum 
of about 5 subjects in the bimekizumab arm and 5 subjects in the secukinumab arm. Centers with 
fewer than 10 subjects will be eligible for pooli ng. The following center pooling algorithm will 
be used for each geographic region:
Has been changed to:
In order to obtain reasonable estimates of variabil ity for a treatment arm at a given center, a 
minimum of 10 subjects will be considered accepta ble for a center to be included in the model 
without pooling. Given the 1:1 randomization allocation scheme at the start of the study , this 
should provide a minimum of about 5 subjects in the bimekizumab arm and 5 subjects in the secukinumab arm. Centers with fewer than 10 subjects will be eligible for pooling. The following center pooling algorithm will be used for each geographic region:
Change #43
Section 14.3.2.1 Analysis of the secondary efficacy variables
PUBLICea Severia Seve
based onbased on
ing is baing is ba
a 320mga 320mg
CCCCCCCCCC 
CCCCCCCCCCCCCOOOOOOOOOOOOPPPPPPPPPPPPYYYYYYYYYYYY 
Thissdocuments
r each each 
een chaen cha
order torder to
minimuminimu
withwitcannotab
cts willwill
iven theven the
cts in ths in th
ubjectbjectbe ana
le estile estiused Q8WQ8W
alysislysitoall 
d on thd on t
W, reWrsuppy Index; QIndex; 
subjectsubje
es
pppppppppppppoooooooooooorrrrrrrrrrrrtttttttttttt 
aaaaaaaaaaaaannnnnnnnnyyyyyyyyyyyy 
mmmmmmmmmmmmaaaaaaaaaaaarrrrrrrrrrrrkkkkkkkkkkkkkeeeeeeeeeeeettttiiiiiiiinnnnnnngggggg tion 
aaaaaaaaauuthorizati
applicatione bi
s will bes will b
eographicograph
nged to:ged to
obtain reobtain r
m of 10of 10
olinand e concon
1:1 rand:1 rand
mekimekiany ates of vates of 
nsidesidextensions Q4W=eveW=ev
ts initialls initia
subjects bjects 
pectivelyectively
o
ooooooooorrrrrrrrrrrr  
vvvvvvvvvvvvaaaaaaaaaaaarrrrrrrrrrriiaaaaaaaaaaaaatttttttttttttiiiiiiiiiiiiioooooooooooonnnnnssssss 
thhhhhhhhheeeeeeeeeeereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 157 of 263The following has been added:
PASI75 response at Week 4 will be analyzed for all subjects in the RS based on the randomized 
treatment group at Baseline.
Additionally, PASI100 at Week 48 will be evaluated as a secondary efficacy variable. The way 
the analysis for this variable is conducted will depend on which comparison is being made. The 
planned comparisons are as follows:
xCompare all subjects initially randomized to bimekizumab (regardless of re-randomization 
assignment at Week 16) to all subjects initiall y randomized to secukinumab based on the RS 
(H4)
xCompare subjects who were assigned to bimekizumab 320mg Q4W at Week 16 to 
secukinumab based on the MS (H 5)
xCompare subjects who were assigned to bimekizumab 320mg Q8W at Week 16 to 
secukinumab based on the MS (H6)
Change #44
Section 14.3.2.2 Analysis of the other efficacy variables
Other efficacy variables will be summarized by treatment and visit and will generally be 
summarized based on imputed data (NRI and mult iple imputation [MI] for binary and continuous 
variables, respectively, unless otherwise stated in the SAP). In some cases, variables may also be 
summarized based on observed case data (ie, subjects with missing data or who have 
prematurely discontinued IMP are treated as mi ssing). There may be cases where the multiple 
imputation model fails to converge. In such si tuations, the last observation carried forward 
(LOCF) approach will instead be used to impute the missing data. If LOCF is used instead of 
multiple imputation for this reason, this will be  clearly specified in the corresponding table 
summary. Should there be no missing data for a study variable, then only observed case data will 
be presented. Note that for LOCF imputation, an y missing data or data collected following 
discontinuation of IMP will be imputed with the most recent previous value. See Section 14.7 for 
further details.
Time to PASI75/90/100 response will be estimated and presented using the Kaplan-Meier 
product-limit method for each treatment. Time to a given response will be defined as the length 
in days from the first dose of IMP until the first date when the response is achieved. Subjects 
who discontinue IMP prior to achieving a res ponse will be censored at the date of IMP 
discontinuation. Subjects who reach the Week 48 Visit without achieving the given PASI 
response will be censored at the date of the Week 48 Visit. The median time to response, 
including the 2-sided 95% CI, will be calculated for each treatment. Between group differences 
(bimekizumab vs secukinumab) will be analyzed with the log-rank statistic.
In general, data will be summarized by visit through Week 48. However, for PASI responder 
variables (PASI75, PASI90, PASI100) and IGA responder variables (IGA 0/1, IGA 0), as well as 
selected other efficacy variables, summaries w ill be prepared for time points between Weeks 16
and 48 among those subjects who were responders  at Week 16. Further details will be provided 
in the SAP.
Has been changed to:PUBLICe statee state
data (iedata (ie
e treatede treated
verge. Inverge. In
be ubeCOPYvariablvariab
by treatby treat
nd muld mu
d
This documentm the the 
continuentinue
ntinuatioinuatio
sponse wonse w
includinincludi
(bim(bimcannot willwil
90/100 r0/100 
method ethod 
firfibem
LOCFLOCF
 be i be usedsu
ed to id to i
on, this w, this 
issingssing
itoas m
uch situch sisupport ment aent a
iple impuple im
in the SAn the S
subjectssubject
missinmisany andandmarketing Week 16eek 1
8W at WeW at Wauthorization he 
mizationzation
ed on thd on th
66
application for eachr eac
st dose ofdose o
IMP prioMP pri
n. Subjec. Subj
ill be cenl be ce
the 2the 2 -sii
maband sponsepons
hhanyat
putatioputati
puted wuted wextensionsAP).)
s with mwith m
ng). Theg). Th
uationtions, s,
pute thepute the
will be cll be cl
ta for a forortationtatio
 In sIn svariations ee
visit anisit an
n[thereof. to 
ek 16 tk 16 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 158 of 263Other efficacy variables will be summarized by treatment and visit and will generally be 
summarized based on imputed data (NRI and multiple imputation [MI] for binary and continuous 
variables, respectively, unless otherwise stated in the SAP). In some cases, variables may also be 
summarized based on observed case data (ie, subjects with missing data or who have 
prematurely discontinued IMP are treated as mi ssing). There may be cases where the multiple 
imputation model fails to converge. In such situations, the last observation carried forward 
(LOCF) approach will instead be used to impute the missing data. If LOCF is used instead of 
multiple imputation for this reason, this will be  clearly specified in the corresponding table 
summary. Should there be no missing data for a st udy variable, then only observed case data will 
be presented. Note that for LOCF imputation, an y missing data or data collected following 
discontinuation of IMP will be imputed with the most recent previous value. See Section 14.7 for 
further details.
Time to PASI75/90/100 response will be estimated and presented using the Kaplan-Meier 
product-limit method for each treatment. Time to a given response will be defined as the 
length in days from the first dose of IMP until the first date when the response is achieved. 
Subjects who discontinue IMP prior to achieving a response will be censored at the date of 
IMP discontinuation. Subjects who reach th e Week 48 Visit without achieving the given 
PASI response will be censored at the date  of the Week 48 Visit. The median time to 
response, including the 2-sided 95% CI, will  be calculated for each treatment. Between 
group differences (bimekizumab vs secukinumab) will be analyzed with the log-rank 
statistic.
In general, data will be summarized by visit through Week 48. However, for PASI 
responder variables (PASI75, PASI90, PASI100) and IGA responder variables (IGA 0/1, 
IGA 0), as well as selected other efficacy var iables, summaries will be prepared for time 
points between Weeks 16 and 48 among those subjects who were responders at Week 16.
Further details will be provided in the SAP.
Time to PASI75/90/100 response will be estimated and presented using the Kaplan-Meier 
product-limit method based on the RS by initially randomized treatment groups 
(Bimekizumab vs secukinumab). This could make the interpretation of the data 
challenging given that there are two different bimekizumab dosing regimens starting at Week 16, but it is anticipated that most respon ses will be observed by Week 16 when all 
bimekizumab subjects are on the same regimen. Time to a given response will be defined as 
the length in days from the first dose of IMP until the first date when the response is achieved. Subjects who discontinue IMP prior to achieving a response will be censored at 
the date of IMP discontinuation. Subjects who reach the Week 48 Visit without achieving 
the given PASI response will be censored at th e date of the Week 48 Visit. The median time 
to response, including the 2-sided 95% CI, will  be calculated for each treatment. Between 
group differences (bimekizumab vs secukinumab) will be analyzed with the log-rank 
statistic.
In general, data will be summarized by visi t through Week 48. All summaries of data up to 
Week 16 will be based on the RS for the 2 randomized treatment groups (bimekizumab 
and secukinumab). For visits after Week 16, by-v isit summaries will be prepared for the 
following 3 groups of subjects:PUBLIC zed by vzed by vBLPASI90PASI9UB ther effther efPUd4 8d4PCOPY eekeek4Y the Wethe WePY ill be cal be caOP kinumainumaCO
Thisdocumentb 
 in dayn day
ed. Subjd. Sub
date of Ite of 
he givengiven
to respto resp
grogrocannotas
ukinukinu
that thehat the
is antics anti
subjeubjebesponsons
ed oned onused in thin tsedcaccad amongmonged di nt h ein thse
ewto PASPASocy vacy vatosupport culatulatb) will bwill or
sit throuit throusuSI10SI1sany sit wisit wy48 Vis48 Visanyted fedamarketing ee
sing the Kng theeti nse will be will kehen the ren thearwill bewill bmithitauthorization d of of 
able ble 
case dataase dat
follllowinowin
SectiSecti
applicationipap
ts are ots are 
from thefrom t
ects who ects wh
MP discoMP disc
PASI resASI r
nse, incse, inand ab). Tb). 
re are twe are t
ated tted tany ll be ell be
he RS bhe RS b
ThisThextensions ugh Wegh Wens00) and 0) and ioriables, ables,nsthose suhose sute SAP.SAP.exor anaanrvariationsbe 
responesponns e censorcensoronhout achhout achati it. The. Theriafor eachor eachvaalyalyvthereof.g g
n14.714.7
KaplanKaplanhedefindefinth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 159 of 2631. Subjects in the MS summarized by the 3 maintenance treatment groups (bimekizumab 
320mg Q4W, bimekizumab 320mg Q8W, and secukinumab). Note that while the MS is
primarily defined for the evaluation of d ata after Week 16, these summary tables will 
include data at all visits (Bas eline to Week 48) to provide a comprehensive summary of 
subjects by maintenance treatment group for the MS.
2. A subset of Group 1 above. Specifically, this will include only th ose subjects who are 
responders at Week 16 for the variable bein g summarized. This will provide an 
assessment of how efficacy is ma intained among Week 16 responders.
3. Subjects in the RS summarized by the 2 randomized treatment groups (bimekizumab 
and secukinumab). Data from Baseline to Week  48 will be included in these tables. This 
provides an intent-to-treat analysis among al l randomized subjects in the study through 
Week 48.
All efficacy variables will be summarized  in the manner described for Group 1 above. 
Summaries for Groups 2 and 3 will be done only  for a subset of efficacy variables, namely, 
PASI75/90/100, IGA Clear or Almost Clear, Scalp IGA Clear or Almost Clear, pp-IGA Clear or Almost Clear, mNAPSI75/90/100, and DLQ I 0/1. Further details on these analyses 
will be provided in the SAP.
Change #45
Section 14.7 Handling of dropouts or missing data
Missing data for the secondary efficacy variables (which are all binary) will be imputed using 
NRI. Additionally, the 2 additional approaches desc ribed above for the primary efficacy variable 
will be used for the secondary efficacy variables.
Has been changed to:
Missing data for the secondary efficacy variables (which are all binary) will be imputed using 
NRI. Additionally, the 2 additionalmissing data-handling approaches described above for the 
primary efficacy variable will be used  for the secondary efficacy variables.
Change #46
Section 14.9 Determination of sample size
A total of 700 subjects will be randomly assigned in a 1:1 ratio to one of the following treatment 
groups:
xBimekizumab 320mg (350 subjects)
xSecukinumab (350 subjects)
Has been changed to:A total of 700 subjects will be randomly assigned in a 1:1 ratio at Baseline to one of the 
following treatment groups:
xBimekizumab 320mg (350 subjects)PUBLIC s or misor mis
efficacy efficacy
ional aional a
effieffCOPY DLQL
This document 14.9 De4.9 De
otal of 7al of 7
groups:oups:
xxBBcannot 2 addadtiable wiable wbedary efdary ef
ditiditibusedppropro
cacy varcy vartovariabvariab
oacheachesupport ing datang dat
bleslany FurFumarketing t
in the sn the 
d for Grd for G
of efficacyeffica
r or Almr or A
rthertauthorization re 
imekizumekiz
hese taese ta
t
application terminatermina
00 subjectsubje
zumandnn
l be usebe usany acy varacy va
allmissimisadextensions  (whichwhich
s describdescri
ables.bles.or variationsro
cy variy var
most Clmost C
er detair detaithereof.m
bles. Tes. T
udy thrdy thr
up 1 aup 1 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 160 of 263xSecukinumab (350 subjects)
18.2 Protocol Amendment 1.1
Rationale for the amendment
The primary rationale for this local amendment was to incorporate the use of photographs of skin 
and nails during Schedule of study assessments only  for sites in the US, Australia, Belgium, 
Poland, and Germany and only for patients who consent (see Table 5‒1).
Modifications and changes
Specific changesChange #1 
Section 5 Study Design, Table 5‒1.
The specific assessment requiring the taking of photographs of skin and nails during Baseline, 
Weeks 1, 2, 4, 8, 12, 16, 32, and 48/EOT was added as stated below (table header used for 
clarification and was not changed):
Visita/
Week
Protocol 
activity
ScreeningTreatment Period
SFUbBaseline 
(first1234812 16 20 24 28 32 36 40 4448/
PEOT
Photographs of 
skin and nails 
(subset of sites)X XX XX X X X X
Change #2
Section 8.1
Added the following text: “In case subjects agree to participate in the photography sub-study 
(see Section 9.12) they will need to sign a separate informed consent form.”
Change #3
Section 8.2 Treatment Period
Added text referring to the assessment requirin g photographs of skin and nails during the 
following time points:
x Baseline
x Week 1
x Week 2
x Week 4
x Week 8
x Week 12
x Week 16PUBLIC 448
BLC
XXBLBLBLI
PPUBBLCOPYTreatmeTreatmY
OPOPOPYCOOP
This document Trere
ext refext refe
wing timng tim
BB
xxcannotxt:t:
ey will ny will n
eatmatmbe ““In Inused ededededto XXXXtosupport 1212 1616
spport
sssupppsany Perioderiodyaaanamarketing and nailsnd nail
ow (tablew (tabauthorization kin in 
application nt Periont Peri
rring to tring to
e points:point
selineline
ek 1ekanda
eed to ed to any e subjee sub
sigextensX
tetensions 2020ns
XXnnns
tetensonor 2orvariationss du
e headeheade
atiariariarivarithereof. uringuring
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 161 of 263x Week 32
x Week 48/EOT
Change #4
Section 9.12 PhotographsThe following text was added as subsection 9.14
At certain clinical sites, representative photographs of the changes in skin and nail appearance 
will be captured. Subjects who consent to th e procedure will have full body (anterior and 
posterior views) photographs taken. Only those subjec ts with nail disease at Baseline will have 
nail photographs taken. Only those subjects with  palmoplantar disease at  Baseline will have 
photographs of their palms or soles of their feet taken. Only those subjects with scalp disease at 
Baseline will have scalp photogra phs taken. Photographs will be anonymized and will be used 
for publication purposes.
Study sites selected for photography will be trained and receive standardized photographic 
equipment by a centralized photographic vendor. Photographs will be electronically transferred 
from the site to the vendor.
At the end of the study, the site will receive an electronic file of all subject photographs for 
archiving.
The central photography vendor will tabulate and tran sfer all subject photos to the Sponsor at the 
end of the study.
18.3 Protocol Amendment 2
No subjects were enrolled under this amendment.
Rationale for the amendmentThe protocol has been amended for the following reasons:
xExtended the study duration for an additional 96 weeks in an Open-Label Extension Period. 
Changes include addition of a new schedule of assessments for the additional 96 weeks, additional other objectives and endpoints, and updates to Section 8, Study procedures by 
visit.
xAdded planned re-randomization by treatment regimens and PASI response at Week 48 in
the OLE Period.
xClarified secondary efficacy variable for IGA response at Week 16, and added other efficacy 
variables for IGAxBSA and PASE score suggestive of PsA.
xModified the text in Section 7 to include guidance for allowing subjects the option to 
self-inject IMP at home after Week 48.
xUpdated Section 12.2.1 (Evaluation of PDILI) for improved clarity and consistency with 
other Phase 3 studies of bimekizumab in subjects with PSO.
xAdded statistical analyses for the OLE Period.
Modifications and changesPUBLICbulatebulate
ndmendme
der thider tCOPY n electroelectr
This documentplannelanne
OLE PeLE Pe
Clarifielarifie
variavaria
xxcannot duratura
additionddition
er objecobjec
dbended foed f
tiontionuseds amenmen
orto nt 22
nddsupport nic ic 
nd transfed transany file of file omarketingelinein
with scawith sc
mized andized a
standardizandard
will be eill beauthorization earancearance
or and and 
line wilne wi
e wile wi
application ree--randorand
iod.d.
d secondasecond
bles for Iles for I
dandfofo
of a neof a n
ves andes andany he follhe fo
r an adr an aextensions er a
ment.ment.or ll subll subvariationszed phoed pho
electronelectron
f all subjall subjthereof. hah
l have have 
lp diseap disea
d will bd will b
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 162 of 263Global changes:
The following changes were made throughout the protocol:
xThe maximum duration of the study has been changed from 69 weeks to 165 weeks 
throughout the document.
xCross references to the new schedule of assessments (Table 5-2) for the 2-year extension 
have been made throughout the document. 
xThe term “Treatment Period” has been changed to “double -blind Treatment Period” 
throughout the document to clearly distinguish it from the OLE Period.
xThe list of abbreviations was updated accordingly.
xMinor spelling, editorial, and formatting changes were made throughout the document.
Change #1
Section 1 Summary, third and fourth paragraphs: 
Approximately 935 subjects will be screened in  order to have 700 subjects randomized in the 
study. For each subject, the study will last a maximum of 69 weeks and will consist of 3 periods, 
a Screening Period (2 to 5 weeks), a double-blind Treatment Period (48 weeks; final dose at 
44 weeks), and a Safety Follow-Up (SFU) Period (20 weeks after the final dose of 
investigational medicinal product [IMP]).
During the first 16 weeks of the Treatment Period, eligible subjects will be randomized 1:1 to 
receive one of the following blinded IMP regimens:
Has been changed to:
Approximately 935 subjects will be screened in  order to have 700 subjects randomized in the 
study. For each subject, the study will last a maximum of 69165 weeks and will consist of 
34periods, a Screening Period (2 to 5 weeks), a double-blind Treatment Period (48 weeks; final 
dose at 44 weeks),Week 44), an Open-Label Extens ion (OLE) Period (96 weeks; final dose 
at Week 136 for subjects receiving bimekizumab 320mg Q8W and at Week 140 for subjects 
receiving bimekizumab 320mg Q4W); and a Safety Follow-Up (SFU) Period (20 weeks after 
the final dose of investigational medicinal product [IMP]).
During the first 16 weeks of the double-blind Treatment Period, eligible subjects will be 
randomized 1:1 to receive one of the following blinded IMP regimens:
Change #2
Section 1 Summary, 8ththrough 11thparagraphs: 
At Week 48, all subjects will undergo the Week 48 study assessments and will enter the SFU 
Period. 
Has been changed to:
Atthe completion of the Week 48 , allvisit assessments, subjects may receive open-label 
bimekizumab treatment for an additional 96 weeks. All subjects enrolling in the OLE 
Period will undergo, after signing a new ICF, be  evaluated for eligibility, be randomized, 
and receive their first dose of bimekizumab in the OLE Period. PUBLIC ).).
atment Ptment P
ded IMPed IMPCOPYer tr 
imum omum 
ind Treand Tr
Period (eriod (
ThisPdocument first 1rst 1
zed 1:1 td 1:1 t
nge #2ge #2
Section ection 
AAt Wt Wcannot4444
ects rects re
umab 3mab 3
invesnvestigti
16 w16 wbeiod (2 d (2
4)4), an, anused be screee scree
dy will y will
totto reggsupporttmem
0 weeksweek
eriod, eliriod, eli
gimensimenany 70070
99weekweek
ent Pernt Pmarketing out the dout the do
0 sub0s uauthorization d” d 
application gatio
weeks of teeks o
o receive eceiv
 SummaSumm
8a8andeivingvin
20mg Q0mg Q
onal nal any weekwee
Openpen-LaLa
g bigbextensionsigible suible s
s::
ned in oed in o
st a maa m
kor aftftvariations bjects raects ra
s and wand w
eriod (48od (48
fter ther ththereof. ocumencumen
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 163 of 263During the OLE Period eligible subjects will  receive the following IMP regimens as 
determined by the subject’s treatment regimen and PASI response in the double -blind 
Treatment Period. 
At Week 48, subjects receiving:
xBimekizumab 320mg Q4W who achieve PASI90 at Week 48 of the double-blind 
Treatment Period will be randomized 1:1 to receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W.
xBimekizumab 320mg Q4W who do not achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q4W.
xBimekizumab 320mg Q8W who do not achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q4W.
xBimekizumab 320mg Q8W who achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q8W.
xSecukinumab who do not achieve PASI90 at Week 48 of the double-blind Treatment 
Period will receive bimekizumab 320mg Q4W.
xSecukinumab who achieve PASI90 at Week 48 of the double-blind Treatment Period
will be randomized 1:1 to receive bimekizumab 320mg Q4W or bimekizumab 320mg 
Q8W.
At Week 96, for subjects receiving bimeki zumab 320mg Q4W, if PASI90 is achieved, the 
subject’s dosing interval will change fr om 320mg Q4W to 320mg Q8W (default), unless, 
based on medical judgment, the In vestigator decides differently.
During the OLE Period, subjects will atten d study visits at Weeks 52, 56, 64, and 72, and 
then every 12 weeks. 
All subjects not enrolling in  the OLE Period will have the Week 48 study assessments and 
will enter the SFU Period.
Change #3
Section 3.3 Other objectives: 
The following text was added:
xAssess the maintenance of efficacy of bimekizumab dosing Q4W versus Q8W
xAssess the safety and efficacy of initiating bimekizumab therapy in subjects who 
received secukinumab in the double-blind Treatment Period
Change #4
Section 4.2.1 Secondary efficacy variables: 
xIGA response (0/1) (defined as Clear or Almost Clear with at least a 2-category improvement 
relative to Baseline) at Week 16
Has been changed to:PUBLIC g bimekg bime
hange frange fr
the Invthe In
ececCOPY W
W.W.
Week 48eek 4
ekizumekizum
This document ng texg tex
ess the ss the
Assess Assess 
recerece
ChaChcannot d.d.
her objer obje
xt wxtbein the in theused estes
s will atwill atto om 3m 3
tigatoigatosupport of thf t
ab 320mb 320m
zumab 3umab 
320m320any f f
he dohe dmarketing of the the 
of the dof the d
the dothe dauthorization oubleuble-bb
d
application ctivev
was addedas add
maintenamainten
the safetyhe safe
ved secued secuand es: es:anyLE PerLE Peextensions 320mg Q0mg 
mg Q4Wg Q4W
r decidedecide
tendndstustor g Qg Qvariations u
ubleuble--bb
ubleble--blb
Q4WQ4Wthereof. ubleble--blb
bleble--blb
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 164 of 263xIGA response (0/1) at Week 16(defined as Clear or Almost Clear with at least a 2-
category improvement relative to Baseline) at Week 16
Change #5Section 4.3.1 Other efficacy variables: 
The following text has been added:
xAbsolute and percent change from Baseline in the product of IGA and BSA (IGAxBSA)
xShift from Baseline in  PASE score suggestiv e of PsA (<47 versus ≥47)
Change #6
Section 5.2 Study periods: 
This study will include 3 periods, a Screening Period (2 to 5 weeks), a double-blind Treatment 
Period (48 weeks; final dose at 44 weeks), and a SFU Period (20 weeks after the final dose of IMP). The end of the study is defined as the date of the last visit of the last subject in the study.
Has been changed to:
This study will include 34periods, a Screening Period (2 to 5 weeks), a double-blind Treatment 
Period (48 weeks; final dose at Week 44), an optional OLE Period (96 weeks ),; final dose at 
Week 136 for subjects receiving bimekizumab 320mg Q8W and at Week 140 for subjects 
receiving bimekizumab 320mg Q4W), and an SFU Period (20 weeks after the final dose of 
IMP). The end of the study is defined as the date of the last visit of the last subject in the study.
Change #7
The following section has been added:
5.2.3 OLE Period
After completion of the Week 48 visit assessments, subjects will be allowed to enroll in the 
OLE Period. All subjects enroll ing in the OLE Period will sign a new ICF, and then receive 
the following IMP regimens as determined by  the subject’s treatment regimen and PASI 
response in the double-blind Treatment Period. 
At Week 48, subjects receiving:
xBimekizumab 320mg Q4W who achieve PASI90 at Week 48 of the double-blind 
Treatment Period will be randomized 1:1 to receive bimekizumab 320mg Q4W or 
bimekizumab 320mg Q8W.
xBimekizumab 320mg Q4W who do not achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q4W.
xBimekizumab 320mg Q8W who do not achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q4W.
xBimekizumab 320mg Q8W who achieve PASI90 at Week 48 of the double-blind 
Treatment Period will receive bimekizumab 320mg Q8W.PUBLIC kizumkizu
W), andW), and
nned as thed as t
nanCOPY ng Periodg Perio
an optin opti
ma
This document susu
ekizumaizum
reatmeneatmen
bimekbimek
xxBiBicannotects cts ene
regimenegime
doubleouble
ubjecbjecbe WeekWeek 44
nrnrused dded:ded:to e support (2 t2 
nal OLEal OL
b 320mg 320mg
an SFU PSFU 
date of date oany to 5 wo5marketing a doubledouble b
weeks afteeks aft
of the laof the lauthorization GAxBSAAxBSA
applications receivis receiv
b 320mg320m
t Period Period
zumab 3umab 
kizumkizumandollinlli
s as detas de
ind Trnd Tany visit assisit as
ng in tng inextensionsQ
Perioderiod
f the lastf the lasor PeP
8W 8W a
(variationser the the
ast subjet subje
weeks), eks),
erioderiothereof. blind Tblind T
finfi
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 165 of 263xSecukinumab who do not achieve PASI90 at Week 48 of the double-blind Treatment 
Period will receive bimekizumab 320mg Q4W.
xSecukinumab who achieve PASI90 at Week 48 of the double-blind Treatment Period
will be randomized 1:1 to receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W.
At Week 96, for subjects receiving bimekizumab 320mg Q4W, if PASI90 is achieved, the 
subject’s dosing interval will change fr om 320mg Q4W to 320mg Q8W (default), unless, 
based on medical judgment, the Investigator decides differently.
During the OLE Period, subjects will atte nd study visits at Weeks 52, 56, 64, and 72, and 
then every 12 weeks. At study vi sits, IMP will be administered in the clinic by sc injection 
as applicable. In between study visits, subjects will self-inject IMP at home.
All subjects not enrolling in the open-label study will have  the Week 48 study assessments 
and will enter the SFU Period.
The assessments to be performed at each OLE Period visit are presented in Table 5-2.
Change #8
Section 5.3 Study duration per subject:For each subject, the study will last a maximum of up to 69 weeks, as follows:
xScreening Period: 2 to 5 weeks
xDouble-blind Treatment Period: 48 weeks (final dose at Week 44)
xSafety Follow-Up Period: a SFU Visit is pl anned 20 weeks after the final dose of IMP 
Has been changed to:
For each subject, the study will last a maximum of up to 69165 weeks, as follows:
xScreening Period: 2 to 5 weeks
xDouble-blind Treatment Period: 48 weeks (final dose at Week 44)
xOLE Period: 96 weeks (final dose at Week  136 for subjects receiving bimekizumab 
320mg Q8W and at Week 140 for subjects receiving bimekizumab 320mg Q4W)
xSafety Follow-Up Period: a SFU Visit is pl anned 20 weeks after the final dose of IMP visit
Change #9
Section 5.6 Schedule of study assessments
The schedule of study assessments is presented in Table 5-1. At each visit, all study assessments 
should be performed prior to administration of IMP.PUBLIC od: 48 wd: 48 w
a SFU a SFUCOPY mum omum o
Thissdocument 8W
y FollowFollow
nge #9ge #9
ection tion 
The The cannot o 
eatment tment 
: 9696wewe
W andW andbe ill l
5 week5 weekused Visiisi
last aast ato eek
it is pti spsupport up to up to 696
ks (finas (finany marketing ic byc b
home.ome.
ekek48 stu48 st
re presere preauthorization the the
unless, nless, 
, and 7and 7
ys cys c
applicationeks
at Weet We
Up PerioUp Pe
.6 Sc6 Schedhe
ule olandPeriod:eriod:
s (fina(finaany maxax
48extensions al dose al dose a
lannenned 2d 
ximuimuor weekweevariations ented inented i
kskthereof. 2, and a
injectiojectio
udy assedy ass
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 166 of 263Table 5 -1: Schedule of study assessments
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first 1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
Informed consent X
Inclusion/exclusion X Xc
Urine drug screen X
Demographic data X
Psoriasis history X
eC-SSRS X X X X X X X X X X X X X X X X X
Significant past medical history and concomitant diseasesX Xd
Physical examc, eX X X X X X
Height X
Body weight X X X X X
Vital signsfX X X X X X X X X X X X X X X X X X
Hematology and biochemistry X X X X X X X X X X X X X
Urinalysis X X X X X X X X
ECG X X X X
Pregnancy testinggX X X X X X X X X X X X X X X
Hepatitis B and C testinghX
PUBLIC 
CLICLICLICLICUB
LI
XXUBUBUBPUBPPPUP
COPY 
YPYPPPYCOPCCCOOOCOCThis 
document X
XXteeeenmeum
estingtinghhocd
cannot 
tX
tttnotXXnonooano
X
aaancac
be bebebebebe
used 
ddddus
dusususus
to XXootsupport 
rtrtrtrt ortpoooup
oupupupsups
any yananannan
marketing 200 242
tinnnm
rke
n
authorization 
ahoapplication X XXnnnonXXtioooc
o
XX
cccaic
XXpliiia
i
XXaaapa
and dnd
XX XXnnndanaaaa
any nyanynynyanya
extensions 
nnnnsonX XXiooons
onnsnsext
nexexxex
or oroororo
variations 2828tinstititioatirivavavaav
thereof. eeerhe
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 167 of 263Table 5 -1: Schedule of study assessments
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first 1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
HIV testingiX
Chest x-rayjX
IGRA tuberculosis test X X
Tuberculosis questionnaire X X X X X X X
PASI X X X X X X X X X X X X X X X X
Percentage of BSA X X X X X X X X X X X X X X X X
Blood sample for bimekizumab/secukinumab plasma concentrations
kX X X X X X X X X X X X
Blood sample for anti
-bimekizumab antibodiesk X X X X X X X X X X X X
IGA X X X X X X X X X X X X X X X X
DLQI X X X X X X X
Patient Symptoms (itch, pain, 
and scaling )X X X X X X X
PHQ -9 X X X X X X X X X X X X X X
scalp IGAlX XlXlXlXlXlXlXlXl
mNAPSImX XmXmXm
pp-IGAnX XnXnXnPUBLIC 
CLICLICLICLICUB
LIC
XXUBUBUBPUBPPPUUUPU
COPY 
YPYPPPYOPCCOOOCOCThis his
document 
eeeenmemmcudo
cannot 
otXX XotototnotXXnnncacacacaca
be XX XXeeebe
used 
ddddus
duu
to XXootsupport 
rtrtrtrtort
XXpoooup
o
XXupupupsups
any yananannan
marketing 200 242
tinnnm
rke
n
authorization 
ahoapplication 
nXX
nnnon
XXaticlicicicicppaa
and XXdndnnnana
any yXayyyanya
extensions 
nXX XXnnnsonX XXiooons
o
X XXnnsnsext
nse
or oroororor
variations 2828tinstititioatiriavavavaava
thereof. eeerhe
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 168 of 263Table 5 -1: Schedule of study assessments
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first 1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
Patient Global Assessment of psoriasisX X X X X X X
PASE X X
PGADA X XoXoXo
WPAI -SHP V2.0 X X X X
EQ-5D-3L X X X X X
Concomitant medication X X X X X X X X X X X X X X X X X X
Adverse eve nts X X X X X X X X X X X X X X X X X X
Randomization X X
IRTpX X X X X X X X X X X X X X X X X X
IMP adminis trationqX X X X X X X X X X X X X X X
BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG= electrocardiogram; eCRF=electronic Case Report Form; eC-SSRS=el ectronic 
Columbia Suicide Severity Rating Scale; EQ-5D-3L=European Quality- of-Life 5-Dimensions 3-Level; HCV=hepatitis C virus; HIV=huma n 
immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; 
IRT=interactive response technology; mNAPSI=Modified Nail Psoria sis Severity Index; PASE=Psoriatic Arthritis Screening and Eval uation; 
PASI=Psoriasis Area Severity Index; PEOT=Premature End of Tr eatment; PGADA=Patient’s Global Assessment of Disease Activity; P HQ-9=Patient 
Health Questionnaire-9; pp- IGA=palmoplantar Investigator’s Global Assessment; PsA=psoriatic arthritis; scalp IGA=scalp- specific Investigator’s Global 
Assessment; SFU=Safety Follow-Up; TB=tuberculosis; WPAI-SHP=Wor k Productivity and Activity Impairment Questionnaire-specific he alth problemICICICICLICBBLLLUB
L
XXPUUUPUP
COPY XYOP
YOPOPOPCOPCCCCThis 
documentst
logy; mgy; m
Index; Pndex; P
IGA=paGA=pa
y FollowFollow
cannot
t X XXtttnot gy Life Qy Life Q
le; EQEQ--5D5D
igator’sgator’
N
nonoobe e XX XXbebebebeb
used XdXXedddus
dusususus
to XXoXXtoooosupport 
ttttortooopoppppsupssuuus
any XX
yanaaa
marketing 200 242
tinnnm
rke
n
authorization 
ahoapplication 3L=
Global Alobal A
APSI=ModPSI=M
EOT=PremT=Pre
moplantar moplanta
Up; TB=tup; TB=
andXXd nduality Indlity In
=Eur=Eur
nnnd
any yXX Xnynynyany
XXaaaa
extensions X
XXsononononson
XX Xnnsnstns
X XXttteextexexxex
or r o
rroro
variations 2828tinstititiova
ativavaava
thereof. eeerhe
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 169 of 263Table 5 -1: Schedule of study assessments
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first 1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
aVisit windows of ±3 days from the first dose from the Week 1 vi sit to the Week 24 visit. Visit windows of ±7 days from Week 28 t hrough Week 48/PEOT. 
The SFU Visit window is ±7 days relative to the scheduled visit date.
bThe SFU Visit will occur 20 weeks after the final dose.
cIncludes evaluation of signs and symptoms of active TB and risk for exposure to TB.
dEnsure no significant changes in medical history.
eThe physical examination will be performed as per Section 12.3.5 .
fVital signs (blood pressures, pulse rate, and temperature) are to be measured prior to  blood sampling, and prior to dosing, whe re applicable.
gPregnancy testing will consist of serum testing at the Screening.  Urine pregnancy testing will be performed at all other visits .
hSubjects who have evidence of or test  positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B su rface antigen; 2) positive for 
anti-hepatitis B core antibody are excluded . A positive test for HCV is defined as: 1) positive for hepatitis C antibody, and 2 )positive via a confirmatory test 
for HCV (for example, HCV polymerase chai n reaction) are also excluded. Subjects w ill also be tested for anti-hepatitis B surfa ce antibody.
iThe HIV test results will not be recorded in the eCRF.
jScreening chest x-ray must occur within 3 months prior to Screening Visit.
kAll blood samples taken prior to dosing.
lThe scalp IGA will be assessed only for those subjects with scalp involvement (scalp IGA score >0) at Baseline.
mThe mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.
nThe pp-IGA will be assessed only in subjects with palmoplantar involvement (pp-IGA score >0) at Baseline.
oThe PGADA is assessed for all subjects at Baseline. At all subseque nt visits, the PGADA is only for subjects with PsA at Baseli ne (defin ed as a past medical 
history of PsA or PASE ≥47).
pIMP administration is based on randomization.
qThe dosing window from Baseline through Week 4 is ±2 days relative  to the scheduled dosing visit. From Week 8 through Week 24 , the dosing window is 
±3 days relative to the scheduled dosing visit.  From Week 28 through the end of the study, the dosing window is ±7 days relative to the scheduled dosing 
visit.
PUBLIC .
o be meas be mea
ning. Urining. Urin
tis B by ais B by a
test for test for 
arear
COPY24 visi24 v
posure toosure to
YYThis 
documento
ne throuthrou
led dosind dosin
cannotj
with nawith n
s with pawith p
t BaselinBaselin
mizatiomizatio
be cts withcts with
ailail
usedHCV iCV 
also excluo excl
o ScreeScree
topr
y of tof theh
is desd e
support TB.B.
red prior ted prior
egnancygnan
fo
any sit windsit winyymarketing 200 242
tinnnm
rke
n
authorization 
ahoapplication .
Week 4 isWeek 4
visit. Fromvisit. Fro
andnvonvo
moplantaoplant
At all suAt all s
any gg
calp involcalp invo
lvemenvem
i
extensions o blood blood 
y testing y testing
llowing cowing c
ined as: 1ed as: 1
ded. Subjd. Subj
Visit.Visit
or 
variations 2828tins
ows of ±7ws of ±7
tititio
thereof. eeerhe
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab
PS0015
Confidential Page 170 of 263Has been changed to:
The schedule of study assessments is presented in Table 5-1 for the Screening and double-
blind Treatment Periods, and in Table 5-2 for the OLE Period . At each visit, all study 
assessments should be performed prior to administration of IMP.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 171 of 263Table 5 -1: Schedule of study assessments, Screening and double-blind Treatment Periods
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first 1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
Informed consent X
Inclusion/exclusion X Xc
Urine drug screen X
Demographic data X
Psoriasis history X
eC-SSRS X X X X X X X X X X X X X X X X X
Significant past medical history and concomitant diseasesX Xd
Physical examc, eX X X X X X
Height X
Body weight X X X X X
Vital signsfX X X X X X X X X X X X X X X X X X
Hematology and biochemistry X X X X X X X X X X X X X
Urinalysis X X X X X X X X
ECG X X X X
Pregnancy testinggX X X X X X X X X X X X X X X
Hepatitis B and C testinghX
HIV testingiX
Chest x-rayjX
IGRA tuberculosis test X XPUBLIC XXICICICICUB
LICUBUBUBPUBP
COPY 
YPYOPOPOPOPCOCCCCThis is tisdocument XX
XXnmememememcu
eststdo
cannotXXtotXXnonoono
X
aaancacccc
beeXX XXeeebebbbb
used 
ddddsdssseusu
to otoooosupport 
ttttortXXpooopoppppsup
any nnnnyanaaa
marketing 2828ke
nkekekerkearrmmmmm
authorization 
a
odsdshouuutauappXXpplication 
onXXononononatiicXXlicicicicppaaaaa
andXXdddd andaaaa
any yXX Xyyynyannnan
extensions Xsson
XXssionsennnxt
nexexxex
or orXXoororor
variations 
nsnsnsnstinstititioatiiaavavavaava
thereof. 3232 33he
ofthhhh
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 172 of 263Table 5 -1: Schedule of study assessments, Screening and double-blind Treatment Periods
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first 1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
Tuberculosis questionnaire X X X X X X X
PASI X X X X X X X X X X X X X X X X
Percentage of BSA X X X X X X X X X X X X X X X X
Blood sample for bimekizumab/secukinumab plasma concentrations
kX X X X X X X X X X X X
Blood sample for anti-bimekizumab antibodies
k X X X X X X X X X X X X
IGA X X X X X X X X X X X X X X X X
DLQI X X X X X X X
Patient Symptoms (itch, pain, and scaling)X X X X X X X
PHQ-9 X X X X X X X X X X X X X X
scalp IGAlX XlXlXlXlXlXlXlXl
mNAPSImX XmXmXm
pp-IGAnX XnXnXn
Patient Global Assessment of psoriasisX X X X X X X
PASE X X
PGADA X XoXoXo
WPAI -SHP V2.0 X X X XXXCLICX
BLLLUB
LUUUPUP
COPY XXY
XX
PYYCOPCCThis 
document 
eeeemeumocd
cannot XXot XX
otototnot
XXnncacacacaca
be bellbebebebe
used 
dedddus
duuuu
to XXoXXtoooosupport Xort
XX XXpooosup
o
XXssuuusu
any XXn
XXnnnyan
marketing 2828ke
n
XXkekekerke
X XXarrm
rmmmm
authorization 
a
odsdshouuutauapplication 
onXXonononc
on
Xcccaicplaaaapa
and XXdandanananan
any Xyynyanynynyany
extensions XXonXXonononson
X XXssins
XX XXttennnext
ne
or oroororor
variations 
nsXXnsnsnsins
XX Xtititioati
XX
iaaava
a
thereof. 3232 33he
ofthhhh
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 173 of 263Table 5 -1: Schedule of study assessments, Screening and double-blind Treatment Periods
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first 1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
EQ-5D-3L X X X X X
Concomitant medication X X X X X X X X X X X X X X X X X X
Adverse eve nts X X X X X X X X X X X X X X X X X X
Randomizati on X X
IRTpX X X X X X X X X X X X X X X X X X
IMP adminis trationqX X X X X X X X X X X X X X X
BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG= electrocardiogram; eCRF=electronic Case Report Form; eC-SSRS=el ectronic 
Columbia Suicide Severity Rating Scale; EQ-5D-3L=European Quality- of-Life 5-Dimensions 3-Level; HCV=hepatitis C virus; HIV=huma n 
immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; 
IRT=interactive response technology; mNAPSI=Modified Nail Psoria sis Severity Index; PASE=Psoriatic Arthritis Screening and Eval uation; 
PASI=Psoriasis Area Severity Index; PEOT=Premature End of Tr eatment; PGADA=Patient’s Global Assessment of Disease Activity; P HQ-9=Patient 
Health Questionnaire-9; pp- IGA=palmoplantar Investigator’s Global Assessment; PsA=psoriatic arthritis; scalp IGA=scalp- specific Investigator’s Global 
Assessment; SFU=Safety Follow-Up; TB=tuberculosis; WPAI-SHP=Wor k Productivity and Activity Impairment Questionnaire-specific he alth problemXXIC; ECG=eECG=e
ean Qualian Quali
essment; ssment; 
fied Nail fied Nail
End En
ICICIC
COPY XXYPYYOPXXOPOPOPCOPCCCCThis 
document 
cannot 
be 
usedsorior
f TreatmTreatm
r’s Globas Glob
WPAIWPAI --SS
toy
GRA=iGRA=
iasis Sasis S
support 
t X XXtttortXXooopo
ctrocardiorocardio
off--fffLife 5Life
nter
pppp
any XXnXXnnnyanaaa
marketing 2828ke
nkekekerke
X XXarrm
rmmmm
authorization 
a
odsdshouuutauapplication 
and 
any 
extensionsgram; eCram; e
-DimensDimens
rferoneron-gaga
everity Inerity In
nt; PGADt; PGA
Assessmssessm
=WorkWork
sXsor rXXrroro
variations 
nsXXnsnsnsins
XX Xtititioatiiaaaaa
XXvavaava
thereof. 3232 33he
of
XXthhhh
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 174 of 263Table 5 -1: Schedule of study assessments, Screening and double-blind Treatment Periods
Visita/
Week
Protocol activity
ScreeningTreatment Period
SFUbBaseline 
(first 1 2 3 4 8 12 16 20 24 28 32 36 40 4448/
PEOT
aVisit windows of ±3 days from the first dose from the Week 1 vi sit to the Week 24 visit. Visit windows of ±7 days from Week 28 t hrough Week 48/PEOT. 
The SFU Visit window is ±7 days relative to the scheduled visit date.
bThe SFU Visit will occur 20 weeks after the final dose if subject does no t enroll in the OLE Period .
cIncludes evaluation of signs and symptoms of active TB and risk for exposure to TB.
dEnsure no significant changes in medical history.
eThe physical examination will be performed as per Section 12.3.5 .
fVital signs (blood pressures, pulse rate, and temperature) are to be measured prior to  blood sampling, and prior to dosing, whe re applicable.
gPregnancy testing will consist of serum testing at the Screening.  Urine pregnancy testing will be performed at all other visits .
hSubjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B su rface antigen; 2) positive for 
anti-hepatitis B core antibody are excluded . A positive test for HCV is defined as: 1) positive for hepatitis C antibody, and 2) positive via a confirmatory test 
for HCV (for example, HCV polymerase chai n reaction) are also excluded. Subjects w ill also be tested for anti-hepatitis B surfa ce antibody.
iThe HIV test results will not be recorded in the eCRF.
jScreening chest x-ray must occur within 3 months prior to Screening Visit.
kAll blood samples taken prior to dosing.
lThe scalp IGA will be assessed only for those subjects with scalp involvement (scalp IGA score >0) at Baseline.
mThe mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.
nThe pp-IGA will be assessed only in subjects with palmoplantar involvement (pp-IGA score >0) at Baseline.
oThe PGADA is assessed for all subjects at Baseline. At all subsequent visits, the PG ADA is only for subjects with PsA at Baseline (defined as a past medical 
history of PsA or PASE ≥47).
pIMP administration is based on randomization.
qThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled dosing visit. From W eek 8 through Week 24, the dosing window is 
±3 days relative to the scheduled dosing visit. From Week 28 through the end of the studyWeek 48 ,the dosing window is ±7 days relative to the scheduled 
dosing visit.
PUBLICy of thy of t
CV is defV is de
lso exclulso exclu
to Screento Screen
thth
COPY TB.B
red prior ed prior
pregnancregnanc
he fohe foThis 
document 
cannot Week 4 iWeek 4 
visit. Frosit. Fr
bemop
At all sAt all 
used scalp involp invo
nvolvemeolveme
plantarlantar
tog Visit.g Visit
support o bloodbloo
testing westing w
lowing criwing c
ned as: 1) pd as: 1)
ed. Subjectd. Subjec
any d samds
marketing 2828ke
n
ws of ±7 ds of ±7 
eriodriod..kekeke
authorization 
a
odsdshouuutauapplication 
and±2 days 2 days
Week Week 22any vovo
equent vquent
extensions positivsitiv
ts will alwill al
vement (ement 
t (mNAP(mNAP
lvemvem
orl beb
ria: 1) ia: 1)
effvariations aysy
mpling, apling, a
perper
thereof. 3232 33he
of
 fromfromthhh
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 175 of 263Table 5 -2: Schedule of study assessments, OLE Period
Visita/
Week
Protocol activity
48 (1st OLE dose)Year 2 Year 3
SFUb52
56
60
64
68
72
76
80
84
88
92
96
100
104
108
112
116
120
124
128
132
136
140
144/PEOT
C CCHCHCHHCHHCHHCHHCHHCHHCC
Informed consent X
EligibilitycX
eC-SSRS XX X X X X X X X XX
Physical examd,eX X X X X X X XX
Body weight X X
Vital signsfXX X X X X X X X XX
Hematology and biochemistry XX X X X X X X X XX
Urinalysis X X X X X X X XX
ECG X X
Pregnancy testing (urine)hXX X X X X X X X XX
IGRA tuberculosis test X X
Tuberculosis questionnaire X X X X X X X X XX
PASI XX X X X X X X X X
Percentage of BSA XX X X X X X X X X
Blood sample for bimekizumab plasma concentrations
hX X X XX
Blood sample for anti ‑bimekizumab 
antibodieshX X X XX
IGA XX X X X X X X X X
DLQI X X X X
Patient Symptoms (itch, pain, and scaling) X X X X X X X X X
PHQ-9 XX X X X X X X X X
scalp IGAiX X X X
mNAPSIjX X X XPUBLIC XXCCCCLICXXLILILICCCLIC
XXBBLLLUB
L
XXUBUBUBPUBPPPUUUPUPPPP
COPY CCYYYYYPYYPPYPYOOPYOOOOCOOCOCOCOCOCThis 
sdocument
tntntntnt nt
, and and 
ennnnumocdod
cannot XXoootnnotnnnnnanc
beeXeeebebbbeb
used
dXXddd sedssseusXXusususus
to oXXoootototototosupport X
torXXorororpporpppopopouppp
Xuuuppppppsupsususususss
any CCnynynynyanyaaannnana
marketing 
1
104104
1088gmarkket
ng
Hmmmm
authorization 
ahoapplication 
onXXXXooonnntionttioioiocat
iocacacacappappppa
and dandaaannnan
any XyXXyyynyXanynynyanyaaaa
extensions 
s X
sssons
XXononononXXsssiooons
onsnsnsenstetetenxtexxxtttext
XXexexexe
orrXrrroroooo
variations 
ons
HHHCooonaioaaatriaaaaririivari
XXvavavavav
thereof. Year 3ear 3112112
11616eoeoothereo
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 176 of 263Table 5 -2: Schedule of study assessments, OLE Period
Visita/
Week
Protocol activity
48 (1st OLE dose)Year 2 Year 3
SFUb52
56
60
64
68
72
76
80
84
88
92
96
100
104
108
112
116
120
124
128
132
136
140
144/PEOT
C CCHCHCHHCHHCHHCHHCHHCHHCC
pp-IGAkX X X X
EQ-5D-3L X X X X
Patient Global Assessment of PSO
PASE X X
PGADAlX X
WPAI-SHP V2.0 X X
Concomitant medication XX X X X X X X X XX
Adverse events XX X X X X X X X XX
Randomization X
IRTmX XX X X X X X X X XX
IMP administration –Q4W n, oX XXXXXXXXXXXXXXXXXXXXXXX
IMP administration –Q8W n, oX X X X X X X X X X X X
BSA=body surface area; C=clinic; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC RF=electronic Case Report Form; eC-
SSRS=electronic Columbia Suicide Sever ity Rating Scale; EQ-5D-3L=European Quality-of-Life 5-Dimensions 3- Level; H=home; HCV=hepatitis C virus; 
HIV=human immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal
product; IRT=interactive response technology; mNAPSI=Modified Nail Psoriasis Severity Index; PASE=Psoriatic Arthritis Screening  and Evaluation; 
PASI=Psoriasis Area Severity Index; PEOT=Premature En d of Treatment; PGADA=Patient’s Global Assessment of Dise ase Activity; PHQ-9=Patient 
Health Questionnaire- 9; pp IGA=palmoplantar Investigator’s Global Ass essment; PsA=psoriatic arthritis; scalp IGA=scalp -specific Investigator’s Global 
Assessment; SFU=Safety Follow-Up; TB=tuberculosis; WPAI SHP=Work  Productivity and Activity Impairment Questionnaire-specific he alth problem
aVisit windows of ±7 days from Week 48 through Week 72. Visit windows of ±14 days from Week 76 through Week 144. The SFU Visit window is ±7 days 
relative to the scheduled visit date.
bThe SFU Visit will occur 20 weeks after the final dose.
cCriteria for OLE Period, Section 6.3.
dIncludes evaluation of signs and symptoms of active TB and risk for exposure to TB.
eThe physical examination will be performed as per Section 12.3.5 .
fVital signs (blood pressures, pulse rate, and temperature) are to be measured prior to  blood sampling, and prior to dosing, whe re applicable.CCCCLICLILILICCCLIC
XXBBLLLUB
L
XXUBUBUBPUBPPPUUUPUPPPP
COPY CCYYYYYPYYPPYPYOOPYOOOOCOOCOCOCOCOCThis ood pood p
documentUp; Tp; 
Week 48Week 4
t date.date.
20 week0 week
d, SectionSectio
of signs f signs
minationination
prespres
cannoting ng
nvestigaestiga
ogy; mNAgy; mNA
EOT=PreOT=Pre
moplantaoplanta
TB=TB=
beegy Life Qgy Life 
ScaleScaleeeused
dXXddd sedXXXXssseusXXusususus
to oXXoootototototosupport 
tororororpporpppopopoupppuuuppppppsupsususususss
any CCnyXXnynynyanyaaannnana
marketing 
1
104104
1088gmarkket
ng
Hmmmm
authorization 
ahoapplication ma
Investivest
uberculosisuberculo
through Wrough W
after the fifter the 
6.3..3.
nd symptomd sympto
be perfep e r f
and r’s Glos Gl
PSI=ModI=Mo
ture Enure En
ga
any Xy ality Indelity Ind
QQ--5D5D-3L
obal b
yyyextensions 
ssssons
XXononononXXsssiooons
onsnsnsenstetetenxteXXXXxxxtttext
XXexexexe
orrXrrroroooo
variations 
ons
HHHCooonaioaaatria XXaaaririivarivavavavav
thereof. Year 3ear 3112112
11616eoeoothereo
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 177 of 263Table 5 -2: Schedule of study assessments, OLE Period
Visita/
Week
Protocol activity
48 (1st OLE dose)Year 2 Year 3
SFUb52
56
60
64
68
72
76
80
84
88
92
96
100
104
108
112
116
120
124
128
132
136
140
144/PEOT
C CCHCHCHHCHHCHHCHHCHHCHHCC
gPregnancy testing will consist of urine pregnancy testing at all visits.
hAll blood samples taken prior to dosing.
iThe scalp IGA will be assessed only for those subjects wi th scalp involvement (scalp IGA score >0) at Baseline.
jThe mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.
kThe pp-IGA will be assessed only in subjects with palmoplantar involvement (pp-IGA score >0) at Baseline.
lThe PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47).
mIMP administration is based on randomization.
nFrom Week 48 through Week 72, the dosing window is ±7 days relative to the scheduled dosing visit. From Week 76 through the Week 144/PEOT visit, the 
dosing window is ±14 days relative to the scheduled dosing visit.
oIf self-injected at home, the subject/caregiver will document the date, body location, kit number and time point  of administration of study medication. All 
used syringes will be disposed of by su bjects/caregivers as determined by the Inves tigator in an acceptable disposal (sharps) co ntainer directly after the 
administration. The subjects/caregivers return  the documentation together with any used/unused containers at the next scheduled  clinic visit.PUBLIC(m(
nvolvemvolvem
(defined (defined 
7 days re7 days re
sing visising vis
ment men
COPY CCY
ement (sement (s
mNAPSNAP
YYYYThis 
document 
cannot 
be 
usedhe date, date, 
determinetermi
entation ntation
totive totive to
support alp IGA p IGA
score >0) core >0
t (pp(pp--IGA IG
s a past mea past me
theth
any CCny
scnynyny
marketing 
1
104104
1088gmarkket
ng
Hmmmm
authorization 
ahoapplication 
and 
any 
extensionssco
edical hdical h
schedulechedul
dy locatidy locat
d by the Iby the I
gether wther 
ort Baset Bas
re >0e >0
variations 
ons
HHHCooonaio
re >0) ae >0) a
l
aaat
thereof. Year 3ear 3112112
11616eoeoothereo
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 178 of 263Change #10
Section 5.7 Schematic diagram:
The study schematic diagram for PS0015 is presented in Figure 5-1 .
Figure 5-1: Schematic diagram
IGA=Investigator’s Global Assessment; IMP=investigational medicinal product; PASI100=Psoriasis Area Severity 
Index complete response; PBO=placebo; Q4W=every 4 weeks; Q8W=every 8 weeks; SEC=secukinumab 
Note: At Week 28 and all following visits, subjects on conti nuous treatment for at least 12 weeks with a persistent 
IGA score ≥3 over at least a 4 -week period are defined as nonresponders and should discontinue IMP.
Has been changed to:
The study schematic diagram for PS0015 from Screening through Week 48 is presented in 
Figure 5-1 , and from Week 48 through Week 144 is presented in Figure 5-2 .
PUBment; IMment; IM
cebceb
UUUUUUUUUUUUUUUUUUUUUUBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIICCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC 
CCCCCOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOPPPPPPPPPPPPPPPPPPPPPPPYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 
This document cannot diagramdiagram
rom Weom Webe ekused P=inveinv
; Q4W=eQ4W=
sits, subjets, subje
periodperiodto estigesti
to
ssssssssssssssssssssssssssssssssssssuppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppoooooooooooooooooooooooooooooooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrttttttttttttttttttttttttt 
aaaaaaaaaaaaannnnnnnnnnnnnnnnnnnyyyyyyyyyyyyyyyyyyyyyyyyyyyyy 
mmmmmmarrrkkkeeettiinnggggggggggg ation 
aaaaaaaauuuuuuuuuuuuuuuuutttttttthhhhhhorizati
application andm for PSfor PS
k 48 th48 thany e
00extensioational mional m
very 4ry 4wewe
cts ons on concon
defineefine
sions 
oooooooooooooooooooooooooooooooooooooooooooorrrrrrrrrrrrrrr 
vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaariaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaatttttttttttttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiioooooooooooooooooooooooons 
ttttttttthhhhhhhhhhhheeeeeeeeeeeeeerrrreeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeooooooooooooooooooooooooooooooooofffffffffffffffffffffffffffffffff.................. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 179 of 263Figure 5-1: Schematic diagram, Screening and double-blind Treatment Period 
(through Week 48)
Screening Treatment period (double-blind) 
Safety follow -up 
visit 20 weeks 
after last dose
Baseline 16
WeekSFU visit 20 
weeks after 
last dose
48Dosing
12 20 24 28 32 36 40 44 48
Primary endpoint
PASI100 response2–5 weeksDosing Dosing Dosing Dosing Dosing Dosing Dosing Dosing Dosing Dosing Dosing
Dosing
(SEC or 
PBO)Open- label 
extension 
periodBimekizumab 320mg Q4WN=700
Secukinumab 300mg Q4Wn=350
n=350Bimekizumab 320mg Q8WBimekizumab 320mg Q4W
1:2 re-
randomization
Open-label
extension
periodor
IGA=Investigator’s Global Assessment; IMP=in vestigational medicinal product; PASI100=Psoriasis Area Severity 
Index complete response; PBO=placebo; Q4W=every 4 weeks; Q8W=every 8 weeks; SEC=secukinumab 
Note: At Week 28 and all following visits, subjects on conti nuous treatment for at least 12 weeks with a persistent 
IGA score ≥3 over at least a 4 -week period are defined as nonresponders and should discontinue IMP.
C
P
UBL
BLI
L
LICLIC LICreatmen
PUPU0mg Q4W
CC
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 
C
ThisIdoc
do
doc
ocum
me
ment 
nten
Bnntentnteeksnt
G
ca
cann
nno
not 
Dosing
Do
osing
(S
EC o
P
Bncotot
be
e bebe
us
used
ed
dededddd dded
mization
 n
to
o totoppo
sup
p
upp
ppuppuppod (doub
port 
po
annnnnnnnnnnnnnnnnnnnnnnnnnnyyyyyyyyyyy 
mmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmarrrrrrrrrrrkkkkk
arrrrrrrrkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeettttttttiiiiiiiiiiiinnnnnnnnnnnnnggggggggggggg 
ingtion 
ti
tio
aaaaaaaauuuuuuuuuuuuuttttttttthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhoooooooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrriiiiiiiiiiiiiiiiiiiiiiiiiiiiiizzzzzzzzzzzzzzzzzzzzzzzzzzzzzaaaaaaaatttttttiiiiii
a
a
a
a
appli
pli
plic
plicatio
o
tio
on 
at
seline
e
 4at
aaatin
an
n
and
nd 
g
 D
dd
a
a
n
ny anyanySe
e
e
t
te
si
sions
s
ns
sns nslind)
exteextetensitensiBimor
ooo
or 
or
variaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaatttttttttttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiooonnnnnnnnnnnnnnnnnnnnnnssssssssssssssssssssss 
sssssss
tttttttttttttttttttttttttthheeeeeeeeeeeeerrrrrrrrrrrreeof. 
ere
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 180 of 263Figure 5-2: Schematic diagram, OLE Period (Week 48 through Week 144)
1:1 re-
randomization
≥PASI90<PASI90
≥PASI90
20 weeks 
after last 
doseWeek 48 Open-label extension period
Safety follow -up 
visit 20 weeks 
after last dose
52 84 Week 60 68 76 92 100 108 116 124 132 140 56 88 64 72 80 96 104 112 120 128 136 144Bimekizumab 320mg Q4W
Bimekizumab 320mg Q8WSecukinumab
300mg Q4WBimekizumab 
320mg Q4W
Bimekizumab 
320mg Q8W
Secukinumab
300mg Q4WBimekizumab 
320mg Q4W
Bimekizumab 
320mg Q8W
≥PASI90
All Q4W All Q4W All All All All* Q4W Q4W Q4W Q4W Q4W Q4W Q4W Q4W Q4W All All All All All Q4W Dosing
Q4W=every 4 weeks; Q8W=every 8 weeks; PASI=Psoriasis Area Severity Index; PASI90=90% improvement 
in the PASI score
*At Week 96, for subjects receiving bimekizumab 320m g Q4W, if PASI90 is achieved, the subject’s dosing 
interval will change from 320mg Q4W to 320mg Q8W (default), unless, based on medical judgment, the 
Investigator decides differently.
Change #11
Section 5.8.1 Study design:
The following text was added:
The addition of the OLE Period will allow collection of long-term efficacy and safety data 
from eligible subjects on open-label bime kizumab for an additional 96 weeks. 
Change #12The following section was added:
Section 6.3 Eligibility for the OLE Period:
Prior to entering the OLE Period, subjects on double-blind study treatment must complete 
all of the Week 48 visit assessments. Prior to initiating the OLE Period assessments, all 
subjects will be asked to read and sign a separ ate ICF. To be eligible to participate in the 
OLE Period of this study, the subject must have completed the do uble-blind Treatment 
Period without meeting any withdrawal criteria  and have been compliant with the ongoing 
clinical study requirements. 
Change #13Section 6.4 Withdrawal criteria:
8. At Week 28 and all following visits, subjects  on continuous treatment for at least 12 weeks 
with a persistent IGA score ≥3 over at least a 4 -week period are defined as nonresponders 
and should discontinue IMP. PUBLIC mCOPY 
Y
Yiasis Areiasis Ar
320mg Q320mg 
g Q8WQ8W
This Cdocument teringering
Week Week
cts will ts will 
LE PerioE Peri
Period Period
cliniclinicannot on was awas 
gibility bility 
gtgtbe penen-lused od will d will
ababto support 4W, if PW, if P
(default), uefault)any 
ny
y Severity ISeverity
A
m
ma
mark
rket
eting
ng 
arr
124
124
aarketin
0
 12
28ararketi
Q4W
Allzation 
a
aut
ut
riza
a
uthorizuthorizw-upp 
weeks
er last dos
application or thr t
he OLE Pe OLE
8 visit avisit 
be asked e asked
d of this d of thi
without mthout m
udy udyand dded:ded:
he Ohe Oany bibimmextensions llow coow co
ekkornless,nlessvariatio
at
ation
ns
ns
ns s
40
0
140
0nss
 36
6
 14s
Index; Pndex; P
I90 is a90 is a
b
the
e
her
ereof
f
of
f. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 181 of 263Has been changed to:
8a.At Week 28 and all following visits up to Week 48, subjects on continuous treatment for at 
least 12 weeks with a persistent IGA score ≥3 over at least a 4 -week period are defined as 
nonresponders and should discontinue IMP.
Change #14
Section 7.2 Treatments to be administered, from 4thparagraph to end:
The dosing scheme is depicted in Table 7-1.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 182 of 263Table 7 -1: Dosing scheme, double-blind Treatment Period
Week
Dose AssignmentBaseline (first dose) 1 2 3 4 8 12 16a20 24 28 32 36 40 44
Bimekizumab 320mg●● ○○○○○○●●●●●●Q4W
●●●●●●●●●●●●●●●●
Q8W
●●○○●●○○●●○○●●○○
Secukinumab 300mg ▲▲ ▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲
Q4W=every 4 weeks; Q8W=every 8 weeksNotes: A bimekizumab 160mg injection is depicted by a black circle (
●). A placebo injection is depicted by a white circle ( ○). Asecukinumab 150mg injection 
is depicted by a black triangle ( ▲). 
aSubjects in the bimekizumab 320mg treatment arm will be re-rando mized 1:2 to receive bimekizumab 320mg Q4W or bimekizumab 320mg  Q8W.PUBLIC mize
COPY placebo inlacebo
ed 1:2 d 1:2
YYThis 
document 
cannot 
be 
used 
to support ectict
o receive breceive
any y
on is don isnyyymarketing ●ng
●●●●etirk
▲▲▲▲ma
authorization 
a
8 33hhhouthaapplication 
and 
any 
extensions 
ormekizumekiz
variations 
s
▲▲▲▲nsssati
s
depicted bpicted 
iatatat
thereof. ●●●●of.re
○○○○het
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 183 of 263Has been changed to:
The dosing scheme for Baseline through Week 44 is depicted in Table 7-1. The dosing scheme 
from Week 48 through Week 140 is depicted in Table 7-2 .
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 184 of 263Table 7 -1: Dosing scheme, double-blind Treatment Period
Week
Dose AssignmentBaseline (first dose) 1 2 3 4 8 12 16a20 24 28 32 36 40 44
Bimekizumab 320mg●● ○○○○○○●●●●●●Q4W
●●●●●●●●●●●●●●●●
Q8W
●●○○●●○○●●○○●●○○
Secukinumab 300mg ▲▲ ▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲
Q4W=every 4 weeks; Q8W=every 8 weeksNotes: A bimekizumab 160mg injection is depicted by a black circle (
●). A placebo injection is depicted by a white circle ( ○). Asecukinumab 150mg injection 
is depicted by a black triangle ( ▲). 
aSubjects in the bimekizumab 320mg treatment arm will be re-rando mized 1:2 to receive bimekizumab 320mg Q4W or bimekizumab 320mg  Q8W.
Table 7 -2: Dosing scheme, OLE Period
Week
Dose 
Assignment
48 (1st 
OLE Year 2 Year 352
56
60
64
68
72
76
80
84
88
92
96
100
104
108
112
116
120
124
128
132
136
140
Bimekizumab 
320mg Q4W●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
Bimekizumab 
320mg Q8W●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●●
Q4W=every 4 weeks; OLE=Open-Lab el Extension; Q8W=every 8 weeks
Notes: A bimekizumab 160mg injection is depicted by a black circle ( ●).PUBLIC mize
earearPU
COPY placebo inlacebo
ed 1:2 d 1:2
YThis 
document cti
cannot 
ototototnnot
bel Extenel Exte
on is dn is d
nnn
be e●●●●beeebeused 
d7676eeedse
to tosupport ectict
o receive breceive
any y
on is don isnyyymarketing ●ng
●●●●etirk
▲▲▲▲ma
authorization 
a
8 33hhhouthaapplicationsion; on;
picted bypicted b
and d●
dddnd
Q8WQ8Wann
any y●●●●nyyyanyaaaa
extensions 
ns8484xtextexteexte
ormekizumekiz
variations 
s
▲▲▲▲nsssati
s
depicted bpicted 
iatatat
thereof. ●●●●of.re
○○○○het
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 185 of 263During the OLE Period, IMP administration on weeks with no scheduled clinic visit should
primarily be performed by subjec ts at home. Self-injection tr aining will be provided to the 
subject/caregiver by qualified site person nel at Week 40 and Week 44. At Week 48 and 
subsequent clinic visits, the subject/caregi ver will perform self-administration under the 
supervision of the site staff to ensure that st udy medication is being properly and safely 
injected. 
Once subjects/caregivers as determined by the In vestigator (or designee) have been trained, 
the study medication may be administered at home. The subject will receive the required 
number of syringes for injections at each visit needed to perform the Q4W or Q8W administrations at home. Subjects who are unable to or decide not to self-inject IMP or 
those without a family member/friend/caregiver who can help, will not be discontinued, but 
may continue to visit the site for unschedu led visits for IMP administration only. 
If administered at home, the subject/caregiver will document the date, body location, kit 
number and time point of administration of study medication. 
All used syringes will be disposed of by subjects/caregivers as determined by the 
Investigator in an acceptable disposal (sharps) container directly after the administration. 
The subjects/caregivers return the docu mentation together with any used/unused 
containers at the next scheduled clinic visit. 
Change # 15Section 7.5 Handling and storage requirements:
The following text has been added:
In addition, the Investigator (or designee) will instruct the subject on how to handle the 
IMP during transport, and how to store the IM P following the instruction guide. Cooler 
bags with freezer packs will be provided to the subjects. Specific attention will be put on the transport from site to home using cold b ags, and the subject will be instructed to put 
the IMP as quickly as possible into his/her refri gerator. In case of broken refrigerator, or 
broken or lost syringes, the subject will info rm the site immediately and new IMP will be 
supplied. All efforts should be made to follow the treatment scheme as per protocol.
Change #16
Section 7.7 Procedures for mo nitoring subject compliance:
Investigational medicinal product will be admini stered in the clinic and compliance will be 
determined at the visit by study personnel. Drug  accountability must be recorded on the Drug 
Accountability Form.
Has been changed to:
InvestigationalDuring the double-blind Treatm ent Period (up to Week 44), investigational
medicinal product will be administered in the cl inic and compliance will be determined at the 
visit by study personnel. Drug accountability must be recorded on the Drug Accountability Form.
After Week 48, self-injection at home will be  possible at the following weeks: Weeks 60, 68, 
76, 80, 88, 92, 100, 104, 112, 116, 124, 128, 136, and 140. Dates, body locations, kit numbers PUBLIC equiremequirem
ded:ed:
(or de(or de
owowCOPY ontant
ation togtion to
ThisIdocument Proroc
gationalational
rmined amined 
ccountaounta
Has bHas cannotes, the, the
s shouldshoul
cedcedbe omeme
ssible issible i
ssusedsignegn
to storestore
e providprovid
eu seu sto ee) wee) wsupport ents:nts:anydirecdire
ther witther wmarketing e disdis
ration onation on
date, boddate, bo
as determs deter
ctlyctlauthorization trainedrained
requiredquired
Q8W Q8W 
ject IMect IM
sconcon
application ures for mres for
medicinalmedicin
t the visitthe vis
bility Formity Fo
chanchanandubjebj
d be mabe maany g cog c
o hio his/hes/h
ect wilct wextensions will instrll inst
the IMPhe IMP
ed to thd to th
oldoldor variations mined bmined 
y after tafter t
th any h any thereof. P or P o
tinued, nued, 
nly. y. 
dy locaty locat
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 186 of 263and time of self-injection will be captured using a home administration form. All used 
syringes will be disposed of by subjects/car egivers as determined by the Investigator in an 
acceptable disposal (sharps) container directly after the administration. The subjects/caregivers return the documentation together with any used/unused containers at 
the next scheduled clinic visit.
Completed home administration forms should be reviewed by the Investigator with the 
subject. If a subject is noncompliant with the study procedures or medications that may 
present a risk to the safety of the subject in th e opinion of the Investigator, then the subject 
should be withdra wn as described in Section 6.4 .
Change #17Section 7.8.1.1 Topical medications, 2
ndparagraph:
Mild and low potency topical steroids will be permitted for use limited to the face, axilla, and/or 
genitalia, as needed. These topical medicati ons should not be used within approximately 24 
hours prior to study visits requiring IGA and PASI measures.
Has been changed to:
MildIn the double-blind Treatment Period, mild and low potency topical steroids will be 
permitted for use limited to the face, axilla,  and/or genitalia, as needed. These topical 
medications should not be used within approxima tely 24 hours prior to study visits requiring 
IGA and PASI measures.
In the OLE Period, the medica tions listed as permitted fo r the double-blind Treatment 
Period will be allowed. In addition, topical steroids and vitamin D analog ointment will be 
permitted for use, as needed.
Change #18
Section 7.9 Blinding, first paragraph, 3rdparagraph, and last paragraph:
Due to differences in presentation between the bimekizumab and secukinumab, special 
precautions will be taken to ensure study bli nding and study sites w ill have blinded and 
unblinded personnel.
During the study the Sponsor will provide blinded and unblinded site monitors for the purposes 
of verifying safety, efficacy, and drug admi nistration and documenta tion records. Unblinded 
study site personnel need to be available in or der to resolve queries. Study monitors and study 
site personnel, blinded to treatment assignment, will not discuss or have access to any drug 
related information.
Has been changed to:
Due to differences in presentation between the bimekizumab and secukinumab, special 
precautions will be taken to ensure study blinding during the double-blind Treatment Period
and study sites will have blinded and unblinded personnel.
During the double-blind Treatment Period of the study ,the Sponsor will provide blinded and 
unblinded site monitors for the purposes of verify ing safety, efficacy, and drug administration 
and documentation records. Unblinded study site personnel need to be available in order to PUBLIC p
ons listeons liste
ition, toition, to
..COPY mild ild andd
and/or geand/or g
oximaoxima
ThisDdocumentg safetsafet
te perso perso
personnersonn
ated infted inf
Has bHas cannotse
ken to en to e
el.
dy the Sy the Sbe ara
ntationtatioused agrapgratopical spical support nitaliaitalia
ely 24 holy 24 
as permas perm
stertany ow potew pote
a, asaamarketing d to tto the fahe f
within appthin apauthorization e 
may may
he subje subj
application ponsor onsor
efficacy,fficac
nnel need el nee
l, bliblindednde
ormation.mation
chanchanand sure sure any , 33
betweenbetween
studstuextensions mitted fitted f
roids anoids a
rdrdpporurs purs variations pproxro
ncy topncy top
neededneeded
prioithereof. ace, axilce, axi
ximxim
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 187 of 263resolve queries. Study monitors and study site personnel, blinded to treatment assignment, will 
not discuss or have access to any drug related information.
For subjects participating in the OLE Period, there will be no blinding and the blinding 
procedures described above will no longer apply.
Change #19
Section 7.10 Randomization and numbering of subjects, last paragraph:
Subject numbers and kit numbers will be tracked via the IRT.Has been changed to:
In the OLE Period, subjects:
xWho received bimekizumab 320mg Q4W and achieved PASI90 at Week 48 of the 
double-blind Treatment Period will be ra ndomized 1:1 to receive bimekizumab 320mg 
Q4W or bimekizumab 320mg Q8W.
xWho received bimekizumab 320mg Q4W and who did not achieve PASI90 at Week 48 
of the double-blind Treatment Period will receive bimekizumab 320mg Q4W.
xWho received bimekizumab 320mg Q8W and who did not achieve PASI90 at Week 48 
of the double-blind Treatment Period will receive bimekizumab 320mg Q4W.
xWho received bimekizumab 320mg Q8W and who achieved PASI90 at Week 48 of the 
double-blind Treatment Period will receive bimekizumab 320mg Q8W.
xWho received secukinumab and who did not achieve PASI90 at Week 48 of the double-
blind Treatment Period will receive bimekizumab 320mg Q4W.
xWho received secukinumab and who achieved PASI90 at Week 48 of the double-blind 
Treatment Period will be randomized 1:1 to receive bimekizumab 320mg Q4W or bimekizumab 320mg Q8W.
At Week 96, for subjects receiving bimekizumab 320mg Q4W, if PASI90 is achieved, the 
subject’s dosing interval will change fr om 320mg Q4W to 320mg Q8W (default), unless, 
based on medical judgment, the In vestigator decides differently.
Subject numbers and kit numbers will be tracked via the IRT during the double-blind 
Treatment Period and the OLE Period .
Change #20
Section 8 Study procedures by visit:
Table 5-1 (Schedule of study assessments) provides a general overview of study assessments. A 
list of procedures to be completed at each visit is described below.
xVisit windows of ±3 days on either side of the scheduled dosing are permitted up to and 
including Week 24; however, the Investigator should try to keep the subjects on the original dosing schedule. From the Week 28 Visit throug h the Week 48/PEOT Visit, visit windows of 
±7 days on either side of the scheduled dosing are permitted; however, the Investigator 
should try to keep the subjects on the original dosing schedule. The visit window is relative PUBLICmg Q8Wmg Q8
will rewill re
b and and ww
will recwill reCOPY eceiveceiv
W and wW and
 will rewill re
W
Thisdocumentber
t PerioPerio
ge #20e #20
ection 8 tion 8
TableTable
listlistcannot cts rets re
erval wrval w
l judgmjudgm
rs and s andbe Q8W.W.
eceeceused eiveive
and nd whwh
randomandomto ho dio di
e bimeb i msupporthoho
eive bimive bi
and nd whowh
ceive bimive bim
dn odnany mekizumekiz
did nodid nmarketing at Week 4Week 4
eive bimeive bim
ot achiet ach
umauthorization 
applicationkit numbkit num
and the nd th
Study prtudy p
(Sche(Scheandvinvi
ll chanchan
nt, thet, theany ng bimg biextensionso a
mekizumekizu
ot act achiehi
mekizumkizum
o achievachiev
zed 1:ed 1or e
chievchievvariations eve PASve PA
mab 320mab 32
ot achiet achie
kizumkizumthereof. 48 of th8 of th
kizumkizum
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 188 of 263to Baseline and applicable for all subsequent  visits. Changes to the dosing schedule outside 
the visit window must be discussed with the Medical Monitor.
xThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled
dosing visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the scheduled dosing visit. From Week 28 through the end of the study the dosing window is ±7 days relative to the scheduled dosing visit.
Has been changed to:
Table 5- 1(Schedule of study assessments) providesand Table 5-2 provide a general overview 
of study assessments during the double-blind Treatmen t Period and the OLE Period, 
respectively. A list of procedures to be completed at each visit is described below.
xVisit windows of ±3 days on either side of the scheduled dosing are permitted up to and 
including Week 24; however, the Investigator should try to keep the subjects on the original dosing schedule. From the Week 28 Visit through the Week 48/PEOT72 Visit, visit
windows of ±7 days on either side of the scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. From the Week 
76 Visit through the Week 144/PEOT Visit, visit windows of ±14 days on either side of 
the scheduled dosing are permitted; however,  the Investigator should try to keep the 
subjects on the original dosing schedule. The visit window is relative to Baseline and 
applicable for all subsequent visits. Changes to the dosing schedule outside the visit window must be discussed with the Medical Monitor.
xThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled 
dosing visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the 
scheduled dosing visit. From Week 28 through the end ofthrough thestudyWeek 72 Visit,
the dosing window is ±7 days relative to the scheduled dosing visit. From Week 76 Visit 
through the Week 144/PEOT, the dosing window  is ±14 days relative to the scheduled 
dosing visit.
Change #21The following sections have been added: Section 8.3 OLE PeriodSection 8.3.1 Week 48 Visit (±7 days relative to Baseline)
The following procedures/assessments will be performed/recorded after completion of 
assessments listed for Week 48 (Section 8.2.13) and prior to administration of IMP:
xSign a separate ICF for the OLE Period
xInclusion/exclusion: Confirm that subject co mpleted the double-blind Treatment Period 
without meeting any withdrawal criteria and has been compliant with the ongoing 
clinical study requirements
xUpon confirmation of subject’s eligibility, randomization will occur
xContact IRTPUBLIChan
l MoniMon
eline threline thr
through through
om Weom WeCOPYe
visit wvisit
ever, thever,
le. le. The vThe 
nges tnges
This document.3.1 W3.1 W
llowing owing
ssmentment
xSignSig
xxcannot ions havns hav
OLEOLE
WeWbe usedek 28k 28
relativeelative
OT, thOT, thtoou
Week 2Week 
8t hthsupport isit winit wi
o the dosithe do
r.
gh Weeh We
4anydodo
dows odows 
nvestignves
ndmarketing elowlow
ermitted ermitted 
he subjecthe subje
PEOTEOT 72rkre permitte permi
osing ssing
fauthorization ±7 7 
eral overal ove
E PeriodPeriod
ww
application PerPe
ek 48 Vik 48 V
procedurprocedu
listed foisted f
a separaseparaand e been abeen 
riodriodany extensions ek 4 is ±ek 4 is ±
, the dohe do
rough thugh th
to the sco the s
dosingosingorng schng scvariations 2ViVi
tted; howd; how
schedulechedul
f ±14 da±14 da
gator shator sh
w is rew is re
hthereof. , 
d up to anup to a
ts on thts on th
isit,isit
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 189 of 263After completion of the above-mentioned proc edures, IMP administration will occur, 
preferably by self-injection under supervision of the site personnel.
Section 8.3.2 Week 52 Visit (±7 days relative to Baseline)
The following procedures/assessments will be  performed/recorded prior to administration 
of IMP:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should 
be obtained prior to blood sampling
xCollection of blood and urine samples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urine pregnancy test
xPASI
xPercentage of BSA
xIGA
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above-mentioned proce dures, administration of IMP will occur for 
subjects on bimekizumab 320mg Q4W dosing only, preferably by self-injection under supervision of the site personnel.
Section 8.3.3 Week 56 Visit (±7 days relative to Baseline)
The following procedures/assessments will be  performed/recorded prior to administration 
of IMP:
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should 
be obtained prior to blood sampling
xCollection of blood and urine samples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urine pregnancy test
xTuberculosis questionnaire
xPASI
xPercentage of BSAPUBLIC COPY 
This documentsigns (sgns (s
obtainedbtaine
Collectollect
dosidosicannotk56 V56 V
ocedurcedurbe 20m0m
rsonnersonneused mentiomentio
mg Qmg Qto support any marketing authorization hould ould 
tained pained p
application ting systing sys
d prior toprior 
on of blon of b
g:g:andsit (±7(±7
/assessassessany W dW 
77dadextensions ned proed pro
dosdosor variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 190 of 263xIGA
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above-m entioned procedures, administration of IMP will occur, 
preferably by self-injection under supervision of the site personnel.
Distribution of IMP and accountability activities for home administration to be performed 
as described in Section 7.2 ,Section 7.5 , and Section 7.7 .
Section 8.3.4 Self-injection at home (Weeks 60, 68, 76, 80, 88, 92, 100, 104, 112, 
116, 124, 128, 136 and 140)
Subjects receiving bimekizumab 320mg Q4W will be given the opportunity for self-
injection of bimekizumab at home on th e following weeks: Weeks 60, 68, 76, 80, 88, 92, 100, 
104, 112, 116, 124, 128, 136 and 140.
Subjects receiving bimekizumab 320mg Q8W will be given the opportunity for self-
injection of bimekizumab at home on the following weeks: Weeks 80, 88, 104, 112, 128, and 
136.
xAdverse events will be captured spontaneously  if the subject decides to visit the site to 
receive the bimekizumab administration. 
xAll used syringes will be disposed of by subjects/caregivers as determined by the 
Investigator in an accep table disposal (sharps) container directly after the 
administration. The subjects/caregivers re turn the documentation together with any 
used/unused containers at th e next scheduled clinic visit.
Section 8.3.5 Week 64, Week 84, Week 108, Week 132 Visits (±14 days relative to 
Baseline)
The following procedures/assessments will be  performed/recorded prior to administration 
of IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should 
be obtained prior to blood sampling
xCollection of blood and urine samples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
UrinalysisPUBLIC0mg Q8mg Q
e e on thon th
apturaptuCOPY W will bW will b
followinfollowin
This xdocument owing pwing p
P::
PhysiPhys
exexcannothe sube sub
ntainertainer
WeekWeek 66be e disdis
eptableptabl
bjebjeuseded spond spo
ministrminist
spossposto tsupport g weekwee
W will bW will b
followinollowinany given thiven th
ks:kmarketing IMPMP
stration tstration
80, 88, 80, 88authorization P wilwil
application 4, W, W
rocedureocedur
cal exam l exam
sure toure toandcts/ts
at the t the 
WeeWeeany d of d of
disposaldisposa
caregcareextensionsbe givegiv
ng weekg week
aneouslaneousl
ation. ion. 
bybyor envariations , 92, 10, 92, 10
he oppoe oppo
WeeksWeeksthereof. l occur, ccur,
to be pto be p
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 191 of 263Urine pregnancy test
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
After completion of the above-mentioned proc edures, administration of IMP will occur
xat each of these visits for subjects on bimekizumab 320mg Q4W dosing, preferably by 
self-injection under supervision of the site personnel
xat Week 64 for subjects on bimekizumab 320mg Q8W dosing, preferably by self-
injection under supervision of the site personnel
Distribution of IMP and accountability activities for home administration to be performed 
as described in Section 7.2 ,Section 7.5 , and Section 7.7 .
Section 8.3.6 Week 72 and Week 120 Visits (±14 days relative to Baseline)
The following procedures/assessments will be  performed/recorded prior to administration 
of IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should 
be obtained prior to blood sampling
xCollection of blood and urine samples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
Bimekizumab plasma concentrations
Anti-bimekizumab antibodies
xTuberculosis questionnaire
xPASIPUBLIC zumazum
he site he site 
ntabilitytability
ectionection
WWCOPY urer
ekizumekizum
site persite per
abab
This document neded
ection otion o
osing:ing:
HHcannotludinguding
(sitting tting 
d priopriobe gegeused .5
eek 120ek 12
essmenssmentoact
5, and, andsupport sonnelnnel
20mg Q0mg Q
ersonnelrsonne
tivitieivitanyminismini
320mg320mgmarketing strastrauthorization 
applicationsystoy
r to bloor to blo
f blood anblood 
ematologmatolo
inalynaand valual
olic olicany uationuatioextensions Q
es for hs for h
Sectionection
 Visits Visits
will bwill orW doW dovariations ation of ion of 
g Q4W Q4W thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 192 of 263xPercentage of BSA
xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xscalp IGA for subjects with scalp involvement at Baseline
xmNAPSI for subjects with nail involvement at Baseline
xpp-IGA for subjects with palmop lantar involvement at Baseline
xEQ-5D-3L
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
xAfter completion of the above-m entioned procedures, administration of IMP will occur, 
preferably by self-injection under supervision of the site personnel
xDistribution of IMP and accountability activities for home administration to be 
performed as described in Section 7.2 ,Section 7.5 , and Section 7.7 .
Section 8.3.7 Week 96 Visit (±14 days relative to Baseline)
The following procedures/assessments will be  performed/recorded prior to administration 
of IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should 
be obtained prior to blood sampling
xCollection of blood and urine samples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
IGRA tuberculosis test
Bimekizumab plasma concentrations
Anti-bimekizumab antibodiesPUBLIC supesupe
untabiliuntabil
Section ection 
sit (±1sit (±1COPY ned prned pr
erviervi
This documentained pned p
llectionection
dosing:osing:
cannot (sittinsittin
prbe ng evang evaused dayda
smentsmentto .22,,
ysyssupportoceduresedure
sion of thon of t
y activitiactivit
SectiSecany marketing authorization 
application g systolsysto
or to bloor to bl
of blood of blood
ematolomatoloand iany uation ouation extensions he
ies for hs for 
onn7.57.5
elativelative
will be pill be por adad
site psite variations dmindmithereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 193 of 263xRecord 12-lead ECG
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xscalp IGA for subjects with scalp involvement at Baseline
xmNAPSI for subjects with nail involvement at Baseline
xpp-IGA for subjects with palmop lantar involvement at Baseline
xPASE
xPGADA (only for subjects with PsA)
xWPAI-SHP V2.0
xEQ-5D-3L
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
At week 96, after completion of the above-me ntioned procedures, ad ministration of IMP 
will occur, preferably by self-injection under supervision of the site personnel
Distribution of IMP and accountability activities for home administration to be performed 
as described in Section 7.2 ,Section 7.5 , and Section 7.7 .
Section 8.3.8 Week 144 Visit (±14 days relative to Baseline)
The following procedures/assessments will be  performed/recorded prior to administration 
of IMP:
xPhysical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should 
be obtained prior to blood sampling
xCollection of blood and urine samples for the following tests should be obtained prior to 
dosing:COPY 
This document 3.8 W8 
lowing owing
MP:P:
PhyPhy
eecannotby seby se
MP and P and 
Sectionection
WeWebe tion oftion of
lflfused to support any marketing aselineselineauthorization 
application 7.2.2
ek 144 Vk 144 
procedurprocedu
ical examcal exam
ure treand injenj
accountccount
SeSeany he abovhe abov
ectionctioextensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 194 of 263Hematology and biochemistry
Urinalysis
Urine pregnancy test
IGRA tuberculosis test
Bimekizumab plasma concentrations
Anti-bimekizumab antibodies
xRecord 12-lead ECG
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xscalp IGA for subjects with scalp involvement at Baseline
xmNAPSI for subjects with nail involvement at Baseline
xpp-IGA for subjects with palmop lantar involvement at Baseline
xPASE
xPGADA (only for subjects with PsA)
xWPAI-SHP V2.0
xEQ-5D-3L
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
Return of IMP and accountability activities fo r home administration to be performed as 
described in Section 7.2 ,Section 7.5 , and Section 7.7 .PUBLICp involvinvol
ail involail invo
h palmoh palmCOPY gg))
This document tata
Contactontact
ReturnReturn
descdesccannot nt mnt mbe tsused plapl
with with to antar ntarsupport ment at ment a
ment ament aany marketing authorization 
application dicationdicatio
IRTRT
f IMP aIMP a
ininSand any sAAextensions BasBas
at Baselat Base
nvolvemvolvem
A))or selinelinvariations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 195 of 263Change #21
Section 8.4 Premature End of Treatment Visit:
The following bullet has been added:
If the subject will be withdrawn from IMP prior to the Week 144 visit of the OLE 
Period, the subject will undergo the same  assessments as the Week 144 visit (see
Section 8.3.8 ), and will enter the SFU Period.
Change #22
Section 8.5 Safety Follow-Up Visit (20 weeks after final dose, ±7 days)
Bimekizumab/ secukinumab plasma concentrations 
Has been changed to:
Bimekizumab /(secukinumab for subjects not entering the OLE Period) plasma 
concentrations 
Change #23
Section 8.6 Unscheduled visit, 2ndparagraph:
If an Unscheduled Visit is conducted due to safety or efficacy reasons, an eC-SSRS assessment 
will be performed with the subject during the visit. If an Unscheduled Visit is conducted for 
reasons other than safety or efficacy concerns (e g, repeated collection of  a laboratory specimen 
due to collection or analysis issues), an eC-SSRS will not be required at these visits.
Has been changed to:
If an Unscheduled Visit is conducted due to safety or efficacy reasons, an eC-SSRS assessment 
will be performed with the subject during the visit. If an Unscheduled Visit is conducted for 
reasons other than safety or efficacy concerns (e g, repeated collection of  a laboratory specimen 
due to collection or analysis issues , injection for subjects not making use of home self-
injections ), an eC-SSRS will not be required at these visits.
Change #24
Section 12.2 Laboratory measurements, Table 12-2
Table 18 ‒6:Laboratory measurements
Hematology Chemistry Urinalysis dipsticka
Basophils Calcium pH
Eosinophils Chloride Albumin (protein)
Lymphocytes Magnesium Glucose
Monocytes Potassium Blood
Neutrophils Sodium Leukocyte esterase
Hematocrit Glucose Nitrite
Hemoglobin BUN Urine dipstick for pregnancy testingbPUBLICg thg th
oncernsncern
), an eC, an eC
ductducCOPY safety osafety 
he vise vis
This sdocument8‒6:‒6:LL
atologyologye
Basophilssophilsum
EosinEosiocddcannot S wiw
aboratoboratbeffic
s issues issue
ll noll nuseded due tdue 
ct durint durin
cacy cacy cto support r efficaceffica
t. If an UnIf an U
(eg, repeag, repe
SRS wilSRS wiany cymarketing OLE PerOLE Pauthorization 
application ry my m
aboratorborato
caplapand t b
easeasanyncnc
njectionjecti
e requie reqextensions ated ced 
ll not benot be
safety osafety 
gthe vishe vis
cerns ernsornschedsche
colcolvariations rio
reasoneason
dthereof. od) d) plpl
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 196 of 263Table 18 ‒6:Laboratory measurements
Hematology Chemistry Urinalysis dipsticka
MCH Creatinine
MCHC ALP
MCV AST
Platelet count ALT
RBC count GGT
WBC count Total bilirubin
LDH
CRP
Lipid panel
NT-proBNP
Serum pregnancy testingb
ALP=alkaline phosphatase; ALT=alanine aminotransfera se; AST=aspartate aminotra nsferase; BUN=blood urea 
nitrogen; CRP=C-reactive protein; GGT=gamma glutamyltransferase; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; MCHC=mean corp uscular hemoglobin concentration; MCV=mean 
corpuscular volume; NT-proBNP=N-terminal pro B-
type natriuretic peptide; RBC=red blood cell; WBC=white 
blood cell
aA urine microscopic examination will be performed if the result for albumin (protein), leukocyte esterase, blood 
or nitrite is abnormal. A urine microscopic examinatio n will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hya line casts, WBC casts, RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals, triphosp hate crystals, yeast, bacteria, amorph ous urates, and amorphous phosphates.
bPregnancy testing will consist of serum testing at the Screeni ng. Urine pregnancy testing will be performed at 
all other visits.
Has been changed to:PUBLIC propr
e performperform
copic exacopic exa
line castsine casts
osphate csphate c
erumeruCOPYtingng
ase; ASTse; AST
utamyltratamylt
mean corpean corp
BB--typtyPY 
This document cannot be usedystalsta
testing aesting tomin
WBC cWBC 
ls, yels, yesupportsferfe
scular hemcular he
e natriuretinatriur
d if the resf the r
nation wation w
astany spartate apartate a
ase; LDase;nymarketing gtingkearmauthorization ootioatitit
rizhouta
application and any extensionssult for allt for a
ill includill includ
s, RBC cRBC c
st, bacterbacter
the Screehe Screorglg
peptidpeptivariations s
io
aminotraninotran
DH=lactaH=lact
lobin obin iatthereof. ofre
th
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 197 of 263Table 18 ‒7:Laboratory measurements
Hematology Chemistry Urinalysis dipsticka
Basophils Calcium pH
Eosinophils Chloride Albumin (protein)
Lymphocytes Magnesium Glucose
Monocytes Potassium Blood
Neutrophils Sodium Leukocyte esterase
Hematocrit Glucose Nitrite
Hemoglobin BUN Urine dipstick for pregnancy testingb
MCH Creatinine Urine drug screen
MCHC ALP
MCV AST
Platelet count ALT
RBC count GGT
WBC count Total bilirubin
LDH
CRPb
Lipid panel
NT-proBNPb
Serum pregnancy testingc
ALP=alkaline phosphatase; ALT=alanine aminotransfera se; AST=aspartate aminotra nsferase; BUN=blood urea 
nitrogen; CRP=C-reactive protein; GGT=gamma glutamyltransferase; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; MCHC=mean corp uscular hemoglobin concentration; MCV=mean 
corpuscular volume; NT-proBNP=N-terminal pro B-
type natriuretic peptide; RBC=red blood cell; WBC=white 
blood cell
aA urine microscopic examination will be performed if the result for albumin (protein), leukocyte esterase, blood 
or nitrite is abnormal. A urine microscopic examinatio n will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hya line casts, WBC casts, RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals, triphosp hate crystals, yeast, bacteria, amorph ous urates, and amorphous phosphates.
bAssessments of NT-proBNP and CRP will no t be performed during the OLE Period.
cPregnancy testing will consist of serum testing at the Sc reening. Urine pregnancy testing will be performed at 
all other visits.
Change #25
Section 12.2.1 Evaluation of PDILI, Table 12-3:PUBLIC PPbbIC
Lipid pLipid pBLUNTNTPUPUPUPUPPPPCOPYPY 
ininOPC
This Sdocumentnd
ric acidc acid
ments ofents of
gnancy teancy te
l other vother v
ChaChacannotproBNproBN
ic examinexamin
ormal. A mal. A
renal renal beal
tein; Gn; G
moglobimoglobi
PPused proBNroB
Serum prerum ped
anine amnine am
GTGusto nell
NPNPbbtosupport torppsuany nyaaaaamarketingr pregnanpregnang
screenreentingkearmauthorization ootioatitit
rizhouta
applicationrine mne 
ubular), hyular), h
ystals, triphstals, tr
NT--proBNproB
ting will cong will 
its.s.
255and NN-te
tion willon wil
micrmicrany gammagamm
MCHC=mMCHC=
erminarminextensions ssonsi
egnancy tnancy tten
otransftransfexor roovariations s
ioiatavthereof. y testingtestingbofre
th
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 198 of 263Table 12 -3: Required investigations and follow up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal 
bilirubinSymptomsaof 
hepatitis of 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNbNA Hepatology consultc
Medical Monitor must 
be notified within 
24hours (eg, by 
laboratory alert) and subject discussed with Medical Monitor ASAP.Immediate, permanent IMP discontinuation. Essential: Must have repeat liver chemistry 
values and additional 
testing completed 
ASAP 
(see 
Section 12.2.1.3 ); 
recommended to occur 
at the site with HCP.Monitoring of liver 
chemistry values at least 
twice per week until values 
normalize, stabilize, or 
return to within baseline 
values. d≥3xULN NA Yes
≥8xULN NA NA Need for hepatology 
consult to be discussed 
(required if ALT or AST ≥8xULN).
Medical Monitor must 
be notified within 
24
hours (eg, by 
laboratory alert) and 
subject discussed with 
Medical Monitor ASAP.Immediate, permanent 
IMP discontinuation.
≥5xULN 
(and ≥2x 
baseline) and 
<8xULN<2xULN No Discussion with Medical 
Monitor required.
Consider need for 
hepatology consult if there is no evidence of resolution (see Follow 
up requirements). 
cFurther investigation –
immediate IMP 
discontinuation not required
(see 
Section 12.2.1.2 ).
IMP discontinuation 
required if any of the following occur:
Subject cannot comply 
with monitoring 
schedule.Essential: Every 
attempt must be made 
to have repeat liver chemistry values and 
additional testing 
completed within 
48 hours at the site 
with HCP (see 
Section
12.2.1.3 ).Monitoring of liver 
chemistry values at least 
twice per week for 2 weeks.d
Immediate IMP 
discontinuation required if 
liver chemistry values 
continue to increase.
After 2 weeks of monitoring 
liver chemistry values:
ALT or AST remains 
≥5xULN <8xULN, IMP 
should be temporarily PUBLICsed sed
T or ASTor AST
Monitor monitor m
fied withfied with
urs (eg,urs (
COPY OImImOOOCOThis his
document oc
cannot MonMon
ConCo
hn
be scussionscussion
totoeal eused by 
alert) andert) and
iscussedcussed
MonitMoni
to st t
support mediate, pediate, p
MP discontP disco
ts
any a
marketing Essential:Essentia
repeat repea
valuva
teetia
authorization 
a
FoFhoutapplication thereher
resoluresol
up ruptio
andreqreq
ider needer nee
patologyatology
isis
anyith Mediith Med
uired.uired
yASAy extensions with th 
AP.APxte
ormanma
nuationuatio
variations liver ver
ues and as and a
esting coesting c
ASAPASAP
SecSec
rria
nent nentva
thereof.EEof
Must haMust ha
chechehe
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 199 of 263Table 12 -3: Required investigations and follow up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal 
bilirubinSymptomsaof 
hepatitis of 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
Liver chemistry values continue to increase
Liver chemistry values 
remain ≥5xULN (and 
≥2x
baseline) after 
4 weeks of monitoring without evidence o
f
resolutionwithheld and subject should undergo repeat test in 2 
weeks.
Continue IMP if ALT or 
AST values <5xULN; continue to monitor at least 
twice per week until values 
normalize, stabilize, or 
return to within baseline values.
If ALT or AST remains 
≥5xULN after second 
re
-test, immediate, 
permanent IMP discontinuati
on required .
Continue to monitor until 
values normalize, stabilize, or return to within baseline values. d
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcar e practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal
aHepatitis symptoms include fatigue, nausea, vomiting, and right u pper quadrant pain or tenderness; hypersensitivity symptoms in clude eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
bIf the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi cal Monitor.
cDetails provided in Section 12.2.1.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
dUnless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB respon sible physician, as needed.
Has been changed to:
PUBLIC 
COPYbaseas
weeks oweeks 
withoutwitho
resolresoCOThis ngednged
documentnative ative 
ALP, theALP, th
2.2.1.12.1.1 T
This wouis wou
monitoringnitorin
ultation wultation w
dt odt o
cannot 
nminotransfnotrans
NA=not A=not
usea, vosea, v
ca
nnno
be 
used 
to support v
tionons
any ter ter 
onitoringonitorin
dence oence fmarketing ues s 
nd nd 
etia
authorization 
a
FoFhoutapplication pplp
miting, aiting, 
se).e).
possibility ssibilit
he elocal helocal h
d usually busually
schedule ihedule
h the hepathe he
andrase; ASase; AS
icablecablnd nd
any 
extensions xte
or 
variations g
f
ria
thereof.EEofhe
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 200 of 263Table 12-3: Required investigations and follow up for PDILI
Laboratory value Immediate Follow up
ALT or AST Total bilirubin Symptomsaof 
hepatitis of 
hypersensitivityConsultation requirements Actions Testing Evaluation
≥3xULN ≥2xULNbNA Hepatology consultc
Medical Monitor must 
be notified within 
24hours (eg, by 
laboratory alert) and subject discussed with Medical Monitor ASAP.Immediate, permanent IMP discontinuation.
eEssential: Must have repeat liver chemistry 
values and additional 
testing completed 
ASAP
(see 
Section 12.2.1.3 ); 
recommended to 
occur at the site with HCP.Monitoring of liver 
chemistry values at least 
twice per week until values 
normalize, stabilize, or 
return to within baseline 
values. d≥3xULN NA Yes
≥8xULN NA NA Need for hepatology 
consult to be discussed 
(required if ALT or 
AST ≥8xULN).
Hepatology consult.
Medical Monitor must 
be notified within 
24hours (eg, by 
laboratory alert) and 
subject discussed with 
Medical Monitor ASAP.Immediate, permanent 
IMP discontinuation.
≥5xULN 
(and ≥2x 
baseline) 
and 
<8xULN<2xULN No Discussion with Medical 
Monitor required.
Consider need for 
hepatology consult if there is no evidence of 
resolution (see Follow 
up requirements). 
cFurther investigation –
immediate IMP discontinuation not required
(see 
Section 12.2.1.2 ).
IMP discontinuation 
required if any of the following occur:
Subject cannot comply 
with monitoring 
schedule.Essential: Every 
attempt must be made to have repeat liver chemistry values and additional testing 
completed within 
48 hours at the site 
with HCP (see Section
12.2.1.3 ).Monitoring of liver 
chemistry values at leasttwice per week for 2
weeks.d
xImmediate IMP 
discontinuation 
required if liver PUBLIC sseCT or T orC N).).L gy consugy consu
al Monitoal Monito
tified wtified
((
COPY ddCImmImm
IOOPCOThis his
document cu
cannot DiscDis
MonMonno
beususbect d
edical Mcal Mbe
used hin n 
g,by by 
ry alert) aalert) a
iscusiscus
to must must 
support ediate, pediate, p
P discontidiscon
ts
any a
marketing Essential: Mential
repeat lirepeat
valueva
test
tinma
authorization 
a
FoFohoutapplication hepahep
there there
resoretio
andonon
tor requor requ
nsider nsider n
atoltol
anywith Mwith Many wiw
or ASAor ASany
extensions d 
ith thxte
oruationuatio
variationsiver
s and adand a
sting comsting com
ASAPASAP ((
SectiSecti
rerearianent nent aaa
thereof.EvEvof
Must havMust hav
r chemchem
er
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 201 of 263Table 12-3: Required investigations and follow up for PDILI
Laboratory value Immediate Follow up
ALT or AST Total bilirubin Symptomsaof 
hepatitis of 
hypersensitivityConsultation requirements Actions Testing Evaluation
Liver chemistry values continue to increase
Liver chemistry values 
remain ≥5xULN (and 
≥2xbaseline) after 
4weeks of monitoring 
without evidence of resolutionchemistry values continue to increase.
After 2 weeks of monitoring 
liver chemistry values:
xALT or AST remains ≥5xULN <8xULN, 
IMP should be 
temporarily withheld 
and subject should 
undergo repeat test in 2 
weeks.
Continue IMP if ALT 
or AST values 
<5xULN; continue to 
monitor at least twice 
per week until values 
normalize, stabilize, or 
return to within baselineBaseline
values.
If ALT or AST remains ≥5xULN after second 
re-test, immediate, 
permanent IMP 
discontinuation required .
Continue to monitor until 
values normalize, stabilize, 
or return to within baseline 
values.dPUBLIC 
COPYbasaYweeks oweeks
without witho
resoluesolCOThis 
sdocdcument cu
cannot 
no
be 
used 
to support onnss
anyer r
onitoringonitorin
dence of dence o
maes 
nd nd mmarketing 
tinma
authorization 
a
FoFohoutapplication 
tio
and 
any 
extensions xte
or 
variations ari
thereof.EvEvofer
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 202 of 263Table 12-3: Required investigations and follow up for PDILI
Laboratory value Immediate Follow up
ALT or AST Total bilirubin Symptomsaof 
hepatitis of 
hypersensitivityConsultation requirements Actions Testing Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=a s soon as possible; AST=aspartate aminotransferase; HCP=healthcar e practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal
aHepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tendern ess; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
bIf the subject also has ≥2xULN ALP, the possibility of an indication of biliar y obstruction should be discussed with the Medi cal Monitor.
cDetails provided in Section 12.2.1.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
dUnless an alternative monitoring schedule is agreed by the Inve stigator and UCB responsible phy sician. Determination of stabili zatio n is at the discretion of 
the Investigator in consultation with the hepatologist (a s applicable) and UCB responsi ble physician, as needed.
eDetails provided in Section 12.2.1.2.1
PUBLIC 
COPYconsulcon
gastroentastroen
d UCB reUCB r
d UCB reUCB reThis 
document 
cannot 
be 
used 
to supportponson
ponsible ponsible 
any uldl
by the try the 
ologist.logist.
ible phible
marketinminotransfenotran
ry; ULN=u; ULN=
 hypersensyperse
d be disd be d
ting tin
authorization 
a
FoFohoutapplication 
and 
any 
extensions 
or ysiys
variationsupp
sitivity tivity
scussed wcussed w
ating phyating phy
hysician.sician
ician,ician,
thererarase; HCse; HC
per limper lim
ereof.EvEvofer
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 203 of 263Change #26
Section 12.2.1.2.1 IMP restart/rechallenge:
Rechallenge with IMP can occur only if ALL of the following requirements are met:
xThe results of additional testing and monitoring described in Section 12.2.1.3 and 
Section 12.2.1.1 confirm a nondrug-related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie,  a subsequent alternative diagnosis fully 
explains the hepatic findings).
xThe subject has shown clear therapeutic benefit from the IMP.
xSubject’s ALT or AST elevations do not exceed ≥5xULN.
xSubject’s total bilirubin is <2xULN.
xSubject has no signs or symptoms of hypersensitivity or hepatitis.
xThe rechallenge is approved by the UCB responsible physician, DMC, and a hepatologist. 
xSubject agrees to the Investigator-recommended monitoring plan.
Has been changed to:
Subjects who are immediately discontinued from IMP due to having met certain criteria 
for PDILI (as described in Section 6.4.1 and Table 12-3 ), but for whom an alternative 
diagnosis is confirmed, ie, drug-induced live r injury is excluded, can rarely restart IMP.
Rechallenge with IMP can occur only if ALL of the following requirements are met at the time 
of the rechallenge :
xThe results of additional testing and monitoring described in Section 12.2.1.3 and 
Section 12.2.1.4 confirm a nondrug-related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie,  a subsequent alternative diagnosis fully 
explains the hepatic findings).
xThe subject has shown clear therapeutic benefit from the IMP.
xSubject’s ALT or AST elevations do not exceed ≥5xULN.
xSubject’s total bilirubin is <2xULN.
xSubject has no signs or symptoms of hypersensitivity or hepatitis.
xTheDuring the double-blind Treatment Period, the rechallenge is approved by the UCB 
responsible physician, DMC, and a hepatologist.
xDuring the OLE Period, the rechallenge is approved by the UCB responsible physician.
xSubject agrees to the Investigator-recommended monitoring plan.
Change #27
Section 12.4.4 Data Monitoring and Adjudication Committees
The DMC membership includes experienced clinic ians and a statistician, all of whom have 
expertise in clinical trials. Cardiovascular a nd Neuropsychiatric Adjudication Committees will PUBLIC11aa
uced livced li
only if Aonly if A
stinstiCOPY d mom
ued fromed from
nd ndTT
This document toto
ect has nt has 
TheheDurDurmresporespo
xxDDcannothown clwn cl
T or ASor AS
otal bial bibeciatee
dings).dings)usedg and mand m
nondrugndrug
d syds yto ALLsupportIMP dIMP d
able 12ble 12 -3
er injuryinjur
L of theof thany ng png pmarketing an, DMCn, DM
plan.planauthorization 
applicationirubin isirubin i
o signs orsigns 
ng the dog the d
nsible phyble ph
g thegt handar therthe
elevatilevatiany ptompto
raperapextensionsy is exs ex
he followe follow
nitoringitoring
elated clated c
msmsore tt
, but , but
cllvariationsC, and a and a
to hao hathereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 204 of 263also periodically review data from this trial. Both Data Monitoring and Adjudication Committee 
members may not participate in the study as principal or co-Investigators, or as study subject 
care physicians. The duration of membership for the committees will be inclusive of planned analyses for PS0015. Detailed role, scope, responsib ilities, and complete pr ocedures, as well as 
the identity of members, are described in the separate committee charters.
Has been changed to:
The DMC membership includes experienced clin icians and a statistician, all of whom have 
expertise in clinical trials. Cardiovascular a nd Neuropsychiatric Adjudication Committees will 
also periodically review data from this trial. Both Data Monitoring and Adjudication Committee members may not participate in the study as principal or co-Investigators, or as study subject 
care physicians. The duration of membership for the committees will be inclusive of planned 
analysesdata through the last subject completing the Week 48 Visit for PS0015. Detailed
role, scope, responsibilities, and complete procedures, as well as the identity of members, are 
described in the separate committee charters.
Change #28
Section 14.1 Definition of analysis sets:The following text has been added:
The Open-label Set (OLS) will consist of all subjects that receive at least 1 dose of IMP at 
Week 48 or later in the OLE Peri od (including the Week 48 dose).
Change #29
Section 14.2 General statistical considerations,  second and fifth paragraphs and title of 
figure 14-1:
The statistical analysis of the primary efficacy  variable and secondary efficacy variables will 
account for multiplicity and control the familywise Type I error rate at a 2-sided alpha level of 0.05 by using a fixed sequence testing procedure. 
The hypotheses associated with the subsequent te sts are for secondary efficacy endpoints and are 
based on testing for superiority relative to secukinumab. Figure 14-1 presents the details on this 
procedure.PUBLIC(includ(inclu
al consial consiCOPY all suball su
di
This document cannotated wed w
r superiosuperiobecont
ence tesence teused imary efmary ef
trol trol toeratioeratiosupport jects thaects th
ng the Wg the any marketing ss
lusive ousive 
or PS001r PS001
dentity of dentity oauthorization ave ve 
ittees wittees w
ion Comn Com
study sudy s
application and h the the
rity relaty relaany  famfa
ng procg pro
subssuextensions Week
s, secon, secon
ficacy vacacy v
milymilorrecerec
k 48 k4 8variations eivithereof. m
ubject bject 
plannelanneo 5..DetaDeta
f membememb
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 205 of 263Figure 14 1: Hypotheses testing of secondary efficacy endpoints
BKZ=bimekizumab; PASI=Psoriasis Area Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeksNote: Tests for H
1, H 2, H 3, and H 4are based on all subjects initially randomized to bimekizumab compared to 
secukinumab. For H 5and H 6, testing is based on the subjects re-randomized at Week 16 to bimekizumab 320mg 
Q4W, and bimekizumab 320mg Q8W, respectively, compared to secukinumab.
Has been changed to:
The statistical analysis of th e primary efficacy variable and selected secondary efficacy variables 
will account for multiplicity and control the family wise Type I error rate at a 2-sided alpha level 
of 0.05 by using a fixed sequence testing procedure. 
The hypotheses associated with the subsequent tests are for selected secondary efficacy 
endpoints and are based on testing for superiority relative to secukinumab. Figure 14-1 presents 
the details on this procedure.
PUBLICSeverity Severity
ased on alsed on al
g is basedg is based
Q8W, resQ8W, res
CCCCCCCCCC 
CCCCCCCCCCCCCOOOOOOOOOOOOPPPPPPPPPPPPYYYYYYYYYYYY 
This document thcannot d sequsequ
ociated ciated 
re basedbased
his pros probeprimp
y and cy and 
uenuenused pectivctiv
marymartosub
n the sn the s
vely,elysuppndex; Q4Wex; Q4W
bjects injects 
bj
pppppppppppppoooooooooooorrrrrrrrrrrrtttttttttttt 
aaaaaaaaaaaaannnnnnnnnyyyyyyyyyyyy 
mmmmmmmmmmmmaaaaaaaaaaaarrrrrrrrrrrrkkkkkkkkkkkkkeeeeeeeeeeeettttiiiiiiiinnnnnnngggggg tion 
aaaaaaaaauuthorizati
application on 
cedure.cedure.and ce te 
with theith the
testinestinany efficffi
ntrol thentrol th
esting estinextensions W=every 4every 
nitially raitially r
jectstsrere-r
comparedmpared
cacycac
o
ooooooooorrrrrrrrrrrr  
vvvvvvvvvvvvaaaaaaaaaaaarrrrrrrrrrriiaaaaaaaaaaaaatttttttttttttiiiiiiiiiiiiioooooooooooonnnnnssssss 
thhhhhhhhheeeeeeeeeeereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 206 of 263Figure 14 1: HypothesesHypothesis testing of secondary efficacy endpoints
BKZ=bimekizumab; PASI=Psoriasis Area Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeksNote: Tests for H
1, H 2, H 3, and H 4are based on all subjects initially randomized to bimekizumab compared to 
secukinumab. For H 5and H 6, testing is based on the subjects re-randomized at Week 16 to bimekizumab 320mg 
Q4W, and bimekizumab 320mg Q8W, respectively, compared to secukinumab.
Change #30
Section 14.3.2.2 Analysis of the other efficacy variables, third paragraph through end of 
section:
In general, data will be summarized by visi t through Week 48. All summaries of data up to Week 
16 will be based on the RS for the 2 randomized treatment groups (bimekizumab and 
secukinumab). For visits after Week 16, by-visit su mmaries will be prepared for the following 3 
groups of subjects:
4. Subjects in the MS summarized by the 3 maintenance treatment groups (bimekizumab 
320mg Q4W, bimekizumab 320mg Q8W, and secukinumab). Note that while the MS is 
primarily defined for the evaluation of data after Week 16, these summary tables will include 
data at all visits (Baseline to Week 48) to provide a comprehensive summary of subjects by maintenance treatment group for the MS.
5. A subset of Group 1 above. Specifically, this will include only those subjects who are 
responders at Week 16 for the variable being su mmarized. This will provide an assessment of 
how efficacy is maintained among Week 16 responders.
6. Subjects in the RS summarized by the 2 randomized treatment groups (bimekizumab and 
secukinumab). Data from Baseline  to Week 48 will be included in these tables. This provides
an intent-to-treat analysis among all randomized subjects in the study through Week 48.
PUBLICSeverity Severity
ased on alsed on al
g is basedg is based
Q8W, resQ8W, res
CCCCCCCCCC 
CCCCCCCCCCCCCOOOOOOOOOOOOPPPPPPPPPPPPYYYYYYYYYYYY 
This5document bjej
ects in thts in th
0mg Q4mg Q4
primaririmari
data data 
mmcannote summsumm
 the RSthe RS
For visitsr visit
cts:ts:be theused pectivctiv
e othe othtosub
n the sn the s
vely,elysuppndex; Q4Wex; Q4W
bjects injects 
bj
pppppppppppppoooooooooooorrrrrrrrrrrrtttttttttttt 
aaaaaaaaaaaaannnnnnnnnyyyyyyyyyyyy 
mmmmmmmmmmmmaaaaaaaaaaaarrrrrrrrrrrrkkkkkkkkkkkkkeeeeeeeeeeeettttiiiiiiiinnnnnnngggggg tion 
aaaaaaaaauuthorizati
application aft
e MS MS sumsu
W, bimekW, bime
y defineddefine
at all visitall visi
nancnancand arizedzed
for the 2or the 2
ter Wer Wany r effef
d by vbyextensions W=every 4every 
nitially raitially r
jects rets re-r
comparedmpared
ficafica
o
ooooooooorrrrrrrrrrrr  
vvvvvvvvvvvvaaaaaaaaaaaarrrrrrrrrrriiaaaaaaaaaaaaatttttttttttttiiiiiiiiiiiiioooooooooooonnnnnssssss 
thhhhhhhhheeeeeeeeeeereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 207 of 263All efficacy variables will be summarized  in the manner described for Group 1 above. 
Summaries for Groups 2 and 3 will be done only for a subset of efficacy variables, namely, 
PASI75/90/100, IGA Clear or Almost Clear, Scalp IGA Clear or Almost Clear, pp-IGA Clear or Almost Clear, mNAPSI75/90/100, and DLQI 0/1. F urther details on these analyses will be 
provided in the SAP.
Has been changed to:
In general, data will be summarized by visit through Week 48 in the double-blind Treatment 
Period and then by visit in the OLE Period separately. All summaries of data up to Week 16 
will be based on the RS for the 2 randomized treatment groups (bimekizumab and secukinumab). 
For visits after Week 16 in the double-blind Treatment Period , by-visit summaries will be 
prepared for the following 3 groups of subjects:
7. Subjects in the MS summarized by the 3 maintenance treatment groups (bimekizumab 
320mg Q4W, bimekizumab 320mg Q8W, and secukinumab). Note that while the MS is 
primarily defined for the evaluation of data after Week 16, these summary tables will include 
data at all visits (Baseline to Week 48) to provide a comprehensive summary of subjects by maintenance treatment group for the MS.
8. A subset of Group 1 above. Specifically, this will include only those subjects who are 
responders at Week 16 for the variable being summarized. This will provide an assessment of how efficacy is maintained among Week 16 responders.
9. Subjects in the RS summarized by the 2 randomized treatment groups (bimekizumab and 
secukinumab). Data from Baseline  to Week 48 will be included in these tables. This provides 
an intent-to-treat analysis among all randomized subjects in the study through Week 48.
All efficacy variables in the double-blind Treatment Period will be summarized in the manner 
described for Group 1 and 3 above. Summaries for Group s2and 3 will be done only for a 
subset of efficacy variables, namely, PASI75/90/100, IGA Clear or Almost Clear, Scalp IGA 
Clear or Almost Clear, pp-IGA Clear or Almost Clear, mNAPSI75/90/100, and DLQI 0/1.
In the OLE treatment period, efficacy variables  of interest generall y will be summarized 
descriptively by the combined treatment regi men in the double-blind treatment period and 
re-randomized treatment in the OLE,
In general, efficacy variables will be summar ized using descriptive statistics by treatment 
group and scheduled visit during the OLE Peri od based on Baseline at beginning of the 
study unless otherwise specified. 
Further details on thesethe above analyses including analysis in the OLE Period will be 
provided in the SAP.
Change #31
Section 14.4 Subgroup analyses:
Subgroup analyses will be performed on the primar y and secondary efficacy variables that are 
part of the fixed sequence testing procedure described in Section 14.2 . The following variables 
for subgroup analyses will be defined: age, gender, disease duration, region, weight, body mass 
index, prior systemic chemotherapy or photot herapy, prior biologic exposure, prior systemic PUBLIC eek
y the 2 ry the 2 r
eline to Wline to W
mong allmong al
oublouCOPY is will inis will in
eing sumeing sum
k 16 rk 16 
This documenteffiffi
d schedsched
unless onless o
ther deter det
provideprovide
ChaChcannott perioperio
e combicomb
reatmeeatme
icacy cacy beam
IGA CIGA C
ododusedblindlind
ve. Sume. Sum
mely, Pmely, Ptorandomrando
Tsupport mmarizemariz
spondersponde
andomizendomize
eek 48 wek 48 w
mizany ude onlude onl
eddmarketing ups (bimeps (bim
te that whe that 
se summsumm
hensive sensiveauthorization atment ment 
to Weekto Week
d secukinsecuki
aries wries w
applicationt
variablevariabl
uled visit ed visi
herwise herwise
ails on s on thtpin the SAn the S
1andeffef
ned treaed tre
in then thanyS
r or Almr or A
ficacyicacextensionsed tread trea
will be iwill be 
zed subjed sub
reatmereatme
maries faries f
SI75/9I75/or tvariationswh
mary tabary ta
summarsumma
ly thosey those
This wThis wthereof. um
ill be l be 
mekizumaekizum
ile thele the
bl
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 208 of 263therapy of any kind, Baseline disease severity, an d antibody positivity. These summaries will be 
based on imputed data (NRI) and will include descriptive statistics only.
Has been changed to:
Subgroup analyses will be performed on the primary  and secondary efficacy variables that are 
part of the fixed sequence testing procedure described in Section 14.2 . The following variables 
for subgroup analyses will be defined: age, gender, disease duration, region, weight, body mass index, prior systemic chemotherapy or phot otherapy, prior biologic exposure, prior primary 
failure to biologics, prior systemic therapy of any kind, Baseline disease severity, and antibody 
positivity. These summaries will be based on imputed data (NRI) and will include descriptive statistics only.
Change #32
Section 14.5.1 Safety analyses, first paragraph:
Safety variables will be analyzed for all subjects in the SS. This will include all subjects who 
took at least one dose of study medication. Adverse events will be coded according to the 
Medical Dictionary for Regulatory Activities. Adve rse events will be su mmarized descriptively 
by treatment group, primary system organ class, High Level Term (HLT), and PT. Additional 
tables will summarize AEs by intensity and relationship to IMP, AEs leading to withdrawal from 
the study, SAEs, and deaths. Safety topics of inte rest will be summarized and will be described 
in greater detail in the SAP. 
Has been changed to:
Safety variables will be analyzed for all subjects in the SS. This will include all subjects who 
took at least one dose of study medication. Selected analyses will also be presented for MS 
and OLS. Adverse events will be coded according to the Medical Dictionary for Regulatory 
Activities. Adverse events will be summarized descriptively by treatment group, primary system 
organ class, High Level Term (HLT), and PT. Addi tional tables will summarize AEs by intensity 
and relationship to IMP, AEs leading to withdrawal from the study, SAEs, and deaths. Safety 
topics of interest will be summarized and will  be described in greater detail in the SAP. 
Change #33Section 14.8 Planned interim analysis:
After the final Week 48 Visit, an interim analysis will be performed based on all data available at 
that time. Further details related to this interim analysis will be outlined in the SAP. A final 
analysis and final clinical study report will be  prepared once all data (through the SFU Visit) 
have been collected.
Has been changed to:
After the final Week 48 Visit, an An interim analysis will be performed based on all data 
available is planned at that time. FurtherWeek 48 , details related to this interim analysisof 
which will be outlineddocumented in the SAP . Additional interim analyses may be 
performed (details of which will be docu mented in the SAP). Corresponding interim 
Clinical Study Reports (CSRs) may be written . A final analysis and updated final clinical 
study reportCSR will be prepared once all data (through the SFU Visitvisit and including the 
OLE Period) have been collected.PUBLIC d for alld for al
y medicy medic
bebeCOPYrse se
High LeHigh L
lationshations
of f intereintere
ThisAdocumentnal Wal W
e.FurthFurth
ysis andis and
ave beene bee
Has bHas cannote sumsum
lannedannedbe m (H(H
Es leadEs lead
mmusedationion
coded aded a
be summsumm
HLT)HLTtosubjecsubje
nnSeSesupport p to t
t will bewill b
cts itany wilwi
el Term el Term
o IMP IMPmarketing ill includel inclu
be codede code
ll be ll bauthorization es 
mass mass 
mary ary 
nd antibnd antib
e descripdescri
application interimteri
k4848VisV
er details er detai
final clininal clin
collectedollect
chanchanand arizriz
many and nd
ng to witng to w
ed anded anextensions in the Sn the S
ected acted a
cordingording
arized drized d
PTPTor uuvariationsde all sall s
d accordd accord
summasumma
(HLT),HLT)
P, AEs leAEs le
ummammathereof. tiv
ubb
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 209of 26318.4 Protocol Amendment 3
This was a global amendment. The changes are detailed below in Amendm ent 3.1.
18.5 Protocol Amendment 3.1
Rationale for the amendment
The protocol has been amended for the following reasons:
xMoved subject self -injection training into the start of the OLE Period at Week 48.
xAdded the description of the Patient Global Assessment o f PSO, which was inadvertently 
deleted in global Protocol Amendment #2, back into Section 9.
xUpdated the name and contact information of the Clinical Trial Biostatistician.
Global changes:
Minor spelling, editorial, and formatting changes were made through out the document.
Specific changes:
Change #1
Clinical Trial Biostatistician
Name:
Address: UCB Biosciences
8010 Arco Corporate Drive, Raleigh, NC 27617, USA
Phone:
Fax:
Has been changed to: 
Name:
Address: UCB
208 Bath Road, Slough, SL1 3WE, UK
Phone:
Fax:
Change #2
Table 5‒2: Schedule of study assessments, OLE Period
Table Footnote “n”
nFrom Week 48 through Week 72, the dosing window is ±7 days relative to the scheduled 
dosing visit. From Week 76 through the Week 144/PEOT visit, the dosing window is ±14 
days relative to the scheduled dosing visit.
Has been changed to:PUBLIC porate Drorate DLIC
PUPUCOPY C
ThisTdocument enmhange #ange 
TablTablcannotUCBCB
208 208no
ccccacot be bused edusutove, Rave, Rtosupport po
leigluppany marketing istician.istician.
ughhout theout tauthorization advertendverten
application Bath Rath R
onat
pliclicplicplic 2atioicaand RoaRoadany anextensions gh, NC 2h, NC 2s
nsteexor orvariations e docudocthereof. um
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 210 of 263n From Week 48 through Week 72, the dosing window is ±7 days relative to the scheduled 
dosing visit. From Week 76 through the Week 140 Visit, the dosing window is ±14 days 
relative to the scheduled dosing visit. 
Change #3Section 7.2 Treatments to be administered, paragraph 5
During the OLE Period, IMP administration on weeks with no scheduled clinic visit should 
primarily be performed by subjects at home. Se lf-injection training will be provided to the 
subject/caregiver by qualified site personnel at Week 40 and Week 44. At Week 48 and 
subsequent clinic visits, the subject/caregiver  will perform self-administration under the 
supervision of the site staff to ensure that study medication is being properly and safely injected. 
Has been changed to:
During the OLE Period, IMP administration on weeks with no scheduled clinic visit should 
primarily be performed by subjects at home. Se lf-injection training will be provided to the 
subject/caregiver by qualified site personnel at Week 40 and Week 44 Week 48. Additional 
training may be provided by site staff at subsequent clinic visits as needed. At Week 48 and 
subsequent clinic visits, the subject/caregiver  will perform self-administration under the 
supervision of the site staff to ensure that stud y medication is being properly and safely injected. 
Change #4
Section 7.5 Handling and storage  requirements; paragraph 6
In addition, the Investigator (or designee) will instruct the subject on how to handle the IMP 
during transport, and how to store the IMP following the instruction guide. Cooler bags with 
freezer packs will be provided to the subjects. Sp ecific attention will be put on the transport from 
site to home using cold bags, and the subject will be instructed to put the IMP as quickly as 
possible into his/her refrigerator. In case of broken refrigerator, or broken or lost syringes, the subject will inform the site immediately and new IMP will be supplied. All efforts should be made to follow the treatment scheme as per protocol.
Has been changed to:
In addition, the Investigator (or designee) will instruct the subject/ caregiver on how to handle 
the IMP during transport, and how to store the IMP following the instruction guide. Cooler bags 
with freezer packs will be provided to the subjects/ caregivers . Specific attention will be put on 
the transport from site to home using cold bags, and the subject /caregiver will be instructed to 
put the IMP as quickly as possible into his/her refrigerator. In case of broken refrigerator, or 
broken or lost syringes, the subject will inform the site immediately and new IMP will be 
supplied. All efforts should be made to follow the treatment scheme as per protocol.
Change #5
Section 7.8.1.1 Topical medications; paragraph 3
In the OLE Period, the medications listed as permitted for the double-blind Treatment Period 
will be allowed. In addition, topical steroids and vitamin D analog ointment will be permitted for 
use, as needed. 
Has been changed to:PUBLICrage reqage re
esignee)esignee)
ore the Iore the 
d to thd to COPYentn
l perforl perfo
y medicy med
ThisCdocumentngg
er packpack
sport froport fr
he IMP e IMP
roken orken o
suppliesupplie
ChChcannot menme
to::
Investigvestig
transpranspbeimmedme
nt schnt schusede subjeubje
the subjhe subj
r. In caIn ca
diditowi
MP folMP fol
cttsupport ationio
uirementremen
ll instrl instany visivis
selfself--fffadmad
n is ben is bmarketing and nd 
uled clinicled cli
g will be pwill b
eek 44 ek 44 Wmaits aitsauthorization uld d 
o the he 
and and 
der the er the
safesafe
applicationator
ort, andort, and
will be prwill be 
m site to m site t
as quicklyquick
lost syrinst syr
All effAll efand r (or d(or dany ely andely an
me as peme as peextensionsts; pa; pa
ruct the uct the 
owing thwing th
s. Specif. Speci
ect will ct will 
of of brobr
dor aravariationsprovidrovi
Week 48eek 48
as neede neede
ministrainistr
eing prong prothereof.y injectinject
c visit svisit s
ded
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 211 of 263In the OLE Period, the medications listed as permitted for the double-blind Treatment Period 
will be allowed. In addition, anytopical steroids and vitamin D analog ointment will be 
permitted for use, as needed. These topical medications sh ould not be used within 
approximately 24 hours prior to study visits requiring IGA and PASI measures .
Change #6
Section 7.9 Blinding; paragraphs 4-7
During the double-blind Treatment Period of the study, the Sponsor will provide blinded and 
unblinded site monitors for the purposes of verify ing safety, efficacy, and drug administration 
and documentation records. Unblinded study site personnel need to be available in order to 
resolve queries. Study monitors and study site personnel, blinded to treatment assignment, will 
not discuss or have access to any drug related information.
Study sites will be required to have a written blinding plan in place, signed by the Principal 
Investigator, which will detail the site’s steps for ensuring that the double -blind nature of the 
study is maintained. Sites will be instructed to keep study subjects blind to the IMP as detailed in 
the site blinding plan.
Further details are provided in the study manual and site blinding plan.
For subjects participating in the OLE Period, there will be no blinding and the blinding 
procedures described above will no longer apply.
Has been changed to:
During the double-blind Treatment Period of the study, the Sponsor will provide blinded and 
unblinded site monitors for the purposes of verify ing safety, efficacy, and drug administration 
and documentation records. Unblinded study site personnel need to be available in order to 
resolve queries. Study monitors and study site personnel, blinded to treatment assignment, will 
not discuss or have access to any drug related information. This will continue at least until all 
subjects have completed the double-blind Treatment Period of the study.
During the double-blind Treatment Period of the study, the Sponsor will provide blinded and 
unblinded site monitors for the purposes of verify ing safety, efficacy, and drug administration 
and documentation records. Unblinded study site personnel need to be available in order to 
resolve queries. Study monitors and study site personnel, blinded to treatment assignment, will 
not discuss or have access to any drug related information.
Study sites will be required to have a written blinding plan in place, signed by the Principal 
Investigator, which will detail the site’s steps for ensuring that the double -blind nature of the 
study is maintained. Sites will be instructed to keep study subjects blind to the IMP as detailed in the site blinding plan.
Further details are provided in the study manual and site blinding plan.
For subjects participating in the OLE Period, there will be no blinding and the blinding 
procedures described above will no longer apply.PUBLIC er aper 
ment Perment Per
e purpe purp
blblCOPY l and siteand sit
d, there w, there 
pplypply
Thisdocumenteries. Sies. S
uss or hss or h
dy sites y sites
nvestigavestiga
study study
thethecannot d t
blind Trind Tr
onitors nitors 
tion reon re
tbeo any any 
the dothe dousedoses oes o
inded stunded stu
and stuand st
drdtood of td of 
of vfvsupportwill be nll be n
heany blinding lindingmarketing nt assigassi
igned by gned b
doubleouble -b
cts blind ts blinauthorization ded andded and
ministranistra
in orden orde
gn
application or 
cords. Uords. U
udy monity mon
ave accesse acce
will be reqll be r
tor, whichor, whic
maintaiaintaand atment ment 
the puthe pany g relatg rela
bleble--blinblinextensions e study, tudy, 
erifyingrifying
dy site py site 
y site psite p
tor variations y
blind nnd 
to the Ito the I
g plan.plan.
blindinlindinthereof. r to to 
ment, wment, w
the Prinhe Prin
na
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 212 of 263Change #7
Section 8 STUDY PROCEDURES BY VISIT; paragraph 1, second bullet
xThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled 
dosing visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the scheduled dosing visit. From Week 28 through the Week 72 Visit, the dosing window is ±7 days relative to the scheduled dosing visit. From the Week 76 Visit through the Week 144/PEOT, the dosing window is ±14 days relative to the scheduled dosing visit.
Has been changed to:
xThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled 
dosing visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the 
scheduled dosing visit. From Week 28 through the Week 72 Visit, the dosing window is 
±7 days relative to the scheduled dosing visit. From the Week 76 Visit through the Week 140
Visit Week 144/PEOT, the dosing window is ±14 days relative to the scheduled dosing visit.
Change #8
Section 8.3.1 Week 48 Visit (±7 days relative to Baseline); paragraph 1
The following procedures/assessments will be performed/recorded after completion of 
assessments listed for Week 48 (Section 8.2.13) and prior to administration of IMP:
Has been changed to:
The following procedures/assessments will be performed/recorded after completion of 
assessments listed for Week 48 of the double-blind Treatment Period (Section 8.2.13) and 
prior to administration of IMP:
And the following paragraph regarding subject self-injection was added:
Self-injection training will be provided to the subject/caregiver by qualified site personnel 
to allow self-injection to be performed at home  after Week 48. Additional training may be 
provided by site staff at subsequent clinic visits as needed (see Section 7.2).
Change #9
Section 8.3.5 Week 64, Week 84, Week 108, Week 132 Visits (±14 days relative to Baseline)
Has been changed to:
Section 8.3.5 Week 64 (±7 days relative to Basel ine), Week 84, Week 108, Week 132 Visits 
(±14 days relative to Baseline)
Change #10Section 8.3.6 Week 72 and Week 120 Visi ts (±14 days relative to Baseline)
Has been changed to:
Section 8.3.6 Week 72 (±7 days relative to Baselin e) and Week 120 Visits (±14 days relative 
to Baseline)PUBLIC ents willents wil
of the dft h e  d
P:P:COPYo Base Bas
performperfo
2.13) an.13) an
This documentchangehang
n 8.3.58.3.5
4 days rdays 
ChangeChang
SecSeccannot at subsu
Week 6Week 6
dbebe pp
be perfbe per
bsebseused egardingardin
proviprovto ubleblesupported/d/
d prior toprior t
be perfore perfo
blinblany ); par); pa
recordrecormarketing ays relays rel
e dosing wdosing w
Visit throuVisit thr
to the scho the scauthorization isit.sit.
schedusched
application 4, WeWe
to:o:
Week 64Week 6
elative toative 
#1010
6and ququ
eekekany ed d
med atmed a
ent clinent cextensions rmed/remed/re
nd Tred Tre
g subjecsubjec
to tto tor admadvariations heduedu
graph 1graph 
ded afteed afte
dminisministhereof. uled ed 
ive to the to th
windowwindow
ugh theugh the
uleduled
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 213 of 263Change #11
The following subsection was inadvertently deleted from global Protocol Amendment #2. 
The subsection has been added back and subsequent subsections were renumbered.
Section 9.9 Patient Global Assessment of psoriasis
The Patient Global Assessment of PSO is a PSO- specific item in which the patient responds 
to the multiple- choice question, “How severe are your psoriasis-related symptoms right 
now?” Possible responses to the question a re “no symptoms,” “mild symptoms,” “moderate 
symptoms,” “severe symptoms,” or “very severe symptoms.”
The Patient Global Assessment of psoriasis will be performed at the visits specified 
Table 5‒1.
Change #12
Section 15.1 Informed consent
The following sentence was added:All subjects enrolling in the OLE Period will sign a new ICF.
18.6 Protocol Amendment 4
Rationale for the amendment
The protocol has been amended for the following reasons:
xChange the sponsor company name from “UCB Biopharma SPRL” to “UCB Biopharma 
SRL” since the name of the legal form of th e entity UCB Biopharma has changed into 
“société à responsabilité limitée” abbreviated “SRL”.
xUpdate the name and contact information for the Study Physician.
xUpdate withdrawal criterion to be valid through the entire study, not just up to Week 48.
xMoved the PHQ-9 variable from an other efficacy variable to an other safety variable
xMoved the PHQ-9 description from the assessment of efficacy section to the assessment of 
safety section
xClarify duration of monitoring for the DMC  and the Cardiovascular and Neuropsychiatric 
Adjudication Committee.PUBLIC or the folr the fo
any namany nam
e lege leCOPY n a nn a
44
This document ctiotio
ify duray dura
Adjudicadjudicacannot criteite
Q9 varia9 varia
PHQHQ--9 d9
onnbe ntact act 
rionrionusede fe 
al formform
tée” abbée” ab
infinfto o
from “rom support wing wing reany CF.CF.marketing authorization onds nds 
ght ht 
“modermoder
pececifieifie
application descriscr
ion of moon of m
ion Common Comand to
ble frome from
iptiiptiany mmatiat
be valibe vextensions asons:sons:
UCB BiCB Bi
f the enft h e  e n
reviatedeviated
onor variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 214 of 263Specific changes:
Change #1
Change #1
Sponsor name on the cover page 
Sponsor
UCB Biopharma SPRL
Allée de la Recherche 601070 Brussels
BELGIUM
Has been changed to:Sponsor
UCB Biopharma SRL
Allée de la Recherche 601070 Brussels
BELGIUM
Change #2
Sponsor name on the title page in the study contact information
SponsorUCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels BELGIUMHas been changed to:
Sponsor
UCB Biopharma SRL
Allée de la Recherche 60
1070 Brussels BELGIUMPUBLIC ge inge COPY 
This document Biopharmiophar
lée de lée de l
1070 1070cannot 60
GIUMGIUM
ged toged tobe usedthe stuhe stto support any marketing authorization 
application ma ma SRLSRL
RechercRecher
ssels Bsels Band any extensions dy contay contor variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 215of 263Change #3
Study Physician
Name:
Address: UCB Biosciences
8010 Arco Corporation Drive
Raleigh, NC 27617
USA
Phone:
Fax:
Has been changed to: 
Name:
Address: UCB Biopharma SRL
Chemin du Foriest
B-1420 Braine- l’Alleud
Belgium
Phone:
Fax:
Change #4
Section 4.3.1 Other efficacy variables
The following bullet has been deleted
xChange from Baseline in Patient Health Questionnaire -9 (PHQ -9) scores
Change #5
Section 4.3.2 Other safety variables
The following bullet has been added:
xChange from Baseline in Patient Health Questionnaire -9 (PHQ -9) scoresPUBLIC LIC
UBPUPUCOPY Y
This document #55
on 4.3.2n 4.3.
The follhe foll
xxcannothas behas be
BaselinBaselinbe acy vaacy vaused dto otsupport upsany ymarketing intinin
kein
maauthorization 
application Other Other
wing buwing bu
frandn deledele
n Patin Patiany ablesables
tedtextensions s
ionor variations onnn
atithereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 216 of 263Change #6
Section 6.4 Withdrawal criteria
8a. At Week 28 and all following visits up to Week 48, subjects on continuous treatment for at 
least 12 weeks with a persistent IGA score ≥3 over at least a 4 -week period are defined as 
nonresponders and should discontinue IMP. 
Has been changed to:
8b. At Week 28 and all following visits, subjects on continuous treatment for at least 12 weeks 
with a persistent IGA score ≥3 over at least a 4 -week period are defined as nonresponders 
and should discontinue IMP. 
Change #7
Section 9.4 Patient Health Questionnaire-9
This subsection has been moved to Section 12.3.8
Change #8
Section 12.3.8 –Patient Health Questionnaire-9
A new subsection has been added (moved from Section 9.4):
The PHQ-9 is a multipurpose instrument  for screening, diagnosing, monitoring, and 
measuring the severity of depression (K roenke et al, 2001). The PHQ-9 scores for 
depression range from 0 to 27, with higher scores  indicating worse state. A score of 5 to 9 is 
considered to be minimal symptoms of depression. A score of 10 to 14 is considered minor depression, dysthymia, or mild major depre ssion. A score of 15 to 19 is considered to 
indicate moderately severe major depression, and a score ≥20 is considered to be severe 
major depression.
The PHQ-9 will be assessed at the visits specified in Table 5-1 and Table 5-2.Refer Section 6.4 for PHQ-9-related withdrawal criteria.
Change #9
Section 12.4.4 Data Monitoring and Adjudication Committees
The DMC membership includes experienced clinic ians and a statistician, all of whom have 
expertise in clinical trials. Cardiovascular a nd Neuropsychiatric Adjudication Committees will 
also periodically review data from this trial. Both Data Monitoring and Adjudication Committee 
members may not participate in the study as principal or co-Investigators, or as study subject care physicians. The duration of membership for the committees will be inclusive of data 
through the last subject completing the Week 48 Visit for PS0015. Detailed role, scope, 
responsibilities, and complete procedures, as well  as the identity of members, are described in 
the separate committee charters.PUBLIC nn
moved fmoved 
nstrumestrume
pressiopressio
27, wi27, COPY naireaire
Thisadocument e #9#9
tion 12on 12
The DMThe DM
expeexpcannot assessessesse
.4 for Pfor Pbeild
re majore majused(
th highh high
toms ofoms o
d majd majtont f
KroenKroe
hsupport rom Sectom Sec
for scror any marketing authorization st 12 wet 12 we
nrespondespond
application HQHQ
4.44 DaD
C membmem
clandd at theat the
99--rranyd
depresdepreextensionstion 9.on 9
reeningeenin
keeetetalal
r scoresr scores
depressepress
depreepreor 4variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 217 of 263Has been changed to:
The DMC membership includes experienced clinic ians and a statistician, all of whom have 
expertise in clinical trials. Cardiovascular a nd Neuropsychiatric Adjudication Committees will 
also periodically review data from this trial. Both Data Monitoring and Adjudication Committee 
members may not participate in the study as principal or co-Investigators, or as study subject 
care physicians. The DMC will monitor the study thro ugh the last subject completing the 
Week 48 and SFU visit (for subjects not participating in the OLE period). The 
Cardiovascular and Neuropsychiatric Adjudica tion Committees will monitor the study 
through the last subject completing the OLE and SFU Periods for PS0015. Detailed role, 
scope, responsibilities, and complete procedures, as well as the identity of members, are described in the separate committee charters.
18.7 Protocol Amendment 5
This was a global amendment. The changes are detailed below in Amendment 5.1.
18.8 Protocol Amendment 5.1
Rationale for the amendment
Change the dose regimen at Week 64 (or at the next scheduled clinic visit after implementation 
of Protocol Amendment #5.1 if the subject has already completed the Week 64 visit) from bimekizumab 320mg Q4W to bimekizumab 320mg Q8W, based on pooled data from the Phase 3 
studies (PS0008, PS0009, and PS0013), which demons trated that during the maintenance period 
bimekizumab 320mg Q8W provided essentially the same efficacy as bimekizumab 320mg Q4W.
Add pregnancy tests every 4 weeks during the OLE Period.
Corrected the visit window for the Week 24 visit from 7 days to 3 days.
Added provision for collecting a concurrent sample  for central laboratory testing if laboratory 
tests are performed locally.
In addition, minor corrections, including typographical/grammatical errors, have been made.
Modifications and changes
Global changes
No global changes have been made.
Specific changes
Change #1
Section 1, Summary; Section 5.2.3, OLE Period; Section 7.10, Randomization and 
numbering of subjects 
At Week 96, for subjects receiving bimekizumab 320mg Q4W, if PASI90 is achieved, the 
subject’s dosing interval will change from 320mg Q4W to 320mg Q8W (default), unless, based 
on medical judgment, the Investigator decides differently.
Has been changed to:PUBLICmab
), whic, whic
d essentd essen
eeks dureeks dur
r the r thCOPY next schnext 
has alreahas alrea
b320m320
This documentchangehange
ecific cific c
ChangChang
SecSecannot ctiotio
and chnd ch
gesgesbe ons, inons, usedWeek 2Week 2
a concurconcurtong ngthethe
4support dy comcom
mgQ8W, Q8W
demonstrdemon
ally the slly the 
OLany duled cluled 
mplemarketing mendmentendmeauthorization he 
study study
tailed roiled ro
bers, areers, are
application have beehave be
hangesanges
#1#1and angesngesany uding uding ttextensions tratedated
same effame ef
LE PeriE Peri
visit frovisit fro
ent samnt samorbaasedsed
dt hdt hvariations nt 
linic visnic vis
ted theed thethereof. 5.1.5.1.
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 218 of 263The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W at Week 64 or at the next scheduled clinic visit after 
implementation of Protocol Amendment #5.1 if the subject has already completed Week 64.
Change #2
Section 5.6, Schedule of study assessments
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 219 of 263Table 5-2: Schedule of study assessments, OLE Period
Visita/
Week
Protocol activity
48 (1st OLE dose)Year 2 Year 3
SFUb52
56
60
64
68
72
76
80
84
88
92
96
100
104
108
112
116
120
124
128
132
136
140
144/PEOT
C CCHCHCHHCHHCHHCHHCHHCHHCC
Pregnancy testing (urine)gXX X X X X X X X XX
IMP administration –Q4W n, oX XXXXXXXXXXXXXXXXXXXXXXX
IMP administration –Q8W n, oX X X X X X X X X X X X
gPregnancy testing will consist of urine pregnancy testing at all visits. 
PUBLIC 
COPY CCYXXYYYYPYY
XXXPPYPYOOPYXXOOOOCOCOCOCOOThis 
document 
cannot 
be 
used 
to support XX
XXtorororor
any CCnyXXnynynyanyXXaaannnana
marketing 
1
104104
1088gmarkket
ng
Hmmmm
authorization 
ahoapplication 
and 
any 
extensions 
or rrrrvariations 
ons
HHHCooonaioaaatria XXXXaaaririivari
XXvavavavva
thereof. Year 3ear 3112112
11616eoeoothereo
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 220 of 263Has been changed to:
Table 5-2: Schedule of study assessments, OLE Period
Visita/
Week
Protocol activity
48 (1st OLE dose)Year 2 Year 3
SFUb52
56
60
64
68
72
76
80
84
88
92
96
100
104
108
112
116
120
124
128
132
136
140
144/PEOT
C CCHCHCHHCHHCHHCHHCHHCHHCC
Pregnancy testing (urine)gXXXXXXXXXXXXXXXXXXXXXXXXX
IMP administration –Q4W n, o, p X XXXXXXXXXXXXXXXXXXXXXXX
IMP administration –Q8W n, oX X X X X X X X X X X X
gPregnancy testing will consist of urine pregnancy testing at all visits. Home pregnancy test kits will be provide d to participants for use between clinic
visits.
pQ4W IMP administration only applies to those su bjects who have not yet changed to Q8W at Week 64, or at the next scheduled clinic visit (ie, Week 
72, Week 84, Week 96, Week 108, Week 120, or Week 132) if the subject has already completed the Week 64 visit after implementati on of 
Protocol Amendment #5.
PUBLIC XXCIC visits. isits. HoHo
ts who has who h
ek 132) iek 132) 
IIICCCCOPY
YYHHCPPYPYYY OOPY
Y
XXXXOOOPOPPCOOPXXXCOCOCOCOCThis 
document 
cannot 
be 
used thehe
tove not ye not 
subjsubj
support XXXtorXXXXororortpporXX
pppopopopppo
me pregnapregna
yet
pppppp
any nyHHCnynynyany
Xaa
marketing 9
100100
1044tttinnnmarkket
n
authorization 
autapplication 
and 
any 
extensionsXsncy testcy tes
changedhanged
ct has alrhas al
sssor XXorororororo
variations
10810
1212iaions
CHHiaiaiataria
XXXXaaarvaXvvvv
thereof. YeaYeerererther
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 221 of 263Change #3
Section 5.7, Schematic diagram
Figure 5-2: Schematic diagram, OLE Period (Week 48 through Week 144)
1:1 re-
randomization
≥PASI90<PASI90
≥PASI90
20 weeks 
after last 
doseWeek 48 Open-label extension period
Safety follow -up 
visit 20 weeks 
after last dose
52 84 Week 60 68 76 92 100 108 116 124 132 140 56 88 64 72 80 96 104 112 120 128 136 144Bimekizumab 320mg Q4W
Bimekizumab 320mg Q8WSecukinumab
300mg Q4WBimekizumab 
320mg Q4W
Bimekizumab 
320mg Q8W
Secukinumab
300mg Q4WBimekizumab 
320mg Q4W
Bimekizumab 
320mg Q8W
≥PASI90
All Q4W All Q4W All All All All* Q4W Q4W Q4W Q4W Q4W Q4W Q4W Q4W Q4W All All All All All Q4W Dosing
PASI=Psoriasis Area Severity Index; PASI90=90% improvement in the PASI score; Q4W=every 4 weeks; 
Q8W=every 8 weeks
*At Week 96, for subjects receiving bimekizumab 320mg Q4W, if PASI90 is achieved, the subject’s dosing interval 
will change from 320mg Q4W to 320mg Q8W (default), unless, based on medical judgment, the Investigator 
decides differently.PUBLIC=90% im90% im
mekizumaekizuma
20mg Q820mg Q8COPY PY9292OPPY
8888 96PYPYPYPY
This document cannot be used to320
(defau(defausupport 00011
rovement ovemen
0mg Q4mg 
)any any108108yaany
44 112nynymarketing g 
mmrketing
Q4WW Q4WQ4WAllAll Aauthorization authauthSaa
application and any extensions in the the
4W, if PAW, if P
, unless, unlessor PAPAvariations ria 1166 1212riariaio
a120120aationQ4WQ4W QQAllAlthereereof. herefollow -u
20 wee
after last 
hhth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 222 of 263Has been changed to:
Figure 5-2: Schematic diagram, OLE Period (Week 48 through Week 144)
PASI=Psoriasis Area Severity Index; PASI90=90% improvement in the PASI score; Q4W=every 4 weeks; 
Q8W=every 8 weeks
Note: The subject’s dosing interval will change from bimekizumab 320mg Q4W to bimekizumab 320mg Q8W 
at Week 64, or at the next scheduled clinic visit (ie,  Week 72, Week 84, Week 96, Week 108, Week 120, or 
Week 132) if the subject has already completed the Week 64 visit prior to implementation of 
Protocol Amendment #5.1.
Change #4
Section 5.8.2, Dose selectionTherefore, a bimekizumab dose of 320mg Q4W through Week 16 and 320mg Q4W or Q8W 
thereafter was selected for this study.
Has been changed to:
Therefore, a bimekizumab dose of 320mg Q4W through Week 16 was selected for this study.
Based on pooled data from the Phase 3 studies (PS0008, PS0009, and PS0013), during the 
maintenance period bimekizumab 320mg Q8W provided efficacy results similar to 
bimekizumab 320mg Q4W. Therefore, at Week 64, subjects receiving 
bimekizumab 320mg Q4W will switch to receive bimekizumab 320mg Q8W. Subjects who are receiving bimekizumab 320mg Q4W treatment who already completed the Week 64 
visit at the time of implementation of Protocol Amendment #5.1 will be switched to 
bimekizumab 320mg Q8W at the next scheduled clinic visit. This change in dosing interval 
PUBLICSI90=90SI90=90
al will chal will ch
ledled
LIIIIIIIIIIIICCCCCCCCCCCC 
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 
Thismdocumentbimbim
was selwas sel
been chaen cha
hereforerefor
BaseBasecannot ose selese sele
mekizmekizbe usedangeng
linic visinic vis
y compcomp lelto % im
e fromef r o msupmprovemmprove
uppppppppppppppppppppppppoooooooooooorrrrrrrrrrrrtttttttttttt 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy 
mmmmmmmmmmmmmmmmmmmmmmmmmmmmaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaarrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeettiinggggggg tion 
aaaaaaaaaaaaaaaaaaaaaauuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuttttttttttttttttttttttttttttttttttttttttttttttttttttttthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhoooorrrriizati
application ti
umab doumab do
ected for tted for
nged toged t :
, a bimeka bime
poolpoand onnany extensionsment in thment in th
m bimekizimekiz
(ie, Weeke, Wee
ed the Wthe W
nssssssssssss 
oooooooooooorrrrrrrrrrrr  
vaaaaaaaaaaaaaaaaaarrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrriiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaattttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiooooooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnsssssssssssssssssssssssssssssssssssssssssssssssssssssssss 
thhhereeeeooooffffffffffffffffffffffffffffffffff..............  
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 223 of 263will reduce subject and site burden, while allowing collection of more long-term safety data 
on the bimekizumab 320mg Q8W dosing regimen.
Change #5
Section 7.2, Treatments to be administeredThe following text has been added:
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W at Week 64 or at the next scheduled clinic visit after 
implementation of Protocol Amendment #5.1 if the subject has already completed the Week 64 visit. 
PUBLIC COPY 
This document cannot be used to support any marketing complmpauthorization fter ter 
letet
application and any extensions or variations thereof. ed the d the 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 224 of 263The following table:
Table 7 -2: Dosing scheme, OLE Period
Week
Dose 
Assignment
48 (1st 
OLE Year 2 Year 352
56
60
64
68
72
76
80
84
88
92
96
100
104
108
112
116
120
124
128
132
136
140
Bimekizumab 
320mg Q4W●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
Bimekizumab 320mg Q8W ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●●
OLE=Open-Label Extension; Q4W=every 4 weeks; Q8W=every 8 weeksNotes: A bimekizumab 160mg injection is depicted by a black circle (
●).
Has been changed to:
PUBLIC 
COPY 
YThis 
document 
cannot 
be 
used 
to support 
any ymarketing 
101
112112gkting
●●●●●kkketttrk
●●●●am
authorization 
autaapplication 
and 
any 
extensions 
or 
variations ●n●●nnnstontttio
thereof. Year 3ar 31161
2020ofofofthere
of
●●●●thththeth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 225 of 263Table 7-2: Dosing scheme, OLE Period
Week
Dose 
Assignment
48 (1st 
OLE) Year 2 Year 352
56
60
64a,b
68
72a,b
76
80
84a,c
88
92
96a,b
100
104
108a,c
112
116
120a,b
124
128
132a,c
136
140
C C C H C H C H H C H H C H H C H H C H H C H H
Bimekizumab 
320mg Q4W●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
Bimekizumab 320mg Q8W ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●●
C=clinic; H=home; OLE=Open-Label Extension; Q4W=every 4 weeks; Q8W=every 8 weeksNotes: A bimekizumab 160mg injection is depicted by a black circle (
●).
aThe subject’s dosing interval will change from bimekizumab 320mg Q4W to bimekizumab 320mg Q8W at Week 64 or at the next scheduled clinic 
visit (ie, Week 72, Week 84, Week 96, Week 108, Week 120, or Week 132) after implementation of Protocol Amendment #5.1 if the subj ect has 
already completed the Week 64 visit.
bSubjects whose dosing interval is changed to bimekizumab 320mg Q8W should be dosed at this visit and w ill receive kits for home administration 8 
weeks later.
cSubjects whose dosing interval is changed to bimekizumab 320mg Q8W  should NOT be dosed at this visit and will receive kits for ho me 
administration 4 weeks later.
PUBLIC ee
320mg320mg QQ
mabmab 320320
COPY 
Yevery 8 wevery 8 
Q4W toQ4W t
k 132)k 132
YYYThis 
document 
cannot 
be 
used 
to mggQ8WQ8
support bimekizumekiz
after impleter imp
W shouldW should
Ws hW
any nksks
umnnny
marketing 
112112ting
CC Htitintingktin
●●●●●●kkkem
rk
●●●mmmam
authorization 
a
YearYearho66utututautapplication 
and 
any 
extensionsbe dosebe dos
hould NOould N
ormentament
variations ●●●nonononaton
abb320m320m
ti
atatat
thereof. 
1
120120a,baere
of
HHereereretherethththth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 226 of 263Change #6
Section 7.9, BlindingThe following text has been added:
After all subjects have completed the double -blind Treatment Period of the study and the 
interim analysis has occurred, unblinded study site personnel can perform assessments in 
the OLE Period of the study.
Change #7
Section 8.2.8, Week 24 Visit (±7 days relative to Baseline)
Has been changed to:Section 8.2.8, Week 24 Visit (±3 days relative to Baseline)
Change #8
Section 8.3.4, Self-injection at home (Weeks 60, 68, 76, 80, 88, 92, 100, 104, 112, 116, 124, 
128, 136 and 140)
Subjects receiving bimekizumab 320mg Q4W will be given the opportunity for self-injection of 
bimekizumab at home on the following weeks: Weeks 60, 68, 76, 80, 88, 92, 100, 104, 112, 116, 
124, 128, 136 and 140.
Subjects receiving bimekizumab 320mg Q8W will be given the opportunity for self-injection of
bimekizumab at home on the following weeks: Weeks 80, 88, 104, 112, 128, and 136.
Has been changed to:
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W at Week 64 or at the next scheduled clinic visit (ie, Week 72, 
Week 84, Week 96, Week 108, Week 120, or Week 132) after implementation of Protocol Amendment #5.1 if the subject has already completed the Week 64 visit. 
Subjects receiving bimekizumab 320mg Q4W will be given the opportunity for self-injection of 
bimekizumab at home on the following weeks: Weeks 60, 68, 76, 80, 88, 92, 100, 104, 112, 116, 
124, 128, 136, and 140 . This only applies to those subj ects who have not yet changed to 
bimekizumab 320mg Q8W.
Subjects receiving bimekizumab 320mg Q8W will be given the opportunity for self-injection of
bimekizumab at home on the following weeks: Weeks 80, 88, 104, 112, 128, and 136.
Subjects of childbearing potential should cond uct a home pregnancy test every 4 weeks. In 
case of a scheduled home self-injection the pregnancy test needs to be performed immediately prior to self-injecting bimekizuma b at home. If the pregnancy test result is 
positive, IMP should not be administer ed and the site should be contacted.PUBLIC 20mg Q420mg Q
lowing lowing 
bbCOPY eks 60,ks 60,
Thisbdocumentreceivinceivin
zumab umab 
, 128, 1128, 1
imekizmekiz
SubjSubjcannotintervnterv
mggQ8WQ8W
96, We6, We
ndmendmenbe used 320mg Q20mg Q
llowinglowinto weeksweekssupport 68, 76, 8, 76, 
W will bW will b
s: Ws: Wany marketing authorization he e 
nts in ts in 
application ek 
#5#5.1.1ifi
g bimekizbimeki
t home home o
6, and 14, and 
mabmab 32032
ceivand willwill
W at Weeat We
108, W108, any l chanchextensions be givengiven
Weeks 60eeks 60
Q8W wilW wil
weeks: eeks:or , 888variations 8, 99thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 227 of 263Change #9
Section 8.3.5, Week 64 (±7 days relative to Bas eline), Week 84, Week 108, Week 132 Visits 
(±14 days relative to Baseline)
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:
Has been changed to:
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W as follows:
xAt Week 64 if the subject has not completed the Week 64 visit prior to implementation 
of Protocol Amendment #5.1.
xAt Week 84 if the subject has already completed the Week 72 visit prior to 
implementation of Protocol Amendment #5.1.
xAt Week 108 if the subject has already completed the Week 96 visit prior to 
implementation of Protocol Amendment #.15.
xAt Week 132 if the subject has already completed the Week 120 visit prior to 
implementation of Protocol Amendment #5.1.
Subjects whose dosing interval is being changed to bimekizumab 320mg Q8W will receive 
kits for home administration as follows:
xSubjects whose dosing interval is being changed to bimekizumab 320mg Q8W at Week 
64 should be dosed at this visit, and will r eceive kits for home administration 8 weeks 
later (Table 7-2).
xSubjects whose dosing interval is being changed to bimekizumab 320mg Q8W at 
Week 84, Week 108, or Week 132 should NOT be dosed at that visit, and will receive 
kits for home administration 4 weeks later (Table 7-2).
The following procedures/assessments will be performed/recorded. If IMP is administered on 
site during this visit, they need to be performed/recorded prior to administration of IMP:
Change #10
Section 8.3.5, Week 64 (±7 days relative to Bas eline), Week 84, Week 108, Week 132 Visits
(±14 days relative to Baseline)
After completion of the above -mentioned procedures, administration of IMP will occur
xat each of these visits for subjects on bimekizumab 320mg Q4W dosing, preferably by self-
injection under supervision of the site personnel
xat Week 64 for subjects on bimekizumab 320mg Q8W dosing, preferably by self-injection 
under supervision of the site personnel.
Distribution of IMP and accountability activities for home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7.PUBLIC g chg c
ows:ws:
val is beval is b
s visit, as visit, aCOPY mpletedmpleted
ntnt#5#5.1.1
hanangg
Thisxdocument #10#10
on 8.3.5n 8.3.
14 days4 days
After Aftercannotures/aes/ass
sit, theyt, theybe WeeWe
trationtratioused rval is val is 
ek 1ek 1toingg
d will d willsupport ed to bimto bi
g chanchaany he Weehe Weemarketing o im
visit priorsit pri
eek 96 viek 96 authorization mplemple
application , Week 6Week
relative elative
mpletiopletioand ssmesme
need toneed toany 2 sh2 sh
weeksweek
ntsntextensions nged to ged to
eceive kceive 
eing ching ch
houhouorekizumkizuvariations visit priovisit prio
ek 120 vk 120 vthereof.mentationtatio
r to r to 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 228 of 263x
Has been changed to:
After completion of the above -mentioned procedures, administration of IMP will occur:
xAt each of these visits for subjects on bi mekizumab 320mg Q4W dosing, preferably by 
self-injection under supervision of the site personnel. This only applies to those subjects 
who have not yet changed to Q8W after implementation of Protocol Amendment #5 .
xAtWeek 64 only for those subjects on bimekizumab 320mg Q8W dosing, preferably by 
self-injection under supervision of the site personnel.
Distribution of IMP and accountability activities for home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7. Home pregnancy test s will be provided 
for testing every 4 weeks as appropriate (Table 5 ‒2).
Change #11
Section 8.3.6, Week 72 (±7 days relative to Baselin e) and Week 120 Visits (±14 days relative 
to Baseline)
The following text has been added:
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W as follows:
xAt Week 72 if the subject has already completed the Week 64 visit prior to 
implementation of Protocol Amendment #5.1.
xAt Week 120 if the subject has already completed the Week 108 visit prior to 
implementation of Protocol Amendment #5.1.
As depicted in Table 7-2 ,subjects whose dosing interval is being changed to 
bimekizumab 320mg Q8W at one of these visits should be dosed at this visit and will receive kits for home administration 8 weeks later.
Change #12
Section 8.3.6, Week 72 (±7 days relative to Baselin e) and Week 120 Visits (±14 days relative 
to Baseline)
Distribution of IMP and accountability activities for home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7.
Has been changed to:
Distribution of IMP and accountability activities for home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7. Home pregnancy test s will be provided 
for testing every 4 weeks as appropriate (Table 5 ‒2).PUBLIChange frange f
lows:lows:
has alrhas alr
colcolAmACOPYeline) aeline)
This document #12#12
on 8.3.6n 8.3.6
BaselinBaselin
DistribDistrib
desdescannot,
Q8WQ8W
me adme admbe ocol
subjesubjeused mendmnd
has alras alr
llAmAmtoady cody co
mesupport om bimekm bim
many d WeekWeemarketinge pep
ests will ests willauthorization ts 
#5#5.
rably byrably by
erforerfor
application Week 72Week 7
e)
on of Ion of 
Sand t oneone
nistratistratany ndd
s whoses whose
e of teo fextensions kizumizu
mpleted pleted 
nt#5#5.1.1
ady comdy com
menmenor mamavariations 120 Vi120 Vithereof. med as ed as 
be prove prov
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 229 of 263Section 8.3.7, Week 96 Visit (±14 days relative to Baseline) 
The following text has been added:
The subject’s dosing interval will change from bimekizumab 320mg Q4W to 
bimekizumab 320mg Q8W at Week 96 if the subject has already completed the Week 84 
visit prior to implementation of Protocol Amendment #5.1. As depicted in Table 7-2,
subjects whose dosing interval is being changed to bimekizumab 320mg Q8W at Week 96should be dosed at this visit, and will receive  kits for home administration 8 weeks later.
Change #13
Section 8.3.7, Week 96 Visit (±14 days relative to Baseline) 
Distribution of IMP and accountability activities for home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7.
Has been changed to:
Distribution of IMP and accountability activities for home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7. Home pregnancy test s will be provided 
for testing every 4 weeks as appropriate (Table 5 ‒2).
Change #14
Section 12.2, Laboratory measurements 
Clinical laboratory assessments consist of serum  chemistry, hematology, and urinalysis. A 
centralized laboratory will be used to supply all laboratory test supplies and analyze all blood and urine samples for hematology, biochemistry, and urinalysis measurements. Any unscheduled 
laboratory testing should also be collected using the central laboratory. 
Has been changed to: 
Clinical laboratory assessments consist of serum  chemistry, hematology, and urinalysis. A 
centralized laboratory will be used to supply all laboratory test supplies and analyze all blood 
and urine samples for hematology, biochemistry, and urinalysis measurements. Any unscheduled 
laboratory testing should also be collected using the central laboratory. If tests are done locally, 
a concurrent sample should also be sent to the central laboratory whenever possible.
Change #15
Section 12.3.2, Pregnancy testingThe following text has been added:
Subjects of child-bearing potential should conduct a home pregnancy test every 4 weeks. 
Home pregnancy tests will be provided to participants for use at Weeks 60, 68, 76, 80, 88, 
92, 100, 104, 112, 116, 124, 128, 136, and 140. At weeks on which IMP dosing is scheduled asuremasurem
cocCOPYfor homfor ho
onon7.7.7.
Table 5Table 
This document amplemple
ry testintestin
currenturrent
ChaChcannot : 
y assessassess
oratory ratory 
es fes fbe ologyog
lso be clso be useden
nsist of ist of 
sed to sud to su
y,ybbto ts ts support Ho
‒2).2).anyadminisdmin
me preme pmarketing tion to beion to bauthorization k9696
later.ter.
application will bell be
or hemator hema
g should ashould
sample sample 
115and ments coents co
euany chemche
llected ullectedextensions serum chrum ch
pply all ply all 
mismisor variations tration tration t
egnancgnancthereof. performperform
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 230 of 263(specified in Table 5-1 and Table 5-2), a negati ve urine pregnancy test  result should be 
obtained immediately prior to the administration of IMP. In the case of a positive 
pregnancy test result, IMP should not be ad ministered and the site should be contacted.
Change #16
Section 14.7, Handling of dropouts or missing data
Missing data for the secondary efficacy variables (which are all binary) will be imputed using 
NRI. Additionally, the 2 missing data-handling approaches described above for the primary 
efficacy variable will be used for the secondary efficacy variables.
Has been changed to: 
Missing data for the secondary efficacy variables (which are all binary) will be imputed using 
NRI. Additionally, the 2 missing data-handling approaches described above for the primary efficacy variable will be used for the secondary efficacy variables. Additional missing data 
handling approaches may be described in the SAP.
18.9 Protocol Amendment 5.4
Rationale for the amendment
The protocol has been amended for the following reasons:
xTo collect additional long-term safety data, 
xTo explore safety data with subjects who ha ve temporarily stopped bimekizumab and could 
have been exposed to other treatments, and 
xTo provide an additional 48-week treatment period for subjects continuing their current 
treatment or reinitiating treatment at the Week 144/OLE2 Baseline Visit.
Modifications and changes
Global changes
The following global changes were made throughout the protocol:
xAn additional 48-week open label treatment period was added (OLE2 Period).
xThe maximum duration of the study has been changed. For the subjects in the OLE2 Period, 
maximum study duration will depend on the time between their participation in the OLE until 
Week 144 and the start of the OLE2 Period; ie, 209 weeks for subjects still being treated in 
the OLE Period and who will directly roll over to the OLE2 Period at Week 144; 225 weeks for subjects who have completed Week 144 and the SFU; these subjects will have a 4-week 
Screening Period before reinitiating treatm ent in the OLE2 Period; Between 209 and 225 
weeks for subjects who have completed Week 144 and are participating the in the SFU (for these subjects, the maximum study duration will depend upon when they stop the 20-week SFU period to enter the 4-week OLE2 Screening Period).
xImplementation of a new schedule of assessments  (Table 5-3) for the OLE2 Period have been 
made. PUBLICfollowfollow
safety dsafety d
h subjecth subject
er treatr treatCOPY P.P.
wini
This documentitionalional
e maximmaxim
maximumaxim
WeeWee
ththcannot chaha
global clobal c
4be reat
angangusedments,ents
week trweek tr
tmenmentowho hwho h
asupport g reasonsreason
ta, a, any marketing y) will bey) will b
ed aboved abov
es. s. AdditAddauthorization uted usinted usin
heprimaprim
application hangenge
8--week oweek
mum duratum dur
m study dstudy
k 144 and144 and
LE PeLE Peand eses
swswany at thtextensions s:
ve tempe temp
nd 
atment tment 
he Whe Wor variationse for tfor t
tional monal mthereof. ary r
imputeimpute
thehe
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 231 of 263xSchematic diagram (Figure 5-3) for the for the 4-year extension have been made
xA list of inclusion and exclusion criteria has been added for participating in OLE2 Period
xThe description of the treatment to  be administered has been adapted to take into account the 
treatment to be administered in OLE2 Period. A new dosing scheme from Week 144/OLE2 Baseline through OLE2 Week 40 has been added (Table 7 ‒3).
xAddition of the study procedures by visit has been made for the OLE2 Period (Section 8.4)
Specific changes
Change #1
Section 1, Summary 
Approximately 935 subjects will be screened in  order to have 700 subjects randomized in the 
study. For each subject, the study will last a maximum of 165 weeks and will consist of 
4 periods, a Screening Period (2 to 5 weeks), a double-blind Treatment Period (48 weeks; final dose at Week 44), an Open-Label Extension (OLE) Period (96 weeks; final dose at Week 136 for 
subjects receiving bimekizumab 320mg Q8W and at Week 140 for subjects receiving 
bimekizumab 320mg Q4W); and a Safety Follow-U p (SFU) Period (20 weeks after the final dose 
of investigational medicinal product [IMP
Has been changed to: 
Approximately 935 subjects will be screened in  order to have 700 subjects randomized in the 
study. For each subject, the study will last a maximum of 165 weeks and will consist of 
5periods: a Screening Period (2 to 5 weeks), a double-blind Treatment Period (48 weeks; final 
dose at Week 44), an Open-Label Extension (OLE) Period (96 weeks; final dose at Week 136 for 
subjects receiving bimekizumab 320mg Q8W and at Week 140 for subjects receiving 
bimekizumab 320mg Q4W) followed by a Safety Follow-Up (SFU) Period (20 weeks after the 
final dose of investigational medicinal product [IMP ] depending on subject’s participation in 
the second OLE Period [OLE2 Period]; see paragraph below).
And the following paragraph was added
Subjects participating in the OLE2 Period (implemented as part of Protocol amendment 
5.4) will enter the OLE2 Period after complet ing the OLE Period (at Week 144), including 
subjects in the SFU period and subjects wh o have completed the SFU Period. The OLE2 
Period will be a 48-week treatment period with  final visit at OLE2 Week 48, followed by a 
SFU Period (SFU2, 20 weeks after the final dose of IMP administered in the OLE2 Period). 
Change #2
Section 1, Summary 
The following text was added
After the implementation of Protocol Amendm ent #5.4 (addition of a 48-week treatment 
period, ie, OLE2 Period), subjects will be invite d to continue or reinitiate their treatment as 
per the following OLE2 Groups:PUBLIC screenecreene
y will laswill las
(2 to 5(2 to 5 w
abel EabeCOPYat Weat W
ww--Up (SUp (S
ThisSdocumenter tr 
n the Sthe S
will be will be
U PeriodPeriod
ChangChang
SeScannot d [O[O
aragrapragrap
ipatingating
the Ohe Obeol
l medil medi
OLE2OLEusedxtensiotensi
320mg Q20mg
lowedowed
itoa m
eks), aeks), support d in order in orde
maximmaxiany 140 for40 fo
U) PerioU) Periomarketing ects randcts ran
s and willand wi
atment Pement P
weeks; fweeksauthorization n 8.4)8.4)
applicationin th
LE2 PerLE2 Pe
U periodU perio
a 48a 48-weewe
(SFU2, 2SFU2,
#2#2andh was adwas ad
he Ohe Oany yy
al prodal pro
eriod];eriod];
dextensionsr to havo hav
mum of um of
doubleouble b
(OLE) (OLE) 
Q8W andW and
a Safa Saor variationsll coc
eriod (4iod (4
final dofinal do
subjectssubject
iod (20 wd (20 wthereof. domizedomized
onsisonsi
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 232 of 263xOLE2 Group A: Subjects in the treatment phase of the OLE Period at the time of 
Protocol Amendment #5.4 implementation will  attend the Week 144 Visit and directly 
roll over to the OLE2 Period . These subjects will continue receiving bimekizumab 
320mg Q8W for 40 additional weeks, starting fr om the first treatment visit of the OLE2 
Period (ie, Week 144/OLE2 Baseline Visit; the Week 144 Visit will coincide with the 
Week 144/OLE2 Baseline Visit and data collecte d at this visit will be used as baseline 
data for subjects entering the OLE2 Period).
xOLE2 Group B: Eligible subjects who have completed the Week 144 Visit and are in 
the SFU or have completed the SFU of the OLE Period at the time of Protocol Amendment #5.4 implementation, will reinitia te their treatment in the OLE2 Period 
after having undergone Screening assessments during a 4-week OLE2 Screening 
Period. The first dose will be administer ed at the Week 144/OLE2 Baseline Visit and 
data collected at this visit will be used as baseline data for the OLE2 Period. Subjects in 
OLE2 Group B with an IGA score ≥3 at the Week 144/OLE2 Baseline Visit will be 
treated with bimekizumab Q4W for the first 16 weeks, and then will switch to bimekizumab 320mg Q8W. Subjects in OLE2 Group B with an IGA score <3 at the 
Week 144/OLE2 Baseline Visit will be treated with bimekizumab Q8W from the Week 
144/OLE2 Baseline Visit. 
During the OLE2 Period (Week 144/OLE2 Base line to OLE2 Week 48), all subjects will 
attend study visits every 12 weeks. All subjects will be treated until OLE2 Week 40 (last 
dose of bimekizumab 320mg Q8W).
Following completion or early withdrawal from the OLE2 Period, subjects will undergo the 
SFU of the OLE2 Period (SFU2) and will return for the SFU2 Visit 20 weeks after the last 
dose of IMP administration.
Change #3
2.2.1.2 Ongoing studies
Eight additional studies of bimekizumab in the treatment of PSO are ongoing.
xPS0008 is a Phase 3, multicenter, randomized, double-blind, parallel-group, active-
comparator-controlled study to evaluate the efficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO.
xPS0009 is a Phase 3 randomized, double-blind, placebo- and active comparator-controlled 
study to evaluate the efficacy and safety of bimekizumab administered sc to adult subjects 
with moderate to severe plaque PSO.
xPS0010 is a Phase 2b, double-blind, placebo-controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and pharmacodynamics ( PD) of bimekizumab in adult subjects with 
moderate to severe chronic plaque PSO.
xPS0011 is a long-term extension study for subjects who completed PS0010 to assess the 
long-term safety, tolerability, and efficacy of bimekizumab.subsu
withdrawwithdraw
U2) andU2) andCOPY d witd w
E2 Basel2 Base
bjectbject
Thisxdocumentatortor--cc
ects withts with
PS0009 0009 
studystudy
wiwcannot es
udies ofdies o
a PhasePhase
onbe used towal
will rewill rsupport ine to One to O
will be twill b
l from fromany mekizmek
OLmarketing 2 ScrScr
BaselineBaselin
OLE2 PerLE2 Pe
2 BaselinBaseli
d then wthen 
with an with a
zuauthorization e 
d are inare in
ocol col 
OLE2 PLE2 P
reeee
application 3, mult mul
trolled stuolled s
moderatmodera
s a Phasea Phas
to evaluao evalu
moderamoderand bimekizmekiz
tiiany extensions the OLthe OL
urn for rn for orreatedeatevariationsne V
will switll swi
n IGA scIGA s
umab Qumab Q
E2 WeE2 Wthereof. eriod riod
ning ng 
e Visit aVisit
riod. Suriod. Su
Visit Visit 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 233 of 263xPS0013 is a Phase 3, multicenter, randomized withdrawal, double-blind, placebo-controlled 
study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque PSO.
xPS0014 is a Phase 3, multicenter, open-label study to assess the long-term safety, tolerability, 
and efficacy of bimekizumab in adult subjects  with moderate to severe chronic plaque 
psoriasis.
xPS0016 is a Phase 2a, subject-blind, investigator -blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO.
xPS0018 is a long-term extension study for eligib le subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab.
Bimekizumab is also being evaluated in the tr eatment of other indications (eg, PsA, axSpA, 
hidradenitis suppurativa). Additional information on the clinical data for bimekizumab is 
available in the current version of the IB. 
was changed to:
All ongoing studies at the time ofProtocol Amendment #5.4 implementation are presented
and described in the current version of the IB. 
Change #4
Section 5.2 Study periodsScreening Period (2 to 5 weeks), a double-blind Treatment Period (48 weeks; final dose at Week 
44), an optional OLE Period (96 weeks; final dose at Week 136 for subjects receiving 
bimekizumab 320mg Q8W and at Week 140 for subjects receiving bimekizumab 320mg Q4W), and an SFU Period (20 weeks after the final dose of IMP). 
Was changes to:
This study will include the following periods: 
xA Screening Period (2 to 5 weeks) 
xA double-blind Treatment Period (48 weeks; final dose at Week 44) 
xAn optional OLE Period (96 weeks; final dose at Week 136 for subjects receiving 
bimekizumab 320mg Q8W and at Week 140 for subjects receiving bimekizumab 320mg 
Q4W) followed by a SFU Period (20 weeks after the final dose of IMP administered in the 
OLE Period depending upon subject’s participation in the OLE2 Per iod), and 
xAn optional 48-week OLE2 Peri od followed by a SFU Period (SFU2, 20 weeks after the 
final dose of IMP administered in the OLE2 Period).
The OLE2 Period was added as per Protoco l Amendment #5.4 at the time when subjects 
will still be treated in the OLE (prior to Week 1 44 Visit) or will have finished treatment in 
the OLE (after complet ing Week 144 Visit):
xSubjects in the treatment phase of the OLE Period at the time of Protocol Amendment 
#5.4 implementation will attend the Week 144 Vi sit and directly roll over to the OLE2 PUBLIC ), a), adoudou
96 we96 COPY mendmmend
B. B. 
This document bl
ptional Oional O
mekizumekizum
Q4W) Q4W) f
OLEOLE
xxcannote the fothe f
Period (2riod (2
lind Tnd Tbe usedeks; fins; fi
t Week Week 
fter theter thtoee--blinblin
nasupport 
dany  #5.4#5.4 immarketing to aso as
ions (eg, Pons (eg
ta for bima for bauthorization urse of rse of 
severe severe 
sesses
applicationeatmenteatmen
OLE PerioE Per
mab 320mab 320m
ollowed bllowed
Period dPeriod 
onand lowinwin
o 5 weo 5 weany ngngpeextensions d TreatmTreatm
l dose atdose a
140 for s0 for s
nal doal dor variations mekizekiz
mplemmplemthereof. s the safthe saf
PsA, axPsA, ax
zumzum
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 234 of 263Period. These subjects will continue receiving bimekizumab 320mg Q8W for 40 
additional weeks, starting from the first tr eatment visit of the OLE2 Period (ie, Week 
144/OLE2 Baseline Visit; the Week 144 Visit will coincide with the Week 144/OLE2 Baseline Visit and data collected at this visit will be used as baseline data for subjects 
entering the OLE2 Period).
xEligible subjects who have completed the Week 144 Visit and are in the SFU or have 
completed the SFU of the OLE Period at the time of Protocol Amendment #5.4
implementation, will reinitiate their treatment in the OLE2 Period after having undergone Screening assessments during a 4-week OLE2 Screening Period. The first 
dose will be administered at the Week 144/ OLE2 Baseline Visit and data collected at 
this visit will be used as baseline data for the OLE2 Period. Subjects in OLE2 Group B with an IGA score ≥3 at the Week 144/OLE2 Baseline Visit will be treated with 
bimekizumab Q4W for the first 16 weeks, and will then switch to bimekizumab 320mg 
Q8W. Subjects in OLE2 Group B with an  IGA score <3 at the Week 144/OLE2 
Baseline Visit will be treated with bimekizumab Q8W from the Week 144/OLE2 Baseline Visit.
During the OLE2 Period (Week 144/OLE2 Baseline to OLE2 Week 48), all subjects will
attend study visits every 12 weeks. All subjects will be treated until OLE2 Week 40 (last dose of bimekizumab 320mg Q8W).
Following completion or early withdrawal from the OLE2 Period, subjects will undergo the 
SFU of the OLE2 Period (SFU2) and will return for the SFU2 Visit 20 weeks after the last dose of IMP administration.
Change #5
Section 5.2.3 OLE Period
The following sentence was added:
The last dose bimekizumab 320mg Q8W in the OLE Period will be administered at Week 
136. The End of Treatment Visit of the OL E Period will be the Week 144 Visit.
Change #6
The following section was added:
Section 5.2.5 OLE2 Period
Subjects enrolled as per Protocol Amendment #5.1 will be treated in the OLE Period until 
Week 136 (last dose of bimekizumab 320mg Q8W) and will be followed in a SFU Period for 20 weeks after attending the Week 144 Visit (see Section 5.2.3) . After the implementation of 
Protocol Amendment #5.4 (addition of a 48 -week treatment period, ie, OLE2 Period), 
subjects will be invited to continue or reiniti ate their treatment as per the following OLE2 
Groups:
xOLE2 Group A: Subjects in the treatment phase of the OLE Period at the time of 
Protocol Amendment #5.4 implementation will  attend the Week 144 Visit and directly 
roll over to the OLE2 Period . These subjects will continue receiving bimekizumab 
320mg Q8W for 40 additional weeks, starting fr om the first treatment visit of the OLE2 PUBLICrawal awal
nd will nd will COPYseline tseline
cts will cts w
frf
This Pdocument ng seg s
5.2.5 O2.5 O
bjects enects e
Week 13Week 13
20 we20 w
PrPcannotmama
atmentment
ectioectibe addedde
ab 32ab 3used ed:ed:to support be
om the Om the O
etuturn forrn foanyOLE2 WOLE2 
treatedtreatmarketing in OLn O
treated treated
to bimekbime
he Week Week
m the We the Wauthorization ve 
ng g
d. The fThe f
a colleccollec
LELE
application n was adn was a
LE2 PeriE2 Pe
rolled asolled a
6 (last do(last d
afterafterand Visit osit any mg Q8Wmg Q8W
of thfextensionsOL
r the Sthe Sor E2 PeE2 Pvariations14
eek 14ek 14
Week 48Week 48
ed until untilthereof. ed atd 
2 GroupGroup
with with 
kiizumabzumab
44/OL4/OL
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 235 of 263Period (ie, Week 144/OLE2 Baseline Visit; the Week 144 Visit will coincide with the 
Week 144/OLE2 Baseline Visit and data collecte d at this visit will be used as baseline 
data for subjects entering the OLE2 Period).
xOLE2 Group B: Eligible subjects who h ave completed the Week 144 Visit and are in 
the SFU or have completed the SFU of the OLE Period at the time of Protocol Amendment #5.4 implementation, will reinitia te their treatment in the OLE2 Period 
after having undergone Screening assessments during a 4-week OLE2 Screening 
Period. The first dose will be administer ed at the Week 144/OLE2 Baseline Visit and 
data collected at this visit will be used as baseline data for the OLE2 Period. Subjects in 
OLE2 Group B with an IGA score ≥3 at the Week 144/OLE2 Baseline Visit will be 
treated with bimekizumab Q4W for the first 16 weeks, and then will switch to bimekizumab 320mg Q8W. Subjects in OLE2 Group B with an IGA score <3 at the 
Week 144/OLE2 Baseline Visit will be treated with bimekizumab Q8W from the Week 
144/OLE2 Baseline Visit. 
During the OLE2 Period (Week 144/OLE2 Baseline to OLE2 Week 48), all subjects will 
attend study visits every 12 weeks. All subjects will be treated until OLE2 Week 40 (last 
dose of bimekizumab 320mg Q8W).
Following completion or early withdrawal from the OLE2 Period, subjects will undergo the 
SFU of the OLE2 Period (SFU2) and will return for the SFU2 Visit 20 weeks after the last 
dose of IMP administration.
The assessments to be performed at each vi sit of the OLE2 Period are presented in
Table 5-3 .
Change #7
Section 5.2.5 Safety Follow-upAll subjects, including those withdrawn from IMP, will have a SFU Visit 20 weeks after their 
final dose of IMP.
The assessments for the SFU are presented in Table 5‒1and Table 5‒2.
Was changes to:
Section 5.2.5 Safety Follow-up Period
The assessments for the SF U Visits are presented in Table 5‒1, Table 5 ‒2,and Table 5-3.
Two SFU Periods are considered since Protocol Amendment #5.4 implementation: a first 
SFU following the OLE Period and a second SFU (SFU2) following the OLE2 Period (added as per Protocol Amendment #5.4 implementation).
Subjects having completed Week 144 Visit and who are in the SFU or have completed the 
SFU will be invited to reinitiate their treatment in the OLE2 Period. 
Subjects still being treated in the OLE Period (not having attended Week 144 yet) will have 
the opportunity to directly roll over in the OL E2 Period without participating in the first 
SFU.PUBLIC at eachat eachCOPY ll ll
fromrom tht
returnreturn
This(document s to:to
5.2.5 S5.2.5 S
e assessmassess
Two SFTwo S
SFUSFUcannot thosehose
s for theor thebe w-upup
wwused to support e OLOL
for the or the
visit of thisit of tany tede
LE2 PLE2marketing switcwit
GA score GA score
ab Q8W fQ8W
2 Week 4Week
d untid unauthorization od 
g 
isit andt an
d. SubjeSubj
Visit wilsit wi
ch th
application SFU
afety Follafety Fo
ments fornts fo
U PeriodPeriod
winiand thdhd
U areU areany rawn frawnextensions he OLEe OLEor FUFUvariations 48), all 8), all 
il OLE2 OLE2
Period,eriod
U2 VU2 Vthereof. be be
o 
<3 at t3 at 
from thfrom th
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 236 of 263Subjects who decide not to participate in OL E2 Period will undergo the first SFU period 
for 20 weeks after their last dose in the OLE Period.
All subjects who have completed treatment in  the OLE2 Period (ie, have completed the 
OLE2 Week 48 Visit), or have withdrawn from IMP during the OLE2 Period before OLE2 
Week 48 , will have a SFU2 Visit 20 weeks after their final dose of IMP administered up to 
OLE2 Week 48.
Change #8
Section 5.4 Study duration per subjectFor each subject, the study will last a maximum of up to 165 weeks, as follows:
xScreening Period: 2 to 5 weeks
xDouble-blind Treatment Period: 48 weeks (final dose at Week 44)
xOLE Period: 96 weeks (final dose at Week 136 for subjects receiving bimekizumab 320mg 
Q8W and at Week 140 for subjects receiving bimekizumab 320mg Q4W)
Safety Follow-Up Period a SFU Visit is planne d 20weeks after the final dose of IMP visit
Was changed to:
For each subject, the study will last a maximum of up to 165 weeks, as follows:
xScreening Period: 2 to 5 weeks
xDouble-blind Treatment Period: 48 weeks (final dose at Week 44)
xOLE Period: 96 weeks (final dose at Week 136 for subjects receiving bimekizumab 320mg 
Q8W and at Week 140 for subjects receiving bimekizumab 320mg Q4W) followed by a 
Safety Follow-Up Period: a SFU Visit is planned 20 weeks after the final dose of IMP 
visit in the OLE Period (this SFU will not apply to subjects directly rolling over from 
the OLE to the OLE2 Period [see Section 5.2.5 ])
Subjects eligible for the OLE2 Period (added as part of Protocol Amendment #5.4) will 
enter the OLE2 Period after completing Week  144 of the OLE Period. The OLE2 Period 
will include a 48-week trea tment period with a final visit at OLE2 Week 48 and a SFU 
Period (SFU2) of 20 weeks after the final dose of IMP administered in the OLE2 Period. 
For the subjects in the OLE2 Period, maxi mum study duration will depend on the time 
between their participation in the OLE until Week 144 and the start of the OLE2 Period:
x209 weeks for subjects still being treated in th e OLE Period and who will directly roll 
over to the OLE2 Period at Week 144
x225 weeks for subjects who have completed Week 144 and the SFU; these subjects will 
have a 4-week Screening Period before reinitiating treatment in the OLE2 Period. Note: for, these subjects the study duration will not be continuous.
xBetween 209 and 225 weeks for subjects wh o have completed Week 144 and are 
participating the in the SFU. For these subjects, the maximum study duration will PUBLIC a maximmaxim
kss
eriod: eriod: COPY20week20wee
This documente a 48a 48
(SFU2) SFU2) 
the subhe su
betweenetween
xx22cannot riodiod
OLE2 PLE2 P
e fofor ther the
2 Peri Periber su
iod: a iod: a 
d( t hd( t hused 48 we we
dose at dose at
ubjecubjecto eekeeksupport um of up tm of up any fter thefter thmarketing s:
)
eceiving bceivin
320mg 20mauthorization 
application O
od afterd afte
week treaek tre
of2020wew
jects in tcts in
their parheir pa
ekskandis 
eriod [riod [
OLE2LE2anyrere
U VisitU Vis
SFU wSFU 
seeextensionsto 165o 165
s (final d(final d
Week 13Week 1
ceiviceivor variationsbimekiimeki
Q4W)Q4W)
final dofinal dothereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 237 of 263depend upon when they stop the 20-week  SFU period to enter the 4-week OLE2 
Screening Period.
Change #9
Section 5.6 Schedule of study assessmentsTable 5-3 Schedule of study asse ssments, OLE2 Period, was added:
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 238 of 263Table 5 -3 Schedule of study assessments, OLE2 Period
Visit a/
WeekOLE2 PeriodOLE2 Screening b
W144/OLE2 
Baseline
OLE2 W4
OLE2 W8
OLE2 W12
OLE2 W16
OLE2 W24
OLE2 W32
OLE2 W36
OLE2 W40
OLE2W48/
PEOT
SFU2 c
C H H C H C H C H C C
Protocol activity OLE2 Groups A + B
Informed consent Group B Group A
Eligibility Group B Group A+B
Urine drug screen Group B
Significant past medical history 
and concomitant diseasesdGroup B
Physical exam eGroup B Group Af+ B X X X X X
Body weight Group Ae+ B X
Vital signs gGroup B Group Af+ B X X X X X
Hematology and chemistry Group B Group Af+ B X X X
Urinalysis Group B Group Af+ B X X X
Pregnancy testing (urine) hGroup B Group Af+ B X X X X X X X X X X
Hepatitis B and C testing Group B
HIV testing iGroup B
IGRA TB test Group AfX
Tuberculosis questionnaire Group B Group Af+ B X X X X
PASI Group B Group Af+ B X X X X
Percentage of BSA Group B Group Af+ B X X X XPUBLIC 
LICCCB
C
B
BBBLUBUBUBUBUBP
COPY 
PY HH
PPYPYOPYCOThis SAAsdocumentGroupGroupt
GroGrntmememememeaireeumcdo
cannotGroup roup 
GroupGrouot
p BB GGnnnnan oup Bup Bananananc
be Af+
p Ap Aee+ B+e
AAffb
used 
dusBBusususus
to totototototsupport Cortuppppppppsu
any 
OO
Hanya
marketing 
LE2 W24E2 W2
2ngm
et
authorization 
aaua
GappGrouGroapplication Group AGroup ouonatup BBatatatiaticaaaa
Group BGroupplaaappaa
and  BB
Af+ B+ Bd
p AAff+ +na
any yanaa
extensions 
ssssonssssionsennnex
neexexex
or rvariations 
OO
LE2 WLE2 Wio
H
riavav
thereof. 
f3
reth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 239 of 263Table 5 -3 Schedule of study assessments, OLE2 Period
Visit a/
WeekOLE2 PeriodOLE2 Screening b
W144/OLE2 
Baseline
OLE2 W4
OLE2 W8
OLE2 W12
OLE2 W16
OLE2 W24
OLE2 W32
OLE2 W36
OLE2 W40
OLE2W48/
PEOT
SFU2 c
C H H C H C H C H C C
Protocol activity OLE2 Groups A + B
IGA Group B Group Af+ B X X X X
DLQI Group Af+ B X X X
Patient Symptoms (itch, pain, 
and scaling)Group Af+ B X X X X
PHQ-9 Group B Group Af+ B X X X X
ECG Group Af
Blood sample for bimekizumab 
plasma concentrations jGroup Af
Blood sample for 
anti-bimekizumab antibodies jGroup Af
scalp IGA Group Af
mNAPSI Group Af
pp-IGA Group Af
EQ-5D-3L Group Af
PASE Group Af
PGADA Group Af
WPAI-SHP V2.0 Group Af
eC-SSRS Group B Group Af+ B X X X X X
Concomitant medication Group B Group Af+ B X X X X XPUBLIC 
CCCCCLICUB AAff+ B+ BUUUU
ffP
COPY CPYPPYPYCOCThis edicaicisdoioniondocument 
tnmememememeumocdo
cannot GroGro
GroGrootnnnnnananananac
be A
up Aup Abe
used 
ds f
ssseus
to tototototosupport XXorppppoppupppp
any HHany
marketing 
OLEOLE
E2 W32W32m
et
gmmmm
authorization 
ahoaaauaapGroGroapplicationGro
GroupGroun
GroGronatatatatiaticaaaplaaaapaa
and up AAffd
oup Aup Affana
any nya
extensions 
s
XXnssss
ssssinsennnx
nxxteex
or ro
variations 
OLOoCC
ooonio
OLOLriav
thereof. E
2 W362 W36
fffth
of
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 240 of 263Table 5 -3 Schedule of study assessments, OLE2 Period
Visit a/
WeekOLE2 PeriodOLE2 Screening b
W144/OLE2 
Baseline
OLE2 W4
OLE2 W8
OLE2 W12
OLE2 W16
OLE2 W24
OLE2 W32
OLE2 W36
OLE2 W40
OLE2W48/
PEOT
SFU2 c
C H H C H C H C H C C
Protocol activity OLE2 Groups A + B
Adverse events Group BkGroup Af+ B X X X X X
IRT Group B Group Af+ B X X X X X
Bimekizumab administration 
Q4W/Q8Wl, m, nGroup BlX X X X X X X
Bimekizumab administration 
Q8Wm, nGroup A+BlX X X X X
BSA=body surf ace area; C=clinic; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC-SSRS=electronic Columbia Suicid e Severity Rating Scale; 
IGA=Investigator’s Global Assessment; H=home; IMP=investigational medicinal product; IRT=interactive response technology; OLE =open label extension; PASI=Psoriasis 
Area Severity Index; PHQ-9=Patient Health Questionnaire-9; PSO=p soriasis; Q4W=every 4 weeks; Q8W= every 8 weeks; SFU2=Safety Fol low-Up #2; TB=tuberculosis; 
W=Week.
Note: Subjects may self -inject IMP at home; self-injection training will be provid ed to the subject/caregivers by qualified site personnel. 
aVisit windows of ±14 days from the first dose at all visits except SFU2. The SFU2 Visit window is ±7 days from final dose.
b Assessment for the OLE2 Screening is applicable to subjects in OLE2 Group B, ie, subjects who agreed to reinitiate their treat ment after having completed the Week 144 Visit. 
cThe SFU2 Visit will occur 20 weeks after the final dose.
d Only applicable for subjects who completed the SFU period; only new or modified medical history since completing SFU will be en tered in eCRF.
eThe physical examination will be performed as per Section 12.3.5.
fThese tests are performed as part of Week 144 visit (the Week 144 Visit coincides with the Week 144/OLE2 Baseline Visit for sub jects in Group A, ie, direct enroller from 
OLE to OLE2 Period).
gVital signs (sitting systolic and diastolic blood pressure, pulse rate, and temperature) are to be measured prior to blood samp ling, and prior to dosing, where applicable.
hUrine pregnancy testing will be performed at all visits. Pregnanc y test results must be negative prior to administering IMP. Ho me pregnancy test kits will be provided to 
participants for use between clinic visits.
iThe HIV test results will not be recorded in the eCRF.
jAll blood samples taken prior to dosing.
kCollected only from subjects in the SFU.
PUBLICXXUBLIC 
CCCCCLICUBA+BA+BlUUUU
COPY CPYPPYPYCOCThis y fromrom
documentformorm
of Week Week 
nd diastold diastol
will be perbe pe
ween clineen clin
will not bill not 
taken praken pr
subsub
cannotion tran tr
all visits visits 
Group B, ie, oup B, ie, 
he final dfinal d
only new or m new or m
med ased a
beti
9; PSOPSO
inininin
used sty Index; Index; 
gationalational
pssse
to tototototosupport XXorpXpppopp
XXupppp
any HHany
marketing 
OLEOLE
E2 W32W32m
et
gmmmm
authorization 
ahoaaauaapplication fied med m
per Section er Section
4 visit (the Wvisit (th
blood presblood pre
rmed at med at all 
visits.isits.
recorded incorded in
osingosin
andg ww
xcept SFpt SF
ects whts wh o agro agr
ical cal
any riasis; Qriasis
ll be prol be p
U2
extensions X
s
XXnsi
nssss
s
XX
sssix
ns
CG=electG=elect
icinal cinal 
Qxxte
or ro
variations 
OLOoCC
ooonio
OLOLriav
thereof. E
2 W362 W36
fffth
of
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 241 of 263Table 5 -3 Schedule of study assessments, OLE2 Period
Visit a/
WeekOLE2 PeriodOLE2 Screening b
W144/OLE2 
Baseline
OLE2 W4
OLE2 W8
OLE2 W12
OLE2 W16
OLE2 W24
OLE2 W32
OLE2 W36
OLE2 W40
OLE2W48/
PEOT
SFU2 c
C H H C H C H C H C C
Protocol activity OLE2 Groups A + B
lQ4W IMP administration only applies to those subjects who have entered the OLE2 Period as part of Group B, and had an IGA ≥3 upon entry of OLE2 Period. These 
subjects will receive Q4W dosing for 16 weeks, then will change from Q4W to Q8W dosing. Subjects who have entered the OLE2 Period as part of Group B with an IGA 
<3 upon entry of OLE2 Period will receive Q8W dosing from the W144/OLE2 Screening Visit onwards.
mThe dosing window is ±14 days relative to the Week 144/OLE2 Baseline Visit.
nIf self-injected at home, the subject/caregiver will document the date, body location, kit number and time point of administrat ion of study medication. All used syringes will 
be disposed of by subjects/caregivers as determined by the Inve stigator in an acceptable disposal (sharps) container directly a fter the administration. The subjects /caregivers 
return the documentation together with any used/unused containers at the next scheduled clinic visit.
PUBLIChe 
4W to QW to 
44/OLE2 /OLE2 
seline Visseline Vi
date, boddate, bod
vestigatorvestigator
ntainers antainers a
COOLE2 POLE2
Q8COPY CPYPPYPYCOThis 
document 
cannot 
be 
used the nehe n
tolocat
an accean acc
ext sxt
supporriod as partod as pa
W dosing. Sudosing
creening Viening V
ion, kiion,
ort or
any HHany
marketing 
OLEOLE
E2 W32W32m
et
gmmmm
authorization 
ahoaaauaapplication 
and 
any 
extensionsubj
sit onwat onw
t number number 
able dispole disp
heduled ceduled c
orf Grouf Gro
cts whcts whrrvvariaOLOLriations 
OLOoCC
ooonioriav
thereof. E
2 W362 W36
fffth
of
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 242 of 263Change #10
Section 5.7 Schematic diagram
Figure 5-3 was added:
Figure 5-3 Schematic diagram, OLE2 period (from OLE2 Screening through OLE2 
Week 48)
IGA=Investigator’s Global Assessment; IMP=investigational medicinal product; OLE=Open Label Extension; 
Q4W=every 4 weeks; Q8W=every 8 weeks; SFU2=Safety follow-up; W=week
Note: Q4W/Q8W IMP administration only applies to those subj ects who have entered the OLE2 Period as part of 
Group B, and had an IGA ≥3 upon entry of OLE2 Period. Th ese subjects will receive Q4W dos ing for 16 weeks, 
then will change from Q4W to Q8W dosing.
Change #11
Section 
5.8 Rationale for study design and selection of dose
5.8.1 Study design
The following paragraph was added:
The OLE2 Period will 1) collect additional long-term safety data; 2) explore safety data in 
subjects who have temporaril y stopped bimekizumab and coul d have been exposed to other 
PPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLIIIIICCCCCCCCCCCCCC 
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOOOOOOOOOOOOOOOPPPPPPPPPYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 
This 5document d had had
change frhange fr
Changehange
SectSectcannotobal Assebal Asse
ks; Q8Ws; Q8W
IMP admMP ad
an Ian
ooooooooooooottttttttttttt 
bbbbbbbbbbbbeeeeeeeeeeee 
uuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuusssssssssssssssssssssssssssssssssssssssssssssssssssssssseeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeedddddddddddddddddddddddddddddddddddddddddddddddddddddd 
ttttttttttttttttttttttttttttttttttttttttooooooooooooooooooooooooooooooooooooooooooooooooooooo  
ssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuupppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppoooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrtttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt 
aaaannnnnnnnnnyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy 
mmmmmmmmmmmaaaarrrrrrrrrrrrrkkkkkkkkkkkkkketing horization OLE2 OLE2 
autho
application ev
inistratistrat
GA ≥3 upo GA ≥3 up
m Q4W toQ4W
#11#11and sment; IMment; IM
very 8 wery 8 
dddddddddd
aaaaaaaaaaaannnnnnnnnnnnyyyyyyyyyyyy 
eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeexxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttteeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeennnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnsssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiioooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnsssssssssssssssssss 
ooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrr 
vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaarrrrrrriiiiiiiiiaaaaaaaaatiiioooooooooonnnnnnnnns 
thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 243 of 263treatments; and 3) provide an additional 48-wee k treatment period for subjects continuing 
their current treatment or reinitiating trea tment at the Week 144/OLE2 Baseline Visit.
Change #12
5.8.2 Dose selection
The following paragraph was added:
Subjects who are participating in the OLE Period  can directly roll over to the OLE2 Period 
and continue receiving bimekizumab 320mg Q8W. Eligible subjects who are in the SFU of 
the OLE Period or who have completed the SFU at the time of Protocol Amendment #5.4
implementation can reinitiate their treatment in the OLE2 Period based on their current disease activity, as measured by IGA: subjects  with IGA score <3 will receive bimekizumab 
320mg Q8W, whereas subject s with IGA score ≥3 will receive 16 weeks of bimekizumab 
320mg Q4W, in line with the original initial treatment period, followed by 320mg Q8W for 
the remaining dosing timepo ints of the OLE2 Period. 
Change #13
The following sections were added:
6.4 Eligibility for the OLE2 Period
Prior to initiating the OLE2 Period assessments, all subjects will be asked to read and sign 
a separate ICF. 
6.4.1 All subjects (OLE2 Groups A and B)
To be eligible to participate in the OLE2 Period , all of the following inclusion criteria must 
be confirmed for all subjects:
10. Subject provided informed consent. 
11. Subject is considered reliable and capable of adhering to the protocol (eg, able to 
understand and complete diaries), visit sche dule, and medication  intake according to 
the judgment of the Investigator.
12. Subject completes the OLE Period to Week 144 without meeting any withdrawal 
criteria defined in Section 6.5.
6.4.2 OLE2 Period Group A subjects
To participate in the OLE2 Period, subjects  still treated in the OLE Period and who 
completed the Week 144 Visit by the time of the implementation of Protocol Amendment 
#5.4 will not need to fulfil other eligibili ty criteria than those listed in Section 6.4.1 and will 
continue their treatment from the Week 144/OLE2 Baseline Visit if they do not meet any of 
the withdrawal criteria defined in Section 6.5.
6.4.3 OLE2 Period Group B subjects
Inclusion criteria
To be eligible to participate in the OLE2 Peri od, all of the additional following inclusion 
criteria must be confirmed during the OLE2 Screening Period for subjects who have PUBLIC ssessmsess
ups A aups A a
in the in the COPY me
Thistdocument defe
OLE2 PeLE2 P
participarticip
ompletemplete
#5.4#5.4 w
conconcannotomplemple
f the Inthe In
mpletes letes 
fined ned be ed
reliablreliab
teteused OLELE
d consconsto nd Bd B
E2 P2Psupport nts, all sus, all s
B)B)any marketing on t
eceive bceive 
eks of bimks of b
lowed byowed authorization E2 Peri2 Peri
the SFthe SF
ndmendmen
theirheir
applicationhe Oe
n SectioSecti
riod Groiod Gr
te in the e in th
d the Wethe W
not nenot ne
ianddiadia
vestigatstigat
OLEOLEany t
and capand ca
ries), ries)extensions ub
eriod, ariod, a
tor jects ectsvariations ythereof.#5
currenurren
imekizmekiz
mekizuekiz
320mg320m
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 244 of 263attended Week 144 and are in the SFU or have completed the SFU before Protocol 
Amendment #5.4 implementation:
13. Female subjects must be:
Postmenopausal: Menopause is defined as  12 consecutive months of amenorrhea, 
for which there is no other obvious pathological or physiological cause.
Permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy)
Or, if of childbearing potential (and engage d in sexual activity that could result in 
procreation), must be willing to use a high ly effective method of contraception 
throughout the duration of the study until 20 weeks after last administration of 
IMP, and have a negative pr egnancy test at OLE2 Screening. The following methods 
are considered highly effective when used consistently and correctly
oCombined (estrogen and progestogen) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal, or transdermal)
oProgestogen-only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implantable)
oIntrauterine device 
oIntrauterine hormone-releasing system 
oVasectomized partner
oAbstinence as a form of birth control is generally not allowed in the study unless 
abstinence is in accordance wit h a subject’s preferred and common lifestyle. 
Study personnel must confirm the continued use of abstinence is still in 
accordance with the subject ’s lifestyle at regular intervals during the study.
14.Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as 
they have no active symptomatic disease.
Exclusion criteria
Subjects in the OLE2 Group B are not permitted to enroll in the OLE2 Period if any of the 
following exclusion criteria is met:
15. Female subjects who plan to become pregnant during the OLE2 Period or within 
20 weeks following final dose of study medication.
16. Subject has developed any medical or psychi atric condition that, in the opinion of the 
Investigator, could jeopardize or woul d compromise the subject’s ability to participate 
in the OLE2 Period.
17. Any subjects with an ongoing SAE, or a history of serious infections, the Medical 
Monitor must be consulted prior to the subject’s entry in the OLE2 Period, although 
the decision on whether to enroll the subject remain s with the Investigator.PUBLIC of birthof birth
cordanccordanc
must cmusCOPY ng systg sy
This documentexclusxclus
male sumale su
200weewee
16.16.SubSubcannot e OLEOLEbeis o
mptommptomusedonfirmfirm
subjectubject
f Crf Crto co
witwith h
msupport em 
ontrol ntroany marketing he followfollo
rrectlyrectly
raceptionaceptio
dermal)rmal)
ted ted wiauthorization tomy)omy)
result result 
aceptionceptio
istratitrati
application 2 GroupGrou
n criteriacriter
bjects whbjects w
ks followifollow
ect has dct has d
gatand any hn sn
tic diseic disextensions is geneis gene
subjectubject
the conthe con
s lifestylifesty
sd isd ior variations n 
th inhith inhithereof. on of n of 
wing metng me
associassoc
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 245 of 26318. Subject had a positive or indeterminate IGRA in the OLE study to Week 144, unless 
appropriately evaluated and treated as per Section 12.3.1 .
19. Subject may not participate in another study of a medicinal product or device under 
investigation
20. Subject has a history of chronic alcohol or drug abuse within 6 months prior to reentry 
as assessed by medical history, site intervie w, and/or results of the urine drug screen.
21. Subjects who have used systemic treatments after Week 144 must have stopped this 
treatment 1 month prior to receiving the first bimekizumab injection in the OLE2 Period (See Section 7.8.2 regarding prohibited medications).
22. Subject has erythrodermic, guttate, or pustular form of PSO.
23. Subject is noncompliant with the study proced ures or medications in  the opinion of the 
Investigator.
24. Subject has a clinical laboratory value meeting any of the following criteria:
h.≥3.0x ULN of any of the following: ALT, AST, alkaline phosphatase (ALP); or 
>ULN total bilirubin ( ≥1.5xULN total bilirubin if known Gilbert’s syndrome)
i. A laboratory value meeting any of the following criteria:
◦Absolute neutrophil count <1.0x10
3/μL
◦Absolute lymphocyte count <0.2x103/μL
Subjects may enter the OLE2 Period if the result is transient. If a retest is required, it 
must be done within 1 to 2 weeks.
25. Subject has concurrent acute or chronic viral hepatitis B or C or HIV infection. 
Subjects who have evidence of, or tested positive for hepatitis B or hepatitis C are excluded. A positive test for the hepatitis B virus is defined as: (1) positive for 
hepatitis B surface antigen or (2) positive for anti-hepatitis B core antibody. A positive 
test for the hepatitis C virus (HCV) is defined as: (1) positive for hepatitis C antibody (HCV Ab) and (2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction).
26. There is confirmation of a pregnancy, as evidenced by a positive pregnancy test (see 
Section 12.1.4 for more information regarding pregnancies).PUBLIC <1.0x<1.0
ountount <0<0
LE2 PerE2 Per
22weekweeCOPY ASTAS
bilirubibilirub
the follthe foll
x10x10
This document s concon
onn12.112.1cannotantn
itis C vs C v
d (2)(2)popo
chain rhain r
firfirbest for for
tigen tigenused s..
te or chor ch
e of, oe of, o
thhtood if tod if support wing cwing 
/μLL
x101033/μL/μ
thethanyalinealin
if knowif know
crimarketing ons in thens in th
e followinfollow
phpauthorization ntry ry 
reen.een.
ed ed this this
he OLE2OLE
applicat4ation eactc
mation ofmation 
for mofor mandrusus(H(H
itive viaive via
tion)ionany hepathepa
r (2) pos(2) po
HCVHCextensions result iresult 
onic virnic vir
tested stedor variations ng criteg crite
hosphatosphat
wn Gilbn Gilb
eria:eria:thereof. e opinioe opinio
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 246 of 26327. Subjects showing:
xSuicidal ideation in the past month prior to the OLE2 Screening Visit as indicated 
by a positive response ("Yes") to either Question 4 or Question 5 of the eC-SSRS.
xAny suicidal behavior since last visit.
28. Subject has presence of moderately severe or severe major depression, indicated by a 
score ≥15 on the PHQ -9. Medication used to treat depr ession should be stable for 
4 weeks prior to Week 144/OLE2 Baseline.
29. Subject has developed any active malignancy or history of malignancy prior to the 
OLE2 Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer.
30. Subject has received any live (includes attenuated) vaccination within the 8 weeks prior 
to the Week 144/OLE2 Baseline Visit.
Change #13
Section 7.2 Treatments to be administered
The following text and Table 7-3 were added:
After the implementation of Protocol Amendm ent #5.4 (addition of a 48-week treatment 
period, ie, OLE2 Period), subjects will be invite d to continue or reinitiate their treatment as 
per the following OLE2 Groups:
xOLE2 Group A: Subjects in the treatment phase of the OLE Period at the time of 
Protocol Amendment #5.4 implementation will  attend the Week 144 Visit and directly 
roll over to the OLE2 Period . These subjects will continue receiving bimekizumab 
320mg Q8W for 40 additional weeks, starting fr om the first treatment visit of the OLE2 
Period (ie, Week 144/OLE2 Baseline Visit; the Week 144 Visit will coincide with the 
Week 144/OLE2 Baseline Visit and data collecte d at this visit will be used as baseline 
data for subjects entering the OLE2 Period).
xOLE2 Group B: Eligible subjects who have  completed the Week 144 Visit and are in 
the SFU or have completed the SFU of the OLE Period at the time of Protocol 
Amendment #5.4 implementation, will reinitia te their treatment in the OLE2 Period 
after having undergone Screening assessments during a 4-week OLE2 Screening 
Period. The first dose will be administer ed at the Week 144/OLE2 Baseline Visit and 
data collected at this visit will be used as baseline data for the OLE2 Period. Subjects in 
OLE2 Group B with an IGA sc ore ≥3at the Week 144/OLE2 Baseline Visit will be 
treated with bimekizumab Q4W for the first 16 weeks, then will switch to bimekizumab 
320mg Q8W. Subjects in OLE2 Group B with an IGA score <3 at the Week 144/OLE2 
Baseline Visit will be treated with bimekizumab Q8W from the Week 144/OLE2 Baseline Visit. 
During the OLE2 Period (Week 144/OLE2 Baseline to OLE2 Week 48), all subjects will 
attend study visits every 12 weeks. All subjects will be treated until OLE2 Week 40 (last 
dose of bimekizumab 320mg Q8W).PUBLICol lAmenAme
s will bes will b
ps:ps:
s in ths in th
iiCOPY ed:d:
This document U or hor 
ndmentdment
ter havir hav
Perioderiod
datadata
OOcannot4/O
Baseliaseli
cts enters enter
up B: Ep B: E
havhavbeditiontion
OLE2OLE2usede treatrea
mplemepleme
od. Thod. Th
allto atmtmsupport dment #5ment #
invited tnvited any marketing within thithin authorization y a a 
r 
ior to thor to th
s squasqua
application ligiblegibl
e completcomp
#5.45.4impim
ng underg unde
The firsthe fir
collectedollected
GroGrand VisVis
ing the ng the 
esesany weeks,week
Baselineaseline
it antaextensions 5.44(a(
to contio conti
ent nt phapha
ntation wation 
e subjsubjor addaddvariations thereof.e
mous oous o
he 8 weehe 8 we
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 247 of 263The dosing scheme from Week 144/OLE2 Baseli ne through OLE2 Week 40 is depicted in 
Table 7‒3.
COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 248 of 263Table 7 -3  Dosing scheme, OLE2 Period
Visits/Week
Dose AssignmentOLE2 PeriodWeek 144/OLE2 
Baseline
OLE2 W4
OLE2 W8
OLE2 W12a
OLE2 W16
OLE2 W24 b
OLE2 W32
OLE2 W36 c
OLE2 W40
CH H CHCHC H
Bimekizumab 320mg Q4W/Q8W d●● ●● ●● ●● ●● ●● ●● ●●
Bimekizumab 320mg Q8W ●● ●● ●● ●● ●● ●●
C=Clinic; H=home; IGA=Investigator’s Global Assessment; IMP=investigational medicinal product; Q4W/Q8W=every 4 weeks for 16 weeks, followed by 
every 8 weeks; Q8W=every 8 weeks; OLE=Open Label Extension; W=week
Notes: A bimekizumab 160mg injection is depict ed by a black circle ( ●).
aSubjects will receive kits for home administration 4 weeks later.
bSubjects will receive kits for home administration 8 weeks later.
cSubjects should NOT be dosed at this visit and w ill receive kits for home administration 4 weeks later.
dQ4W/Q8W IMP administration only applies to those subjects who have entered the OLE2 Period as  part of Group B, and had an IGA ≥3 upon entry of 
OLE2 Period. These subjects will receive Q4W dos ing for 16 weeks until OLE2 Week 16, then will c hange from Q4W to Q8W and will receive their next 
dose at the scheduled clinic visit OLE2 Week 24.
PUBLIC W=wW=
le (e (●●).).
er.
later.ater.
ve kits fove kits fo
ubjects ubjects 
r1r
COPY C
●●PYOP●●OPOPOPOP igationalgational
weekweekCOOOThis 
document 
cannot 
be 
used ho hao ha
weeks uweeks u
tohome ahome a
ve eve
support medicinal edicinartrtany nnnnyanaaaa
marketing 
LE2 W24 E2 W2rk
HHm
authorization 
ahouthaapplication 
and 
any 
extensions ministratioistrati
ntered theered the
til OLE2l OLE2
or rodrod
vaduct; uct;var●●●●ariations 
OLOonat●●
iaaaaarva
thereof. 
W32W32h
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 249 of 263Change #13
Section 7.6 Dug accountability The following sentence was added:
The OLE2 Period will be unblinded and bli nding precautions will not be applicable.
Change #14
Section 7.7 Procedures for mo nitoring subject compliance
After Week 48, self-injection at home will be possible at the following weeks: Weeks 60, 68, 76, 
80, 88, 92, 100, 104, 112, 116, 124, 128, 136, and 140. Dates, body locations, kit numbers and 
time of self-injection will be captured using a hom e administration form. All used syringes will 
be disposed of by subjects/caregivers as determined by the Investigator in an acceptable disposal 
(sharps) container directly after the admini stration. The subjects/caregivers return the 
documentation together with any used/unused containers at the next scheduled clinic visit.
Was changes to:
After Week 48, self-injection at home will be po ssible at the following weeks: Weeks 60, 68, 76,
80, 88, 92, 100, 104, 112, 116, 124, 128, 136, 140, and at the OLE2 Weeks 4, 8, 16, 32, and 
40.Dates, body locations, kit numbers and time of self-injection will be captured using a home 
administration form. All used syringes will be disposed of by subjects/caregivers as determined 
by the Investigator in an acceptable disposal (sha rps) container directly after the administration. 
The subjects/caregivers return the documentation together with any used/unused containers at the 
next scheduled clinic visit.
Change #14
Section 7.8.1.1 Topical medicationsIn the OLE Period, the medications listed as permitted for the double-blind Treatment Period 
will be allowed. In addition, any topical steroids and vitamin D analog ointment will be permitted for use, as needed. These topical medi cations should not be used within approximately 
24 hours prior to study visits requiring IGA and PASI measures.
Was changed to:
In the OLE and OLE2 Periods , the medications listed as permitted for the double-blind 
Treatment Period will be allowed. In addition, any topical steroids and vitamin D analog 
ointment will be permitted for use, as neede d. These topical medications should not be used 
within approximately 24 hours prior to study visits requiring IGA and PASI measures.
Change #15
Section 7.8.2 Prohibited concomitant tr eatments (medications and therapies)
Subjects who take prohibited medications may be withdrawn from IMP but followed until the 
SFU Visit. The decision to withdraw a subject for taking prohibited medications should be made 
in consultation with the Medical Monitor.PUBLICd t
will bewill b
disposadispos
e documdocumCOPY ossible aossible 
6, 6, 140, a140, a
time oime 
ThisCdocument ed tod to
LE LE andan
ment Pment P
intment ment
withinwithincannotmeded
dition, tion, 
as needneed
o study vstudy 
::be medicedi
dicatiodicatioused caticatito entatntasupport nd at td at t
f selfself-finjein
disposed spose
(sharps) sharps
tion ttionany he follohe follo
thethmarketing W
s, kit n, kit n
All used All used 
or in an acr in an a
regivers regivers
next schedext schauthorization Weeks eeks 
application visitssit
OLE2 POLE2
riod wilod wil l
will be pell be p
proximroximandny toptop
d. TheseThese
s reqsr e qany ns
s listed  listed 
picapicextensions of bf b
) containontain
togetherogetheorction ction
by suysvariations returetur
eduled culed c
owing wwing w
OLE2OLE2
wthereof.60, 68, , 68, 
mbers anbers a
d syringesyringe
cceptabceptab
rn thnt h
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 250 of 263Was changed to:
Up to Week 144
Subjects who take prohibited medications may be withdrawn from IMP but followed until the 
SFU Visit. The decision to withdraw a subject for  taking prohibited medications should be made 
in consultation with the Medical Monitor.
Post Week 144 (OLE2 Period)
Subjects who have used systemic treatments after Week 144 must have stopped this 
treatment 1 month prior to receiving the first bimekizumab injection in the OLE2 Period. 
Subjects receiving systemic immunomodulatory medi cations for an indication other than 
PSO must have their eligibility confirmed by the Medical Monitor prior to enrollment in 
the OLE2 Period.
Change #16
Section 7.10 Randomization and numbering of subjects
The following paragraph was added:
Subjects who roll over directly from the OLE Period into the OLE2 Period will continue 
receiving bimekizumab 320mg Q8W and will ke ep their unique 5-digit identification 
number. Subjects who reinitiate bimekizumab after having completed treatment (subjects 
in the SFU of the OLE Period or who have completed the SFU of the OLE Period) will 
receive either bimekizumab 320mg Q4W/Q8W or bimekizumab 320mg Q8W depending on 
their disease activity at time of reentry (bimekizumab 320mg Q4W/Q8W for subjects with 
IGA score ≥3 or bimekizumab 320mg Q8W for subjects with IGA score <3). For these 
subjects, the same unique 5-digit identificati on number used in the study will be reused.
Change #17
Section 8 STUDY PROCEDURES BY VISIT
Table 5‒1 and Table 5 ‒2provide a general overview of study assessments during the double-
blind Treatment Period and the OLE Period, respective ly. A list of procedures to be completed at 
each visit is described below.
xVisit windows of ±3 days on either side of the scheduled dosing are permitted up to and 
including Week 24; however, the Investigator should try to keep the subjects on the original dosing schedule. From the Week 28 Visit through the Week 72 Visit, visit windows of 
±7 days on either side of the scheduled dosing are permitted; however, the Investigator 
should try to keep the subjects on the original dosing schedule. From the Week 76 Visit through the Week 144/PEOT Visit, visit windows of ±14 days on either side of the scheduled 
dosing are permitted; however, the Investigator should try to keep the subjects on the original 
dosing schedule. The visit window is relative to Baseline and applicable for all subsequent 
visits Changes to the dosing schedule outside the visit window must be discussed with the Medical Monitor.
xThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled
dosing visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the PUBLIC ekizumkizu
ho haveho have
mg Q4Wmg Q4W
of reentof reent
ab 320ab 320COPY LE PeriE Per
will kewill ke
ma
This documentwindowindow
luding Wuding W
dosing sosing s
±7±7dada
shscannot OCC
55‒‒22prpr
Periodriodaa
scribedcribedbe EDUEDusedmg Qg Q
it identiidentitoW/
y (bim(bim
Q8W8Wsupport od ind i
ep their p their
b after haafter h
completomplet
Q8W oQ8W
ekany nto thnto tmarketingatio
or to enror to enauthorization d this this 
OLE2 POLE2 P
on otn ot
application below.low
of ±3 dayof ±3 d
Week 24; hWeek 24;
chedule. Fhedule.
ys on eiths on ei
d try totry tandovide a gvide a 
dthe Othe Oany ES BYES BYextensionshav
ted thed th
or bimeor bime
kizumazuma
W for sufor su
fication cationor uniqn
ving cing cvariations he OLEOLE
quequthereof.erioe
her thanr tha
ollmentllment
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 251 of 263scheduled dosing visit. From Week 28 through the Week 72 Visit, the dosing window is 
±7 days relative to the scheduled dosing visit. From the Week 76 Visit through the Week 140
Visit the dosing window is ±14 days relative to the scheduled dosing visit.
xFor the SFU Visit (20 weeks after the final dose), the visit window is ±7 days relative to the 
scheduled visit date.
Was changed to:
Table 5‒1, Table 5 ‒2,Table 5-3 provide a general overview of study assessments during the 
double-blind Treatment Period, the OLE Period, and the OLE2 Period, respectively. A list of 
procedures to be completed at each visit is described below.
xVisit windows of ±3 days on either side of the scheduled dosing are permitted up to and 
including Week 24; however, the Investigator should try to keep the subjects on the original 
dosing schedule. From the Week 28 Visit through the Week 72 Visit, visit windows of ±7 days on either side of the scheduled dosing are permitted; however, the Investigator 
should try to keep the subjects on the original dosing schedule. From the Week 76 Visit 
through the Week 144/PEOT Visit, visit windows of ±14 days on either side of the scheduled dosing are permitted; however, the Investigator should try to keep the subjects on the original 
dosing schedule. The visit window is relative to Baseline and applicable for all subsequent 
visits up to Week 144/OLE2 Baseline Visit. Fr om the Week 144/OLE2 Baseline Visit 
through the OLE2 Week 48/PEOT Visit, visit windows of ±14 days relative to the Week 
144/OLE2 Baseline Visit on either side of the scheduled dosing are permitted; however, 
the Investigator should try to keep the subjects on the original dosing schedule. Changes 
to the dosing schedule outside the visit window must be discussed with the Medical Monitor. 
xThe dosing window from Baseline through Week 4 is ±2 days relative to the scheduled 
dosing visit. From Week 8 through Week 24, the dosing window is ±3 days relative to the 
scheduled dosing visit. From Week 28 through the Week 72 Visit, the dosing window is 
±7 days relative to the scheduled dosing visit. From the Week 76 Visit through the OLE2 
Week 40Visit, the dosing window is ±14 days relative to the scheduled dosing visit.
xFor the SFU and SFU2 Visits (20 weeks after the final dose), the visit window is ±7 days 
relative to the scheduled visit date.
Change #18
Section 8.3.8 Week 144 Visit (±14 days relative to Baseline)
The following paragraphs were added:
If Protocol Amendment #5.4 is implemented at the time subjects are treated in the OLE 
Period (ie, up to Week 144; OLE2 Group A subj ects), these subjects will be invited to 
participate in the OLE2 Period and may dire ctly roll over and continue their treatment 
from the Week 144/OLE2 Baseline Visit as long as they do not meet any of the withdrawal criteria and have provided informed consent.
If Protocol Amendment #5.4 is implemented at the time subjects have completed the Week 
144 Visit and are in the SFU Period of the OL E Period or have completed the SFU of the PUBLICVi
r side r side
keep thkeep th
de the vide the vi
BaseliBaseli
hhCOPYs
or shour sho
ve to Bave to 
Visit. FrVisit. F
isit, vsit, v
This Pdocument e #18#18
ion 8.3n 8.3
The follThe fo
If PIf Pcannot osi
SFU2 VFU2 V
schedulchedulbecheduedu
ing wiing wiusedne throthr
ough Wugh W
m WeekWee
ledldto it winwi
ouousupport om them th
sit windoit wind
f the schehe sc
subjectssubject
ndowndoanyayay
ry to kry to k
ine andne a
Wmarketing mitted uitted 
subjects oubjects o
sit, visit wsit, visit
owever, thwever,
le. From t. From
ys on eys onauthorization ing the g the 
ly. A lisy. A lis
application 8Week Week
wing parwing pa
Aandisitssits(2(
d visit visit dany dosidosingn
dow is ±dow is ±
0extensions eduldu
ts on theon th
w must w must 
ghWeekWeek
eek 24, tek 24, 
8 throu throuorws ofws o
lededvariations he Ine In
theeWeWe
either siither si
eep the sep the s
d applicapplic
Week 14eek 1
±thereof. p to and o and
on thn the oe o
windowwindow
nvesnve
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 252 of 263OLE Period (Group B subjects), these subjects  will be invited to enter the OLE2 Period to
reinitiate their treatment in the OLE2 Period . However, before receiving the first dose at 
the Week 144/OLE2 Baseline Visit, they will  first undergo screening during the 4-week 
OLE2 Screening Period (Section 8.4.1 ).
Change #19
The following sections were added
8.4 OLE2 Period8.4.1 OLE2 Screening (up to 4 weeks) –applicable for OLE2 Group B only
Prior to any study specific activities of the OL E2 Period, subjects who completed the Week 
144 Visit and are in the SFU or have comple ted the SFU of the OLE Period (OLE2 Group 
B subjects) will undergo screening. Subjects who have used systemic tr eatments after Week 
144 must have stopped this treatment 1 month  prior to receiving the first bimekizumab 
injection in the OLE2 Period. Screening procedures may be performed during this time. 
Subjects receiving systemic immunomodulatory me dications for an indication other than 
PSO must have their eligibility confirmed by the Medical Monitor prior to enrollment in the OLE2 Period.
At the Screening Visit of the OLE2 Period (OLE 2 Screening Visit), subjects will be asked to 
read, sign, and date an ICF that has been approved by the Sponsor and an IRB/IEC and that complies with regulatory requirements. Su bjects will be given adequate time to 
consider any information concerning the study given to them by the Investigator or 
designee. As part of the informed consent proce dure, subjects will be given the opportunity 
to ask the Investigator any questions regarding potential risks and benefits of continued 
participation in the study.
The following procedures/assessments will be  performed at the OLE2 Screening Visit for 
subjects in the OLE2 Group B:
xInformed consent
xInclusion/exclusion
xUrine drug screen
xSignificant past medical history including clinically relevant past or coexisting medical 
conditions and surgeries (only applicable for subjects who completed the SFU, only new or modified medical history since completi ng the SFU should be entered in eCRF)
xAEs (only for subjects in the SFU)
xPhysical exam
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should 
be obtained prior to blood sampling
xCollection of blood and urine samples for the following clinical laboratory tests:
Hematology and biochemistry
Urinalysiseen een
rementemen
ning thening th
med conmed con
questioquestioCOPYe Mede M
d (OLEd (OLE
appapp
This documenticant pant p
ditions itions
or modimodi
AEsAEs
xxcannot usionion
g screenscreenbe up B:B:used ns re re
essmenssmentoent pent p
egaregarsupport2 ScreenScree
roved by ved b
. SubjectSubjec
study gitudy gi
rocany l Monl Mo
imarketing omplempl
Period (Oeriod (O
ic treatmtreat
g the firstthe fir
performeerform
s for anfor a
itoauthorization y
eteete
application st medicat medi
and surgand sur
fied medied med
(only foronly for
land any extensionsts wilwi
iven to ven to 
cedure, dure,
ding potng po
will bwill org
he Sphe S
lblbvariationsst b
ed durid duri
n indican indic
tor prioor prio
g Visg Visthereof. d the Wthe W
OLE2 GLE2 G
ments afments af
bimekime
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 253 of 263Urine pregnancy test
Hepatitis B and Hepatitis C
HIV
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xPHQ-9
xeC-SSRS
xPrior and concomitant medication (including  new or modified medications initiated 
after SFU)
xContact IRT
8.4.2 OLE2 Baseline Visit
Subjects who will still be treated in the OLE Period at the time of implementing Protocol 
Amendment #5.4 (OLE2 Group A subjects) will attend Week 144 Visit and directly roll 
over to the OLE2 Period to continue thei r treatment (bimekizumab 320mg Q8W). They 
will undergo all study assessments of the Week 144 Visit and will receive bimekizumab 
320mg Q8W at this visit, which will also coincide with the first visit of the OLE2 Period, ie, 
the Week 144/OLE2 Baseline Visit.
Subjects who have completed Week 144 Visit and are in the SFU of the OLE or have 
completed the SFU Period at the time of Protocol Amendment #5.4 implementation (OLE2 
Group B subjects) will reinitiate their treatm ent at the Week 144/OLE2 Baseline Visit, and 
will be assigned a treatment regimen based on  their disease severity at the Week 144/OLE2 
Baseline Visit (bimekizumab 320mg Q4W/Q8W for subjects with IGA score ≥3 or 
bimekizumab 320mg Q8W for subjects with IGA score <3).
Applicable for OLE2 Groups A and B:
xPhysical exam
xBody weight
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should 
be obtained prior to blood sampling
xCollection of blood and urine samples for the following clinical laboratory tests:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
xeC-SSRSPUBLICec
their their
s of the s of the
h will alwill al
e Visit.e Visit
WWCOPY LE PeriLE Peri
ts) wits) w
This documental exaexa
dy weigy weig
Vital sVital 
be obe 
xxcannotizumazuma
mg Q8Wg Q8W
OLE2 GOLE2 G
mbe nitiattiat
ent regent reg
bbused eek 144k 144
the timehe tim
et het hto o cocosupport d at that t
l attend Wattend
eatment atmen
Week 144Week 14
oincidincany hehmarketing d medicamedicauthorization 
application roupoup
htht
gns (sittins (sit
tained pained pand 32020
W for subfor su
ps Aps Aanyir trir t
men basmen ba
mg Qmgextensions(bimbi
4 Visit Visit 
de with e with
Visit anVisit an
of Protf Pro
reareaorWeekWee
mekmekvariations at
ime ofme of
k1thereof. ioons inns i
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 254 of 263xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGA
xPHQ-9
xDLQI
xPatient symptoms (itch, pain, and scaling)
xConcomitant medication
xAEs
xContact IRT
Additional Procedures/assessments applicable for OLE2 Group A 
xInformed Consent 
xECG
xBlood sample for bimekizumab plasma concentrations
xBlood sample for anti-bimekizumab antibodies
xIGRA TB test
xscalp IGA
xmNAPSI
xpp-IGA
xEQ-5D-3L
xPASE
xPGADA
xWPAI-SHP V2.0
At the Week 144/OLE2 Baseline Visit, af ter completion of the above-mentioned 
procedures, administration of IMP will oc cur, preferably by self-injection under 
supervision of the site personnel.
Distribution of IMP and accountability activities for home administration to be performed 
as described in Section 7.2, Section 7.5, and Section 7.7.PUBLICmab anmab anCOPY ma conca conc
i
ThisDdocument HPHP
he WeekWee
rocedurcedu
supervsuperv
Dicannot P V2.V2.be used to supportentrationtratio
bodiesodiesany marketing p A A authorization 
application k 144/OL144/OL
es, admin, adm
ion of ton of and any extensions or variations thereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 255 of 2638.4.3 Self-injection at home (OLE2 Weeks 4, 8, 16, 32, and 40)
Subjects receiving bimekizumab 320mg Q8W will be given the opportunity for self-
injection of bimekizumab at home on the following weeks: OLE2 Weeks 8, 16, 32, and 40.
Subjects receiving bimekizumab 320mg Q4W/Q8W will be given the opportunity for self-
injection of bimekizumab at home on the fo llowing weeks: OLE2 Weeks 4, 8, and 16. At 
OLE2 Week 16, subjects receiving bimekizumab 320mg Q4W/Q8W will switch to bimekizumab 320mg Q8W regimen and will be given the opportunity for self-injection of bimekizumab at home dosed at OLE2 Weeks 32 and 40.
Subjects of childbearing potential should cond uct a home pregnancy test every 4 weeks. In 
case of a scheduled home self-injection the pregnancy test needs to be performed 
immediately prior to self-injecting bimekizuma b at home. If the pregnancy test result is 
positive, IMP should not be administer ed and the site should be contacted.
Adverse events will be captured spontaneously  if the subject decides to visit the site to 
receive the bimekizumab administration. 
All used syringes will be disposed of by subjects/caregivers as determined by the 
Investigator in an acceptable disposal (sharps) container directly after the administration. 
The subjects/caregivers return the docu mentation together with any used/unused 
containers at the next scheduled clinic visit.
8.4.4 OLE2 Week 12, Week 24, and Week 36 Visits  (±14 days relative to OLE2 Baseline)
As depicted in Table 7‒3,subjects receiving bimekizumab 320mg Q4W/Q8W should 
receive IMP at the OLE2 Week 12 Visit, and al l subjects will receive kits for home 
administration 4 weeks later at OLE2 Week 16. All subjects will receive IMP 
administration at the OLE2 Week 24 Visit, and will receive kits for home administration 
8 weeks later. At the OLE2 Week 36 Visit, subjects will not be dosed and will receive kits for home administration 4 weeks later at OLE2 Week 40.
The following procedures/assessments will be performed/recorded at ev ery clinic visit prior 
to administration of IMP:
xPhysical exam
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should 
be obtained prior to blood sampling
xUrine pregnancy test, for applicable subjects
xTuberculosis questionnaire 
xPASI
xPercentage of BSA 
xIGA
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS PUBLICd Weekd Wee
ts receivts receiv
ek 12 Vik 12 V
r at OLr at OL
WeWeCOPYcarea
) contai) conta
ntation tation
sit.it.
k
This documentns s 
tained pned p
rine prene pre
TubeTube
xxPPcannot reses
IMP:MP:
m
(sittinsittinbe weeee
/asse/asseusedE2 W2 W
ek 24 Vi24 V
eek 36 ek 36 
ks lks ltoit, anit, an
WeeWeesupport ogeg
36 Visits 6 Visi
ng bimeg bime
dadany s as s as
r directr dire
ether wthermarketingrformor
ancy tesancy te
tacted.acted.
cides to vdes to
detedeauthorization ction of ion of 
ery 4 wry 4 w
medmed
applicationg systolg systo
rior to blor to b
gnancy tnancy 
rculosis qulosisand any er ar 
ments wments wextensions (±1(
ekizumakizuma
all subjel subj
k 16. Al16. Al
sit, and t, and 
Visit, susit, su
at Oat Oor 14 d14 dvariations visitisi
terminermine
tly aftely afte
with anwith anthereof. eeks.ek
t resultresult
t thett h
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 256 of 263xConcomitant medication 
xAEs
xContact IRT 
The following will be additional assessments will be performed / recorded every 24 weeks 
(ie, OLE2Weeks 24 and 48) prior to administration of IMP
xCollection of blood and urine samples for the following tests should be obtained prior to 
dosing:
Hematology and biochemistry
Urinalysis
xDLQI 
At the OLE2 Week 12 and Week 24 Visit, after completion of the above-mentioned 
procedures, administration of IMP will oc cur, preferably by self-injection under 
supervision of the site personnel.
Distribution of IMP and accountability activities for home administration to be performed 
as described in Section 7.2, Section 7.5, and Section 7.7. Home pregnancy tests will be 
provided for testing every 4 weeks as appropriate ( Table 5‒2andTable 5-3) .
8.4.5 OLE2 Week 48 Visit (±14 days relative to OLE2 Baseline)
The following procedures/assessmen ts will be performed/recorded:
xPhysical exam
xBody weight
xVital signs (sitting systolic BP and dias tolic BP, pulse rate, and body temperature) 
should be obtained prior to blood sampling
xCollection of blood and urine samples for th e following clinical laboratory tests should 
be obtained prior to dosing:
Hematology and chemistry
Urinalysis
Urine pregnancy test
IGRA TB test
xTuberculosis questionnaire
xPASI
xPercentage of BSA
xIGAPUBLICy acy a
7.5.5, and, an
ks as ks as apap
(±14 da(±14 da
essesCOPYcompcom
r, preferr, prefe
ctivictivi
This document ined ned 
HematoHemat
UriUri
cannotg systosysto
ined prned pr
of bloof bloo
priprbe usedyy
ments wents wtop
relatirelatsupport ies for hos for 
Sectionection
ropriateopriateany on of ton of
bly by sbly by smarketing hauthorization eeks eeks 
ained prned pr
application d and and 
or to dor to d oso
logy andlogy an
nalysisalysis
rine prine pand c BP BP
or to blr to bl
urrany andanextensions7.77. H. H
e ((TablTabl
ve to OLto OL
ill be pel be peorme adme a
HoHvariations he abovehe abov
selfelf--fffinjinjthereof. 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 257 of 263xDLQI
xPatient symptoms (itch, pain, and scaling)
xPHQ-9
xeC-SSRS
xConcomitant medication
xAEs
xContact IRT
Return of IMP and accountability activities fo r home administration to be performed as 
described in Section 7.2, Section 7.5, and Section 7.7.
Change #20
Section 8.5 Premature End of Treatment Visit
The following text was added:If a subject is withdrawn from the study during the OLE2 Period:
xThe subject will be withdrawn from IMP, will undergo the same assessments as the 
OLE2 Week 48 Visit (see Section 8.4.5 ) and will enter the SFU2 Period.
xThe subject will be encouraged to return for the SFU2 Visit (20 weeks after the last 
received dose; see Section 8.7).
Change #21
The following section was added:
8.7 Safety Follow-Up Visit 2 (20 weeks after final dose in the OLE2 Period, ±7 days)The following procedures/assessmen ts will be performed/recorded:
xPhysical exam 
xVital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should 
be obtained prior to blood sampling
xCollection of blood and urine samples for the following tests should be obtained at this 
visit:
Hematology and biochemistry
Urinalysis
Urine pregnancy test
xeC-SSRS
xConcomitant medication
xAEsPUBLIC 4.54.
d to retuto retu
77).).COPY ng the Ong the 
MP, MP, wilw
5) an)a n
This documentgns (sns (s
btainedained
Collectiollecti
visit:visit:cannot Visitsi
edures/dures
am m 
sittittbe dded:ded
t 2 (2t 2 (used to support l underunder
d will entwill e
rn for thefor theany LE2 PerLE2 Pe
gomarketing be pepauthorization erfoerfo
application ing systong syst
prior to brior to
on of bloon of blo
matmaandassessmsessmany weeks aweeks aextensionse SFU2SFUorr ther thevariations riod:iod:
the sahe sathereof. rmed ased as
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 258 of 263xContact IRT
Change #22
Section 8.8 Unscheduled VisitAt the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the 
study but prior to the SFU Visit, if deemed necessary for the subject’s safety and well -being.
Was changed to:
At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the 
study but prior to the SFU Visit or SFU2 Visit (depending on which period, OLE or OLE2, 
the participant is in) , if deemed necessary for the subject’s safety and well -being.
Change #23
Section 10.1 Pharmacokinetic variables
The following sentence was added:
Blood samples for the measurement of PK assessments will not be collected in the OLE2 
Period.
Change #24
Section 11 ASSESSMENT OF IMMUNOLOGICAL VARIABLES
The following sentence was added:
Blood samples for the measurement of antibodies  to bimekizumab will not be collected in 
the OLE2 Period.
Change #25
Section 12.2 Laboratory measurements
Table 12 -2  Laboratory measurements
Hematology Chemistry Urinalysis dipsticka
Lipid panel
NT-proBNPb
Serum pregnancy testingc
bAssessments of NT-proBNP and CRP will not be performed during the OLE Period.
cPregnancy testing will consist of serum testing at the Screen ing. Urine pregnancy testing will be performed at 
all other visits.PUBLIC MMUNMMUN
dded:dded:COPY assessmssessm
This document y
enmcudbbAAdddocannotratory matory m
Laborataboratcbe used ment of ent of to OLsupport entsnt
LOGICOGIany s will wilmarketing y t
od, OLEd, OL
wellll--beingbeingauthorization ng the g the 
being.eing.
time dme d
a
tapplication ory ry
onatlicppaandmeasurasur
memeany emextensions CAL VACAL V
antibodntibodor variations noot be t bethereof.uring thring th
or OLEor OL
g.
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 259 of 263Was changed to:
Table 12 -2  Laboratory measurements
Hematology Chemistry Urinalysis dipsticka
Lipid panelb
NT-proBNPb
Serum pregnancy testingc
bAssessments of NT-proBNP and CRP will not be performed during any OLE Period; in addition, lipid panel 
will not be performed during OLE2 Period.
cPregnancy testing will consist of serum testing at the initial Screening. Urine pregnancy testing will be 
performed at all other visits.
Change #26
Section 12.3.2 Pregnancy testingPregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine 
at other visits.
The Screening Visit serum pregnancy testing result s must be negative and received and reviewed 
prior to randomization.A negati ve urine pregnancy test result  should be obtained immediately 
prior to each administration of IMP as specified in Table 5‒1 and Table 5 ‒2. Pregnancy tests 
should be administered to all female subjects of childbearing potential, regardless of their use of 
birth control.
Subjects of childbearing potential should conduct a home pregnancy test every 4 weeks. Home 
pregnancy tests will be provided to participants for use at Weeks 60, 68, 76, 80, 88, 92, 100, 104, 
112, 116, 124, 128, 136, and 140. At weeks on which IMP dosing is scheduled (specified in 
Table 5‒1 and Table 5 ‒2), a negative urine pregnancy test result should be obtained immediately 
prior to the administration of IMP. In the case of a positive pregnancy test result, IMP should not
be administered and the site should be contacted.
Was changed to:
Pregnancy testing will consist of serum testing at the initial Screening. The pregnancy test will 
be urine at other visits , including at the OLE2 Screening Visit.
The Screening Visit serum pregnancy testing result s must be negative and received and reviewed 
prior to randomization.
A negative urine pregnancy test result should be obtained immediately prior to each 
administration of IMP at the visits specified in Table 5‒1, Table 5 ‒2,and Table 5-3 .Pregnancy 
tests should be administered to all female subjec ts of childbearing potential, regardless of their 
use of birth control.
Subjects of childbearing potential should conduct a home pregnancy test every 4 weeks. Home 
pregnancy tests will be provided to participants for use at Weeks 60, 68, 76, 80, 88, 92, 100, 104, 
112, 116, 124, 128, 136, and 140 , and at the OLE2 Weeks 4, 8, 16, 32, and 40 . At weeks on 
which IMP dosing is scheduled (specified in Table 5‒1, Table 5 ‒2,and Table 5-3 ), a negative 
urine pregnancy test result should be obtained imme diately prior to the administration of IMP. In PUBLICspecifispecif
subjectssubjects
ntial shontial sh
ed toedCOPY e SS
results mesults
gnancygnancy
edd
Thisdocument therhe
eening Vening V
to randoo rand
A negatinegati
adminadmi
testescannot siteite
ng will g will
visvisbenegg
of IMPof IMP
shoshusedulduld
participartici
0.At weAt we
ativeativto d condcondsupport must bust 
test resust resu
in n TableTabl
of childbf childbany g. Tg. 
be nebemarketing estingstin
The pTheauthorization ootioattt
riz
ion, lipidn, lipid
gw iwtho
application consisnsi
ss, includ, incl
Visit serusit seru
mizationmizatio
ve urine p urine 
ation otionand ulu
st otoany rinin
n the can the c
d be cobe cextensions5
bearingearing
uct a hoct a ho
ants for nts for
eks on wks on w
ne prepor t shosh
11ananvariations pregnanregnan
egative gative
oulouthereof. l be e 
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 260 of 263the case of a positive pregnancy test result, IMP should not be administered and the site should 
be contacted.
Change #27
Section 12.4.2 Medical historyA complete medical history will be collected as pa rt of the Screening assessment and include all 
clinically relevant past or coexisting medical conditions and surgeries. Findings will be recorded in the eCRF.
Was changed to:
A complete medical history will be collected as part of the initial Screening assessment and
include all clinically relevant past or coexisting medical conditions and surgeries. Findings will 
be recorded in the eCRF. 
For OLE2 Group B, only new or modified med ical history since completing the SFU will be 
collected at OLE2 Screening and entered in eCRF.
Change #28
Section 12.4.4 Data Monitoring and Adjudication Committees
The Cardiovascular and Neuropsychiatric Adjud ication Committees will monitor the study 
through the last subject completing the OLE and SFU Periods for PS0015.
Was changed to:
The Cardiovascular and Neuropsychiatric Adjud ication Committees will monitor the study 
through the last subject completing the OLE, SFU, OLE2, and SFU2 Periods for PS0015.
Change #29
Section 14.1 Definition of analysis sets
The following paragraph was added:
The OLE2 Period Set (OL2S) will consist of al l subjects that receive at least 1 dose of IMP 
at the Week 144/OLE2 Baseline or later in  the OLE2 Period (including the Week 
144/OLE2 Baseline dose).
Change #30
Section 14.3.2.2 Analysis of the other efficacy variables
In general, data will be summarized by vi sit through Week 48 in the double-blind Treatment 
Period and then by visit in the OLE Period separa tely. All summaries of data up to Week 16 will 
be based on the RS for the 2 randomized treatm ent groups (bimekizumab and secukinumab). For 
visits after Week 16 in the double-blind Treatmen t Period, by-visit summaries will be prepared 
for the following 3 groups of subjects:
Was changed to:
In general, data will be summarized by vi sit through Week 48 in the double-blind Treatment 
Period and then by visit in the OLE Period and OLE2 Period separately. All summaries of data PUBLICc A
e OLE aOLE 
opsychiaopsychia
etingetinCOPY cation Cation
Adjudidjud
This bdocument Basease
ge #30e #30
ction 14ion 1
In genIn gen
PerPercannotph wash wa
d Set (OSet (O
44/OLE4/OLE
elinelinbeof analof anausedtri
the OLhe OLtoc Adjc Adj
Esupport Commom
ation Comtion C
d SFUSFU Peany mittemitmarketing assessses
urgeries. Frgeries. F
e complecompauthorization de all e all 
recordedcorded
smsm
application 2 BasBas
dose).dose).
3.2.2.2.2 A
l, data  data
hand addeded
L2S) w2S) w
elieliany is setss sets
d::extensions eriorio
dicationication
,SFUFU,,OOormmittmmit
ds fds fvariationseting ing
eess
teethereof. ent annt an dd
Findinginding
thth
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 261 of 263up to Week 16 will be based on the RS for the 2 randomized treatment groups (bimekizumab and 
secukinumab). For visits after Week 16 in the dou ble-blind Treatment Period, by-visit summaries 
will be prepared for the following 3 groups of subjects:
And the folloing sentence was added:
In the OLE2 Period, selected efficacy variables  of interest will be summarized descriptively 
by OLE2 Period Treatment Gr oup during the OLE2 Period.
Change #31
Section 14.5.1 Safety analysesSafety variables will be analyzed for all subjects in the SS. This will include all subjects who 
took at least one dose of study medication. Selected analyses will also be presented for MS and 
OLS.
Was changed to
Safety variables will be analyzed for all subjects in the SS. This will include all subjects who 
took at least one dose of study medication. Selected analyses will also be presented for MS, 
OLS, and OL2S .
Change #32
Section 14.8 Planned interim analysisAn interim analysis is planned at Week 48, details of which will be documented in the SAP. 
Additional interim analyses may be performed (de tails of which will be documented in the SAP). 
Corresponding interim Clinical Study Reports (CSRs) may be written. A final analysis and 
updated final CSR will be prepared once all data through the SFU visit and including the OLEPeriod have been collected.
Was changed to
An interim analysis is planned at Week 48 and Week 144 , details of which will be documented 
in the SAP. Additional interim analyses may be performed (details of which will be documented 
in the SAP). Corresponding interim Clinical St udy Reports (CSRs) may be written. A final 
analysis and updated final CSR will be prepared once all data through the OLE2 Period and 
SFU2 Visit have been collected.
Change #33
Section 15.1 Informed consent
All subjects enrolling in the OLE Period will sign a new ICF.Was changed to
All subjects enrolling in the OLE Period will sign a new ICF. Similarly, all subjects enrolling 
in the OLE2 Period will sign a new ICF.PUBLIC ysissis
Week 48Week 48
y be pery be per
al Studal Stud
arearCOPY d anald an
ThisWdocument havehave
nge #33ge #33
ection 1tion 1
All suAll scannotplanneanne
nal interal inte
respondispond
dated fdated 
bbbe ededused y RepRep
d once aonce atoormedormed
poportrtsupport details oetails o
(d(any will awillmarketing all sul su
presentedpresented
will incwill in
alsauthorization vely ely 
ubjebj
application g
inal CSal CS
en collecn colle
.11InfoIn
ts enrts enrandat Wt W
m analym anal
g interiinter
Rany Week 4Weekextensions of whichof whic
details otails o
s (CSRs(CSRs
ll data thdata tor variations clude alclude al
so be prso be prthereof. cts whots who
d for MSfor M
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 262 of 26319 DECLARATION AND SIGNATURE OF INVESTIGATOR
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current GCP and local laws and 
requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.
I have received and read all study-related information provided to me.
The objectives and content of this protocol as well as  the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by 
UCB.
All rights of publication of the results reside with  UCB, unless other agreements were made in a 
separate contract.
Investigator:
Printed name Date/Signature
PUBLIC COPY CO
This document cannot be used to support Date/Signate/Sigrtrtany marketing o
reements emenauthorization s of of 
will be trill be 
orizatiorizatio
application and any extensions or atureaturevariations vathereof. ea
n by by 
s were m were m
UCB 01 Oct 2021
Clinical Study Protocol Bimekizumab PS0015
Confidential Page 263 of 26320 SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current GCP.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
Approval Signatures
Name: ps0015-protocol-amend-5.4
Version: 1. 0
Document Number: CLIN-000178914
Title: ps0015-protocol-amend-5.4
Approved Date: 01 Oct 2021
Document Approvals
Approval
Verdict: ApprovedName: Capacity: ClinicalDate of Signature: 01-Oct-2021 16:11:46 GMT+0000
ApprovalVerdict: ApprovedName: Capacity: ClinicalDate of Signature: 01-Oct-2021 16:11:56 GMT+0000
ApprovalVerdict: ApprovedName: Capacity: ClinicalDate of Signature: 01-Oct-2021 16:12:05 GMT+0000UBLIC PUUCOPY O ument mentCC
This document cannnnot nnbe used uuto totoportt ApprovAppro
suppopopNaany marketing authorization 
application annd nyany ysionss: 
pacity
Date 
extensissins
eesoralsal
or orovariations valssthereof. 